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ABSTRACT
A series of experiments, designed to investigate two mutually incompatible 
theories of the catalysis carried out by pepsin, the archetypal aspartic protease, 
were undertaken. Mechanism-activated active-site probes, based on acyl 
hydrazides, were synthesised, but could not be shown to inactivate pepsin. 
Experiments designed to trap a covalent intermediate in pepsin catalysis were also 
carried out, but did not provide any evidence for such an intermediate.
A number of methyl hydrogen 1-aminoalkyl phosphonates have been 
synthesised. They were used, by co-workers in the group, in the synthesis of 
phosphonamidate-containing penta- and hexapeptide-based inhibitors for the 
aspartic protease from HIV-1. These compounds were found to be inhibitors in both 
in vitro and in vivo assays. The best Inhibitors had IC50 values in the low micromolar 
range. Molecular modelling was used to develop a model for the Interaction of these 
compounds with the active site of the protease. This model was used to rationalise 
some of the results obtained from the inhibitors.
Attempts were made to clone, overexpress and purify the protease from E. coli. 
The protease was purified to homogeneity but no activity could be observed. 
Various attempts to obtain activity were unsuccessful.
,
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CHAPTER ONE
INTRODUCTION TO THE ASPARTIC 
PROTEASES AND HIV-1
1.0 Introduction: The aspartic proteases
The aspartic proteases are one of the four known classes of proteolytic enzymes 
that act on interior bonds of proteins (endopeptldases); the other classes are serine, 
cysteine and métallo proteases. The aspartic proteases are so named for the 
presence of two absolutely conserved aspartate residues in the active site (see 
below). The optimal pH of many of these enzymes lies in the range 1-3 and 
consequently they have been previously designated the acid proteases. However, 
since the discovery of several members of this class that have pH optima near 7 the 
term aspartic protease has been adopted. The aspartic proteases are ubiquitous, 
occurring in most phyla, e.g. in viruses (HIV-1 and 2, RSV and AMV), bacteria (B. 
subtillus), protozoa {Tetrahymena), fungi (Endothia parasitica), higher plants {Lotus) 
and vertebrates. They are involved in a wide range of functions in vivo, including 
digestion of dietary protein (pepsins and chymosin), homeostatic regulation (renin) 
and lysosomal protein degradation (cathepsins D and E). The fungal proteases are 
believed to be involved in sporulation and the retroviral proteases cleave viral 
polyproteins during maturation of the virus. The aspartic proteases are also involved 
in a number of pathological conditions; pepsin in gastric ulcers, renin in hypertension 
and cathepsins D and E in muscular dystrophy and neoplastic diseases. The 
aspartic proteases have also been extensively used in food processing, for the 
production of cheese and fermented foods from soya beans.
Alt of the aspartic proteases from these widely differing sources share a high 
degree of structural and sequence homology. They usually have acidic pH optima 
and are inhibited by carboxyl group directed inhibitors and the fungal metabolite 
pepstatin A, which is the general aspartic protease inhibitor.^
o
o
N H
CH. HQ CH.
N
H
OH
Figure 1.0.1: Pepstatin A 
1
1.1 Protease action
All proteolytic enzymes carry out the same superficially simple reaction, the 
addition of water across an amide bond. They have, however, all adopted different 
methods to catalyse this difficult reaction, whilst providing the same factors to 
achieve catalysis. The factors that must be provided by a protease to achieve peptide 
bond cleavage are;
i) a Lewis or Bronsted acid (E) to polarise the scissile carbonyl,
ii) a nucleophile (Nu) to attack the scissile carbonyl and
iii) a proton donor (B-H) to proton ate the departing amine^ (see Scheme 1.1.1 
below).
Proteases need to involve all these different factors in the catalysis to overcome the 
enormous stability of the peptide bond, usually ascribed to its large resonance 
energy 3 of around 17-18 kcal mol"\ Recently, the concept of stabilisation of amide 
bonds by resonance has been the subject of some debate.'*
H — B
R
Nu
R Nu
R’NHc
Scheme 1.1.1: Generalised protease mechanism 
(Nu is water for the aspartic and métallo proteases.)
The serine and cysteine proteases utilise covalent acyl intermediates in the 
cleavage, acylating a nucleophilic hydroxyl or thiol side chain in the active site. In 
contrast the action of the métallo and aspartic proteases involves a nucleophilic 
water molecule and thus these systems are believed to operate by non-covalent 
mechanisms (see below). In the aspartic proteases the residues acting as the Lewis 
or Bronsted acid and the proton donor are not known with certainty.
1.2 Molecular properties of aspartic proteases
1.2.1 Physico-chemical properties
The aspartic proteases are globular proteins with molecular weights in the range 
of 31-40,000 Da, that of porcine pepsin A is 34,644 Da, calculated from its primary 
sequence.5 The aspartic proteases are highly acidic proteins, with a large 
preponderance of acidic over basic residues (40:3 found in the sequence of porcine 
pepsin A).^ This results in a very low pi for these proteins, in the range 2-3, which is 
consistent with their low pH optimum.
The pH-rate profile of the aspartic proteases has been extensively investigated and 
studies of most systems, including pepsin, have revealed a low pK^ and a high pK^. 
In pepsin the pKg values were found to be 1.2 and 4.5.® This led the early 
investigators to propose that two carboxyl groups, one ionised and one not, were
crucial to the catalysis.^ The origin of this large difference in the pKg’s of the two 
carboxyls has been considered frequently. It has often been compared to the pK^
difference in 1,2 dicarboxylic acids® e.g. the pK^'sfor maleic acid are 1.83 and 6.07.^ 
The mandatorily cis arrangement of the carboxyl groups in maleic acid permits the 
formation of very strong intramolecular hydrogen bonds. The hydrogen bond 
between the carboxylate and the hydroxyl group of the undissociated carboxyl will 
greatly stabilise the mono-anion. However, the dianion will be destabilised as the 
negatively charged carboxylates will be forced to be close and co-planar. These two 
effects combine to produce the two widely separated pK^'s of maleic acid, as the first 
ionisation is promoted and the second disfavoured. The two pK^'s of succinic acid 
are, by contrast, 4.16 and 5.61 and those of fumaric acid are 3.03 and 4.44. Thus, the 
active site of the aspartic proteases may constrain its two carboxylate side chains to 
be c/s and coplanar more than they are constrained in succinic acid, but less so than
3
in maleic acid.
HO2C H HOgC CO2H HO2C CO2H>=< >-( . ^ 4
H CO2H H H H H
Fumaric acid Maleic acid Succinic acid
Figure 1.2.1: Dicarboxylic acids
In order to probe the possible involvement of carboxyl groups in the catalysis by 
aspartic proteases chemical labelling experiments using various carboxyl-directed 
agents were undertaken. Among the reagents that have been used are 
trimethyloxonium fluoroborate,*® diazoacetyl amino acid methyl esters,** 1-(p- 
nitrophenoxy)-2,3-propoxide (EPNP)*^ and p-bromophenacyl bromide.*® All of 
these react with aspartic proteases to label at least one carboxyl group. Labelling of 
either one of the two carboxyl groups results in inactivation of the enzyme, as was 
shown by Delpierre and Fruton*'* using *'*C-labelled L-1-diazo-4-phenyl-3- 
tosylamidobutan-2 -one (Tos-L-Phe-CHN2). The rate of incorporation of *^*0 label into 
the protein parallelled the loss of proteolytic activity against either peptide or protein 
substrates. This work was in accord with the obligate involvement of 2 carboxyl 
groups In the mechanism of the aspartic proteases. The origin of the active site 
carboxylates was established as aspartate residues by labelling with hydroxylamine
and performing a Lossen rearrangement to give 2,3 diaminopropanoic acid.*®
Experiments with EPNP showed incorporation of 2 molecules per molecule of
pepsin A, one at Asp-32 and the other at the same Asp as was labelled by the diazo 
reagents.®^'^ This residue is Asp-215 in the sequence of pepsin.*®
OoN-
Figure 1.2.2:1-(p-nitrophenoxy)-2,3-propoxide, EPNP
More recently this epoxide-based approach has been used to develop irreversible 
active site directed inhibitors for the aspartic protease from HIV-1 (see Section 
1.6). It has been shown by e lectrospray mass spectroscopy and X-ray 
crystallography*^^ that the epoxide becomes covalently bound to one of the active 
site aspartates of the protease from HIV-1 , as EPNP does with the monomeric 
proteases.®
The lower pKg in pepsin was assigned to Asp-215 due to its selective reaction with 
diazo compounds such as N-dlazoacetyl-Phe-3-phenyl 2,3-®H propylamide.*® 
However, this assignment is not unambiguous as free energy perturbation 
calculations have shown that the protonation states of the two aspartates are affected 
by the nature of the compound bound at the active site.*® These uncertainties may 
explain some contradictory results obtained with other active-site labelling reagents 
that were used to locate the ionised aspartate. The different reagents may induce the 
two aspartates to adopt different protonation states, therefore giving label 
incorporated at both of the carboxyl groups, dependent upon the group used to carry 
out the labelling.
1.2.2 Structural and sequence properties
The fungal and mammalian aspartic proteases all adopt very similar tertiary folding 
patterns. They are globular proteins with the overall structure consisting of 2 lobes, 
made up of the N- and C-terminal parts of the sequence. The active site lies in a 
deep cleft at the junction between the two lobes. The active site appears to be 
approximately 25 Â long in the X-ray crystal structures (see Section 1.4), which is 
consistent with the ability of the aspartic proteases to bind substrates up to 7 amino
acids in length.®® The active site is sealed off from solvent upon substrate binding by 
a structure known as the flap (residues 71-83 in pepsin). After catalysis the flap 
opens to allow products to leave and new substrate to bind. The flap is clearly of 
pivotal importance in the productive binding of substrates as it sequence is highly
conserved.®*
The aspartic proteases consist mostly of 8-sheet. Indeed pepsin is around 44% 8 
sheet.®® An extensive six stranded anti parallel 8-sheet forms the core of the enzyme, 
three strands being contributed by each of the N- and C-terminal domains. This
dominance of 3-sheet structure has led to the aspartic proteases being classified as 
“all 3" proteins.®® The high proportion of 3-sheet structure and the low amount of a-
helical structure is also seen in circular dichroism studies of pepsin in solution.®'*
A large number of aspartic proteases from widely differing sources have been 
sequenced®* and the sequences show significant homology in some areas. The 
sequences around the 2 active site aspartates, 32 and 215 in porcine pepsin, are 
highly conserved, as would be expected. Homology is also observed around Tyr-75 
in the flap,®* indicating that this region too is crucial for efficient catalysis. This 
conservation of sequence may indicate evolution from a common ancestor.
The D-T-G-(S/T) motif is considered to be diagnostic for the aspartic proteases, and 
has been used to identify aspartic proteases from their sequence, for example the 
HIV-1 protease (see Section 1.6). This motif is important in maintaining the structure 
of the active site through hydrogen bonding (see Section 1.4). The strict conservation 
of this motif is shown in the sequence alignments in Table 1.1.
Table 1.1 Partial sequence alignment for some aspartic proteases.
Enzyme Sequence around residue:
Endothiapepsin
32
DTGSSD
75
YGDG
215
DTGTT
Penicillopepsin DTGSSD YGDG DTGTT
Rat renin DTGSAN YGSG DTGTS
Porcine pepsin DTGSSN YGTG DTGTS
HIV PR DTGADD
1.2.3 Enzymology
As mentioned above the aspartic proteases have a very low pH optimum. The 
reasons for this have been examined in some detail (see Section 1 .2 .1). The 
hydrogen bonding network around the catalytic aspartates (see Section 1.4) is 
believed to greatly stabilise the mono-anionic form of the enzyme. This results in the 
very low first pK^ discussed above (see Section 1.2.1). The high pH optimum of 
human renin (around 5) was believed to be due to it having an alanine residue at 
position 218. This residue cannot hydrogen bond to aspartate 215 and thereby 
stabilise a negative charge. However, as shown above (Table 1.1) rat renin, which 
has a pH optimum almost identical to that of human renin, has a threonine residue at 
position 218. Thus, the hydrogen bond from this residue to Asp-215 appears to have 
little influence on the pH optimum for the enzyme. It has been proposed that the pH 
optimum of renin is influenced greatly by its substrate, angiotensinogen^s and is not 
determined by the active site sequence. This is supported by the work of Tang^® on 
m utagenesis of pepsin and rhizopuspepsin active sites. Mutation of the 
serine/threonine residues at positions 35 and 218 in rhizopuspepsin to alanine had 
no effect on the pH-rate profile for the enzyme, though the catalytic efficiency was 
decreased around ten fold. It was therefore postulated that the hydrogen bond only 
contributes to active site rigidity and not to the pKg of the apartates or the pH optimum 
of the enzyme. A decrease in active site rigidity could lead to a randomisation of the |  
position of the active site water molecule and a consequent decrease in catalytic 
efficiency.
A similar study was carried out on the aspartic protease from HIV-1,27 replacing 
Ala-28, which is in the equivalent position to Ser/Thr-218 in the monomeric 
proteases, with serine. It was found that the mutant enzyme showed a small lowering 
of the optimum pH, but not as large as would be expected if the mutation were to 
confer similar pH properties to the monomeric proteases. The mutant also showed a 
decrease in k^ ^^ , in contrast to the results from the monomeric proteases. This may 
be due to the HIV-1 protease requiring a more flexible active site to accomodate its 
wide range of substrates. The hydroxyl group of Ser/Thr-218 therefore probably does 
not interact with the active site aspartates as expected in either the monomeric or 
dimeric aspartic proteases. The origin of the very low first pK^ in most of the 
monomeric proteases remains, therefore, unclear. It may well derive from the 
coplanar conformation imposed upon the two aspartates by the active site, as
discussed above (Section 1.2.1).
Most of the aspartic proteases have little specificity in their requirements for the 
amino acids flanking the scissile bond i.e. the S  ^ and S-|’ subsites (see Figure 1.2.3),
in the nomenclature of Schecter and Berger,28 are not very stringent.
P3------------------p   Pi--------------------- Pi' --- Pp' ----------------- PV
Scissile bond
Figure 1.2.3: Substrate and subsite nomenclature 
according to Schecter and Berget^^
The best characterised exception is renin, which has only 1 natural cleavage site, 
the Leu 10-Val 11 bond in angiotensinogen. This specificity difference is consistent 
with the respective roles of the more indiscriminate digestive protease such as 
pepsin and the exquisitely tuned specificity of a regulatory protease like renin.
A prominent feature of aspartic protease catalysis is the observation that k^gi for 
peptide cleavage increases with increasing length of the substrate while K|^ remains 
approximately constant.29 Thus, the extra binding energy available from binding 
larger substrates is used to lower the activation energy for the hydrolysis and is not 
expressed in increased strength of binding. The reduction in activation energy 
results in an increase in k^ g^ , but just how this is achieved has been the subject of 
some debate. It has been shown that the rate-determining step in aspartic protease 
catalysis is the loss of products from the active site^o and not the cleavage of the 
scissile peptide bond. Thus, differences in k^^t between different substrates arise 
from differences in the affinity of the active site for the products of cleavage and not 
from differences in the stability of the scissile bond.
All aspartic proteases have a significant electrophilic component in their catalysis 
of peptide bond hydrolysis. This electrophilicity is suggested by the observation that 
the aspartic proteases, in common with electrophilic systems such as H+, catalyse 
the hydrolysis of esters and amides at approximately equivalent rates. This stands in 
contrast to nucleophilic systems such as OH' and the serine proteases which
8
hydrolyse esters much more quickly than amides. Recent ab initio calculations have 
shown that esters are much more likely to be hydrolysed via an anionic intermediate 
whereas amides are more likely to be hydrolysed by a neutral intermediate.8 i Thus, 
the aspartic proteases may well catalyse peptide bond hydrolysis via a neutral 
intermediate (see Section 1.4).
The aspartic proteases are some of the most efficient proteases in Nature, as 
shown in Table 1.2 below:
Table 1.2 Kinetic constants for representative proteases of each ciass.
Enzyme Substrate
Chymotrypsin82
(serine)
AcPAPF*AAANH2 4.5  X 10^
Papain83
(cysteine)
ZGVE*LG 3 x  1Q8
Pepsin82
(aspartic)
ZGAFTOP4P 4.1 X 1Q7
CarboxypeptidaseA88
(métallo)
BzGGG*LOPh 1.5 X 106
The scissile bond is represented by *. OP4P is 4-pyridyl proppxy.
Apart from hydrolysis the aspartic proteases exhibit two other activities against 
peptide substrates, condensation and transpeptidation. Condensation, the direct 
joining of two peptides, one of which need not necessarily be a substrate, to form a 
larger peptide is the basis of action of the activator peptides. Transpeptidation, the 
joining of a fragment of a substrate peptide to another substrate peptide, is discussed 
in detail in Sections 1.3.1.1 and 1.3 .1.2 .
1.3 The mechanism of the aspartic proteases
The large amount of active site sequence homology and sensitivity to the same 
inhibitors among the aspartic proteases indicates that they all the act by the same 
mechanism. Any enzyme mechanism has three components;^"^
i) Kinetic - which addresses the binding/debinding order of substrates and products.
ii) Chemical - which considers the chemical species (intermediates and transition 
states) involved and the free energy profile for the reaction.
iii) Structural - which attempts to show how the enzyme actually lowers the activation 
energy for the reaction catalysed.
Historically, investigations into the mechanism of the aspartic proteases followed 
roughly this path, the first proposed mechanisms being based on kinetic studies and 
product analysis, then on chemical studies and then on X-ray crystal structures.
The nature of aspartic protease catalysis has been the subject of much 
experimentation and many hypotheses. The two active site aspartates must be 
involved, (see above) but their exact role has been unclear, with two classes of 
mechanism having been proposed. The covalent mechanisms postulate a covalent 
intermediate involving part of the substrates and one of the active site aspartates. 
The general base mechanisms propose that one of the aspartate residues forms the 
attacking nucleophile from water bound at the active site. Thus, either one of the 
active site aspartate side chains or an active site water molecule is the nucleophile.
1.3.1 The covalent mechanisms
The covalent mechanisms were the first mechanisms put forward to account for the 
different types of activity of the aspartic proteases. They seemed to economically 
account for the three different activities exhibited by the aspartic proteases acting on 
peptide substrates; hydrolysis, condensation and transpeptidation. Transpeptidation, 
the formation of larger peptides from smaller ones by adding a portion of a substrate 
to itself or another substrate peptide, is a unique property of most of the aspartic 
proteases. There are two types of transpeptidation activity, amino and acyl, and they 
shall be considered in turn. Transpeptidation of either sort is only observed with poor 
substrates and is only seen at pH's close to neutrality (4-6).^®
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1.3.1.1. The amino enzyme mechanism
The existence of a covalent amino enzyme intermediate was proposed after amino :l 
transpeptidation was observed in studies^s of pepsin acting on di- and tripeptides.
The carboxy terminal amino acid of the substrate was observed to be transferred to a 
suitable peptidic acceptor, either another peptide or another molecule of substrate.
This became known as amino transpeptidation. Amino transpeptidation was then 
observed in several similar systems.^® The net effect of amino transpeptidation is to 
exchange the amino terminus of the original peptide substrate (HgN-X-CO) for the 
incoming peptide substrate (Z-CO2H), as shown below.
Z-COgH + H2N-X-CONH-Y-CO2H Z-CONH-Y-CO2H + H2N-X-CO2H i
Scheme 1.3.1: Amino transpeptidation 
where Z may be substrate or a different peptide
The “amino enzyme" mechanism was developed to account for the observation of 
amino transpeptidation products.
E-COsH + HsNX-CONHY-COaH E -C O aH lX -C O N H -Y C O g H ]E -C O N H -Y C O 2H  +
k., k.2 H2N-X-CO2H :|
ÎE-CO-NH-Y-CO2H + HgO E-COgH + HgN-Y-COgHk-3
Scheme 1.3.2: Amino enzyme hydrolysis 
where E represents the enzyme
The amino enzyme mechanism postulated the formation of a covalent bond 
between the enzyme and the carboxy portion of the peptide substrate (NH-Y-CC^H), 
to form a so-called ‘amino enzyme’ intermediate. Two different fates could befall this 
intermediate, E-CO-HN-Y, either hydrolysis to yield H2N-Y-CC^H or reaction with 
another peptide or amino acid acceptor to give the amino transpeptidation product.
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another peptide or amino acid acceptor to give the amino transpeptidation product.
In the scheme above k-j is much greater than k2, and k.i is much greater than k_2 
i.e. a fast reversible formation of the Michaelis complex is followed by relatively slow 
chemical step(s) and/or conformational changes (see below). The net result is the 
production of a long peptide from shorter ones.
The acceptor in amino transpeptidation is the carboxyl group of the substrate or 
other peptide as Neumann etai.^^ showed that transpeptidation did not occur if there 
was no free carboxyl group available. Silver and Jameses have shown that the 
carboxylate anion is required for amino transpeptidation. The inability to trap the 
covalent intermediate^® showed that if it exists, it must occur on the reaction pathway 
after the rate-determining step. If it occurred before the rate-limiting step then the 
concentration of the Intermediate would build up and could therefore be trapped. 
Also, no burst release of product (H2N-X-CO2H) is observed, which would be 
expected if the covalent intermediate occurred before the rate-limiting step. The 
mechanism outlined schematically above for amino transpeptidation makes the 
prediction of ordered product release, N-terminal portion of the substrate first. The 
acceptor peptide and the carboxyl portion of the substrate will not be bound at the 
same time as they are assumed to occupy the same portion of the active site.
This was supported by Fruton et al.^^, who showed that incubation of pepsin with 
Cbz-Tyr-Tyr, Cbz-'^^C-L-Tyr and L-Tyr resulted in ‘■'^C-label incorporation into Cbz- 
Tyr-Tyr at the N-terminal residue. Incubation with ‘•'^C-L-Tyr and Cbz-L-Tyr, however, 
resulted in no incorporation of radioactivity. Therefore, Cbz-L-Tyr is released from the 
active site and the C-terminal L-Tyr is retained long enough for exogenous labelled 
Cbz-L-Tyr to enter the active site and combine with it. This is consistent with the 
kinetics predicted for a mechanism involving an amino intermediate. Ordered 
product release was further supported by the work of Knowles^® in which it was 
shown that the hydrolysis of Ac-Phe-Phe-OMe is inhibited non-competitively by Ac-L- 
Phe and competitively by L-Phe-OMe. This is in accord with a kinetic mechanism in 
which Ac-L-Phe is released first.
The kinetics of product release show a pH dependency. At pH 2 .1 , when the 
carboxyl group is mostly undissociated, Ac-L-Phe is an uncompetitive inhibitor. 
However, at pH 4.3, when the carboxyl is mostly dissociated, Ac-L-Phe approximates 
to a competitive inhibitor. This indicates that the Ac-L-Phe leaves as an anion from
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the hydrolysis and enters as an anion during transpeptidation. This supports the 
work of Silver and James®® on the obligate involvement of the carboxylate anion in 
amino transpeptidation.
The "amino enzyme" formulation received additional support from isotope 
exchange studies of Shkarenkova et al.^^ The failure to observe exchange of free 
amino acids with enzyme-bound amino acid intermediates by Sharon et al.^^ is 
consistent with a covalently bound Intermediate. Sharon e ta l^^  also found that  ^80- 
label is exchanged between L-Phe (and not D-Phe) and H2^®o only in the presence 
of pepsin {i.e. the exchange is enzyme catalysed, see also"^®).
Thus the amino mechanism seemed to be well supported experimentally. However, 
the work of Knowles was re-examined"^"^ and it was found that Ac-L-Phe inhibits the 
cleavage of Ac-L-Phe-L-Tyr partially competitively and partially non-competitively. By 
studying this effect over a range of pH values it was concluded that the order of the 
dissociation of the ternary enzyme-product complex is pH dependent and thus offers
no real information on the order of product release. A similar study"^® was carried out 
on Ac-L-Phe-L-Tyr-OEt and at pH 4.7 ordered release of Ac-L-Phe first and L-Tyr-OEt 
next was observed i.e. an ordered-off mechanism, in accord with an amino enzyme 
mechanism. However, this effect was not observed at pH less than 4 as the kinetic 
mechanism changes to a random or rapid equilibrium type at around pH 3.5. The 
authors suggest that this is due to a group of pK^ around 4 being involved in binding 
the hydrolysis product L-Tyr-OEt at the active site and this binding becomes 
weakened at pH less than 4, allowing the L-Tyr-OEt to leave.
There were several other difficulties with the amino enzyme hypothesis. The 
chemical mechanism for the formation of the 'amino enzyme' was particularly 
problematic, the most plausible theory involving a four-centre exchange reaction (as 
shown in Scheme 1.3.3). This mechanism was first proposed by Knowles,"^® with a 
variant later proposed by C l e m e n t . " ^ ^
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X— G
NH-Y P /X— NH
OH
Y
NH OH
0 ^ 2  x L g
+ XCO2
Scheme 1.3.3: Possible ami no enzyme mechanism 
where E represents the enzyme.
The hypothesis of an intermediate of the type 'E-NH-Y' as the sole intermediate on 
the hydrolysis pathway was shown to be untenable by Silver et a/.^® Their work 
showed that small changes in the nature of X in X-CO-NH-Y, i.e. the N-terminal 
portion of the substrate, produced very large changes in the rates of amino 
transpeptidation and hydrolysis. This is not consistent with an intermediate of the 
type E-NH-Y being involved in catalysis. There were doubts cast by Silver and 
Stoddard^^ upon the interpretation of the product inhibition data of Knowles^^ that 
had Indicated the involvement of an amino-type intermediate. Another problem is the 
chemical mechanism of the reaction between the carboxylate form of the acceptor 
peptide and this intermediate to form the transpeptidation product. It is not trivial to 
develop a chemically plausible mechanism for this reaction. Hunkapiller and 
Richards^^ first suggested that the amino enzyme intermediate may not involve a 
covalent bond, but did not propose a non-covalent mechanism for the hydrolysis. 
They instead proposed an acyl intermediate of the type discussed below. As the 
difficulties with the amino enzyme mechanism grew and other transpeptidation 
activity was discovered attention was turned to a different mechanism.
1.3.1.2 The acyl enzyme mechanism
The observation of acyl t r a n s p e p t i d a t i o n S f  indicated that the 'acyl enzyme' should 
exist, just as amino transpeptidation had suggested the existence of an ‘amino 
enzyme’ intermediate. Acyl transpeptidation involves the transfer of the amino 
portion of the substrate to a suitable peptide acceptor.
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HgN-Z + H2N-X-CONH-Y-CO2H ^  HgN-X-CONH-Z + NgN-Y-COgH 
Scheme 1.3.4: Acyl transpeptidation
An acyl intermediate was proposed as the central intermediate in acyl 
transpeptidation. This hypothesis was supported by the work of Akhtar et al.^^ Their 
results from trapping experiments using tritiated methanol and their observation of a 
covalently bound intermediate in the hydrolysis of Cbz-Tyr-pH]Tyr were consistent 
with an acyl intermediate. However, these experiments proved to be irreproducible 
and were later retracted.^^ The overall pathway of hydrolysis involving a covalent 
acyl intermediate (E-CO-O-CO-X) is outlined below in Scheme 1.3.5.
ki k2
E-CO2H + X-CQ-NH-Y— E-C02H[ X-CO-NH-Y] E-CO-O-CO-X
k_i k_2 +
Y-NH2
^3
E-CO-O-CO-X + H2O E-CO2H + X-CO2H
k-3
Scheme 1.3.5: Acyl enzyme hydrolysis 
where E represents the enzyme
Acyl transpeptidation occurs, instead of hydrolysis, when the acyl intermediate is 
intercepted by a free amino group, from either the substrate or another peptide. The 
mechanism of formation of the acyl intermediate (see Scheme 1.3.6 below) is much 
simpler than the mechanism for the amino intermediate formation.
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X—c
NH-Y X
“ • ^ 0  o + HgN-Y
Scheme 1.3.6: The acyl enzyme mechanism 
where E represents the enzyme
Hunkapiller and Richards^® suggested that this acyl intermediate may then react 
with the freed amino group of HgN-Y to form the covalent amino intermediate 
discussed above. Hence, this intermediate was proposed to be central to both acyl 
and amino hydrolysis and probably therefore to the acyl and amino transpeptidation 
mechanisms.
Acyl transpeptidation reaction products were observed In some cases to give much 
higher yields than the corresponding hydrolysis, indicating that covalent (acyl) 
intermediates may also be required in the hydrolysis process. The experiments of 
Newmark and Knowles^"* on [^^C]Leu-Tyr-pH]Leu showed that both amino and acyl 
transpeptidation occurred simultaneously with this substrate (though acyl 
transpeptidation dominated). They concluded that the relative importance of acyl and 
amino transfer probably depended only on the ease with which the amino and acyl 
portions leave the active site after hydrolysis. A common "intermediate” for both 
hydrolysis pathways is implicit in this suggestion, possibly the acyl intermediate 
shown above.
As for the amino intermediate, the postulated acyl intermediate in the acyl transfer 
could not be trapped with nucleophiles such as hydroxylamine®® and methanol.^^^ 
A somewhat perplexing observation is the lack of either kind of transpeptidation with 
peptide substrates larger than about 7 residues. If covalent intermediates are 
involved in the hydrolysis of both large and small substrates, there being no reason 
to suppose that there is a d ifferent mechanism for the large substrates, 
transpeptidation would be expected. Antonov^® suggested that the lack of (amino) 
transpeptidation observed with a particular substrate was due to an increase in the
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rate of decomposition of the amino enzyme intermediate. It was proposed that the 
larger substrates give less stable covalent intermediates that are hydrolysed before 
they can be trapped by a suitable peptide acceptor. Rich^^ proposed that 
transpeptidation arose due to a slow, structure-dependent release of products from 
the active site. This idea was further developed by Antonov,^® who calculated a 
dissociation constant for the enzyme-product complex that is consistent with the rates 
of transpeptidation seen (see below). Thus, the large substrates may be lost from the 
active site more rapidly than the smaller substrates or, again, that the covalent 
intermediates are less stable for large substrates.
More recently transpeptidation studies®® have been used to investigate the 
incorporation of ^®0 -label into substrate and transpeptidation products from H2^®0 . 
Extensive ""^O-label incorporation into early transpeptidation products challenges 
the suggestion®® that the incorporation could be due to secondary reactions in the 
long incubation tim es used by Antonov.®® Thus, these experim ents on 
transpeptidation provide support for a non-covalent mechanism (see below). The 
authors also found®® that in H2^®0 only one ^®0 atom was incorporated into the 
oxygens of the carboxyl group of the C-terminal cleavage product, which implies that 
the amide cleavage reaction is irreversible.
Other studies on transpeptidation by porcine pepsin have been undertaken by 
Hofmann et a/.®® Only acyl transpeptidation products were observed and then only 
after a lag of some minutes, possibly due to a requirement for the dipeptide 
substrates to bind productively before transpeptidation and release could occur. It 
was pointed out by Silver and James®"* that a lag in formation of transpeptidation 
products is incompatible with the formation of an acyl-enzyme intermediate that is 
subsequently trapped by a suitable acceptor formed during catalysis. This is 
because if the acyl enzyme intermediate was formed the transpeptidation products 
should have begun to appear immediately, with no lag.
The only piece of unequivocal evidence in favour of acyl intermediates in aspartic 
protease catalysis comes from the work of Kaiser®^ on sulfite ester hydrolysis. Here, 
the acyl intermediate could be trapped with hydroxy lamine. It was shown that the 
same active site is used for sulfite and peptide hydrolysis, but that only one of the 
active site aspartates was necessary for sulfitease activity.®^^ The mechanistic
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relevance of the observation of sulfitease activity to the physiological reactions of the 
aspartic proteases remains unclear.
1.3.2 Difficulties with the covalent mechanisms
Studies designed xo trap any covalent intermediates involved in catalysis by 
detection of "burst” release of products at low temperature®®-®® provided no 
evidence for a covalent intermediate with either pepsin or penicillopepsin. The same 
experiments also failed to trap any intermediates by low temperature dénaturation 
and precipitation. As has been pointed out previously®®^ any covalent intermediate 
must come after the rate-determining step, as all attempts to observe a "burst 
release” of product have failed.®^ This stands in contrast to the serine proteases 
where the detection of burst release of products provided good evidence for the 
existence of a covalent acyl intermediate.
The analysis of X-ray crystal structures of aspartic proteases complexed with 
transition state mimics has raised objections to the proposed covalent mechanisms. 
The active site cleft appears to be too small to encompass the acyl (or amino) 
intermediates required.®® However, any deductions based on static crystal structures 
must be assessed carefully, due to the large conformational changes that the 
aspartic proteases are observed to undergo during catalysis®® (see also®^).
A major part of the covalent mechanism hypothesis hinged on the kinetics of 
product release. However, it has been shown by stopped-flow fluorescence that the 
products of hydrolysis of good substrates leave the active site at the same time.®® 
Thus, with relatively poor substrates the interaction of the two products may be 
coupled such that the nature of one influences the rate of departure of the other, 
giving rise to an apparently ordered loss of products. This coupling probably occurs 
through effects on the conformation of the active site and does not relate in any way 
to the chemical mechanism.
The key experiments that have most conclusively refuted the possibility of a 
covalent mechanism have come from the work of Antonov®® and Rich.®® Using 
pepsin Antonov studied the incorporation of '*®0-label into uncleaved substrate and 
transpeptidation products from H2^®0 . The results were only consistent with a non-
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covalent, nucleophilic water mechanism. Antonov also showed that there Is no 
incorporation of ^®0 -label into the active site carboxyl groups of the aspartic 
proteases during peptide bond cleavage.®®*^ Incorporation would be expected if 
either of the two covalent mechanisms outlined above were true, as hydrolysis of 
either of the covalent intermediates would lead to label becoming incorporated the 
active site carboxyls. Rich®® has investigated the spectra of inhibitors bound to 
pepsin, in one case®®^ using Isotope shifts induced by '*®0 from Hg^®0. He has 
shown direct evidence for the formation of a pem-diol tetrahedral intermediate at the 
scissile carbonyl. Both sets of results are incompatible with either covalent 
mechanism, as hydrolysis of either of the covalent active site species mentioned 
above would result in ‘*®0 -label incorporation into the active site carboxyls.
Another difficulty with the covalent mechanisms as presented was their inability to 
account of the observed electrophilicity of aspartic protease catalysis. There seemed 
no good rationalisation for the relative slowness of ester cleavage by the aspartic 
proteases compared to the serine proteases if the aspartic proteases were using a 
nucleophilic carboxylate in the cleavage of esters as well as amides. These 
mechanistic deficiencies and the consistent failure to directly confirm the existence of 
the covalent intermediates led to the suggestion that they may not exist.^® However, 
as was pointed out by Spector in a discussion of possible covalent intermediates in 
aspartic protease catalysis, "the absence of evidence is not evidence of absence".^"* 
Attention was then turned to the development of non-covalent mechanisms, based 
on the concept of the nucleophilic water molecule.
1.3.3 The nucleophilic water mechanism
The nucleophilic water mechanism or general base mechanism is now generally 
accepted as the correct mechanism for the aspartic proteases. In this mechanism an 
active site water molecule is deprotonated by the active site aspartate side-chain of 
lowest pKg and the nascent hydroxide ion then attacks the scissile carbonyl. The 
resulting tetrahedral intermediate then collapses to form the free acid and free amine 
hydrolysis products. The position of the water molecule in the active site and the 
nature of the residues involved in catalysis have been the subject of debate (see
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below), but the overall features of the mechanism are outlined in Scheme 1.3.7.
QP I
o ^ E - ^ o
HO"
Scheme 1.3.7: The nucleophilic water mechanism 
where E represents the enzyme
Exchange of a proton will regenerate the correctly protonated form of the active site 
aspartates.
A major challenge for any non-covalent mechanism is to explain transpeptidation. 
The principle of microscopic reversibility shows that formation of peptide bonds at the 
active site of the aspartic proteases must be possible. The synthesis of peptide 
bonds by pepsin is central to the operation of the activator peptides (see above). At 
neutral pH the overall equilibrium constant for the exchange of one peptide bond for 
another is around 1.®® Thermodynamically, therefore, there is no barrier to extensive
transpeptidation. Kinetically the situation Is less clear. It has been shown®® that the 
dissociation rate constant for the enzyme-product complex must be on the order of 
10 to allow time for an acceptor to be bound and an amide bond to be formed
between them. How this huge (10®-10^ fold) decrease in the dissociation rate for an 
enzyme-substrate complex is achieved is not known.
High resolution X-ray crystallographic studies on various aspartic p r o t e a s e s ^ ^  
show electron density located between the two active-site carboxyl groups. Most 
groups have ascribed this density to a water molecule, due to its constancy under 
various crystallisation conditions. It was therefore proposed that this water molecule 
is the lytic water molecule illustrated above. An alternative proposal, by James,
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postulated a different water molecule as the nucleophile (see Section 1.3.3.1).
Which of the two aspartates has the side chain of lowest pKg has been difficult to 
identify (see Section 1.2.3). It was wrongly assigned initially to Asp-32 on the basis of 
chemical labelling experiments. These were shown later to be faulty as different 
conditions produced different labelling patterns. James/® Newman et al7^ and 
Suguna etal7^^ have found that the electron density assigned to the water molecule 
at the active site was located slightly closer to Asp-32 than to Asp-215, indicating that 
Asp-32 was deprotonated. However, the same effect is not seen in other structures^® 
and the difference is only barely statistically significant in the structures in which it is 
found.
Theoretical approaches have been used in an effort to resolve this problem and 
early quantum mechanical calculations^® were ambiguous, some indicating a small 
preference for ionisation of either Asp-215^®  ^or Asp-32 ®^*^  in renin. Later studies^^ 
showed that the difference in energy between the two aspartates being ionised was 
small for the fungal proteases. Goldblum’^ ^® found a consistent preference for 
ionisation of Asp-32, in accord with the X-ray structure i n t e r p r e t a t i o n . ^ ^ b  However, 
Turi et al7^^  found a preference for ionisation of Asp-215, infiuenced by the 
protonation state of the adjacent Asp-307. The proton may therefore be shared 
equally by the aspartates i.e. it shuttles quickly back and forth between the two 
carboxyl groups, possibly by quantum mechanical tunnelling if the two inner oxygen 
atoms are close enough. The inter-oxygen distance is usually about 2.9 A in the 
crystal structures, but may vary greatly during the catalytic cycle. However, the path 
for proton transfer may not be simply along the line joining the carboxyls and may 
therefore have a high activation energy. Thus, some enzyme molecules may have 
Asp-215 ionised and the rest Asp-32 ionised, with the state changing with difficulty, if 
at all.
There are several mechanistic hypotheses based on the general base concept 
outlined above. They share some common features and differ over the same 
questions. The shared features are those central to the general base mechanism, the 
involvement of the active site aspartate dyad and a nucleophilic water molecule. The 
differences are found in:
i) the proposed protonation state of the tetrahedral intermediate.
ii) the timing of proton switches in the breakdown of this intermediate.
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iii) the direction of binding of the scissile carbonyl with respect to the aspartate dyad.
iv) the nature of the Bronsted/Lewis acid component.
The mechanisms will be listed, then examined and critically evaluated in turn. Six 
distinct hypotheses have been proposed by:
a) James, based on the high-resolution structure of penicillopepsin complexed to 
pepstatin.^®
b) Polgar, the so-called "push-pull" mechanism, involving simultaneous protonation/ 
deprotonation events in the formation and breakdown of the te trahedral 
intermediate.^®
c) Pearl,®® where binding of side-chains on both sides of the scissile bond causes 
rotation of the scissile amide bond out of planarity.
d) Blundell, postulating that the active site is evolved to stabilise a negative charge 
on one of the aspartates and not on the tetrahedral intermediate, as the other 
proteases are. "^*
e) D a v i e s , w h i c h  is a mechanism similar to Pearl’s.
f) Hammings,®2 in which the nitrogen and not the oxygen of the scissile bond is 
protonated prior to nucleophilic attack by the lytic water molecule. This mechanism 
has not yet been fully formulated and will not be discussed further.
1.3.3.1 The mechanism of James
James derives his mechanistic model from the analysis of a high-resolution X-ray 
structure of pepstatin (Figure 1.0 .1) bound to endothiapepsin. The analysis begins 
from a different point of departure to the other contending theories. In the course of 
heavy metal soaking experiments the site between the two active site carboxyl 
groups was found to be favourable for cation binding.^® It was considered unlikely 
that this site becomes occupied, even transiently, by a moiety that becomes 
negatively charged during the catalytic cycle. Thus, the electron density seen 
between the active-site aspartate side chains is said not to be a water molecule, but 
rather an ammonium or hydronium ion. He also stated that this group would be 
displaced by the scissile carbonyl oxygen of an incoming substrate molecule. He 
proposed that the nucleophilic water is the crystallographic water molecule 0-284,
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hydrogen bonded to the side chain of Asp-32 oniy. It lies out of the plane of the 
scissile carbonyl and the two active-site aspartates (and consequently closer to the 
required angle of attack on the scissile carbonyl of 109°). He presents the 
Bronsted/Lewis acid as the proton bonded to Asp-215, the proton donor as bulk 
solvent (or the side-chain of D-32) and 0-284 as the nucleophile. The scissile 
carbonyl thus points toward the active site aspartates.
The first step in the mechanism is the protonation of the scissile carbonyl by the 
proton shared between the two aspartates, possibly concerted with the attack on the 
scissile carbonyl by 0-284, deprotonated by Asp-32. The tetrahedral intermediate 
formed is neutral. Proto nation of the amine leaving group may occur by either of two 
routes. An inversion of configuration at the nitrogen wiil allow reprotonation from the 
bulk solvent, as shown below. Alternatively, a proton relay via Asp-215 from the 
innermost hydroxyl group of the pem-diol intermediate could be used. Nitrogen 
inversion is a very rapid process®®»®"  ^ so should have no effect on the rate of 
catalysis.
An important objection to the mechanism as proposed is that although the site 
between the active site aspartate residues is a cation binding site in the native 
enzyme this is not to say that this is a cation binding site during the catalytic cycie. 
Recent quantum mechanical calculations^^*^ have found that the more stable active 
site arrangement is for this moiety to be a hydronium ion, not an ammonium ion. 
However, the same study found that the most energetically favoured form for the 
active site is to bind a water molecule, not a hydronium ion.
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Scheme 1.3.8: The mechanism of James
The requirement for prior protonation of the scissile carbonyl is shared by acid- 
cataiysed water hydrolysis of amides (see Section 1.5). The pKgOf an amide oxygen
is around 0 to -2®^  so assistance by water attack may be required.
Another fundamental difficulty with this mechanism is that it is based upon a crystal 
structure in which the inhibitor is not congruent with a substrate. The pepstatin 
inhibitor binds in a manner that is most unlike that of a substrate, especially in the 
crucial P-i-P-j’ region. Its Pg' side-chain binds not in the 8 2 ' subsite, but the S-j’ 
subsite, due to a curl in the inhibitor backbone. More substrate-iike inhibitors do not 
show this deviation. Thus, detailed deductions about substrate binding and 
conformation based on this structure are difficult to make confidently. Other crystal 
structures with inhibitors that are more congruent with peptide substrates also show 
that the proposed nucleophilic water, 0284, is displaced by the P^  side c h a i n .
Very recently this mechanism has been retracted in the light of close examination of 
crystal structures of penicillopepsin binding difluorostatine-based inhibitors.®^ In this 
paper James proposes a mechanism essentially identical to that of Davies ‘(see 
1.3.3.5).
In all the mechanisms discussed below the nucleophile is considered to be the
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water molecule hydrogen-bonded between the active site aspartates.
1.3.3.2 The mechanism of Polgar
Polgar’s push-pull mechanism involves a series of simultaneous proton transfers, 
as shown in Scheme 1.3.9, with the active site dyad of aspartates acting as a 
functional unit. He presents the Bronsted/Lewis acid as the proton bound between 
the active site aspartates and the proton donor as D-215. This requires the scissile 
carbonyl to point toward the active site aspartate residues.
The mechanism proceeds as follows. First, deprotonation of the nucleophilic water 
molecule by D-32 and attack on the scissile carbonyl is paraleiled by protonation of 
the scissile carbonyl oxygen to give a neutral gem-diol intermediate. Subsequent 
deprotonation of this tetrahedral intermediate and reformation of the carbonyl group 
is synchronous with C-N bond cleavage and proto nation of the leaving group 
nitrogen. The requirement for the scissile carbonyl to point toward the aspartate dyad 
means that, if the scissile amide is planar, the nucleophilic water molecule will be 
displaced. However, if the scissile amide is distorted from planarity then there is 
available space for the water molecule to remain bound between the aspartate side- 
chains. Hence, it bears a close resemblance to the mechanism advocated by Pearl 
in Scheme 1.3.3.3 below.
Both parts of this mechanism are symmetrical, as both are facilitated by push-pull 
general acid catalysis.
25
Asp 32
L o
R’HN,
Asp 215
Asp 32I
Asp 32
H— O, OHXR'HN
Asp 215 Asp 215
Asp 32
0 = 0I0
1H
OI: -Q m O  
Asp 215
uA,
+
HgNR'
Scheme 1.3.9: The mechanism of Polgar
1.3.3.3 The mechanism of Pearl
The key part of the mechanism of Pearl Is the distortion of the scissile peptide bond 
on binding, leading to a reduction of scissile amide bond resonance. He presents the 
Bronsted/Lewis acid component of catalysis as hydrogen bonds from residues in the 
flap (Gly-76 and possibly Tyr-75 in pepsin) to the scissile carbonyl and the proton 
donor as Asp-215. In this mechanism the scissile carbonyl points away from the 
active site aspartates and the tetrahedral intermediate carries a negative charge, 
which is stabilised by hydrogen bonds from the flap.
Reduction of amide resonance increases the electrophilicity of the scissile carbonyl 
and the basicity of the amide nitrogen. Increasing the carbonyl electrophilicity 
increases the rate of tetrahedral Intermediate formation and increasing the basicity of 
the amide nitrogen increases the rate of breakdown to products. As mentioned 
above an important feature of aspartic protease-catalysed peptide hydrolysis is the 
marked increase of k^ ^^  with the length of the peptide, with little or no change in 
This mechanism was developed to account for these observations.
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1The extra binding energy available from the secondary binding of substrate side- 
chains is utilised to lower the activation energy of the reaction by distorting the 
scissile bond from planarity. The enzyme therefore destabilises the ground state of 
the reaction. It is likely that strain is transmitted through the enzyme rather than 
through the substrate, that is the binding pockets containing the side-chains move 
relative to each other. A similar proposal was first made by Fruton some 20 years
earlier.®^
This model has received a measure of experimental support, with several inhibitors 
having been found to have their scissile bond mimics distorted from planarity. 
Reduced peptide based inhibitors of rhizopuspepsin^^^»^ and the HIV-1 protease®^ 
show the scissile bond mimic to be significantly twisted from planarity. Distortion has 
also been observed in residues flanking the scissile bond®^ in other classes of 
inhibitors. It is known that distortion of an amide group from planarity greatly 
increases the susceptibility of the carbonyl to nucleophilic attack by hydroxide 
ions,^^ as well as increasing the basicity of the nitrogen.^^
Pearl also suggests that the oxyanionic tetrahedral intermediate is stabilised by an 
interaction with the edge of the aromatic ring of Tyr-75, which is conserved in all 
mammalian and fungal proteases so far sequenced.21 Thus, this mechanism also 
postulates some similarities between the serine and the aspartic proteases. This 
interaction between an oxyanion and the aromatic ring was suggested by Blundell 
as a possible mechanism for stabilisation of the oxyanion intermediate.^^ It has been 
estimated^^ that this kind of interaction can stabilise the oxyanion by as much as 5 
kcal mol"’’ . However, while Tyr-75 is invariant in monomeric aspartic proteases it is 
absent in retroviral proteases,®"^ so it is unlikely to be a pivotal feature of the 
mechanism of all aspartic proteases. Also, Suguna et al7^^ could not model the 
proposed hydrogen bond between NH of Gly-76 in the flap and the scissile carbonyl.
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Scheme 1.3.10: The mechanism of Pearl
1.3.3.4 The mechanism of Blundell
The mechanisms of Blundell and Polgar share the important point that the 
tetrahedral intermediate is neutral I.e. protonated, and a function of the aspartate pair 
is to facilitate this proto nation and subsequent deprotonation. However, Blundell 
sees little similarity between the mechanisms of the serine and aspartic proteases.
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particularly with respect to the existence of an oxyanion hole. This is of central 
importance in the serine, cysteine and metalloproteases and a number of 
mechanisms have implicated a similar structure in the aspartic proteases.
D - 3 2
R1-CO2H + HgN Rg
O O'
"O H-
D - 3 2
D - 2 1 5
■O'
D - 2 1 5
H o.
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\ 'O
D - 2 1 5
D - 3 2
D - 3 2
Scheme 1.3.11: The mechanism of Blundell
The key point is the inversion at nitrogen followed by rotation about the C(0 H)2-N 
bond to allow protonation from D-215. This serves the dual purpose of destabilising 
the tetrahedral intermediate by removing a hydrogen bond and activating the amine 
leaving group by protonation. The ionisation states of the aspartates shown are 
supported by a quantum mechanical study on a model system^® showing that 
deprotonated D-32 is around 5 kcal mol'"* more stable than the alternative, 
deprotonated D-215. There is no direct electrophilic activation in the mechanism, in 
contrast to the mechanisms of Pearl and James. The lack of electrophilic activation 
by protonation (as in the mechanism of James) is supported by quantum mechanical 
studies^® showing that the distance between the scissile carbonyl and the proton of 
D-215 is too large for significant interaction. However, the same study indicated that 
there is no possibility of nitrogen being protonated from D-215 during the breakdown 
of the tetrahedral intermediate as they are too far apart. Rotation about the bond
29
bearing the carboxyl group of D-215 is required first.
The hypothesis states that the aspartic proteases stabilise the negative charge 
formed during the cleavage reaction by localising it on the aspartate pair and not on 
the tetrahedral intermediate as the serine, cysteine and metalloproteases do. This 
was considered to be supported by the observation of frequent replacement of S-218 
(in pepsin numbering) by Ala in the aspartic proteases of a higher pH optimum, e.g. 
renin and HIV-1 PR. This replacement means that the anion on D-32 is less 
stabilised by hydrogen bonding and so the optimum pH of an aspartic protease with 
Ala at position 218 will be higher as the anion is more difficult to stabilise at lower 
pH. This assumption was supported by semi-empirical calculations from the group of 
Goldblum®^ on the HIV-1 protease active site. However, recent work by Lin etal.^^'^^ 
has shown that this is not so (see Section 1.2.3), replacement of the serine/threonine 
residue after the D-T-G active site triplet in pepsin and rhizopuspepsin by alanine 
has no effect on the pH-rate profile of either enzyme. Thus, this mechanism too has 
little experimental support.
1.3.3.5 The mechanism of Davies
The mechanism of Davies bears a close resemblance to that of Pearl. The 
intermediate is postulated to be an oxyanion, stabilised by a hydrogen bond from the 
OH of D-32. However, the electrophilic component here is provided by hydrogen 
bonds to the scissile carbonyl oxygen from OH of D-32 and OH of S-38 and not by 
residues in the flap. The. proton donor is D-218, the lone pair on the nitrogen is 
localised, pointing toward it, by a weak hydrogen bond from the carbonyl of the P2 
residue to the NH of the scissile bond (not shown below).
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Scheme 1.3.12: The mechanism of Davies
Which of these mechanisms most truly reflects the chemistry occurring at the active 
site of the aspartic proteases has important ramifications for the design of inhibitors. If 
the tetrahedral intermediate is negatively charged then anionic inhibitors should be 
tightly bound. However, if the intermediate is neutral then anionic species will be 
poorly bound and uncharged inhibitors will function best. This point is discussed 
further in Section 1.6.3.
1.3.4 importance of the S3 site
Holladay et al.^^ reported that the occupation of the S3 subsite in pepsin is 
necessary for the release of transpeptidation products, thus transpeptidation may 
only occur with (small) substrates that do not occupy the S3 subsite. The observed 
delay in release of transpeptidation products noted above may thus be caused by 
the time needed to build up the substrate by transpeptidation to such a size that it 
can occupy the S3 subsite. The importance of interaction of the substrate with the S3 
site is underlined by the approximately 500 fold increase in k^g^for substrates having
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a P3 residue compared with otherwise Identical substrates lacking the P3 residue (at 
constant This could be due to distortion of the substrate, non-productive
binding of a shorter substrate or a conformational change in the enzyme that results 
in more efficient catalysis. Non-productive binding does not affect k^a/Ki^ when 
Michaelis-Menten kinetics are obeyed, as they are for the aspartic proteases, so this 
is not a valid explanation. The idea that a conformational change is involved is 
supported by the observation of multistep binding for inhibitors with a P3 residue and 
single step binding for those without.^®® The same effect is seen in the difference in 
Kj values between the pepstatin analogues shown below, where the statine residue 
(Sta) occupies the S^' pocket.
Table 1.3: Inhibition constants for statine based inhibitors of varying size
Iva-Val-Sta-OEt K,> lO ^lvi
II I va-Val-Val-Sta-OEt K, = 2.4 x 10 '® M
III Iva-Val-Val-Sta-Ala-laa K,= 6.5x lO'® M
IV Iva-Val-Sta-Ala-laa K| = 7.6x10'®M
Analogue II has a isovaleryl (Iva) residue at the P3 position and this difference 
gives rise to the four order of magnitude increase in inhibition over analogue I. 
Similarly for III and IV, occupation of the S3 pocket increases the inhibition of 
penicillopepsin around 3 orders of magnitude.
The most important residue for substrate binding in the S3 pocket is Thr 218 (in 
pepsin numbering), which is conserved as Ser or Thr in every monomeric aspartic 
protease so far sequenced.^"* It accepts a hydrogen bond from the amide NH of the 
P3 residue and donates a hydrogen bond to the CO of the P3 NH,®® so these 
hydrogen bonds are likely to be constant for all substrates. In renin these interactions 
are a b s e n t , so the occupation of the S3 pocket will be less important. The amount 
of hydrophobic interaction the P3 side-chain makes with the S3 pocket is 
v a r i a b l e , s o  the effects of binding a side-chain in the S3 pocket must arise
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from the hydrogen bonds formed. It may be that formation of these hydrogen bonds is 
important in triggering a conformational change that facilitates cleavage or loss of 
product.®® This conformational change may be the rigid body movement observed in 
some crystal structures of aspartic proteases complexed with inhibitors (see Section
1.4.1).
The importance of the S3 site is further demonstrated by the observation that 
certain substrates will change their binding mode and shift the scissile bond if that
places a residue in the S3 pocket.®® Thus, Ac-Ala-Lys-Phe(N0 2 )-(Ala)2-NH2 
incubated w ith pen ic illopepsin  w ill be cleaved between the Phe(N 0 2 ) 
(nitrophenylalanine) and Ala residues and not the favoured cleavage site between 
Lys and Phe(N0 2 ) as this ensures that the S3 pocket is filled by the Ala side-chain. 
This drive to occupy the S3 site may explain the phenomenon of the activator 
peptide, a small non-substrate peptide that, when added to an incubation, increases
the rate at which a substrate peptide is cleaved.^®® The peptide may either form a 
transient condensation product with the substrate or may simply occupy the S3 site 
while the substrate occupies S  ^ and S-j’. In either case a species that occupies the
S3 site is central to the action of the activator peptide. Silver and James'*®®^ showed 
that the key step in activator peptide function is pepsin catalysed condensation of the 
activator and substrate peptides. The resulting large peptide is then cleaved at a 
different bond, much more rapidly than the substrate peptide. This implies an as yet 
unexplained difference in specificity for synthesis and cleavage of peptide bonds by 
monomeric aspartic proteases.
1.3.5 Solvent isotope effects
The nucleophilic water proposal leads obviously to the use of solvent deuterium 
isotope effects to probe the mechanism. Early experiments using this technique gave 
very varied results and were of little use in untangling the important steps in
catalysis. The early work found no isotope effect”*®® using small peptides and phenyl
methyl sulfite. However, an effect was found using (Gly)3-Phe(N0 2 )-Phe-0 Me.‘*®^
Hunkaplller and Richards®® also found a large (3.0) solvent isotope effect (on V^gx 
and not K^) in the hydrolysis of N-trifluoroacetyl-L-phenylalanine by pepsin, the 
largest so far reported.
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Recently, Cunningham et a//®® found a different rate-determining step in the 
cleavage of large and small substrates, leading to solvent isotope effects that vary 
with the size of the substrate. They observed no isotope effect on the cleavage of Ac- 
Lys-Phe(N0 2 )-NH2 and an isotope effect on V^gx 2.1 on the cleavage of Ac-Ala- 
Ala-Lys-Phe(N0 2 )-Ala-Ala-NH2. Proton inventory studies showed that two or more 
protons were involved in the rate-determining step for the large substrate. This step 
was proposed to be the formation of two hydrogen bonds at the S3 subsite (and 
possibly at the 8 3 ’ site also). Significant conformational changes were observed, by 
fluorescence, during the cleavage of the large but not the small substrate, which they 
suggested was the rigid body movement observed by Sali."*®® This movement may 
be triggered by the occupation of the S3 site and the formation of the hydrogen 
bonds between substrate P3 NH and Qt T-218 and P3 CO and NH T-218. However, 
this is not consistent with the solvent isotope effect observed for the small substrate 
N-trifluoroacetyl-L-phenylalanine, which cannot occupy the S3 site. The rate 
determining step for the small substrates was postulated to be the loss of products.
More recent experiments on renin,"*®® pepsin"*^® and chymosin^'*'* have shown a 
solvent isotope effect on V^g^ but not on V^gy/Kj^  ^with a series of hexapeptide or 
larger substrates. isotope effects involve all steps after substrate binding, while 
Vmax/^M effects relate to all steps before the first irreversible step. As the effect is on 
Vmax only and transpeptidation shows that catalysis is readily reversible (see Section
1.3.1), the isotopically-sensitive step Is likely to be the release of the first product. 
This is in accord with the (partially) rate-determining step being product release, as 
was proposed from transpeptidation experiments. This analysis is at variance with
the picture of aspartic protease catalysis put forward by Fruton,®®^ where a rapid 
equilibrium model is proposed i.e. all the steps along the catalytic cycle are in 
equilibrium with each other.
1.3.6 Summary
The mass of data accumulated on various aspects of aspartic protease structure 
and mechanism has not been matched by a development of theories to underpin the 
data. A chemical mechanism very similar to that of Blundell®"* describes well the 
structural side of the aspartic protease mechanism and has some theoretical support. ^
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However, this mechanism does not explain several aspects of aspartic protease 
catalysis, most notably the origin of the solvent isotope effects and transpeptidation, 
as it has no kinetic component. A major difficulty in this area is the lack of good 
experimental support for any of the proposed mechanisms.
The mechanism of Blundell suggests that the tetrahedral intermediate in hydrolysis i%is neutral and this is borne out by quantum mechanical calculations.®^ This neutral 
intermediate is also the central intermediate in acid-catalysed amide hydrolysis (see 
Section 1.5). However, in contrast to the enzymic reactions shown above, the acid- 
catalysed mechanism requires the departing nitrogen to be fully protonated before 
the tetrahedral intermediate begins to break down.
1.4 Structure of the aspartic proteases
The first crystalline protein analysed by X-ray crystallography was pepsin'*'*® and 
since then X-ray crystal structures have been reported for a large number of the 
aspartic proteases. Penicillopepsin,^'*® rhizopuspepsin,^®^ endothiapepsin,'*®®»'*'*^ 
pepsin,"*^® pepsinogen,^chymosin,'*"'^ mucorpepsin"*"*® and renin"*"*® have all had 
their structures solved at high resolution. These crystal structures have revealed 
many interesting features in the global structure and the active sites of the aspartic 
proteases.
It is conventional to describe the aspartic proteases as being folded into two 
structurally similar lobes, an N-terminal lobe and a C-terminal lobe. The lobes are 
related by a pseudo-dyad axis running between the two active site aspartate 
residues and between the two central strands of a large six strand 6-sheet that 
constitutes the core of the enzyme. However, since the interface between the lobes 
consists of a six strand 6-sheet, the structures could well be described as being 
made up of two mainly 6-sheet domains packed onto the interlobe 6-sheet with a 
small a-helix at each end. There are also some other small a-helical portions, but 
these are not well conserved between the different proteases. The a-helical 
segments are in variable positions within the structures and move to accommodate 
changes in crystal packing. They do not, therefore, seem integral to the structures."*®® 
The N-terminal lobe (residues 1-171) is the larger of the two domains and has a
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more extended structure than the C-terminal lobe (172-326 in pepsin). Within the 
lobes there are 2 regions forming compact domains possessing an intra-domain axis 
of symmetry, the C-terminal domain (S 185 to R 307, 123 residues) and the N- 
terminal domain (E 7 to Q 148, 142 residues) for rhizopuspepsin. The intra-domain 
dyad axes are approximately coplanar with the inter-lobe axis and are roughly 
related by it. The domains may be the remnant of the original structure of an 
ancestral protease that underwent two gene duplications to give the four part 
structures seen today."* There is a long (25-30 Â) cleft between the lobes that 
contains the active site. The two catalytic aspartates are located at the end of two psi- 
type loops that extend from each domain into the cleft and are related by the pseudo­
dyad axis."*®® The two aspartate residues are coplanar and rigidly held by an 
extensive network of hydrogen bonds, both inter and intra domain, including the 
unique ‘fireman’s grip’."*®® This refers to the hydrogen bonding between the two 
conserved hydroxy-amino acids in the active site sequence Asp-Thr-Gly-Ser/Thr, 
each hydroxyl group hydrogen bonding to the other's amide nitrogen (see Figure
1.4.1). The resulting rigidity is reflected in the low isotropic temperature factor (B 
factor) for the active site residues of chymosin, averaging 12Â®, compared to the 
average of 24 Â® for the whole molecule."* "*®
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Figure 1.4.1: The '‘fireman’s grip” in pepsin^
As shown below (Figure 1.4.2) the remainder of the active site is also extensively 
hydrogen-bonded, resulting in the entire active site being extremely rigid. This 
combination of conserved sequence and high levels of hydrogen bonding means
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that the active sites of many of the aspartic proteases have very similar three- 
dimensional structures. Sielecki ef a/."*®® found an r.m.s. difference of only 0.24 Â 
between 105 main chain atoms from the active site of three fungal proteases and a 
0.45 A difference between these three enzymes and human renin.
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Figure 1.4.2: The hydrogen bonding network at the active site 
of rhizopuspepsin^^^
The overall fold of the aspartic proteases is shown in Figure 1.4.3 overleaf.
1.4.1 Structures of aspartic proteases with bound inhibitors
These structures have shed much light on the binding mode of substrates and their 
interactions with the active site and the changes induced in both enzyme and 
substrate upon binding. The nature of the changes in the structures of the aspartic 
proteases on binding of inhibitors (and by extension substrates) and the relation of 
these changes to catalysis was for some time not well understood. The first high-
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Figure 1.4.3: The overall fold of the monomeric aspartic proteases
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resolution structures with bound inhibitors showed several interesting features of the 
binding. There is a stretch of antiparallel p-sheet between residues P3 and of the 
inhibitor and residues 217-219 of the C-terminal lobe of the enzyme. There is no 
equivalent structure in the N-terminal lobe, with the only hydrogen bond formed 
between P2 ’ NH and the carbonyl of residue 34. Also observed was the large 
movement of a region known as the f l a p . ‘*24 This 3-hairpin bend structure (residues 
72-81 in rhizopuspepsin) folds over the active site, shielding the active site from 
solvent and providing further binding interactions to the inhibitor. The P^  and P-j’ 
residues of the inhibitor are totally shielded from solvent as a result of this 
movement.^9 The main hydrogen bonding interactions between a peptidic inhibitor 
and the monomeric aspartic proteases are shown in Figure 1.4.4 below.
Thr 219 Gly 217 Gly 34
Asp 77 Gly 76 Ser 74
Figure 1.4.4: Hydrogen bonding pattern between the main-chain of an inhibitor and
endothiapepsin'^^'^ 
where W3 is a water molecule.
The extended conformation of the inhibitor seen in the X-ray structures above is 
reflected in inhibitor conformations observed in n.m.r. studies on inhibitors bound to 
p e p s i n . T h e  importance of the flap can clearly be seen from the above diagram as 
residues D-77, G-76 and 8-74 are all from the flap and provide three strong
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hydrogen bonds to the inhibitor main chain. The formation of these hydrogen bonds 
provides part of the driving force for flap closure. The amount of movement of the flap 
observed on inhibitor binding varies greatly between structures. The differences 
arise from the different initial flap positions in the unliganded proteases, caused by 
different packing interactions between enzyme molecules in the crystal. The flap is 
observed to be highly mobile in the unliganded structures (B value around 30 Â^), 
becoming much more ordered on closing over the active site (B value about 8 
Â2).126 The wide-ranging nature of the conformational changes is also seen in 
circular dichroism studies of pepsin interacting with pepstatin.
There are other structural changes observed in some structures, apart from the 
closure of the flap. There have been reports of independent, rigid body motion of 
subdomains within the structure that are triggered by inhibitor binding. The 
movement of residues 190-303 of endothiapepsin when complexed with a reduced 
peptide inhibitor observed by Sali e t al.^^ was the first reported example. The same 
domain in pepsin was also reported to move as one rigid body, but in a very different 
fashion, by Abad-Zapatero etaL'^^^ Later studies by the same group on glycol-based 
inhibitors of p e p s in ^ sh o w  a similar domain movement to that found by Sali etaL^^ 
This domain can be easily seen in the comparison of X-ray structures of unliganded 
with liganded proteases^^® where it is the point of most divergence between the 
different structures.
This flexible domain aligns well between various structures only if it is allowed to 
move independently of the rest of the protein. This division of the structure accords 
with the tripartite division of the aspartic protease structure discussed above, as the 
C-terminal residues 190-303 correspond to one rigid body and the other rigid body 
corresponds to the central motif and the N-terminal domain. The triggering of a rigid 
body movement was referred to above (Section 1.3.5) as the possible rate-limiting 
step in catalysis. This rigid body movement may provide the means for scissile bond 
distortion postulated by many of the mechanisms discussed above. The residues of 
the flexible domain are used to bind side-chains P^’, P2 and P4 , and the otber 
domain binds the other side-chains. Therefore, movement of the N-terminal domain 
relative to the C-terminal domain, will distort one set of side-chains relative to the 
other. This may distort the scissile bond from planarity as the P^  and P-j’ residues
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flanking the scissile bond are bound by the different domains. Curiously, a 
corresponding change in enzyme fluorescence is not o b s e r v e d , ^ a s  would be 
expected for such a structural readjustment. A rigid body movement has also been 
postulated in the mechanism of the serine proteases.
There seems to be little effect of inhibitor binding on the structure of the active site 
region, the aspartate residues remaining almost completely fixed. This is consistent 
with the rigid active site, reflected in the low B values and extensive hydrogen 
bonding, discussed above. The only movement seen is some disruption of the 
coplanarity of the aspartates.®^
1.5 Modei systems
The daunting complexity of the reactions catalysed by the aspartic proteases has 
led some investigators to the use of small molecule model systems to try and 
illuminate the nature of the chemical steps in the catalysis by aspartic proteases. The 
earliest efforts, by Bender et focussed on the intramolecular hydrolysis of
phthalamic acid and this data was later used as the basis for a mechanistic proposal
for the aspartic p r o t e a s e s . A  similar system, N-/so-propyl di-/sopropylmaleamide, 
was later explored by Kirby ef
.CONHiPr
‘COoH
Figure 1.5.1: N-isoPropyl di-isopropylmaleamide
For a particular carboxyl substituted maleamide the pH-rate profile and the rate 
constant for hydrolysis were found to be comparable to those for pepsin acting on 
small peptide substrates. However, only when the carboxy group and the amide 
were in a specific structural relationship did this effect manifest itself. The relevance 
of this observation to the mechanism of pepsin and the other aspartic proteases was
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not further explored.
The low efficiency of intramolecular general base catalysis was demonstrated in 
further work by K i r b y o n  the hydrolysis of monoaryl malonates and aryl hydrogen 
cyclopropane 1,1 dicarboxylates. Intramolecular general base catalysis is also much 
less efficient in water than nucleophilic c a t a l y s i s . These studies would seem to 
indicate that the aspartic proteases should utilise a nucleophilic type mechanism in 
order to attain the observed rate enhancements for peptide hydrolysis. However, 
intramolecular general base catalysis is expected to be proportionately much more 
efficient in low polarity environments, such as an enzyme active site.^®^ The work of 
Gandour^®® has shown that the reactions of the model compounds used in chemical 
studies all involve the use of anti lone pairs which are much less basic than the syn  
lone pairs. Examination of crystal structures indicates that enzymic catalysis uses 
syn lone pairs.®® The anti lone pairs of the catalytic aspartates are involved in 
hydrogen bonds, leaving the syn lone pairs for involvement in proton transfers during 
catalysis.
O
R ' "OIH
Syn Anti
Figure 1.5.2: Syn and anti carboxyl groups
Kluger and Chin”*®® studied the effect of pH and leaving group on the 
intramolecular hydrolysis of a variety of maleamic acids and found that the nature of 
the rate determining step was strongly dependent on the basicity of the departing 
amine. A mechanism was proposed based on the observation that the rate- 
determining step for hydrolysis of amides of highly basic amines is diffusion apart of 
the amine and the maleic anhydride. It accounts for both acyl and amino 
transpeptidation by postulating a series of covalent intermediates that permit the 
escape of products at appropriate times in the catalytic cycle.
Such systems would seem, in some cases fortuitously, to be attractively simple 
models for the tightly fixed nature of the two aspartate side chains in the active site of
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the enzymes shown in the X-ray crystal structures (see above). All the above studies 
have found that an anhydride is formed, in some cases transiently, between the two 
carbonyls as a final step in the intramolecular catalysis. Analogously, it was 
proposed that an active-site anhydride is formed between the two aspartate side- 
chains in the last step in the catalysis by the aspartic proteases. This has been 
shown not to be so by the studies of Antonov®® on ^®0-label incorporation Into the 
active site aspartates. Thus, these types of model studies have contributed little to 
our understanding of the mechanism of the aspartic proteases.
More recently, model studies have been undertaken on a group of strained bicyclic 
amides by the group of Brown. These have been proposed as models for peptide 
hydrolysis by the serine,cysteine"*®® and aspartic proteases.^®®
n = 1 or 2 : m = 1 or 2
Figure 1.5.3: The strained amides of Brown
In these compounds the nitrogen lone pair is twisted out of the plane of the 
carbonyl group by varying amounts, increasing with decreasing n and m. The degree 
of twisting (or the pyramidalisation of the nitrogen) correlates with the rate of 
hydrolysis by both acid and base, but only to a certain point.^h This is intuitively 
satisfying as it would be expected that twisting of the lone pair out of conjugation with 
the adjacent carbonyl would decrease amide resonance dramatically (see Section
1.4.1.3). After a certain angle of twist is reached there is no more stabilisation to be 
lost and so no more rate increase would be observed. Similar results have been 
obtained by Antonov"*using  quantum mechanical calculations, which showed a 
linear relationship between the pKg of the amide nitrogen and its degree of 
pyramidalisation. The acid-catalysed hydrolysis of amides is controlled by both the 
rate constant for H2O attack on the protonated amide (A-H+) and by the extent of 
protonation.■*'^‘* The greater the distortion the greater the value of the kinetic pKg for 
A-H+. This has been in te r p r e te d ^  ^2 qq providing evidence for water attack on an N -
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protonated form. This is in accord with the mechanism proposed by Hemmings, in 
which protonation occurs on the scissile bond nitrogen prior to nucleophilic attack by 
a water molecule on the amide carbonyl. The thermodynamic site of protonation is 
undoubtedly the nitrogen atom, but there could be a "greater degree of involvement 
of H2O attack on O rather than N-protonated amides."^
Thus these studies also provide support for Pearl’s proposal of substrate distortion 
being a key part of the catalytic armoury of the aspartic proteases. However, once 
again hydrolysis of these amides is, unsurprisingly, most efficiently catalysed by 
dicarboxylic acids that can form anhydrides readily."*®®*  ^ They would therefore 
appear to have have little relevance to current thinking on aspartic protease 
catalysis.
1.6 Introduction: The Human Immunodeficiency Virus-1
1.6.1 HIV-1 and Its target cells
The human immunodeficiency virus (HIV) is a pathogenic human retrovirus, 
carrying its genetic material as a single positive strand of RNA. Two related strains of 
the virus have been identified, HIV-1 and HIV-2 , of which HIV-1 is both more 
widespread and more pathogenic in man. They are members of the lentivirus 
subclass of retroviruses (reviewed in'•43). As such they share some similarities with 
the archetypal lentivirus, the visna virus of sheep e.g. it is cytolytic and immune 
disruptive. They are, however, much more similar to the primate lentiviruses, 
displaying the same life cycle and mechanisms of toxicity (single cell lysis and 
syncytium f o r m a t i o n ) ."• 44 HIV has been identified as the aetiological agent in 
acquired immune deficiency syndrome, A I D S . ^ 4 5  
Those cells that express the CD4 molecule (CD4+ cells) on their surface, which 
binds to the viral coat protein, gp 120 ,'•43 are vulnerable to HIV infection. The 
function of CD4 will be discussed below. The specificity (tropism) for CD4 is 
bestowed by various parts of the viral envelope p r o t e i n . '•47 However, small changes 
in and around the V3 loop of gp120 (the principal neutralising determinant of HIV) 
can greatly alter the cell tropism.^48 yhg identification of the receptor for HIV makes it
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unique, so far, amongst all human retroviruses. The tropism for CD4+ cells is 
probably relative rather than absolute as cells that do not express cell surface CD4 
nor have CD4 mRNA can be infected with HIV.^49 Also, some T-cells that express 
CD4 at a high level have been shown to be resistant to HIV infection.’* C D 4  is also 
expressed by monocytes, colonic cells and glial cells of the brain, making all these 
cells targets for HIV.
1.6.1.1 Overview of HIV infection
HIV binds to a CD4+ cell, and the viral core enters the cell after fusion of the viral 
and cellular membranes (mediated by the viral transmembrane protein gp41). The 
viral genomic single strand RNA is reverse transcribed using viral reverse 
transcriptase/ribonuclease H to viral double strand DNA, which is then integrated at 
specific sites in the host cell chromosome by viral integrase. This process only 
occurs efficiently in activated T-cells."*®^ After a period of very low levels of 
replication (clinical latency) the virus then replicates rapidly, progeny virus bud from 
the cell and the host cell dies. At this stage the presence of gp120 on the cell surface 
also causes CD4 bearing cells to aggregate, forming giant, multinucleated syncytia, 
which results in cell death. The period of clinical latency is usually long (8-10 years) 
and in this time stable infection can be established in certain cell lines. The trigger to 
leave the so-called "slow/low" mode and enter the cytopathic "fast/high” mode is not 
known.
1.6.1.2 Role of CD4 and T-helper ceils In immune réponse
T-lymphocytes recognise peptide antigens (an antigen is any molecule that will 
provoke an immune response) presented on the surface of an antigen presenting 
cell (ARC). This recognition triggers T-cells to carry out their function, either cytotoxic 
action (T-8 cells) or helper action (T-4 cells). Of these cell types T-4 cells, or helper T- 
cells, express CD4 on their surface and are therefore targets for HIV infection. Both 
types of T-cell recognise peptide antigens bound to a polymorphic pocket of one of 
the two types of major histocompatibility complex proteins, MHC-I and MHC-ll.
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MHC’s are a group of proteins involved in self/non-self recognition.
Antigen associated with class II MHC arises from exogenous antigen taken up by 
macrophages and B-cells (which are APC’s) and presented on the cell surface. 
Class II MHO associated antigen is recognised by helper T-cells. This recognition
occurs through interaction of the ap heterodimeric T-cell receptor (TOR) on the T-cell 
with MHC II, around the polymorphic antigen binding pocket. Contact between the 
antigen-MHC complex and the TCR occurs through both the a and p chains of the 
TCR. Only a small subset of T-4 cells will recognise a given peptide antigen as only a 
few T-cells will have the correct TCR sequences to recognise the antigen-MHC 
complex. CD4 and the TCR act as a unit to bind the MHC-antigen complex. The 
function of CD4 is probably to strengthen the interaction between the TCR on the 
helper T-cell and the ARC by forming subsidiary interactions with class II MHC. The 
likely site of interaction between CD4 and MHC II is the non-polymorphic region of 
MHC II. In humans the MHC is known as human leukocyte antigen (HLA).
Cellular immunity (that employing macrophages) and most humoral reponses 
(those dependent on antibodies and acting against extracellular phases of infection) 
are T-helper cell dependent. T-cells act by causing B-cell proliferation and 
differentiation. They also release lymphokines when they are activated, stimulating 
B-cells and increasing cellular resistance to viral infection. Thus, HIV infection of T- 
helper cells eliminates the host’s ability to mount any kind of defence against a 
pathogen and so the host succumbs to opportunistic infections. The mechanism by 
which it does this is unknown, and some possibilities are discussed in Section 
1.6.1.5 below.
1.6.1.3 HIV and its I if e-cycle
Shown below (Figure 1.6.1) is the genomic organisation of the proteins that make 
up the virus.
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where MA = matrix protein 
GA = capsid protein 
p6/p7 NC = nucleocapsid protein 
RN = ribonuciease
PR = protease
RT = reverse transcriptase
IN = integrase
Figure 1.6.1: Genomic organisation of HIV-1
The gag polyprotein contains the structural proteins of the virus; the matrix protein, 
the capsid and the nucleocapsid proteins. The env polyprotein contains gp120, the 
outer coat protein and gp41, a transmembrane protein associated with gp120. The 
po/region contains the enzymes necessary for viral replication, the protease, reverse 
transcriptase, ribonuciease and integrase.
Given below in Figure 1.6.2 is a representation of the overall structure of HIV-1. The 
virus possess a bullet-shape core (characteristic of lentiviruses) made up of the 
capsid (GA, p24) protein. The core contains the 2 single strands of genomic RNA, 
bound to NG and a few copies of the viral enzymes. The outer protein shell is an 
icosadeltahedron, made of the matrix protein (MA, p i 7). The lipid membrane is 
derived from the host cell that the virus budded from.
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Figure 1.6.2: Overall structure of HIV-1^
The genomic organisation of HIV-1 is given below (Figure 1.6.3), showing the 
different reading frames and splicing patterns. The viral genome is extremely small 
(just under 10 kb) so production of the nine different viral proteins requires that 
sections of the genome be utilised more than once. Two reading frames and multiple 
splicing patterns (4 donor and 6 acceptor sites'*®®) of the primary RNA transcripts 
allows the virus to “re-use” large sections of its genome to code for more than one
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protein. The non-spliced transcript provides both the genomic RNA and mRNA for 
translation into the gag-pol-env polyprotein. The transition from the gag to the p o l 
reading frame is brought about by a -1 ribosomal frameshift that occurs just after the 
end of the p6 coding region. The shift occurs in around 11% of casesJ®® allowing 
the production of the 160 kDa pap-po/ polyprotein. The other 89% of cases produce 
gag alone I.e. translation is terminated soon after the frameshift site if the frameshift 
does not occur. As already described pol contains the viral enzymes and env the 
outer coat proteins. The other proteins are regulatory proteins and, along with a 
number of cellular proteins, govern the progress of the virus through the various 
stages of infection (see Section 1.6.1.4).
gag
LTR pol
vpr /□ ir
I vif
Figure 1.6.3: The HIV-1 genome showing splicing patterns 
where LTR = long terminal repeat
1.6.1.4 Viral replication
Given that the structure and the protein constituents of the virus are known it 
became of interest to study how the various properties of the proteins are 
coordinated to replicate the virus. A model for the replication cycle has been 
developed and can be broadly divided into the following steps:
i) Attachment - Viral coat protein gp 120 recognises and binds to cell surface 
CD4.
ii) Penetration - Viral and cellular membranes fuse, mediated by gp41 and the viral 
core enters the cell.
49
iii) Uncoating - Viral RNA and replication enzymes are released into the cell by
proteolysis of the viral capsid, probably by the viral protease.
iv) Reverse transcription - Proviral DNA is produced from RNA by viral reverse 
transcriptase.
v) Integration - Proviral DNA is irreversibly integrated into chromosomal DNA in a 
site-specific manner by viral integrase. This is only efficient in activated T-cells.
vi) Expression - Viral DNA is transcribed and translated by cellular apparatus to 
give viral proteins and RNA. The amount and type of proteins produced is tightly 
regulated.
vli) Post-translational modification - env proteins are glycosylated and the N- 
terminal Gly of p24 is myristoylated by cellular enzymes.
viii) Assembly - Viral proteins migrate to the inside of the plasma membrane, 
proteolytic processing begins and the virion core is assembled.
ix) Budding - Virion core buds out from the plasma membrane, removing some of it 
as it does so and proteolytic processing is completed.
In the early stages of infection short («2 kb), multiply spliced mRNA’s are produced, 
coding for the regulatory proteins. Later in infection full-length mRNA’s are produced 
coding for the gag and pol polyproteins. The trigger for this change is unknown (see 
below). The crucial stage in replicating the virus occurs in step (v) to (vi) above i.e. 
the transition from stably integrated viral DNA producing a small subset of viral 
proteins to actively transcribed DNA producing new virus. This transition is controlled 
by a complex web of interactions between a variety of cellular and viral regulatory 
proteins. The 5 ' and 3 ' long terminal repeats (LTR’s) contain many c/s-acting 
regulatory elements that bind a wide range of viral and host proteins. The regulatory 
proteins tat, rev and nef control the level of synthesis of viral proteins, including each 
other. The trans-activating protein, tat, binds to the so-called TAR sequence in the R 
region of the 5 ' LTR and enhances transcription therefrom, causing a generalised 
increase in the level of viral p r o t e i n s . ' * ® ^  it \s also implicated in increasing the 
efficiency of mRNA translation, possibly at the level of mRNA transport or 
stabilisation.
The regulator of virion proteins, the rev protein, acts to differentially affect the 
synthesis of viral proteins, no structural proteins being synthesised in its absence."*®® 
It has two c/s-acting target sequences in the gag-pol and env genes, the repressive 
CRS sequence and the activating CAR sequence. It is thought that the CRS
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sequence confines the mRNA to the nucleus, but that the CAR-rev interaction can 
override thisJ®® The negative regulator, nef, lowers expression of all viral genes by 
acting on a sequence in the LTRJ®^ The function of the vpr and vpu proteins is not 
well understood and vif is thought to be involved in viral infectivityJ®® Deletion of any 
of these three proteins had no observed effect on viral infectivity or pathogenicity."*®®
These proteins act, together with several cellular proteins (such as NF-kB"*®®), to 
regulate entry of the virus into the late stage of the replication cycle (stage (vi) above) 
and become active. It was previously thought that the virus was in a so-called latent 
stage for the early part of infection and that there was a cellular trigger for entry to the 
late stage. However, it has recently been shown^®"* that HIV is never latent, merely 
replicating at a previously undetectable level. Thus, the cycle given above proceeds 
continously after integration of viral DNA into the host chromosome. However, 
infection only results in a clinically observable change after some considerable 
period of time as very low levels of virus are produced in the early stages of the 
disease. It has been observed that the nature of the virus changes in the course of 
infection. At the early (latent) stages of the disease the virus is slow replicating, low 
yielding and does not cause syncytia. In the late stages the virus replicates rapidly 
and with high yield, readily establishes productive infection and causes syncytia 
formation.
It has been postulated that the long duration of the early stage is due to immune 
surveillance suppressing viral replication, during which time the virus mutates 
rapidly, eventually exceeding the host’s ability to suppress replication. These viral 
escape mutants (mostly mutants in the V3 loop of gp120) are then extremely 
diverse"*®® constituting several quasi-species. It may be that this continous antigenic 
drift, arising from the high mutation rate, and antigen specific triggering of different T- 
cell clones leads to exhaustion of containment and immune collapse.
The extremely high mutation rate in HIV and other RNA viruses is partly due to the 
lack of exonucieolytic (proofreading) activity in the viral reverse transcriptase."*®® 
This results in extremely error-prone replication (around 1 mutation per 10,000 
bases or 1 mutation per virus per generation)."*®4 However, the possession of a high 
fidelity reverse transcriptase is of little use to the virus as transcription of the 
integrated viral DNA is carried out by the rather error-prone cellular RNA polymerase
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1.6.1.5 Mechanisms of pathogenicity
The results of HIV infection of the immune system are:
i) Severe depletion of CD4+ cells.
ii) Loss of T-helper cell function (independent of the decline in total CD4+ cell count).
Any of the stages in the viral life-cycle could be cytotoxic, but the most likely are 
stages (i), (vi) and (ix). Stage (i), initial binding, may disrupt the proper functioning of 
the CD4-MHC ll-TCR complex (see below). This complex is most important in the 
correct presentation of antigens to B cells and thus the mounting of an antibody- 
mediated immune response. Stage (vi), expression of viral regulatory genes may 
disrupt cellular transcription or translation. The load on limiting cellular machinery 
may be too high to allow the cell to survive i.e. viral mRNA competes for limited 
protein synthesising resources to the detriment of the cell. Stage (ix), budding, may 
destroy membrane cohesion and cause the membrane to become punctured. 
However, due to the close parallels between graft versus host disease and the early 
stages of HIV infection it has been proposed that the pathogenicity of the virus is due 
to its ability to trigger an autoimmune response against helper T-cells.
A type of autoimmune disease may arise through an immune response to gp 120, 
particularly the CD4 binding site. Anti-idiotypic (antibodies against antibodies) gp120 
antibodies might bind to CD4 much as gp 120 is seen to do in vitro and thereby block 
the function of CD4"^ T-helper cells."*®®'"*®® This binding of antibodies to CD4+ cells 
will also lead to their complement mediated destruction and programmed cell death 
(apoptosis)."*®7 It will also make them a target for the normal antibody targeted cell 
killing.
It has recently been proposed that gp 120 is a so-called superantigen and it is this 
property that gives the virus its powerful immune-disruptive effect."*®® Superantigens 
bind to class II MHC and the p chains of the TOR in a non-p chain specific manner 
and stimulate a powerful proliferative response in the T-cells bearing the p chains 
recognised by the superantigen. This activation of T-lymphocytes bearing certain vp 
sequences as part of the p chain of the TCR may result in clonal deletion of these T- 
lymphocytes. It is by such a mechanism that the immune system deletes T-cells 
specific for self antigens."*®® Thus, it is proposed that gp120 causes constant,
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inappropriate activation of T-cells bearing the correct receptor (CD4) by binding to 
both TCR and CD4 at the same time. Experimental support for this theory has come 
from recent work"*^® demonstrating for the first time the existence of a human 
superantigen. It was found that the nucleocapsid protein from rabies virus is a 
superantigen specific for Vp8 bearing T-lymphocytes i.e. T-cells having the so-called 
V8 sequence in the p chain of the TCR.
Another proposal is based on the close structural resemblance between a model for 
gp120 and the C-terminus of HLA-A2 ag c h a i n . Thus, it is hypothesised that 
gp120 on the surface of infected cells, in association with CD4, will induce an 
immune response. The antibodies so induced will target HLA-A2 a2 chain bearing 
cells i.e. T-helper cells, as well as gp120 bearing cells, resulting in their elimination. 
This is consistent with the increase in activity of CD8+ killer T-cells and the decline in 
the CD4+ cell count in the early stages of HIV infection as the CD8+ cells are 
engaged in killing the CD4+ cells. In either case the decline of the T-helper cell 
population means that most B and T-8 cell responses cannot be mounted against a 
pathogen."*^®
1.6.2 The HIV-1 protease
After it was recognised that HIV contained a protease that was absolutely required 
for viral maturation a huge multi-disciplinary effort was launched to study the 
enzyme, its properties and its place in the viral life-cycle. The state of knowledge on 
the HIV protease is summarised In the following sections.
1.6.2.1 Role of the protease
The HIV-1 protease is, like the other viral enzymes, a minimal enzyme, just large 
enough to carry out its allotted task. Its homodimeric nature (see below) allows the 
use of a very small coding region whilst retaining activity. Protease activity is mostly 
expressed at a late stage of the life-cycle (see Sections 1.6 .1.3 and 4), when it 
releases and activates the viral structural proteins and enzymes from the viral 
poly protein to form mature infectious virus. The cleavages carried out are involved
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and facilitate the assembly of complex arrays of proteins for which self-assembly may 
not be adequate. It has recently been shown that the protease also has some role in 
the early stages of the life-cycle; at the integration s t a g e a n d  the activation of 
proviral t r a n s c r i p t i o n . "*^4 protease activity also appears to be involved in the 
uncoating stage as protease defective virus particles are stable under conditions that 
disrupt mature virions."*^® The protease of the related retrovirus, equine infectious 
anaemia v irus (EIAV) has been shown to be involved in hydro lysis of the 
nucleocapsid (NC) proteins to release viral RNA into the c e l l ."*76 very recently it has 
been shown that the HIV-1 protease has a similar role. A second protein processing 
pathway, involving regulated in situ cleavage of the NC protein within intact capsids, 
has been f o u n d ."*77 Thus, the protease is required for early events in replication and 
protease inhibitors may therefore be useful for preventative therapy, as well as for 
treatment to prevent viral spread in the late stages of infection.
During steps (vii) and (viii) in the replication cycle above, the gag and gag-pol 
polyproteins are myristoylated, by a cellular myristoyl transferase,"*7® on glycine-1 of 
the matrix protein MA."*79 This encourages migration of the polyproteins to the'inside 
of the cell membrane,^®® where the myristate hydrocarbon chain embeds itself in the 
membrane, anchoring the polyproteins. This decrease in available dimensions for 
movement increases the effective concentration of the polyproteins and thus 
promotes dimérisation to form active protease. Once dimérisation occurs release of 
the protease from the polyprotein is autocatalytic.
The kinetics of proteolytic processing show that the processing occurs in fra/?s"*®"* 
i.e. intermolecularly, which is the least sterically demanding route. It is possible that 
the so-called p6* region (which lies between the coding regions for p6 NC and the 
protease) of the gag polyprotein sterically blocks the active site in the same way as 
the active site of the aspartic protease zymogens is blocked by the propeptide.®4 
However, there is a poor sequence alignment between p6* and the propart of the 
aspartic proteases, so they may not function in the same way. Instead, the protease 
may be activated by displacement of p6* on conformational change induced by 
association of the gag-pol poly protein with gag or viral RNA or by pH change as the 
immature virion buds from the cell."*®® On deletion of the p6* region from the viral 
genome the efficiency of gagr-po/processing by the protease is increased"*®® so it is
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possible that p6* is involved in some way in reducing or regulating protease activity. 
The importance of the timing of processing is shown by the loss of infectivity and viral 
assembly in cells infected with HIV-1 that bears the protease as a single chain 
monomer i.e. pre-assembled and permanently a c t iv e ." *®4
The cleavages carried out by the protease in the viral polyprotein are shown in the 
diagram below, Figure 1.6.4.
2 3 10 11
p17 p24 P7 p6
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gp120 gp41
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Figure 1.6.4: The in vivo cleavage sites of the HIV-1 protease
The various cleavage sites in the polyprotein are not acted upon by the protease at 
the same rate, resulting in an ordered release of the constituent proteins."*®® This 
ordered release was shown to correlate with the rate of cleavage of synthetic 
peptides based on these gag cleavage sequences."*®® Ordered cleavage may be 
required for regulation of proper interaction and assembly of the viral core and coat
proteins. "*®7
1. -Ser-Gln-Asn-Tyr * Pro-lle-Val-Gln-
2 . -Ata-Arg-Val-Leu * Ala-Glu-Ala-Met-
3. -Ala-Thr-lle-Met * Met-Gln-Arg-Gly-
4. -Pro-Gly-Asn-Phe * Leu-Gln-Ser-Arg-
5. -Ser-Phe-Asn-Phe * Pro-Gln-lle-Thr-
6 . -Thr-Leu-Asn-Phe * Pro-lle-Ser-Pro-
7. Leu-Glu-Lys-Glu * Pro-lle-Val-Gly-
8 . -Ala-Glu-Thr-Phe * Tyr-Val-Asp-Gly-
9. -Arg-Lys-lle-Leu * Phe-Leu-Asp-Gly-
10.§ -Arg-Glu-Lys-Arg * Ala-Val-Gly-lle-
§ Note: This cleavage is probably carried out by a cellular tryptase."*®®
Figure 1.6.5: Sequences of cleavage sites in the gag-pol polyprotein
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1.6.2.2 Classification of the protease
Having identified several areas where protease activity is crucial for viral replication 
it then became of interest to identify the class of protease to which the HIV-1 protease 
belongs and thereby rationally develop inhibitors for it. The protease was classified 
as an aspartic protease initially on the basis of its sequenceJ®® as it exhibits the 
absolutely conserved active site triplet of aspartic proteases (Asp-Thr-Gly) (see 
Section 1.2 .2 ). The sequence shows that there is only one aspartate residue per 
chain, so to provide the pair needed for catalysis the enzyme must be a homodimer, 
with one aspartate being provided by each 99 amino acid monomer (Asp-25). This 
makes the enzyme exactly symmetrical, except for the differing protonation states of 
the aspartates i.e. it possess almost perfect Cg symmetry. This symmetry is broken on 
substrate or inhibitor binding,^®® see below. The classification as an aspartic 
protease was supported by inhibition by pepstatin A,"*®^  the archetypal aspartic 
protease inhibitor (see Section 1.1) and by abolition of activity on mutation of the 
active site aspartate to alanine.^®® Definitive proof of the classification was provided 
by the crystal structure"*®® which clearly showed the expected dimer structure and 
the active site containing the D-T-G triads.
1.6.2.3 Properties of the protease
The protease is a somewhat atypical aspartic protease in many respects. Its pH 
optimum is unusually high, around 5 .5 ,"*®4 making it more like renin than the rest of 
the aspartic protease family. The reason for this rather high optimum compared to 
most of the monomeric aspartic proteases is not clear (see Section 1 .2 .3 ). The 
protease is homodimeric, with a monomer molecular weight of around 10,750 Da^®4 
and the dissociation constant for dimer formation is 10 nM.^®® The dimérisation 
allows the functional structure of the larger, monomeric aspartic proteases to be 
conserved whilst using considerably smaller polypeptides. It is thus a minimalist 
aspartic protease. The necessity of dimérisation for activity may provide a control 
point in the maturation of the virus (see Section 1.6 .2 .1)"*®® preventing premature 
processing.
It also seems that the retroviral proteases are somewhat less catalytically active
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than the mammalian aspartic proteases, with the highest turnover number for HIV-1 
protease^^^ around 70 S"1, whereas for pepsin the turnover number can be as high 
as around 400 This low efficiency may not be a limitation on viral maturation
as the ratio of protease molecules to cleavage sites is around 1:80J^^
1.6.2.4 Substrate specificity
The in v/Vo cleavage sites of the protease show that it is required to perform a small 
number of highly specific cleavages at sites containing a wide range of amino acid 
sequences. This small number of cleavages in a very large protein provides a false 
impression of the specificity of the enzyme as it shows good activity against a very 
diverse range of peptides. There are three factors that are involved in determining 
the rate at which a given site in a peptide or protein substrate will be cleaved; 
accessibility, conformation and sequence. These three factors must combine in the 
In vivo situation to give the low number of cleavages observed in the gag-pol 
polyprotein. Unfortunately, the predictive value of these criteria is sometimes 
poor."*^ ®
In protein substrates of the HIV-1 PR there is an absolute requirement for structure, 
as denatured gag polyprotein and other denatured proteins are not s u b s t r a t e s .^ ^ o  
Not only is some kind of structure required it appears that the conformation of the 
peptide or protein has a profound effect on cleavage efficiency^oi i.e. a particular 
kind of structure is required. This is supported by the observation that heat-denatured 
rat lactate dehydrogenase is not a substrate for the protease, but partially pH 
denatured rat LDH is.**^ ® However, 2D-NMR investigations of peptide substrates for 
HIV-1 PR and AMV PR have shown that they have only random conformation in 
s o lu t io n .202 Conformationally restrained circularised peptides have been shown not 
to be substrates.201 it has also been found that a decameric peptide from the active 
site of LDH is cleaved as quickly as the same sequence in the protein. However, the 
conformations of the peptide free in solution and in the enzyme tertiary structure are 
very different.
The third determinant for cleavage, sequence, has been extensively investigated 
using small synthetic peptides, usually based on the gag-pol cleavage sites shown
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above. This work is based on the assumption that cleavage sites in proteins and 
peptides are often cleaved at similar rates.203 These peptides usually occupied S4- 
S4’. In some sequences it has been found that seven amino acids, spanning P4-P3 ’, 
are required for c l e a v a g e , 2 0 4  while some sequences do not require a P4 residue to 
be c le a v e d .2 0 5  Therefore, some sequences require only 6 residues to be cleaved, 
other sequences require 7 residues.
Three of the gag-pol sites contain the consensus sequence Ser(Thr)-Xaa-Yaa- 
Aromatic*Pro, which is a common cleavage sequence amongst the retroviral 
p r o t e a s e s .2 0 6  The remainder show hydrophobic residues at P  ^ and P-j’ which also 
occur frequently in retroviral protease cleavage s i t e s , 2 0 7  with no 6-branched 
residues allowed at P^  in either protein or short peptide s u b s t r a t e s .208 This could be 
related to the observation that cis proline residues (as are found in several HIV-1 PR 
cleavage sites) are almost never preceded by 6-branched amino a c id s .2 0 9  Studies 
aimed at determining which of sequence and conformation is the dominant influence 
on the rate of cleavage have provided ambiguous r e s u lts .2 0 3
An extensive analysis of retroviral protease processing sites has allowed the sites 
to be classified into classes;2iO type 1 sites have Pro at P^’ and type 2 have Ala, Leu 
or Val at P '^. A similar classification2f 1 postulates a third class having Glu/GIn at the 
Pg' position and hydrophobic residues at P^  and P i’. It is possible that these sites 
are functionally different and contribute toward the ordered processing discussed 
above. In this context it is interesting to note that the amino terminus of the capsid 
protein CA is always a type 1 site and the carboxyl terminus is always a type 2 site, 
but this is the only example of such conservation in cleavage sites in 10 different 
v i r u s e s .202 Also, sites cleaved in non-viral proteins are nearly always of Class III.210
In the course of these investigations it has been observed that k^ g^  for cleavage 
increases with length of the peptide, while K|  ^remains approximately constant2 i 1 as 
was observed in the cleavage of peptides by the monomeric AP’s (see Section
1.2.3). However, this was not observed in a similar study by Billich et aA2 l 2 The 
reason for this discrepancy is as yet unclear. If it is shown that there is no change in 
kcat with peptide length then the mechanism of HIV-PR activation of peptide 
substrates will need to be reexamined.
Extensive experimentation and analysis has allowed the determination of the
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favoured residues to occupy each of the subsites P4-P4 ’ in the enzyme. Analysis of 
40 cleavage sites in various (viral and non-viral) proteins allowed Poorman ef 
to assign specificity indices for each of the subsites in the enzyme binding site. A 
similar analysis of cleavage of synthetic peptides^os found that the site was much 
more stringent in its requirements that the S^’ site. Both studies also found that the 
S2 ’ site was by far the most stringent, followed by S-j and Sg. These observations are 
difficult to rationalise given the symmetry of the protease, which means that the Sp 
and Sp‘ subsites are made up of the same residues. The explanation probably lies in 
cooperativity in substrate side-chain binding between the various subsites.
Context dependency has also been shown to be an important influence on the 
efficiency of cleavage of a given peptide bond.2‘'4 jh is  study compared the efficiency 
of cleavage of p1-p7 (Met-Met) and p17-p24 (Tyr-Pro) junctions when the sequences 
flanking the scissile bond are interchanged i.e. Increasing amounts of one site 
replaced by the other. The effect of a given residue on the kinetic parameters for 
cleavage varies greatly with the residues that are around it in the substrate. The 
influence of residues distant from the scissile bond is further demonstrated by the 
large difference in the rate of cleavage of two peptides, of overall different sequence, 
at the sequence Asn-Phe*Pro. The peptides were found to be cleaved at rates 
differing by about 30-fold.^^2
Sites very distant from the scissile bond i.e. beyond 84  and 8 4 ’ also have a large 
influence on the rate of cleavage. It has been shown that octapeptides of the same 
sequence as the cleavage sites in the polyprotein do not show the large differences 
in cleavage rates that are shown by those sites in the gag-pol po lyprotein.214 
Therefore, additional conformational or steric features or binding determinants 
beyond P4 and P4 ’ are required by the protease to achieve maximal rates of 
cleavage. This is curious as the crystal structures of the protease complexed with 
various inhibitors clearly show that residues beyond P3 and P3 ’ have very little, if 
any, specific interaction with the enzyme.
1.6.2.5 Mechanism of the protease
The mechanism of the HIV-1 protease has not been explored with the same
59
thoroughness as that of the monomeric proteases as it is assumed that they will be 
the same. The studies on the kinetics of product release have shown that with some 
substrates the N-terminal fragment is released first, as was seen for several pepsin 
substrates (see Section 1.3.1.1). However, some substrates show random release of 
the two fragments from a central c o m p le x .^ f  5 it js not known if the ordered release is 
a pH dependent phenomenon, as it is for some pepsin substrates (see Section
1,3.1.1), The studies of Northrop et on solvent isotope effects on pepsin 
catalysis also support an ordered release mechanism.
Studies2i5 on ^^O-label incorporation from ‘•^O-labelled water into peptide 
substrates have indicated that the intermediate in peptide bond hydrolysis is a 
neutral amide hydrate,as suggested by Blundell for the monomeric proteases (see 
Section 1.4). Studies on the pH-rate profile^i® have shown that at high pH the rate 
determining step is chemical, whereas at low pH it is product re lease (or 
conformational change). Solvent Isotope effect studies have shown that there is no 
effect on ^V/K^ and a variable, but greater than 1, effect on V ^ .  The lack of an 
effect on ^V/K^ is ascribable to a high forward commitment and the effect on 
arises from the simultaneous transfer of two protons in the breakdown of the 
tetrahedral intermediate.218 These effects are consistent with those observed with 
the monomeric aspartic proteases (see Section 1 .3.5).
Chemically, therefore, the mechanism of the HIV-1 protease is essentially identical 
with that of the monomeric aspartic proteases. Kinetically, the mechanism is less well 
understood.
1.6.3 Inhibition of the HiV-1 protease
The HIV-1 PR is a promising therapeutic target in AIDS and HIV infection for several 
reasons:
i) Its central role in the life-cycle. It has been shown that mutagenic inactivation (see 
above) or de letion^i^ of the protease results in the production of non-infectious, 
immature virions. Unlike reverse transcriptase inhibitors such as AZT^iG and ddl, 
protease inhibitors are active against virus in chronically infected cells as well as 
attenuating acute infection of uninfected cells.^^® This is not unexpected given that
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the protease acts mostly In the latest stages of the viral life-cycle. Protease inhibitors 
have been shown to prevent viral replication in chronically infected cells and to 
prevent viral spread to uninfected c e l l s .220 other inhibitors have been shown to be 
able to clear viral signs from acutely infected cells in a few d a y s .221  This action may 
derive from the inhibition of the action of the protease on the viral nucleocapsid 
protein early in the replication cycle (see Section 1.6 .2 .1).
ii) High selectivity over host enzymes can easily be achieved. The unusual cleavage 
sites for the protease (aromatic-proline), which are not cleaved by mammalian 
proteases, allow highly selective inhibitors to be designed based on an aromatic- 
proline scissile bond analogue. This will make them much less cytotoxic than reverse 
transcriptase inhibitors, a significant advance as AZT is very toxic in h u m a n s .222
iii) The low rate of mutation in the protease. A further problem with AZT and related 
therapies is the rapid emergence of resistant mutants.223 These result from single 
point mutations in the reverse transcriptase sequence. The likelihood of protease 
inhibitor resistant mutants emerging is much smaller as the protease is a very small 
and highly conserved enzyme, leaving little opportunity for active mutants to occur. 
This is supported by recent observations224 that the protease gene from a number of 
clinical isolates has a very similar sequence to that of the laboratory strain HIV-1 lllb. 
The substitutions all occur away from the active site region, suggesting that these 
enzymes should all be Inhibited similarly to, if not identically with, the enzyme from 
the laboratory strain. There have, however, been reports of the emergence of 
inhibitor resistant mutants.225
1.6.3.1 Development of HIV-1 protease inhibitors
When the HIV-1 protease was identified as a promising site of Intervention in the 
viral life-cycle much of the early work was based on the principles of inhibitor design 
developed during the search for effective renin l n h i b i t o r s . 2 2 6  Knowledge of the 
substrate specificity gained from good peptide substrates was used to generate lead 
peptide sequences. The scissile amide bond in these sequences was replaced by a 
suitable transition state a n a l o g u e . 2 2 7  in the renin case the sequence was derived 
from the sequence of angiotensinogen and replacement of the scissile bond in 
peptides derived from angiotensinogen gave potent renin i n h i b i t o r s . 2 2 8  a  similar
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approach with the HIV protease using a variety of scissile bond analogues also 
yielded some very potent inhibitors. In this case the peptides were derived from the 
sequences of the favoured cleavage sites in the gag-pol polyprotein.
Amongst the scissile bond rep lacements used were phosphinic ac id ,229
hydroxyethy lam ine, 230 (x,a d ifluo roke tone,23 i reduced p e p tid e ,232 
hydroxyethy lene,233 statine and de riva tives,234 di hydroxy et hy le ne,235 
allophenylnorstatine228 and phosphonamidate237 (see Figure 1.6.6). Generally the 
potency of the analogues increases in the order: reduced peptide, statine, 
phosphinic acid, a,a-difluoroketone, dihydroxyethylene, hydroxyethylene and 
hydroxyethylamine.
Reduced peptide
OH .O H  
H N . : C :  X H
Hydrated difluoroketone Statine
HN.
OH
I X HX'
R
Hydroxyethylene
O
Phosphonamidate
Hydroxyethylamine
OH
R OH
Dihydroxyethylene
Phosphinate
Ph O 
Allophenylnorstatine
Figure 1.6.6: Scissiie bond anaiogues
All of the inhibitors shown above probably act as so-called collected substrate 
ln h ib i t o r s 2 3 8  / .g ,  they replace both of the substrates in amide bond hydrolysis, the 
peptide and the lytic water molecule. Other scissile bond analogues have been 
developed, but have been less throughly explored e.g. amino h e m ik e t a ls .2 3 9  ^  has 
been noted that a substrate of less than 6 amino acids is not cleaved by the
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e n z y m e . However, the same requirement does not seem to apply to Inhibitors as 
good inhibition has been acheived using tetrapeptide mimics (i.e. inhibitors that only 
occupy S 2 to and pentapeptide m i m i c s . 2 3 3 9 .1  One of these pentapeptide
mimics233i js the most potent HIV-1 protease inhibitor so far produced with a Kj of 
0.03 nM (Figure 1.6.7).
P h
O H
Boc-NH
P h‘
Figure 1.6.7: A pentapeptide mimic inhibitor for the H iV-l protease
1.6.3.2 Symmetric Inhibitors
One of the most prominent differences between the mammalian and the retroviral 
aspartic proteases is the homodimeric nature of the retroviral enzymes and their 
resultant symmetry. Recently, inhibitors that possess greater or lesser amounts of 
symmetry about the scissile bond analogue have been prepared and tested, to 
exploit this inherent symmetry in the target enzyme. They have been based on
hydroxyethylene,233c,g,h,I dihydroxyethylene235c,d difluo roketone23ia and
phosphinate24i scissile bond analogues. However, not all the symmetric inhibitors 
have proved to be improvements over the non-symmetric v e r s io n .2 3 3 d  Symmetric 
inhibitors offer two pharmacological advantages over the non-symmetric versions. 
They are somewhat smaller than the unsymmetrical inhibitors, which usually gives 
higher solubility and better transport across membranes, giving higher in vivo 
efficacy. They also have fewer peptide bonds due to the use of peptide mimicking 
moieties at their termini, which prolongs their lifetime in vivo as they are not such 
good substrates for host proteases. Many of the peptide-based inhibitors suffer from 
poor in vivo performance compared to their in vitro efficacy due to poor absorption 
into cells and their short lifetime in the circulation. Symmetric inhibitors such as the
63
one shown in Figure 1.6.8 below overcome these problems to some extent and this 
inhibitor has been found to be a potent inhibitor of the protease in an in vitro and an 
in vivo situation (IC50 0.67 nM in vitro).
PhPh OHOHOH
NH NH
Figure 1.6.8: L-700,417, a potent symmetrical inhibitof^^^ 
for the HIV-1 protease
1.6.3.3 Non-substrate based inhibitors
Other routes have been taken to avoid the presence of peptide bonds in HIV PR 
inhibitors. A screening program at Glaxo U.K. has discovered penicillin-based 
inhibitors containing almost no peptide like structure.^"^^ Similar approaches from 
other groups have unearthed a wide range of compounds that are inhibitors of the 
protease; d is u lfo n a te s ,d ic a r b o x y l ic  a c i d s , f l a v o n e s , 2 4 6  boronated 
porphyrlns247 and cerulenin.248 These compounds are all assumed to bind in the 
active site, but this has only been demonstrated for the penicillin-based inhibitors. 
Some metal ions have been found to be non-competitive inhibitors of protease.^'^®
A complementary approach to active-site directed inhibition has been prevention of 
dimérisation by disruption of the dimer interface with peptides derived from the 
sequence at the dimer Interface. This is a promising approach if non-peptide 
dimérisation inhibitors can be developed as no host protease can possibly be 
inhibited by this route as they are all catalytically active as monomers. However, to 
date only moderate (micromolar) inhibition has been achieved by this route.^so
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A search of the Cambridge Small S tructures Database for compounds 
complementary to the protease active site yielded the anaesthetic haloperidol as a 
lead inhibitor.251 However, it has since been shown that, although haloperidol is an 
Inhibitor, it is non-competitive and binds additively to the protease with the active site 
directed inhibitor, pepstatin A (Figure 1.0.1).252 Thus, in spite of careful design, 
haloperidol is not an active site directed inhibitor, as expected, but inhibits by an 
undesigned and unanticipated route, probably by binding to the dimer interface.
1.6.4 Structure of the HIV-1 protease
As mentioned above definitive proof of the classification of the HIV-1 protease as an 
aspartic protease was provided by an X-ray s t r u c t u r e . There have been three 
other structures of the unliganded protease published, one of low quality using 
recombinant protease,253 another at higher resolution also using recombinant 
protease254 and one of a chemically synthesised protease.255 The differences 
between these last two structures are small.
The structures all show the dimeric structure predicted, with the dimer interface at 
residues 1-5 and 95-99 of each monomer. The interface consists of two 
interdigitating p-sheets made up of these residues. In the unliganded state the flaps 
(residues 33-59) project out into the solvent and are disordered. The flaps serve the 
same purpose in the HIV-1 protease as they do in the monomeric aspartic proteases. 
Thus, the flaps exclude solvent from the active site and they form further interactions 
between the substrate and the enzyme. These conclusions are supported by 
molecular dynamics simulations, both in vacuo^^^ and under PBC solvation 
c o n d i t i o n s . 2 5 7  The simulations show correlated motions between the flap and 
another region of the protease, the so-called cantilever, residues 59-75. These areas 
are correlated both between and within monomers, implying cooperative movements 
in these parts of the protease as the flaps open and close.
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1.6.4.1 Structures of the protease complexed with Inhibitors
Of great importance in Inhibitor design has been the X-ray crystal structures of the 
protease complexed with a variety of different compounds. These include inhibitors 
based on such scissile bond analogues as h y d r o x y e t h y l e n e , 258 statine,259 
hydroxyethylamine (JG-365250 and U-85548e25t), symmetric hydroxyethylene (A- 
7 4 7 0 4 2 8 2  and L-700,41 l252j^ reduced peptide (MVT-101263) and 
d i h y d r o x y e t h y l e n e . 2 8 4  These structures have provided the drug designer with a 
wealth of useful information on the nature and size of the enzyme's subsites. The fold 
of the protease when liganded with an inhibitor (not shown) is illustrated on the 
ribbon diagram overleaf (Figure 1.6.9).
When the various structures are compared it is interesting to note that parts of the 
enzyme may shift by up to 1Â r.m.s. displacement on inhibitor b in d in g .2 4 2  This fits 
well with the information on cooperativity of motion within the enzyme revealed by 
molecular dynamics s t u d i e s . 2 5 8 ,2 5 7  However, when the various inhibitors are 
compared they differ very little in their conformation, particularly in the P^-Pi' 
r e g io n .2 8 5  The constancy of the bound conformation of the published inhibitors has 
allowed the development of a model for the interaction between our inhibitors and 
the enzyme (see Section 2.5.1).
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Figure 1.6.9: Overall fold of liganded HIV-1 protease
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A most striking feature of these crystal structures is the presence of a water 
molecule in the active site that acts as a bridge between the flaps and the inhibitor. 
This interaction is absent in the monomeric aspartic proteases and may present 
another route to inhibitors of the protease. This interaction is considered to be crucial 
fo r some types of inh ib itors to achieve optima l binding. A diagram m atic 
representation of the hydrogen bond pattern around an inhibitor at the active site is 
shown below (Figure 1.6.10).
Gly 27' Asp 29Asp 29'
Asp 25' Asp 25
Gly 48'
lie 50 lie 50
Figure 1.6.10: Hydrogen bonding interactions between the HIV-1 protease and a
hydroxyethylene inhibitor^^^
Comparison with the monomeric proteases shows that the P3 pocket has the Asp 
29’ residue as its primary binding residue. It has been suggested that this residue 
does not play the same role in binding substrates as the equivalent residue in the 
monomeric versions, Thr 219, does.^67 This is because there can only be one 
hydrogen bond formed between the substrate and Asp-29, compared to two with 
threonine. Thus, the pivotal role of the P3 pocket in the monomeric aspartic protease 
catalysis (see Section 1.4.2) is not mirrored by the HIV-1 protease. For a fuller 
examination of the importance of the S3 site of the HIV protease in inhibitor binding 
see Section 2.5.
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on inhibitor binding. The amide hydrogen of Gly 51A hydrogen bonds to the carbonyl 
of lie 50B, but the amide hydrogen of Gly 51B hydrogen bonds to solvent 
w a t e r .2 5 9 ,2 6 3 ,8 2  T h is  Is  reflected in large differences in the backbone torsion angles 
for Gly 50A (\\f = -20° to -45°) and He 51A ((() = -60° to -95°) compared to Gly 50B (\y = 
120° to 160°) and He 51B (cj) = 75° to 120°).^®'^ Another interesting feature of these 
structures is that they show some of the inhibitors adopting multiple binding 
m o d e s .2 5 8 d .2 5 9 ,2 6 3  This is probably due to the symmetry of the enzyme providing 
two almost energetically equivalent sets of interactions within the active site, thus 
allowing two binding modes.
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%
%There are indications in these structures that asymmetry is induced in the enzyme |
2.0 Results and discussion
2.1 Mechanistic studies on pepsin
When these studies began the question of the mechanism of the aspartic proteases 
was still unresolved, with several mutually incompatible theories based on the 
nucleophilic water concept being propounded. Examination of the early literature 
showed that there were many questions left unanswered by the nucleophilic water 
mechanisms and so attention was also turned to the covalent mechanisms (see 
Section 1.3.1). In an effort to provide more definitive data two parallel sets of 
experiments were devised, one set based upon the existence of an acyl intermediate 
and the other based upon the nucleophilic water mechanism.
2.1.1 The search for covalent intermediates
Experiments were designed to investigate the possibility of covalent intermediates 
in the mechanism, which may better account for the transpeptidation activity of the 
aspartic proteases than the non-covalent mechanisms. The experiments were 
directed at locating an acyl intermediate, as the amino intermediate has been firmly 
discounted on a number of grounds (see Section 1.3.1 .1). A lso, it had been 
proposed®^ that the acyl intermediate was the central intermediate in catalysis. It was 
decided to attempt to trap this covalent 'acyl-enzyme' intermediate (see Section
1.3.1.2 ), using a nucleophilic species. Experiments to trap the acyl intermediate had 
prev ious ly been carried out, unsuccessfully, using exogenous ly added 
nucleophiles.^^ It was decided that a more fruitful approach might be to release a 
highly nucleophilic species at the active site by enzymic turnover. Thus, a substrate 
analogue was required that would, on turnover, release a nucleophilic species at the 
active site.
Acylated aromatic hydrazines (mimics of substrate dipeptides) were chosen as the 
mechanism-activated inhibitors. If they are hydrolysed by the enzyme they would 
release an aromatic hydrazine at the active site. The highly reactive hydrazine may 
then react with the acyl intermediate as shown below (Scheme 2.1.1). A covalent 
complex formed between the enzyme and the hydrazine released can easily be
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identified by UV spectroscopy on the inhibited enzyme. The nitrophenyl hydrazides 
may be preferred as inhibitors in this respect due to the very strong absorption of the 
nitrophenyl ring in the near UV and visible regions. This will allow straightforward 
detection of any protein labelled with nitrophenyl hydrazine.
NH NH
X HgN— NH n
X-CO2 +
o ^ E '^ 0
Scheme 2.1.1: Theoretical mechanism for the action of the acyl hydrazides
In line with the well-known preference for pepsin to have aromatic residues in its 
S-j and S-j' sites^^ it was decided to synthesise the trapping agents with a 
phenylalanine residue at Pj. Originally only the phenyl and nitrophenyl versions 
were to have been used. However, these are 'frameshift' inhibitors (or substrates), in 
that the aromatic ring of the hydrazine, which corresponds to the side-chain of the 
carboxy terminal amino acid of a dipeptide, is one atom too close to the scissile 
bond. As shown below (Figure 2.1.1), the benzylhydrazide is a much better mimic of 
a genuine dipeptide substrate.
The hydrazine should compete efficiently with water for attack on the anhydride. It 
is far more nucleophilic, although the stereochemistry of attack on the acyl 
intermediate is probably not optimal, as it probably is for the active site water 
molecule. Closure of the so-called 'flap' over the active site on substrate binding (see 
Section 1.5.1) is thought to exclude water from most of the active site during the 
catalytic cycle. Thus, any nucleophile at the active site will be more effective due to 
the decreased solvation. Also, exclusion of water would remove a competing
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nucleophile from the active site, increasing the probability of trapping by the 
hydrazine.
The resulting acyl hydrazide is much more stable than the anhydride intermediate 
and should therefore be amenable to isolation. Thus, if it could be shown that the 
hydrazine is covalently bound at the active site of the enzyme, this would be very 
good evidence for the existence of a covalent anhydride at the active site. A similar 
approach to inhibiting the HIV-1 protease has since been tried and was found to 
fail.
HaC
H,C-
CHs T CH
Boc-L-phenylalanyl benzyl hydrazide 
Putative inhibitor
H,C
Boc-L-phenylalanyl phenyl hydrazide 
Putative inhibitor
,OH
Y0 CH.
Methyl N-acetyl phenylalanyl tyrosinate
Substrate
Figure 2.1.1: The hydrazide trapping compounds
The synthesis of the para-nitrophenylhydrazide from para-nitrophenylhydrazine 
and methyl Boc-L-phenylalaninate presented some problems. The reaction showed 
little, if any, sign of progress by t.I.c. in various solvents. N.m.r. spectroscopy showed 
little dimunition of the methoxy peak at 3.74 p.p.m., which would have been 
indicative of the reaction proceeding. Various methods were attempted to force the 
reaction, including long reaction time (up to 72 hours reflux), higher boiling solvents
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(f-butanol and toluene) and enhanced concentrations of reactants. None of these 
methods could be shown to improve the reaction. It was thus decided to explore the 
same reaction with two other hydrazines, name ly pheny lhydrazine and |  
benzylhydrazine. Both of these should be much more nucleophilic than the para- 
nitrophenylhydrazine as the highly electron-withdrawing nitrophenyl group is in 
conjugation with the lone pairs of the hydrazine nitrogens. In the case of 
phenylhydrazine the much less electron withdrawing phenyl ring is in conjugation 
with the lone pairs and with benzylhydrazine the lone pairs are not conjugated at all.
The reaction with hydrazine itself was also examined and could be unambiguously 
shown to have gone to completion by the disappearance, within 2 hours, of the 
methoxy peak from the proton n.m.r. spectrum of the reaction product. With 
phenylhydrazine the reaction was much less facile, but gave about a 50% reduction 
in the integral of the methoxy signal after 24 hr. reaction. Benzylhydrazine gave 
complete reaction overnight. Thus, the use of the nitrophenylhydrazine was 
abandoned in favour of the more reactive benzylhydrazine.
The reactions of phthalic anhydride and succinic anhydride with phenylhydrazine 
and nitrophenylhydrazine were used as models for the proposed reaction shown 
above (Scheme 2.1.1). These two anhydrides were chosen as models for the 
extensively hydrogen-bonded and highly constrained nature of the active site (see 
Section 1.4). The reaction of nitrophenylhydrazine with phthalic acid proceeded, as 
expected, very quickly. The reaction with succinic anhydride was much slower, not 
being complete after four days. An n.m.r spectrum of the crude reaction mixture 
showed that the reaction had proceeded only partia lly. The reactions with 
phenylhydrazine proceeded more quickly. The reactions with benzylhydrazine were 
quicker still (being complete in a few hours, depending on the solvent used).
The putative acyl intermediate is probably much more like succinic anhydride than 
phthalic anhydride (as it retains a degree of conformational freedom that the phthalic 
anhydride lacks). Given the s lugg ish nature of the reaction between 
n itropheny lhydraz ine  and succ in ic anhydride it seemed tha t the 
nitrophenylhydrazine would be unlikely to react quickly enough with the acyl 
intermediate to give a detectable amount of trapping product. The reaction of the 
benzyl or phenylhydrazine may have been rapid enough to observe some trapping.
Also, the enzyme active site is desolvated, which would make the hydrazines much 
more nucleophilic than they are in solution. This, coupled with their proximity to the |  
acyl intermediate suggested that there was a reasonable chance to detect trapping.
The synthesis of acylated phenylhydrazines (and other mono-substituted
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hydrazines) extends back to the work of F i s c h e r  ^69 who produced 1-acetyl 2- 
phenylhydrazines by reacting phenylhydrazine and acetic anhydride. Since that time 
several methods have been applied to the acylation of substituted hydrazides. Buzan 
et used DCC and acetic acid to acetylate phenylhydrazine and Weygard and 
Steglich^^^ used DCC (and cyanomethyl esters) to make amino acid tritylhydrazides. 
DCC (with HOBT) has also been used to couple hydrazine to the free carboxyl 
termini of p e p t id e s .Y u r 'e v  et used tetrachlorosilane to activate carboxyl 
groups (by the formation of tetracyloxysilane) to attack by phenylhydrazine to give 
acylated phenylhydrazines. Kelly et al. 274,275 ^^d others^^® have used the azide 
method and Hoffmann et a/.277 used a method involving 4-substituted 2-thio 5- 
thiazolidones. The most utilised method is an enzymatic synthesis (after Bergmann 
and Fraenhal-Conrat^^®) of phenylhydrazides directly from the amino acid using 
papain in a cysteine containing buffer. This method has been used by Waidschmidt- 
Leitz and Kuhn^79 and Milne and c o - w o r k e r s . 280 However, in common with 
Boinonas St. Guttmann et it was decided that the mixed anhydride method 
would be most suitable as it is clean and efficient. The DCC mediated coupling gave 
purification difficulties in my hands.
It was also decided to synthesise an assay peptide for pepsin, to allow its activity to 
be assessed before and after the hydrazide inhibition experiments. The peptides 
chosen were N-acety l-L-pheny la lany l-L-tyrosy l methyl ester or N-acety l-L- 
phenyla lanyl-L-tyrosine, after C le m e n t.T h e y  were chosen for their ease of 
synthesis and the straightforward assay method (spectrophotometrically at 237 nm).
Various methods were investigated for the synthesis of N-acetyl-L-phenylalanine. 
Stirring L-phenylalanine at room temperature with 1.1 equivalents of acetic 
anhydride in acetic acid (an initially considered method) produces extensive 
racémisation. This racémisation by acetic anhydride or trifluoroacetic anhydride had 
been reported in several cases,282 presumably due to aziactone formation282e,f 
(see Scheme 2.1.2). Aziactone formation promotes racémisation because the alpha 
proton is made very acidic, due to the adjacent carbonyl and vinyl groups, and 
consequently is easy to remove. Reprotonation occurs from either side of the 
resulting double bond, giving racémisation at the alpha carbon. However, there are 
reported exceptions to the intermediacy of azlactones.^®®
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^ î  + AcOH
” - \  /cICH3
Scheme 2.1.2: Aziactone formation In N-acetylated ami no acids
It has been reported that Schotten-Baumann conditions give good yields and no 
r a c é m i s a t i o n , 2®2d,g go this was tried (the use of pyridine and acetic anhydride was 
rejected as it is reported to result in at least partial racemisation284)_ There are 
several alternative methods that could have been deployed, for instance acylase I 
and sodium acetate,^85 ketene^®® or pentaflurophenyl acetate.287 Eventually the 
optimal method was found to be the use of N-methoxy diacetamide,^®® as the 
reaction proceeds without racémisation and in good yield. A variant of the mixed 
anhydride method was used for the coupling.
The coupling method also had to be carefully chosen. The azide method^SQ was 
considered as it can be used to couple unprotected amino acids. Therefore, methyl 
N-acetyl-L-phenyalaninate was synthesised and reacted with hydrazine to give theA-' lracyl azide. Treatment with nitrous acid at 4 °C (generated In situ from sodium nitrite 
and hydrochloric acid) gave the acyl azide, which was very unstable. Reaction of the 
acyl azide, without purification, with the unprotected L-tyrosine should have given the 
dipeptide. However, the acyl azide was difficult to isolate and the reaction proceeded 
in poor yield (10-20%). Thus, mixed anhydride coupling with methyl L-tyrosinate was 
used instead, giving an isolated yield of the dipeptide of 50%. Methyl ester protection 
was tried and it was found that saponification with sodium hydroxide on the model
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on the mode l compound methy l N -acety l-L -phenya laninate  did produce 
racém isation (as judged by the optica l rotation of the iso lated N-acety l 
phenylalanine). Thus deprotection was carried out using potassium carbonate in 
aqueous methanol, which had been shown by model studies to produce much less 
racémisation. Once synthesised the peptides were tested in the assay"^^ and were 
found to give unreliable results.
Both of the acyl hydrazides discussed (Figure 2 .1 .1) were incubated with pepsin 
under a variety of conditions. However, neither of the acyl hydrazides gave any 
consistently detectable loss in activity, even after prolonged incubation. Also, the 
addition of exogenous hydrazine (at concentrations up to 1 mM) failed to reduce 
activity. Furthermore, it proved impossible to unequivocally demonstrate turnover of 
the acylated hydrazides. Attempts to identify the products of turnover, Boc-L- 
phenylalanine or free aromatic hydrazine, either by difference U.V. spectroscopy or 
by t.I.c. using a variety of solvent systems, were unsuccessful.
The difficulty of reliably assaying pepsin proved a handicap in these studies. Three 
different assays were used. The haemoglobin assay, based on Know les’290 
modifications of the method of A n s o n ,^91 used for much of this work was found to be 
difficult to reproduce. The dipeptide based assay also proved to be irreproducible. 
The few results obtained from assays using the nitrophenylalanine containing assay 
peptide (Cbz-His-Phe(N0 2 )-Phe-0 Me, see Experimental section) were insufficient to 
generate a firm model for the interaction between pepsin and the acyl hydrazides.
The reason for the lack of observable turnover is not clear. Dipeptide substrates for 
pepsin containing phenylalanine at P^  usually have K|^’s around 1-5 thus
the hydrazides were used at concentrations from 10 mM downward. This should be a 
sufficient concentration to ensure that binding will take place. The conclusion from 
these studies appears to be that the hydrazides are not bound by pepsin at all.
After the failure to obtain any positive results from the mechanism generated 
hydrazines a different method was attempted. The work of Hofmann and Fink®® on 
cryoenzymological methods for identifying covalent intermediates in aspartic 
protease catalysis suggested a different approach. By reducing the temperature of 
incubations of pepsin in methanol they hoped to slow down covalent intermediate
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q/ 293 made extensive use of the dipeptide L-ieucyl-L-tyrosyl amide in their 
investigations of the mechanism of pepsin transpeptidation as it gives very high 
levels of transpeptidation products. If any covalent intermediate is formed in the 
reactions leading to cleavage (transpeptidation or hydrolysis) then this peptide 
should give maximum concentrations of the intermediate at pseudo-equilibrium, thus 
maximising the probability of trapping it.
This peptide was used as the substrate in a series of low-temperature quench 
experiments. In these experiments low temperatures were used not only to try and 
suppress the hydrolysis of the covalent intermediate but also to promote a trapping 
reaction with an exogenous nucleophile. Trapping was carried out by rapidly 
injecting an aliquot of an incubation of pepsin and the substrate into an organic 
solvent containing sodium borohydride as the nucleophile source. It was thought that 
if any active-site anhydride (see Scheme 2.1.3, where X is leucine) is formed during 
the course of substrate cleavage then it would be susceptible to borohydride 
reduction. In contrast the free acid groups of the substrate or enzyme would not be 
reduced. This reduction could produce either or both of two products, depending on 
the site of attack by the hydride anion. Reduction of the substrate derived carboxyl 
group would give leucinol (XCH2OH) and reduction of the active site carboxyl would 
give the active site alcohol (E-CH2OH).
"0  0 “T I + XCHO  XCH2OH
o ^ E - ^ o
x-co "  o ^ E ^ o
Scheme 2.1.3: Possible reduction paths for the putative acyl Intermediate
where E represents the enzyme.
The original effort was directed at identifying any leucinol formed, using t.I.c., by
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comparison with an authentic sample. This approach can be modified so that 
detection is performed using high field n.m.r. spectroscopy, which was expected to 
be a more sensitive method. As a check for the occurrence of transpeptidation the 
initial products of transpeptidation of Leu-Tyr-NH2, Leu-Leu, Leu-Leu-Leu and Leu-
Leu-Tyr-NH2®®® were synthesised and used as standards for t.I.c on silica plates.
The developing system used was that of A n t o n o v MeOH: EtOAc: NH3 (35:65:3).
The peptides were synthesised using Boo and methyl ester protection and coupled 
via the mixed anhydride method.®®® The use of DCC and the azide method had 
been explored previously and were found to be much inferior to the mixed anhydride 
method. This strategy was chosen over Cbz protection as Cbz-L-leucine is an oil and 
is much more difficult to isolate pure than Boc-L-leucine.
The experiments were performed at a variety of temperatures (-10 to -25 °C), in a 
range of solvent mixtures (0 -20% ethanol in THF) containing sodium borohydride 
(0.5 to 5 mM). The lowest possible temperature was necessary to try and slow the 
rate of hydrolysis of the acyl intermediate on dénaturation of the protein in the 
organic mixture. Incubation of the Leu-Tyr substrate and pepsin at varying 
concentrations was carried out and aliquots removed at intervals and added to a 
large excess (25 fold) of the cryo-quenching mixture. Much care was taken to ensure 
that the aliquot did not freeze on contact with the cold organic mixture, as then the 
slow thawing would result in complete hydrolysis of the acyl intermediate before it 
could be trapped by borohydride. Temperatures lower than -25 °C always resulted in 
a degree of solidification of the aliquot on contact so most experiments were carried 
out at -25 °C. Control samples consisting of only Leu-Tyr amide or only pepsin were 
also run for comparison.
After low temperature trapping, the organic solvents were removed under reduced 
pressure and a portion of the remaining aqueous phase applied to a t.I.c. plate and 
developed as above. The remainder was desalted on a small Sephadex G-25 
column and the protein containing fractions (which absorb at 280 nm) were 
collected, lyophilised and analysed as discussed below. Unfortunately, although 
some of the transpeptidation products could be identified by t.I.c. no leucinol could 
be unambiguously identified. Organic extracts of the aqueous phase were also 
taken, dried, evaporated and analysed by n.m.r. and further t.I.c., and still no leucinol 
could be observed. The possibility of trapping of the anhydride by ethanol in the 
cryo-quenching solution, to give leucine ethyl ester or an esterified active site
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carboxyl, was also considered. Quenching in neat THF avoided this problem.
Attention was turned to the protein, and attempts were made to identify an 'altered' 
form of pepsin by comparisons of mobility on denaturing polyacrylamide gels.^®® 
Isoelectric focussing would probably have proved the more useful technique as the 
reduction of an active site carboxyl group will alter the overall charge on pepsin. This 
charge will be reduced still further if lactonisation occurs with the remaining active 
site carboxyl group.
To facilitate the observation of any pepsin of altered mobility it was decided to |
develop a method to remove the phosphate group on serine-68 . This gives rise to %
two bands on SDS gels, one due to the phosphorylated protein and one to the non- 
phosphorylated form. The faster running form is probably dephosphorylated.®®^ 
Perlmann removed the phosphate group from pepsin and pepsinogen using 
intestinal alkaline phosphatase.®®® Initial dephosphorylation experiments on 
desalted pepsin from the quench experiments and on native pepsin were carried out 
using commercial alkaline phosphatase. However, this gave poor results so the ^
phosphatase was further purified by DEAE-cellulose chromatography, followed by 
ultrafiltration. The concentrate was then used for further experiments, which still 
failed to give one band from pepsin on the SDS gels.
A consistent problem with this approach was the difficulty in visualising the pepsin 
run on SDS gels. Pepsin was poorly and irregularly stained with Coomassie Brilliant 
Blue G250, as has been noted by several authors.®®® This effect may be due to the 
low level of basic amino acids in pepsin (1 lysine, 2 arginine and 2 histidine from 327 
In total®®®). Similarly, zeins, proteins isolated from corn seed that contain almost no 
lysine and little (around 3%) arginine, have been shown®®"* to give very low 
absorbance readings in the Bradford assay.®®® The binding of Coomassie Blue to 
proteins has been shown to correlate with both the basic and hydrophobic amino 
acid content,®®® so poor binding may not just be due to low levels of basic amino 
acids.
Other stains tried included Naphthol Blue Black and Fast Green FGF. Fast Green
proved to be the best of those tried, however, the staining was still not very sensitive
or reliable. The irregular staining problem could also be partially overcome by
loading the gels at much higher levels than is normal (protein concentrations of 4-16
mg ml'"* were used compared with the normal range of 0 .2-2 mg ml'"*). None of these
experiments could be shown to provide evidence for formation of pepsin with altered
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experiments could be shown to provide evidence for formation of pepsin with altered 
electrophoretic behaviour. It Is expected that the loss of one carboxyl group from æ 
pepsin (as it is converted to the alcohol) would result In a change In Its 
electrophoretic mobility. However, given that there are 43 acidic residues In 
p e p s i n , t h e  loss of just one may well have no observable effect.
2.1.2 Face of attack of the lytic water molecule
A still unresolved question In the nucleophilic water mechanisms Is the orientation 
of the scissile carbonyl within the active site. Does It point In toward the active site 
aspartates, or outward toward the flap? Several theories favour the first 
alternative,2“’ others the latter.^o In an attempt to resolve this conflict an 
experiment was designed to attempt to trap the tetrahedral Intermediate proposed In 
these mechanisms. At the same time It was hoped that stereochemical information 
on the direction of water attack on the scissile carbonyl could be derived.
The two possible modes of attack by the lytic water molecule are shown below 
(Scheme 2.1.4).
R2i^r ^ o -
Scheme 2.1.4: Two possibilities for the direction of water attack upon the scissile
bond
The two possible directions for attack upon the scissile carbonyl by labelled 
water result In two possible Isotopomers of the tetrahedral Intermediate, as shown
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above. It was hoped that this intermediate could be trapped by positioning a group 
close to it that possessed a suitably oriented leaving group. Thus, a substrate for this 
experiment would be a peptide with an amino acid at that had a side-chain 
modified to contain a good leaving group. The isosteric valine analogues, the
b r o m o b u t r y in e s ,^ 0 4  |ent themselves ideally to the task.
Cr NH
OpH H
N ' I  "COgH 
■ H
Figure 2.1.4: The trapping peptide 
X = Br, Y = CH3 - 3R eplmer 
X = CH3 , Y = Br - 3S eplmer
This sequence for the trapping peptide was chosen as phenylalanine is known to
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Figure 2.1.3: (2S, 3S) 2-amino-3-bromobutyrine hydrochloride
This compound and its C-3 eplmer, the 3R compound, have bromine as a good 
leaving group that it was hoped would be suitable for trapping the tetrahedral 
intermediate. An attempt was made to predict which of the two epimers of the 
bromobutyrine would be the most likely to trap the tetrahedral intermediate using
molecular modelling. A crystal structure of unliganded p e p s i n with a tripeptide, 
N-acetyl-L-phenylalanyl-bromobutyrine-L-alanine (Figure 2.1.4) manually docked 
into the active site was examined. No good guide as to the most favourable eplmer 
for trapping could be obtained.
that these favoured residues would ensure that the peptide bound productively in the 
and P2 ’ pockets and not non-productively in any other of the enzyme subsites. 
This w ill ensure that the scissile bond lies on the N-terminal side of the 
bromobutyrine to maximise the probability of trapping the oxyanion.
An outline of the trapping experiment is given below (Scheme 2.1.5). The 
experiment was to have been carried out in ‘•^O-labelied HgO. The amount of 
trapping was expected to be very small indeed, so very sensitive methods would 
have been needed for detection. Mass spectrometry seemed ideally suited to this 
task as only small amounts of material would be needed and the sensitivity of 
detection of any ^^O-label incorporated into the product lactims would be high.
OH
Scheme 2.1.5: Trapping of oxyanion intermediate by bromobutyrines
The products will be isolated as the lactims (C) (from product (A) above) and (D) 
(from product (B) above) and analysed by mass spectrometry.
82
T -T -
Figure 2.1.5: Lactims, the proposed finai product of the bromobutryine oxyanion
capture experiments
It is assumed that the two oxygen atoms of the grem-diolate are in rapid protonic 
equilibrium, at a rate much faster than either or k2 in Scheme 2.1.5. Which of the
two epimers of the bromobutyrine gives the most incorporation of ^0 -label into the 
lactims will provide information on the face of approach of the lytic water molecule to 
the scissile carbonyl bond.
The syntheses of the two epimers of the bromobutyrine were carried out initially 
following the method of Akhtar and Gani,^®^ which is outlined in Scheme 2.1.6 .
HoN CHg f-OH
COgH H 
L-Threonine
(i) PhCHgOCONH
COoH H
PHg 
OH
(A)
Cr HgN+ Br
COgH H
(ii)
(iv)
(2R, 3S)-2-amino-3-brQmgbutyrlne hydrochloride
CbzNH
hW
cc
^O H
OgMe H 
(B)
(III)
CbzNH
hV t '
COgMe H
BrCHg
(C)
Reagents: (i) PhCH2 0 C0 CI, NaHCOg, water, 25°C, 3 h.
(ii) CH2N2 , diethyl ether, 25°C, 1 h.
(iii) CBr^, PPh^, benzene, 25°C, 90 min.
(iv) 12 M hydrochloric acid, glacial acetic acid (1:1 v/v), 100°C, 2 h. 
Scheme 2.1.6: Synthesis of the (2R,3S) bromobutyrine
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If the same approach was to be followed for the synthesis of the 3R epimer then a 
source of L-a//o-threonine, the starting material, was required. This is available 
commercially but is prohibitively expensive, so a synthetic route was required. The 
initial approach is shown in Scheme 2.1.7.
H COoH HoN
HOgC CHg 
Mesacpnic acid
" • H * 'COgH H
COgH 
CHo
(A) (B)
GF3 CONH PO-O-O-COC6 H4 GI 
’ ^GHa
H^
GF3 GONH POGI 
V I £*GHo
GOgM©
(E)
H t r
GF3GONH
IV
GOgMe
(D)
COgH 
GH3
H'^ 
GOgM©
(C)
Reagents: (i) p-Methylaspartase, Mg2+, K+, H2O, 30°C, 45 h.
(ii) (CF3C0)2C0, THF, 25°C, 2 h.
(iii) Methanol, 25°C, 20 mins.
(iv) SOCI2. 80°C, 1 h.
(v) 85% mCPBA, pyridine, Et2 0 , 0°C, 4 h.
Scheme 2.1.7: The attempted synthesis of L-allo-threonine
The final two steps of the synthesis, which were not achieved, are the thermally 
promoted radical rearrangement of the perester to give N-protected, O-m- 
chlorobenzoyl methyl L-a//o-threoninate, which would then be subjected to acid 
hydrolysis, to give L-a//o-threonine hydrochloride.
Compound (0) is produced as a mixture of the a  ester and the p acid and the a 
acid and the p ester as shown by 2 methoxy peaks in the proton n.m.r. spectrum. The 
two regioisomers may be resolved by a fractional crystallisation, which proved to be 
extremely difficult. In an attempt to increase the selectivity of the opening of the
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methyiaspartic acid anhydride the reaction was carried out at 0 °C and -10 °C, but 
without significant effect. The mixture was carried through to reaction with the 
mCPBA, but the mixture of regioisomers from this reaction could not be separated 
either. Once the L-a//o-threonine is obtained the synthesis of the (2R, 3R) 
bromobutyrine would proceed exactly as for the (2 R, 3S) diastereomer.
The most obvious route to L-a//o-threonine is a Mitsunobu-type inversion of the C-3 
centre of L-threonine, however this has been shown to result in elimination.^^® Thus 
an alternative synthesis of the starting material was required. It was considered that 
the approach outlined in Scheme 2 .1.8 might provide L-a//o-threonine cheaply in 
reasonable quantity. The initial step is difficult, as the usual aqueous work-up of 
Sharpless epoxidations cannot be used due to the high water solubility of the 
epoxide product.®®^ Sharpless oxidation®®® and opening of the epoxide with 
ammonia would then complete the synthesis.
H.C\
,0H
HqC. HoC.
COgH
NHa PH
,£^ CHa
1 1COgH H
Reagents: (i) tBuOOH, Ti(iPrO)4, (2R, 3R)-{+)-DIPT, CH^CIa,-78 °C.
(ii) RuCIg.SHgO. NalO^.
(iii) NHg.
Scheme 2.1.8: The new synthesis of L-alio-threonine
However, whiist this was in progress the same route was published.^os 
In the initial synthesis of the bromobutyrines (Scheme 2.1.6) the finai step is acid
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hydrolysis of the amino and carboxy protecting groups in one step, yielding the 
bromobutyrine hydrochloride. This is unsuitable for further coupling as it is carboxy 
unprotected. This acid deprotection step is necessary as the bromine-carbon bond is 
not stable to the hydrogenation conditions usually employed to remove the 
benzyloxycarbonyl group. As a result the bromobutyrine methyl ester, which is 
required for further peptide coupling, cannot be produced directly from the fully 
protected bromobutyrine if benzyloxycarbonyl amine protection is used. The carboxy 
group could be reprotected after the acid deprotection, but this is inefficient.
Unprotected amino acids can be coupled in weakly alkaline aqueous solution by 
the azide coupling method. This method was explored using the model coupling of 
acetyl-L-phenylalanine and L-valine. The azide method has the additional attraction 
that it has been reported that it is the only method to provide racemisation-free 
coupling of N-acetylated amino ac ids.®However ,  poor yields resulted and the 
procedure did not appear well suited to the model system. The carboxy protection 
chosen for the L-valine residue had to be carefully chosen as no base-sensitive 
groups could be used or the base employed may have racemised the N-acetyl-L- 
phenylalanine. Thus, acid-sensitive fe/t-butyl protection was investigated. Several 
methods were investigated for synthesising ferf-butyl-L-valinate. These included 
acid-catalysed estérification with liquid isobutylene®'*'* and reaction of the acid 
chloride or mixed carboxylic anhydride®"*® with fe/t-butanol and/or sodium tert- 
butoxide. None gave significant amounts of product (as Judged by the lack of a f-butyl 
signal around 1.5 p.p.m. in the proton n.m.r spectrum) so the approach was 
abandoned. The use of fe/t-butyl protection would have allowed selective removal of 
a base-sensitive N-protecting group. Consequently it was decided that Fmoc®"*® (9- 
fluorenylmethyloxycarbonyl) and or Boo (tertiary butoxycarbonyl) amino protection 
would be used, which can be easily removed without affecting the carbon-bromine 
bond.
Fmoc seemed ideal as it is easily put on and removed and its base, rather than 
acid, lability means that the free amine product is produced, which can be used 
directly in the coupling procedure. It also allows the carboxy blocking group, in this 
case a methyl ester, to be retained right through the synthesis, thus increasing the 
overall yield. The Fmoc group was put on using Fmoc chloroformate®"*® and no 
production of dipeptide was observed thus eliminating the need to use Fmoc 
a z i d e . ® similar advantages arise from the use of Boo protection, except that the
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amine salt arising from the acid catalysed removal of the Boo group would need to 
be neutralised prior to coupling. Both approaches were tried and the Boc group 
proved superior due to greater ease of handling of some of the synthetic 
intermediates. Unfortunately, the synthesis of the peptides for the experiment was not 
completed as attention was directed elsewhere.
In summary the series of experiments carried out on pepsin were inconclusive or 
incomplete. The attempts at trapping a possible covalent intermediate gave only 
negative information. After the trapping experiments were carried out the aspartic 
protease from HIV was brought to our attention. It seemed an attractive target for a 
variety of mechanistic and active site directed studies due to its small size (see 
Section 1.6.2) and availability. It was hoped that information gleaned from these 
studies would be of use in the design of therapies for HIV Infection, based on 
inhibition of the protease.
2.2 Design of HIV-1 Protease inhibitors
In undertaking the design of a novel class of HIV protease inhibitors the strategy 
developed so successfully in the design of renin inhibitors was followed.®®® In this 
strategy a good peptide substrate sequence is identified and its scissile amide bond 
replaced by a non-cleavable analogue. A good substrate sequence can be identified 
from a consensus of sequences of preferred peptide and/or protein substrates. It is 
assumed that good substrate sequences will provide strong binding for the inhibitor 
as all the binding energy available will be expressed in binding and not in distorting 
the ligand as occurs with substrates.
We searched for a scissile bond analogue that possessed maximum congruency 
to the transition state, or stable intermediate, for the reaction catalysed by the 
protease. A moiety was required that possessed the most similar geometry, charge, 
hydrogen bonding capacity and size possible. The principle underlying the 
insistence on close mimicry was two-fold. First, transition state analogues were 
expected to be bound tightly by their target enzyme.®^® Second, all other classes of 
scissile bond analogues so far developed lack one or more hydrogen bond donors 
or acceptors compared to the stable intermediate and this may have an influence on 
the active site structure (see below). The phosphonamidate moiety was eventually
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chosen as the scissile bond mimic. When this work was begun little was known 
about the properties of phosphonamidates as aspartic protease inhibitors, and no 
phosphonamidate-based HIV-1 protease inhibitors had been published. The use of 
a phosphorus containing transition state analogue has the additional advantage that 
®‘*P n.m.r. spectroscopy may be used to investigate rates and equilibria in binding to 
the protease.
As discussed in Section 1.3.3 the exact nature of the stable intermediate in amide 
hydrolysis by the aspartic proteases is unknown. A phosphonamidate and its methyl 
ester with the two possible tetrahedral stable intermediates are shown in Figure 
2 .2 .1. It can be seen that they have very similar charge distributions, geometry and 
size. Phosphorus-oxygen single and double bonds are about 10-15% longer than 
the corresponding carbon-oxygen bonds.®"*® This allows the P=0 double bond in the 
phosphonamidate to mimic the lengthening of the carbonyl bond as it is attacked by 
the lytic water molecule.
Substrate
‘NR'o
I HO. .OH 
Gem-diol
R
Q
X
OCHg
S .^NR'o
H' "R 
Phosphonamidate methyl ester
RJx<X
Gem-dlolate
0-
NR'2 X NR'pH" "R 
Phosphonamidate
Figure 2.2.1: Comparison of the possibie stable intermediates and
phosphonamidates
As the pKg for the phosphonamidate is around 3,®"*^  at the pH optimum for the 
HIV-1 protease (5.5, see Section 1.6.2) it will be negatively charged. Thus, the 
phosphonamidate will not be a good mimic for the neutral tetrahedral intermediate 
under the conditions of testing. If it should be that the stable intermediate in 
hydrolysis is the uncharged gem-diol-like amide hydrate (see Section 1.3.3) then the
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phosphonamidate methyl ester would be expected to be the closest mimic. The 
charge congruency of the phosphonamidate methyl ester and the pem-diol-like 
tetrahedral intermediate has been proved by semi-empirical quantum mechanical 
calculations carried out using MOPAC 6.0 with the AM1 m e th o d .^ Th e  results are 
given below in diagrammatic form, with the partial charges residing on each atom 
shown. A similar calculations have been carried out^^^ and similar results were 
obtained.
-0.628 -0.463 -0.393 -0.422
I 1 /;:
N C H
0.243 
186 OH
- 0 .
N; CH/-0.147
1.093 -0.559
08
0.471
H
-0.613
0.454
Figure 2.2.2: Charge density comparison of a model phosphonamidate methyl
ester and a model amide hydrate
The crucial points of similarity are the oxygens and the nitrogen of the hydrate and 
of the phosphonamidate methyl ester. The partial charges on the oxygens can be 
seen to be similar, showing again the close analogy between the two moieties. An 
ab initio calculation was recently carried out on phosphonamidates and similar 
results to those given above were found.^^ In the same study it was found that the 
stable intermediate for acid-catalysed peptide bond hydrolysis is likely to be the 
neutral amide hydrate (see Section 1.3.3). Phosphonamidates were not good 
models for this stable intermediate but phosphonamidate methyl esters were found 
to be better. The transition state for amide hydrolysis was found to be zwitterionic.
Only the phosphonamidate, hydroxyethylamine, norstatine and reduced peptide 
scissile bond mimics (see section 1.6.3) possess a nitrogen atom in the residue. 
The dihydroxyethylene inhibitors also have a hydrogen bond acceptor at this 
position (the C-terminal C-OH group). It has been proposed that the P i’ nitrogen in
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HIV-1 protease substrates is involved in hydrogen bonding to the OH of aspartate 25’ 
at the active site.^fs Possession of a hydrogen bond acceptor at this position in an 
inhibitor could potentially be important for maximising binding and will affect the 
conformation of the active site aspartates. Therefore, we considered it important to 
retain this interaction in our inhibitors to provide as close a mimic for the tetrahedral 
intermediate as possible.
The other aspect of the design to be considered was the nature of the amino acid 
sequence flanking the scissile bond. At the time this work commenced, most of the 
data available on the subsite specificity of the HIV-1 protease had been derived from 
studies on the gag-pol polyprotein cleavage sites. Thus, our Inhibitors were initially 
based on sequences derived from these sites. A striking feature of these sites in the 
viral polyprotein is the number with proline at P^’ (see Section 1.6.2). This cleavage 
is unique to the retroviral proteases as Xaa-Pro bonds are not cleaved by the 
mammalian or fungal aspartic p r o t e a s e s . ^ o ^  This property can therefore be used to 
build selectivity into our inhibitors as if a Phe-Pro scissile bond mimic is used the 
resulting inhibitor will not be tightly bound by host proteases, only the HIV protease. 
Retroviral aspartic proteases all seem to require minimally hexameric substrates 
(see Section 1.6.2), which indicated that an inhibitor with 6 binding determinants 
would be required. The amino acid at P^  was found to be nearly always large and 
h y d r o p h o b i c . ^ 2 0  Considering all the above a candidate sequence was designed:
Phe-Asn-Phe * Pro-lie-Val
All the residues of this sequence occurred at least twice in the same position in the 
cleavage sites found in the gag-pol poly protein, thus this sequence should be a 
good substrate. Replacement of the scissile Phe-Pro bond should then provide a 
good inhibitor. Replacing phenylalanine at P3 by the Boc protecting group gave the 
sequence of the target compound 000 (Figure 2.2.3). Thus the initial target has 6 
binding determinants (like a hexapeptide) but only 3 peptide bonds. A very similar 
design strategy has recently been used in the development of a//ophenylnorstatine- 
based inhibitors for the HIV-1 protease^^^ which were found to be quite potent (Kj’s 
of the best inhibitors around 10 nM).
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CH,
CH,
CH,
CONH;O v v
o
Figure 2.2.3: The initial target compound, DG 000 
where R = H or CH3
The program of synthesis, testing, modelling of the target compounds and 
evaluation of results was carried out in conjunction with Mr. Nicholas Camp and Mr. 
David Perry. The synthesis of the central aminophosphonic acid moiety and most of 
the in vitro testing was carried out by me. Some of the later assays were carried out 
by Mr. David Perry. The aminophosphonic acid moiety was incorporated into the 
inhibitors by Mr. Nicholas Camp, as shown in Scheme 2 .2 .1. The compounds were 
also tested in an in vivo assay by Dr. Derek Kinchington at St. Bartholomew’s 
Hospital.
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\  /
uA.CHg "NH
H 1 PO(OPh)a
CHaPh'^
CHo
oA.
(A)
'NH or  |/OMe
.OH2 OH Ph^
(B)
III, IV, V
Compound 000 VI, VII
MeO
Obz-HN.
(C)
Scheme 2.2.1: The synthesis of compound 000
Reagents: (i) 2.2 eq. NaOMe, MeOH, r.t.; (ii) 2.5 eq. NaOH, MeOH, r.t.; (iii) SOCI2, 
CH2CI2 , r.t. then; (iv) HN-Pro-ile-NHiBu.HCI, NEtg, CH2CI2 , r.t.; (v) Chromatographic 
resolution on silica EtOH/ CH2CI2 5:95; (vi) Pd/C, H2, MeOH, r.t.; (vii) Boc-Asn, 
iBuOGOCI. NMM, THF, -15°G.
The phosphonamidate is produced from the methyl ester (compound 000) by 
treatment with 4 eq. LiOH in dioxane. The synthesis of compounds (A) and (B) will be 
discussed in detail in Section 2.3. The stereochemistry of the 2 resolved 
diastereomers of compound 000 and the 4 diastereomers of the methyl ester (the 
phosphorus of the methyl ester is chiral) was assigned by Nicholas Gamp using a 
combination of X-ray crystallography on a synthetic intermediate, chemical 
degradation, '•h, and ^ ’•P n.m.r. spectroscopy.
2.3 Synthesis of the phosphonamidate portion
The phosphonamidates were synthesised by coupling activated aminophosphonic 
acid half esters to various peptides, as shown in Scheme 2.2.1 above. The half
92
esters were activated for the coupling by conversion to the phosphoryl chloride with 
thionyl chloride. Therefore, an efficient route to N-protected aminophosphonic acid 
half esters was required. These species were then used by Nicholas Camp to 
assemble the inhibitors prior to testing.
2.3.1 Synthesis of aminophosphonic acids
The synthesis of aminophosphonic acids, which are close analogues of the amino 
acids, has attracted much interest and a wide variety of methods have been 
developed. The study of phosphorus analogues of the naturally occurring amino 
acids was begun by C h a v a n e ^ ^ t  gnq the first phosphonamidate containing peptides 
were synthesised by lm o t o ^ 2 2  and M a r t e l l . ^ 2 3 , 3 2 4  Much work since then has been 
directed at the synthesis of 1-aminoalkylphosphonic acids and their esters and 
peptides containing phosphonamidate moieties (see Figure 2.3.1).
NH, ^
H" •P(0 H)2
R
Figure 2.3.1: A 1-aminoalkyiphosphonate
Also, due to their closer resemblance to carboxylic acids, the alkylphosphonous 
acids (which have 1 OH group) have been extensively studied and most of the 
analogues of the naturally occurring amino acids have been s y n t h e s i s e d . ^ ^ s
Various approaches to the synthesis of racemic 1-aminophosphonic acids have 
been taken. The classical route is the addition of trialkyl phosphites to imines in 
refluxing toluene.^^® A milder method involves the addition of trimethylsilyl esters of 
phosphorus acids to imines in dichloromethane at 0 Recently the three-
component condensation of a carbamate, aldehyde and phosphorus triester has 
been extensively exploited to give N-protected alkyl and aryl^^s phosphonic 
diesters. Also, oxidative decarboxylation of a-aminocarboxylic acids to give 0-acetyl 
N,0 acetals and subsequent reaction with a trialkyl phosphite has been used. The
decarboxylation has been carried out electrochemically^^^*^^® or with lead
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t e t raace ta te .A f te r  considering all these alternative routes it was decided to opt for 
the three-component coupling developed by Oleksyszyn et which gives
diphenyl phosphonates. Two further reactions would then provide the required 
phosphonate half-esters (Scheme 2.3.1).
o
R-CHO + (PhO)3P + PhCHg-O-CO-NHg AcOH Ph—
P(0Ph)2
KF, MeOH or 
NaOMe, MeOH
Cbz—NH
H'/WT;—
NaOH. MeOHR'
\^O H
\ mo
Cbz—NH 
H'/w^— p' 
^ P (0 Me)2
Scheme 2.3.1: Synthesis of the N-protected 1-aminoaikylphosphonate half esters
The diphenyl phosphonate was formed, in only moderate to poor yields (29-53% 
depending on R), by the three component condensation, then transesterified by 
treatment with sodium methoxide^^^ or potassium fluoride in methanoP^'^ to give the 
dimethyl phosphonate. Removal of one methoxy group by treatment with sodium 
hydroxide and subsequent chlorination provides the phosphoryl chloride derivative, 
suitable for coupling to the C-terminal peptidic moiety. However, this route gave a 
low overall yield (around 15-25%), due to the inefficient first step.
A more obviously direct route is to use trimethyl phosphite, instead of triphenyl 
phosphite, in the three component coupling to give the dimethyl phosphonate 
directly. The removal of step two would increase the overall yield. However, when 
this was tried under the conditions of the three component coupling a product without 
methoxy group signals in the proton n.m.r. was formed. The reasons for this are 
unclear as some kind of reaction does definitely occur (the reaction is highly 
exothermic in the first few minutes) but the desired product is isolated in very low
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yield. As judged by P n.m.r. the product from this reaction also contained no 
phosphorus. The reaction therefore does not proceed as for triphenyl phosphite, 
where the first step Is probably attack on the aldehyde by the phosphite (Scheme 
2.3.2).
0H+
R'
HO:
R
OPh
RO
OA.R O ' "NH
H 1------P0(0Ph)2
R'
Scheme 2.3.2: Possible mechanism for the three component coupling
A possible alternative mechanism involves initial attack by the carbamate (instead 
of the phosphite) on the aldehyde, followed by reaction of this intermediate with the 
phosphite (Scheme 2.3.3). This has precedent in the three component coupling
involving formaldehyde.^^^ Thus efforts were made to preform the possible reaction 
intermediate between the aldehyde and the carbamate and then react this species 
with trimethyl phosphite in a separate step. Since trialkyl phosphites add to
i m i n e s , a t t e m p t s  were made to synthesise the imine by acid-catalysed 
dehydration. Other attempts used acetic anhydride or acetyl chloride to generate the 
0-acetyl intermediate that would then eliminate to give the imine. These all proved 
fruitless, as no addition product could be detected by t.I.c or proton n.m.r. 
spectroscopy. A variant on this reaction was tried, using lead tetraacetate to give the
imine from racemic N-protected amino acids.^^® The imine was then treated with
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trimethyl phosphite or the dimethyl phosphite anion but the reaction was found to be 
unreliable and was therefore replaced by the three component coupling (Scheme 
2.3.1).
RO' 'NHa
OA.R O ' "NH
0H+
P(0Me)3 R
H 1----- P0(0Me)2
R'
A  A^ O ^  NH-
OA, H
OH
R'
AcCI or AC|P
R'
-AcOH
OA OAcO ' NH-
R*
Scheme 2.3.3: Proposed reaction to give three component coupling with trimethyl
phosphite
An obvious variant on the initial inhibitor sequence would be to replace the 
phosphophenylalanine residue at P-j with the phospho analogue of tyrosine. This 
requires a protected version of para-hydroxy phenylacetaldehyde for the three 
component coupling, probably para-methoxy phenylacetaldehyde. This is not 
commercially available, so a number of possible routes to it were examined. As 
shown in Scheme 2.3.4 there are a number of alternatives. The most obvious is 
oxidation of para-methoxy phenethanol (route A). Several mild methods of oxidation 
were explored, such as the Swern,^^^ Parikh^^® and Collins^^® oxidations and the 
use of PCC.^"^^ None proved to be effective, giving mixtures of products that could 
not be identified, as well as a small amount of aldehyde (as judged by a peak around 
9 p.p.m. in the proton n.m.r.). Swern^^^ found that the oxidation of 2-phenylethanol 
gave only a 23% isolated yield of the corresponding aldehyde, consistent with the 
results found in this study.
Several routes from para-methoxy phenylacetic acid or derivatives were 
considered. Reduction of the acid chloride (route B) with lithium tri-ferf-butoxy
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aluminium hydride^^"* or bis(triphenylphosphine)tetrahydroboratocopper^^^ proved 
ineffective. Reduction of the methyl ester^^^ or the Weinreb amide^"^"  ^with diisobutyl 
aluminium hydride were also considered but not attempted.
A rather different approach (routes C and D) was also tried, joining a suitably 
protected aldehyde fragment (bromoacetaldehyde diethyl acetal) to the para position 
of anisole and then deprotecting. This can be done using a Grignard reagent or 
lithium salt generated from a p-haloanisole (route C), or under Friedel-Crafts 
conditions (route D). Neither of these routes proved to be successful.
(A) MeO CHgCHgOH — L?.j— MeO /  % CHgCHO
(B) MeO /  % CHgCO-CI CHgCHO
(C) MeO Br i) n-BuLi, hexane ^
ii) B rC H 2C H (O E t)2  
Iii) H+. HgO
MeO CHgCHO
(D) MeO
i) B rC H 2C H (O E t)2AlClg
ii) H+. H2 O X MeO GH2GHO
Scheme 2.3.4: Possible syntheses of p-methoxy phenylacetaldehyde
The difficulty with the third route, metallating a p-haloanisole to generate a 
nucleophile, is that the position of iithiation or formation of the Grignard migrates 
around the phenyl ring so as to become ortho to the methoxy group. The metallations 
are reversible, so they give the most stable form of the metallated ring. The most 
stable form occurs when the metal of the carbon-metal bond of the anion is able to 
interact with the electron-donating substituent i.e. is ortho to the substituent. 
Migration of metallation so that it becomes ortho to an electron-donating substituent 
is commonly observed in similar systems.®^® Generation of either the Grignard or the 
phenyllithium species, followed by quenching with clearly showed (by proton 
n.m.r. spectroscopy) that deuterium was incorporated ortho to the methoxy group.
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Therefore, the anion had undergone migration from its original para position so as to 
become ortho to the methoxy group. No clean reaction could be observed with the 
Friedel-Crafts route. Both routes were therefore set aside and new methods 
examined.
An initially favourable route identified was the reaction of commercially available 
para-methoxy styrene with thallium (III) nitrate^^® in methanol to give para-methoxy 
phenylacetaldehyde in one step. However, to scale up the reaction to the 50-100 
mmol scale required would require the handling of large quantities of toxic thallium 
(III) nitrate and result in large amounts of toxic thallium (I) by-products. It was 
considered that metallating p-methoxy benzyl bromide and reacting the resulting 
anion with methyl formate or formyl chloride may have provided a workable route but 
this was not attempted. In conclusion the difficulties encountered in the synthesis of 
para-methoxy phenylacetaldehyde proved insuperable and other approaches to the 
phospho analogue of tyrosine were sought.
The three component condensation (Scheme 2.3.2) has two major disadvantages. 
It depends upon the aldehyde being readily available or easily prepared and it does 
not work with formaldehyde. A  variation has been reported for fo r m a ld e h y d e ^ s s  ^ut 
this was found to be unreliable in our hands. Thus another approach to the 1- 
aminoalkylphosphonates was required, and a route that solves both of these 
problems is outlined below (Scheme 2.3.5).
i) LDA II
^  R h -N -C H — P(0Me)2
R
NaH, H-P(0)(0Me)2
o
(A) (B)
H2N-NH2
EtOH
O
IIHgN— CH— P(0 Me)2 
R
(C)
Scheme 2.3.5: Synthesis of dimethyl 1 -aminoalkylphosphonates
The compound A in this scheme is phthalimido protected dimethyl 1-aminomethane
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phosphonate. This can then be converted to its anion with a strong base and 
alkylated with any required side-chain. The use of LDA or other such bases (such as 
LHMDS) is to be preferred for this reaction over nBuU, as nBuLi could demethylate 
the phosphonate in preference to deprotonation. Phthalimido N-protection seemed 
especially suitable for this reaction, as there is no acidic amide proton. It was 
expected that this proton would be removed by the base and the resulting anion on 
nitrogen would suppress anion formation or alkylation on carbon. However, the work 
of Steglich^"^^ has shown that this is not so, and alkylation on carbon a to an amide 
NH proceeds in good yield. Treatment of intermediate (B) with ethanolic hydrazine 
should provide dimethyl 1-aminoaikyl phosphonates. S im ilar treatm ent of 
intermediate (A) would give dimethyl 1-aminomethane phosphonate.
Surprisingly, the first step in Scheme 2.3.5 did not proceed if it was performed as for 
the ethyl a n a l o g u e . ^ ^ 3  Treatment of N-bromomethyl phthalimide with neat trimethyl 
phosphite gave no detectable reaction by t.I.c., in contrast to the vigorous reaction 
observed with triethyl phosphite, where ethyl bromide is rapidly evolved from the 
reaction. Several variations on this method were attempted, using longer reaction 
times and elevated temperatures, without success. The literature method for the 
methyl analogue^"^® is long and was found to give only moderate yields (45-55%). 
Thus, a new method was developed, as outlined above, using the anion of dimethyl 
phosphite, generated with sodium hydride. Isolated yields of compound A from this 
route approached 85%.
When this route was applied to the synthesis of dimethyl  1 - 
aminobenzylphosphonate very low yields of product were formed. Quenching the 
alkylation reaction with deuterium oxide, after addition of LDA, to assess the amount 
of anion formation gave low levels of deuterium incorporation, as judged by proton 
n.m.r. spectroscopy. However, on addition of LDA to the intermediate (B) there was 
almost instant formation of a dark orange colour in the reaction, consistent with 
extensive anion formation. The low level of deuterium incorporation, however, 
indicates that low levels of metallation were achieved. The reason for this is unclear.
A similar approach to that in Scheme 2.3.5 was tried, using a phosphomalonate 
analogue, compound (C) below (Scheme 2.3.6). The presence of a carboxyl ester 
and a phosphonate diester bonded to the same methylene group should result in the 
methylene protons being very acidic, by analogy with malonate diesters. Thus, 
formation of an anion at this centre should be favoured and it was considered that
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subsequent alkylation would be straightforward. Once the alkylated product has 
been formed, decarboxylative saponification (a facile process in the malonates) 
would give the N-protected dimethyl 1-aminoalkyl phosphonate.
All the steps, except for the decarboxylation, are from the literature, the first two 
being straightforward and reasonably high-yielding (around 50% over the two 
s t e p s ) .^ 4 9  It  has also been shown that the construction and alkylation of the 
phosphomalonate species is reasonably simple.^®® A three-component coupling 
reaction was attempted to form the phosphomalonate (C) directly in one step, from 
glyoxylic acid, benzyl carbamate and either trimethyl or triphenyl phosphite. This was 
unsuccessful in either case, as no product could be isolated from the reaction.
CHo T OH EtoO
Cbz-NH Cbz-NH
'•PO{OMe)2 
GOgM©
i) NaH, THF 
ii) R-Br
(D)
_ i) PCIg^  toluene 
''PO{OMe)2 ^  |i)P(0Me)3 CO2MG
(C)
i) NaOH, dioxaneii) Toluene, heat
Cbz-NH
'PO(OMe)2
CHo AO'" "NH
H-^p-OH CO2H
(A)
H+, MeOH
^NHCH
uA.
H-^p-OMe
C02Me
(B)
Scheme 2.3.6: Proposed route to 1-substituted dimethyl phosphonates via
phosphomalona tes
The major difficulty forseen with this route was the lack of selectivity in the base 
hydrolysis between the carboxylic and phosphonate esters. It was expected that the 
phosphonate ester will be hydrolysed first, due to its lower first pK^. If the 
phosphonate ester is hydrolysed (and is therefore anionic) before the carboxylic
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ester then there will be no stabilisation of the negative charge, a to the phosphonate, 
resulting from decarboxylation. Thus, decarboxylation will not be favoured. It has 
been found that it was possible to hydrolyse the carboxylic ester selectively in the 
presence of the dimethyl pho sp hon a te .D ecarboxy la t i on  by heating with 1 
equivalent of triethylamine in toluene should then proceed smoothly.
However, the alkylation step gave several unidentified by-products and no product. 
Quenching the anion (generated with sodium hydride) with ^HgO showed a low (up 
to 30-40% of theoretical) incorporation of deuterium at the methylene group, as 
judged by proton n.m.r. spectroscopy. This indicated a low degree of anion formation, 
which could not be significantly increased by various alterations to the reaction time i
and temperature. The insuperability of this problem led to the route being 4
abandoned. Attention was then turned to stereoselective routes.
2.3.2 Stereoselective routes to aminophosphonic acids
Clearly a stereoselective route to optically active a-aminophosphonic acids would 
be very useful and many methods are available (reviewed in^®^). Addition of 
phosphites to chiral imines was the first method used.^®^ Some approaches have 
alkylated chiral phosphonamidates^^^ or chiral aminomethylphosphonates,^^^ 
whereas other approaches have relied upon alkylating aminomethylphosphonates 
with attached chiral auxiliaries (a variant on the glycine e no late approach). 
Addition of phosphites to nitrones^®® or oxoiminium salts^®^ and the cycloaddition of 
ethylene to a chiral nitrone^^® and subsequent reaction with a phosphite have also 
been utilised. A “reverse” protocol involving the addition of chiral enamines to 
acylim inophosphonates^^^ has been useful only for the production of non- 
proteinogenic amino acid analogues. A few enantiomerically pure 1-aminoalkyl 
phosphonates have been synthesised by a chiral gold (1) complex catalysed 
asymmetric aldol condensation with isocyanomethyl phosphonates.^®^ Electrophllic 
amination of chiral phosphorus-stabilised anions has given good yields and high 
selectivi ty.®®’’ There is one report on the asymmetr ic hydrogenat ion of 
dehydrophosphonic acid derivatives.®®® Lewis acid promoted cleavage of 
homochiral acetals by alkyl phosphites followed by stereoselective amination has
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also been used.^®^
Another possible route to stereodefined phosphonamidates is to resolve racemates 
produced, for example, by the three component coupling (Scheme 2.3.1). It is 
possible either to resolve using a chiral base, to react with the deprotected 
phosphonic acid, or a chiral acid to react with the deblocked amino group. It was 
decided, following literature p re c e d e n t,th a t the simplest route would be to use a 
chiral acid. In this approach (Scheme 2.3.7) the racemic 1-aminoalkyl diphenyl 
phosphonate is made to react with dibenzoyl-(L)-tartaric acid to give two 
diastereomeric salts. These can be resolved by fractional crystallisation and the 
enantiomerically pure 1-aminoalkyl phosphonate released by treatment with sodium 
hydroxide and extraction with dichloromethane.^^® Resolution can also be achieved 
with dibenzoyl tartaric anhydride, by fractionally crystallising the diastereomeric 
imides produced from the reaction with the 1-aminoaikylphosphonate and releasing 
the resolved 1-aminoaikylphosphonate by acid hydrolysis.®®® A similar approach 
uses penicillin acylase, which only hydrolyses the (R) enantiomer ((L)-amino acid 
analogue) of A/-acylated 1-aminoalkylphosphonates.®®^
R-CHO + (PhO)3P + PhCHg-O-CO-NHg AcOH ^ Ph CHa^
2 hr. O" "NH H.aa/|^ —R'
P^(OPh)a
i) HBr, AcOH
ii) NaOH, CHCI3
P h C O -Q
DBTA =
PhCO-O O^j'^OPhOPh
i) DBTA, EtOH
ii) NaOH, CHgCig
NHa 
H«aa/W—R'
O'î^ f'^ OPh
OPh
Dibenzoyl (L)-tartarlc acid
R' = ,CH, ,CH,CHo 'CHo
/OH
CHo /CHg-GH
CHo
HoC
CHo CHo
Scheme 2.3.7: The synthesis and resolution of the 1-aminoalkyl diphenyl
phosphonates
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The two step removal of the Cbz group was necessitated by the great difficulty 
found with hydrogenation. The reaction proceeded very slowly, even under pressure 
and with high proportions of catalyst (up to 30%) in a range of different solvents 
(methanol, ethanol and ethyl acetate). The product also proved Impossible to isolate 
in good yield. Eventually it was found that acetic acid was required in the 
hydrogenation to give a reliable reaction, but even then isolation of the product in a 
pure form was difficult. In contrast the two step method gave good yields (75% over 
two steps) of pure product and could be carried out quickly. Resolution was 
accomplished using the diphenyl phosphonates as the dimethyl esters are not stable 
to the HBr/AcOH treatment. Thus, two steps are required after the resolution, to give 
the half ester suitable for coupling. Resolution was only successfully carried out for 
the benzyl analogue.
The alkylation of aminomethylphosphonates with attached chiral auxiliaries was 
examined as a complement to this method, i.e. for those compounds for which the 
requisite aldehyde for the three component coupling is not readily available (as 
above). A glycine e no late approach was chosen in which a chiral auxiliary, camphor, 
and 1-aminomethanephosphonate are condensed to form a chiral imine, which can 
then be easily alkylated (Scheme 2.3.8). Camphor was selected as the chiral 
auxiliary due to its easy availability and the high enantiomeric excesses reported by 
Schollkopf^®® for the alkylation.
(1S)-(-)-camphor
H2N-CH2-PO(OMe)2 ToluenepTsOH
N ^ ^ P {O M e)2
I) n-BuLI, THF 
il) R-Br
H3N .P(OMe)2 H+
A  ^
N-.«.^P(OM e)2
K
Scheme 2.3.8: Schollkopf’s chiral synthesis of 1-aminoalkylphosphonates
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This method is essentially a stereoselective version of the routes shown in Schemes 
2.3.5 and 2.3.6
The chiral synthesis required an efficient route for synthesising the dimethyl 
aminomethylphosphonate. The variation on the three component coupling with 
formaldehyde^^^ was found to be unreliable in our hands and so other methods 
were examined. The route based on Scheme 2.3.5, deprotecting the phthalimido 
protected dimethyl aminomethylphosphonate with ethanolic hydrazine, was also 
examined and rejected as the product proved difficult to purify. A synthesis based on 
the addition of phosphites to triphenylmethanimine was found to be reliable and high 
yielding (Scheme 2.3.9).^®^ The readily available triphenylmethylamine and 
aqueous formaldehyde are condensed together to give the imine in around 80% 
yield. Reaction with trimethyl phosphite gave the trity l protected dimethyl 
aminomethylphosphonate. Treatment with dry HCI gas in methanol gave dimethyl 
aminomethylphosphonate hydrochloride, suitable for condensation with camphor.
II ToluenePh c  NHg + \ N = C H î
P(OMe)3
c T  ^P(OIVIe)2
o
Scheme 2.3.9: Synthesis of dimethyl aminomethylphosphonate hydrochloride
However, when the condensation reaction was tried very small amounts of the 
imine were formed (less than 10% overall yield).
Another stereoselective route to phosphoamino acids was investigated to 
overcome this problem. In this route the starting point is a N-protected a-amino acid, 
which is transformed Into the mCPBA peranhydride (B), v/a the acid chloride (A). This
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would then be thermally decarboxylated with retention of configuration at the a 
c e n t r e , t o  give the m-chloro benzoyl ester (C). This could then be made to react 
with dimethyl phosphite (or its anion) with inversion at the a centre to give the 
phosphoamino acid diester. To give phospho analogues of the L-amino acids the D- 
peranhydride would be required. This is easily available from the D-amino acid. 
Preliminary investigations on this route indicated that yields were low for the 
formation of the peranhydride.
C b z -N H
0001
(A)
(i)
Obz— NH
a O' ,0,
(B)
0 -!
01
\  /
Obz— NH
O.
(D)
(iii)
Obz— NH
• 0 -II0
(C)
.01
\  /
Scheme 2.3.10: Alternative stereoselective synthesis of phosphoamino acids 
Reagents; (i) mCPBA, Et2 0 , pyridine, (ii) Toluene, reflux, (iii) HPO(OMe)2 , toluene.
2.4 Phosphorus based protease inhibitors
Phosphorus based inhibitors have also been developed for other classes of 
proteases and other aspartic proteases. The work of Powers^^^ has shown that 
serine proteases are selectively and covalently inhibited by (a-aminoalkyl) diphenyl
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phosphonates. Phosphonates and phosphonamidates show non-covalent but still 
potent inhibition of the metalloproteases t h e r m o ly s in ^ ^ ^  a n d  carboxypeptidase 
Phosphonates were also found to be potent inh ib ito rs  of pepsin and 
penicillopepsin.^^'^ Bartlett^^^ has produced phosphinate based inhibitors for pepsin 
that were among the most potent yet found for the enzyme.
2.4.1 Phosphorus based inhibitors for the HIV-1 protease
The use of phosphorus based inhibitors for the HIV-1 protease has been 
investigated by a number of groups. Grobelny ef demonstrated that tetrahedral 
phosphinates incorporated into peptides capable of minimally spanning P2-P3 ’ are 
effective in vitro as highly potent inhibitors of HIV-1 protease. Similar conclusions 
were arrived at by Dreyer et a/.377 Affinity for the enzyme was found to be quite 
sensitive to substitution at the P-j and P i’ sites, with the Phe-Phe analogue providing 
superior binding to its Phe-Pro counterpart (see compounds (A) and (B)). Analogues 
containing a Phe-Pro mimic were poor inhibitors (see below). The binding affinity of 
phosphinate inhibitors was also sensitive to pH; a 500-fold increase in affinity was 
observed for some compounds as the pH was lowered from 6.5 to 4.5 (see below).
H
N.
Ph/
OH
Val-Val-NH
O
(A)
Compound (A) possesses a K, value of 0.6 nM at pH 4.5.
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m
H
.N,
Ph
O
/
OH
Val-Val-NH
(B)
Compound (B) possesses a Kj value of 450 nM at pH 4.5. A similar compound (the 
so-called “exploding transition state analogue") has recently been synthesised by 
Ikeda et and has a Kj of 8.2 nM at pH 6 .2 .
The HIV-1 protease is a 02 -symmetric dimer, (see Section 1.6.2.2 ) and this 
symmetry has been exploited in the design of symmetrical phosphorus-based 
inhibitors (see Section 1.9.2). Recently, Reyman et synthesised the first 
symmetrical phosphinic acid-based inhibitors for the HIV-1 protease. Compound (C), 
as a mixture of stereoisomers, gave an IC50 value of 36 nM at pH 5.5.
o
H / OH H
Cbz-Val
Ph Ph
Val-Cbz
(C)
Whilst optimising symmetry, compound (C) in fact has the disadvantage of 
positioning the benzyl group at incorrectly. Compound (A) is a more accurate 
substrate analogue, despite the fact that a carbon atom replaces the nitrogen present 
at P i' in the substrate. Compound (B) also positions Pro at P-j’ incorrectly. This 
incorrect positioning of some of the binding determinants within the active site may 
cause a decrease in binding affinity. Hence, compound (C) is more active than 
compound (A) which is in turn more active than compound (B). However, 
incorporation of a phosphinate into a different HIV inhibitor, compound (D), led to a 
disappointing Kj of 4.5 pM.380
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H H /O H  °
,N _
S er-A la -A la^ Val-Val-NHg
H N
(D)
The decreased potency at the assay pH (6.0) is thought to be due to the negative 
charge on the phosphinic acid. Inhibitors based on phosphinic acid have proven 
extremely potent against pepsin, where the assay pH is 3.5 and the neutral, 
protonated form of the phosphinic acid is predominant. It is proposed that there is an 
unfavourable electrostatic interaction between the negatively charged phosphinate 
and the aspartate carboxylate at the active site, which reduces inhibitory potency. 
This theory is supported by the decrease in the Kj of compound (D) to 120 nM at pH 
3.6. Also, peniciliopepsin is much iess inhibited by this class of inhibitor than pepsin, 
due to the higher pH optimum of peniciliopepsin, which means that the preponderant 
form of the inhibitor at the assay pH is anionic. The inhibition of peniciliopepsin also 
shows pH dependency, increasing with decreasing pH, supporting the hypothesis of 
the neutral phosphinic acid as the active species.^^®^-^®’^ A similar phenomenon is 
observed with phosphinate inhibitors of renin.^82 Compound (B) and its analogue 
(see above), however, both have very low Kj’s at high pH, possibly indicating that 
their inhibition is not very pH dependent.
L ite ra ture  precedent therefore seemed to ind icate  tha t the 
phosphinate/phosphonamidate based inhibitors would be poor inhibitors, due to the 
adverse charge interaction with the active site carboxylate. The neutral methyl esters 
therefore seemed to be more promising targets. Surprisingly, however, a variant on 
compound (C) above was found to be around 40-fold more potent as the deprotected 
form (presumably anionic at the assay pH) than as the ethyl ester.383 This is 
supported by the observation of “surprising pH dependence" of the inhibition of a 
stereodefined version of compound (B).^^4 yhe reason for this reversal is unknown. 
To date there has been only one report of phosphonamidate-based inhibitors for the 
HIV-1 protease, by McLeod
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.CFgCONH CFoCONH
N H r
Figure 2.4.1: The phosphonamidate inhibitors of McLeod et
where R = H or CH3
The compounds are racemic dipeptide mimics, with \CqqS in vitro of around 50 pM. 
It is interesting that these compounds are inhibitors at all, as the protease is known to 
require hexapeptide substrates (see Section 1.6.2.4) and the shortest inhibitors of 
other classes so far published are tetrapeptide mimics. Also, the difference in 
in h ib ito ry  potency between the neutrai methyl esters and the anionic 
phosphonamidates is very small (the phosphonamidates have approximately a 50% 
higher IC50 than the methyl esters). With the phosphinates and phosphonates 
discussed above the difference is much more marked. There has also been one 
report of moderately potent, symmetric N-PO-N based inhibitors, with Pro at S  ^ and 
Si'38G
2.5 Results of inhibitor testing
Before beginning assays on our inhibitors it was necessary to validate our assay 
conditions and obtain a value for the substrate used (KARV-Nle-Phe(N0 2 )-EA- 
NI0 -G-NH2). This was performed essentially as described by Richards et The 
assay relies on monitoring a decrease in absorbance at 300 nm, due to cleavage of 
the Nle-Phe(N0 2 ) bond. The initial velocities (at less than 20% reaction) and 
substrate concentrations were plotted on a Lineweaver-Burke plot, shown below.
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Km for substrate
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- 0 . 4 0.8 1/S(^M-1) .20.2 0.4 0.6- 0.2 0.0
K|  ^found = 33 |aM
The for the substrate was determined from the slope and the intercept of the line 
and was found to be 33 pM under the assay conditions, which compares well with 
the literature value of 35 Thus our assay conditions were validated.
The initial inhibitors were tested using a variety of co-solvents. At first DMSO was 
used (at 2% final concentration) but was found to interfere with the assay as It 
absorbs quite strongly at 300 nm. It has also been found that DMSO acts as an 
inhibitor for HiV-1 protease and causes its activity to decline.^®® Some of the 
inhibitors were soluble enough to be assayed using 100 pM stocks in the assay 
buffer, but others were not. Eventually methanol (at 2% final concentration) was 
selected as the cosolvent of choice as it has no interference with the assay and has 
only a moderate effect on the enzyme activity. Once we obtain an IC50 value for an 
inhibitor we can obtain the Kj simply from the relationship:
Kj= IC50/1 + (S/Km)
Our initial target compound 000 was prepared according to the strategy outlined 
above and was tested as both the methyl ester and the phosphonamidate.
Boc-N-F-YLPOgH-Nl-P-l-NHIBu
Compound 000
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It was expected that at the assay pH (5.5) the phosphonamidate would be entirely 
anionic.^'’^ This was supported when compound 000 was tested as a mixture of two 
epimers at the a-carbon of the phosphophenylalanine residue and found to have an 
ICgQ value of 60 pM (see graph below). This rather high value confirmed the 
expectation that the anionic compounds would be poor inhibitors and attention was 
turned to the methyl esters.
The graphical treatment of the data is based on that of Dixon.389
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All four diastereomers of the methyl ester analogue of compound 000, compound 
100 , were synthesised as for compound 000 , omitting the final deprotection step. 
They were then tested individually and the results are shown below.
Boc-N-F-\|/[PO(OCH3)-N]-P-l-NHiBu
Compound 100
1 1 1
Î :
Table 2.1 : Test results for compound 100
Code Epimer IC50 (pM)
no. at (C,P) in  v itro in  vivo
1001 (R, R) 20 45.
1002 (R. S) 140 >100
1003 (S, R) 300 N.T.
1004 (S, S) 73 N.T.
The deprotected version of the compound was found to be a poorer inhibitor than 
the ester, as predicted above. This is probably due to the repulsive interaction 
between the anionic phosphonamidate and the active site aspartate, see above. 
However, the difference in the potencies is much smaller than would be expected 
from the literature values quoted above, where the differences are often greater than 
an order of magnitude. The reason for this is unclear, and molecular modelling has 
been unsuccessful in assisting the development of a hypothesis. These results are,
however, entirely consistent with those reported (see above) by McLeod et 
where a very small difference in the inhibitory potency of phosphonamidates and 
their methyl esters was also observed.
The relative inhibitory potencies of the compounds show some interesting trends.
As expected the (R) configuration at the a-carbon of the phosphophenylalanine 
residue gives the more potent inhibitors (compare 1001 with 1003 and 1004). It is 
known that peptidic inhibitors of the HIV-1 protease having D-configured amino acids 
(equivalent to the (S) configuration of the phosphophenylalanine residue) at P-|’ are 
poor inhibitors for the HIV-1 protease. For example, Cushman etal.^^^ found that D- 
Phe at P i ' increases ICgg by 11 fold over the L-Phe epimer in a series of 
hydroxyethylene inhibitors. It is known that for the mammalian aspartic proteases if 
one of the residues flanking the scissile bond (P  ^ or P^') is of the (D) configuration 
then the scissile bond is rendered completely resistant to cleavage^®"* i.e. the 
peptide is not bound.
The variable effect of the configuration at phosphorus on the IG50 is more difficult to 
understand. Comparison of 1001 with 1002 and 1003 with 1004 shows two opposite 
effects. In the first case the change from (R) to (S) configuration increases the IC50
1 1 2
and in the second the same change decreases the IC50. This difference has been 
partly rationalised using molecular modelling (see Section 2.5.1).
The IC50 values obtained are somewhat higher than expected for a hexapeptide 
inhibitor. A program of modification was undertaken to explore the effect of the P3 
residue on binding, and a panel of compounds were synthesised that lacked a P3 
group. The P3 group was chosen for removal as molecular modelling (see Section 
2.5.1) indicated that it may have little effect on inhibitory potency. Compound 200 
was chosen as the target for this experiment and was synthesised and resolved by 
Nicholas Camp as outlined in Scheme 2.2.1.
Cbz-F-\i/[P0 (0 CH3)-N]-P-l-NHiBu
Compound 200
In compound 200 the Pg asparagine residue in compound 100 is replaced by the 
Cbz protecting group and the P3 group is deleted. The Cbz group was chosen as it is 
a good analogue of the benzyl group that is often found at P2 in many potent 
inhibitors. These compounds were tested in the in v/Vo assay only and the results are 
shown below.
Table 2.2: Test resuits for compound 200
Code No. Sequence Epimer ICgQ (pM)
at (C,P) in vitro in  vivo
2001 CbzF-y-P-l-NHiBu (R,R) N/T 3
2002 (R,S) HfT 25
2003 (S,R) N/T 100
2004 " (S,S) N/T 25
The results show that the configuration at phosphorus has a variable influence on 
the IC50, compare 2001 with 2002 and 2003 with 2004. In the first case a switch from 
(S) to (R) increases the IC50, in the second the same change decreases the ICgg. 
This is consistent with the results obtained from compound 100. The basis for this 
effect probably lies in the cooperativity between the binding site and the active
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site diad of aspartates. The equivalence of the ICgg values for 2002 and 2004 is also 
d ifficu lt to understand, as the configuration at the a-carbon of the 
phosphophenylalanine residue usually has a large influence on the potency of an 
inhibitor (see above). Strikingly, the loss of the P3 residue appears to have had 
essentially no effect on the inhibitory potency of the compounds.
In common with other studies on HIV-1 protease inhibitors (see Section 1.6.3.2) we 
explored compounds based on pseudo-symmetric scissile bond analogues. The 
Phe-\y[PO(OCH3)-NH]-Phe and Cha-\}/[PO{OCH3)-NH]-Phe (where Cha represents 
cyclohexylalanine) analogues were investigated. A variety of unresolved, epimeric 
inhibitors of the sequence of compound 300 (see below) were synthesised, based 
on these scissile bond mimics. The results from compound 200 were also taken into 
account, so that compounds with and without a P3 residue were synthesised.
X-\|/[PO(OCH3 )-NH]-Phe-ne-NHIBu
Compound 300
Table 2.3: Test results for compound 300
Dde No. Sequence Epimer IC50 (pM)
of X at (C,P) in v itro  in vivo
3001 Cbz-F mixture 2 2
3002 Cbz-Cha mixture 1 5
3003 Boc-N-F mixture 2 N/T
3004 Boc-N-Cha mixture 4 N/T
These compounds are mixtures of 4 diastereomers and the diastereomers are not 
produced in equal amounts. Therefore, the IC50 of the most active diastereomer 
could be less than 25% of the IC5Q for the mixture, if that diastereomer only shows 
significant activity. Once again the presence or absence of a P3 group appears to 
have almost no influence on the inhibitory potency (compare 3001 with 3003 and 
3002 with 3004).
As has been observed frequently with other systems the pseudo-symmetric
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inhibitors are more potent than the non-symmetric analogues. The increased 
potency of these pseudo-symmetric inhibitors is mirrored by the lower and higher 
kcat/KM for substrates containing an Aromatic * Aromatic scissile bond compared with 
those containing an Aromatic * Proline scissile b o n d . 2 0 7 ,3 9 2  y^is is shown in the 
kinetic parameters for the following two substrates, which differ only in their P^' 
residue:
S-Q-N-Tyr* Pro-I-V
S“Q-N“Tyr * Tyr-I-V
K|  ^2.3 mM
K|  ^0.8 mM
kcat/Ki^ 60.9 mM'^min'f
kcat/K[^ 91.2 mM'^min"^
However, the Aromatic * Proline scissile bond analogue does not always result in a 
decreased inhibitory potency compared with the pseudo-symmetric Aromatic * 
Aromatic a n a l o g u e . Hydroxyethylamine based inhibitors with Aromatic * Proline 
scissile bond mimics are often equipotent with, or more potent than, the equivalent 
Aromatic * Aromatic version. This may be due to the water-bridged hydrogen bond to 
the flaps of the protease (see Section 1.6.4), pulling the ends of the P^  and P-j’ 
residues down away from the active site aspartates and pushing the Pro residue up 
into the S-j’ pocket, filling it more fully. However, this will only occur when there is 
sufficient distance between the hydrogen bond donors in the inhibitor, to allow the 
peptide backbone to adopt a more curved structure. Thus, this effect is observed with 
the hydroxyethylamine compounds, but not with hydroxyethylene compounds, which 
have one atom less between the hydrogen bond donors involved in bonding to the 
water molecule.
Having observed the rather small influence of the Pg group on inhibition we 
attempted to determine the optimal Pg side-chain to determine if the requirements for 
this side-chain were the same as for other classes of inhibitors. Literature 
precedent^^^ indicated that a favourable side-chain at this position was the 
quinoline-2-carbonyl (Qua) moiety (see Figure 2.5.1).
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Figure 2.5.1: The qulnoline-2-carbonyl (Qua) moiety
Thus a compound of the following sequence was prepared as a mixture of epimers 
at C-1 of the phosphophenylalanine residue and phosphorus:
Qua-N-F-\i/[P0(0CH3)-N]-F-l-NHiBu
Compound 400
This compound was found to have an IC50 of 37 in the in vitro assay and 50 |xM 
in the in vivo assay. A similar compound with a Cha-Pro scissile bond mimic was 
also prepared and a single diastereomer ((R), (R)) tested which was found to give an 
IC50 of 15|xM in the in vitro assay. These results are consistent with those found for 
the compounds 100 and 300, where it was shown that the P3 residue has little effect 
on the inhibitory potency. However, the quinoline-2-carbonyl moiety increased the 
IC50, rather than decreasing it as was expected from literature precedent. Clearly the 
nature of the optimal P3 residue is different for the phosphonamidates than for other 
classes of inhibitor. The reason for this is not understood.
The most striking observation from all these compounds is the near equivalence of 
the IC50 in vitro and the IC50 in vivo. This is almost entirely unprecedented and runs 
counter to many other results of in vivo testing of HIV-1 protease inhibitors and 
inhibitors of many other enzymes. In the case of other protease inhibitors the ratio of 
in vivoXo in vitro IC50 is usually around 10-100.^93 in the case of our compounds the 
ratio is around 1:1 to 1:5 (see above). Therefore, either the effective concentration of 
the inhibitor in the cells is the same as the concentration in the medium or the 
compound Is broken down in the cell to give a potent inhibitor of some aspect of viral 
metabolism. It is unlikely that the internal and external concentrations are nearly 
identical for two reasons. Firstly, these inhibitors probably will not easily be able to
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idiffuse across the lipid membrane to enter the cell. Secondly, as all exogenous 
compounds, particularly peptidic ones, are metabolised to some extent in the cell (in 
this case by host proteases) the concentration of the inhibitor inside the cell will fall 
steadily with time. Thus, it is possible that the effective inhibitor is some metabolic by­
product of the target compound.
2.5.1 Molecular modelling of Inhibitor-protease interactions
The basis for much of this work was the structure of the reduced peptide inhibitor 
MVT-101 complexed with the protease.^^^ MVT-101 was chosen as it is highly 
congruent to the substrate and consequently to our inhibitor. The hydroxyethylene 
inhibitors are also congruent to the substrate but the hydroxy group is hydrogen 
bonded to the active site aspartates. This may induce a bias into the starting active 
site structure that may affect the outcome of subsequent calculations. The sequence 
of inhibitor 100 was built onto the peptide backbone of MVT-101 (see Figure 2.5.2).
HgC y 3 H  
O CH
N
Figure 2.5.2: MVT-101
This gave an approximation of the bound conformation of the inhibitor in the active 
site. A substructure minimisation in the active site of the HIV-1 protease allowed the 
altered side-chains to relax into the enzyme subsites and adopt reasonable bound 
conformations. The bound conformation of compound 1001 is shown in Figure 2.5.3.
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Figure 2.5.3: The modelled bound conformation of compound 1001
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The interactions between the P3 residue (the Boo group) and the residues of the S3 
pocket were examined in this model structure to identify interactions important for 
binding. A conformational search was then carried out on a substructure consisting 
of the Boo group and those residues having one or more atoms within 6 Â of the 
atoms of the Boo group. This was designed to identify the low energy conformations 
of the Boo group in the S3 pocket and the interactions made with the selected side- 
chains.
A further set of calculations were carried out in which the methylene of the reduced 
peptide moiety was replaced by PO(OCH3), to give the full sequence of our target 
compound. This was carried out using the INSIGHT program to take advantage of
the generalised force-field available in INSIGHT (GFF91^®^>^^^) that allows 
calculations to be carried out on systems for which high-quality bond parameters are 
not available. The differences in the side-chain conformations between the structures 
with and without phosphorus were found, as expected, to be very small (the two 
structures overlaid with an r.m.s. displacement of around 0.1 Â).
The number of interactions found in either case between the Boc residue and the 
enzyme were found to be limited. The main contacts made by the Boc group at P3 
are with residues Val 82B, Gly 48A and Arg 8B of the S3 pocket (A represents amino 
acids from one of the monomers, B from the other). All these contacts are non-polar 
and are not expected to contribute greatly to the binding energy. The major polar 
interaction in the S3 pocket, with Asp 29A, was not always observed with the Boc 
group, which probably reflects deficiencies in the methodology rather than an actual 
lack of interaction. Thus, it is not expected that this residue will add greatly to the 
potency of our compounds. The interactions identified compare reasonably well with 
the interactions identified in the published X-ray structures of inhibitors co­
crystallised with the protease and are illustrated in Figure 2.5.4
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Figure 2.5.4: interactions in the F3 pocket 
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The observed improvement in the binding of the Phe-Phe and Cyc-Phe scissile 
bond analogue containing inhibitors over those containing Phe-Pro was 
investigated. The possible interactions of the different P^' side chains with the S^’ 
pocket were examined using two different crystal structures. The model structure of 
Weber^^® which has a Tyr-Pro containing substrate was used initially. The 
coordinates for the structure of the protease co-crystallised with a proline-containing 
hydroxyethylamine inhibitor, JG-365^®® (Figure 2.5.5) were then made available.
H HN
OH N
H‘CONN.
Figure 2.5.5: JG'365
The Pro residue in the model structure forms van der Waals contacts with only 3 
residues, Leu 23A, Val 82A and lie 84A and packs against Asp 25A. In the JG-365 
structure the Pro residue is in contact with residues Pro 81 A, Val 82A, lie 84A and
Gly 49B. In contrast the P-j Phe side-chain in the symmetric A-74707^^^ forms 
contacts with Leu 23A, Val 80A, Pro 81 A, lie 84A, Asp 28B and lie 50B. Thus, proline 
at P-j’ has less Interactions with the S^’ subsite than phenyalanine at P-j’, which is 
consistent with the usually less potent inhibition of proline-containing analogues.
This large alteration in the conformation of the active site on binding inhibitors of 
differing steric requirements has been observed before.^^^ should be noted that in 
spite of the deficiencies of the Weber model structure it is probably a better model for 
the interactions between our inhibitors and the enzyme than JG-365. This is due to 
the “bending” effect of hydroxyethylamine inhibitors discussed above, arising from 
water-bridged hydrogen bonding to the flap.
The procedure carried out using MVT-101 to build a model of our inhibitors was 
repeated for JG-365 and for the substrate Ser-Gln-Asn-Tyr-Pro-lle-Val from the 
model structure of Weber. The structures were subjected to substructure minimisation 
and the resulting interactions compared. Essentially the same results were obtained 
for the interactions with the P3 pocket. The interactions between the Pro residue and
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the S^’ pocket were found to be different for the JG-365 based structure than for the 
model substrate structure, probably due to the bridging water mediated bending of 
the inhibitor backbone. Which one represents a better model for the interactions 
actually present in the enzyme-inhibitor complex is not known and awaits an X-ray 
crystal structure.
The configuration at phosphorus was investigated by building both enantiomers at 
phosphorus into the active site (on the inhibitor with the (R) configuration at carbon) 
and minimising the structures as above. Subsequently, molecular dynamics 
simulations were carried out on a substructure consisting of residues 22-27 of each
monomer and the central residues (Phe-\j/[POOGH3]-Pro) of the inhibitor in both 
configurations at phosphorus. It was found that the (8 ) configuration (see Figure 
2.5.6) disrupted the coplanarity of the active site aspartates, due to the intruding 
methyl group. This disruption of the active site hydrogen-bonding network is an 
unfavourable process and is consistent with the less potent inhibition observed with 
the inhibitors having an (8 ) configured phosphorus atom.
O: O:
OH
O
HoC-
O:
(S ) (R)
OH
O'
O:
Figure 2.5.6: The epimers differing at phosphorus
The (R) configured phosphorus has the phosphoryl oxygen pointing toward the 
aspartates and allows them to retain their hydrogen bonding network and remain 
coplanar. Given that this analysis is correct it becomes difficult to account for the 
equivalence in binding potency of inhibitors 2002  and 2004 (see above). The 
explanation may lie in the extensive cooperativity of the residues of the active site, 
allowing 2 different configurations at phosphorus to form interactions of equivalent 
strength with the enzyme.
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All the above work is based on the assumption that our inhibitors bind In the same 
way as substrates and other substrate-based inhibitors such as M V T - 1 0 1 .  This could 
be demonstrated in two ways. Firstly, if it could be shown by kinetic analysis that 
these are competitive inhibitors then they must bind in the active site, in competition 
with the substrates. Alternatively, if the P-j ’ residue were of the D-configuration then 
an active-site directed inhibitor would bind more weakly, by around an order of 
magnitude, than an inhibitor of the L-configuration at p^’,390 It was also assumed 
that our inhibitors only have one binding mode in the active site, or, if there were two, 
that one represents only a small fraction of the total. This can only be demonstrated 
unambiguously with a highly refined X-ray crystal structure determination.
2.5.2 Time-dependency of inhibition
During the analysis of these inhibitors it was decided to explore the possibility of 
time-dependency of inhibition. Time-dependent inhibition of aspartic proteases has 
been observed with statine based inhibitors.^^^ It has also been observed with 
phosphonamidate inhibitors of the metalloprotease thermolysin.^®® Rich^^^ 
postulated that this slow binding is due to a two-stage binding process, an initial fast 
formation of a ‘collision’ complex, followed by slow isomérisation to the tightly bound 
form. He^^® has speculated that in the aspartic proteases this slow isomérisation is 
due to displacement of the tightly bound water molecule between the active site
carboxyls. However, X-ray crystal structures of various aspartic proteases complexed
1with inhibitors show that this water molecule is lost when other, non-slow binding, |
inhibitors are co-crystallised with the e n z y m e . ‘• 2 9  Also, some very potent statine I
based inhibitors of renin show no biphasic a s s o c ia t io n ,^90  thus potency is also not a j  
common feature of the slow-binding inhibitors. Equally, some potent inhibitors of 
renin do show biphasic b in d in g .^ 9 1  j\^q active site water molecule in the monomeric 
aspartic proteases has recently been shown not to be tightly bound at the active 
site.402 Solvent isotope partitioning was used to show that the active site water 
molecule desorbs from the ternary (enzyme-substrate-water) complex at a rate four 
times higher than k^ g^ . The physical basis for this observation is unclear as 
inspection of a model of the substrate-enzyme interaction indicates that large
1 2 3
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conformational changes must take place (possibly even debinding of substrate) for
the water molecule to be able to leave the active site.
Fruton®^ has proposed that the slow step in aspartic protease catalysis is a
conformational change, which is observed to be rapid in the cleavage of good 
substrates. However, as has been pointed out by Frick et enzymes have 
minimised kinetic obstacles to conformational changes when binding substrates but 
not inhibitors. It is likely that the inhibitor adopts a different conformation at the active 
site than the substrate. Therefore, the conformational change needed to optimise 
interactions between the enzyme and the inhibitor will be different to, and 
consequently slower than, those needed to optimise the interactions between the 
enzyme and the inhibitor. The initial binding may be binding of the main
determinants of specificity, the P-j and P-j’ sites,”* a n d  the slow step may be the 
rest of the inhibitor side chains binding at a rate that is dependent on the 
conformational flexibility of the active site.
Shown below is a plot showing the loss in HIV-1 protease activity with time in the 
absence and presence of methanol and the presence of inhibitor 3004 (a pseudo- 
symmetric inhibitor) made up In a stock solution in methanol.
Time-dependency of HIV-1 protease inhibition
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The black diamonds (♦  ) show decline in activity of the protease in the presence of 
2% methanol alone. The black squares (■) show the decline in the presence of 5 pM 
3004 in 2% methanol. The white squares (□) show the decline in activity of the 
enzyme in the absence of methanol and inhibitor. This decline may be due to
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autoproteolysis.^®® Clearly there is no difference in these values, so the inhibition is 
not time-dependent.
2.5.3 Further work
There are two areas that may be explored in future. Conformationally restrained 
analogues, with a cyclic structure at linking the side-chain to one of the 
phosphoryl oxygens will allow the flexibility of the S-j pocket to be examined. 
Hopefully, the restraint will reduce the loss in entropy on binding and increase 
inhibitory potency. Compounds with glycine at P-j’ will also be synthesised to 
examine the influence of the P^’ side-chain on inhibition and the effect of increased 
conformational freedom at this point.
2.6 Cloning, overexpression and purification of the HIV-1 protease
As an adjunct to the work on the inhibitors it was decided to attempt to clone and 
overexpress the protease in the bacterium, E. coli. The protease has been expressed 
in a number of systems, including E. insect cells^°^ and yeast cells.^^®
Various strategies have been used to obtain active protease, including expression of 
the protease as a fusion protein with non-HIV proteins"^ "^^ ®'*^ * or as part of the gag or 
pol precursor p r o t e i n s . T h e  protease has also been chemically synthesised
by a number of groups.^^^
Our strategy for obtaining the protease is outlined in Scheme 2.6.1. Firstly, the 
protease gene, contained in a plasmid, pRP14, was amplified, using the polymerase 
chain reaction (PCR) (see Section 2 .6 .1). The two oligonucleotide primers for this 
amplification contained the 6 base-pair cleavage sites for one of two restriction 
endonucleases (Eco R1 and Bam HI). The PCR amplified DNA is then cleaved with 
Bam HI and Eco R1 and ligated into the plasmid pGEX-2T.^^^ Ligation places the 
protease gene in frame with another protein (GST, see Section 2.6.2), under the 
control of an inducible promoter. The ligated plasmid is then transfected into the E. 
C O //strain JM 101^*°^  and the protease purified from the cells after induction.
125
HIV PR
—  / /PCR
GSTamplification
Protease gene Amplified pro tease genepRP14
i) Cleave
ii) Ligate
GST
Ttirombin///////////
Recombinant plasmid
i) Transfect
II) Select and grow 
transformants
Hi) Harvest and lyse
////////// Glutathione affinity 
chromatography
///////////
IH il l l l l l l
•A/W»
Pepstatin affinity 
chromatography
Mostly pure 
fusion protein
/
Mixture of soluble cell proteins
Pure HIV-1 protease
Scheme 2.6.1: Outline of strategy for the overexpression and purification of the
HIV-1 protease
This PCR-based approach to obtaining recombinant proteins has been christened 
Expression Cassette PCR (ECPCR) by Schreiber^^^
2.6.1 The PCR reaction
The PCR reaction (polymerase chain reaction) is a highly efficient method for 
selectively amplifying a DNA sequence that lies between 2 known sequences on 
opposite strands of double strand DNA.'^'*^ Two oligonucleotides which are 
complementary to the sequences that flank the DNA of interest are used as primers 
for a series of synthetic reactions catalysed by a heat-stable DNA polymerase (the 
so-called Taq DNA polymerase). The complementary sequences are 21 b.p. long, 
which will ensure strong and specific binding at only the required sequence in the 
template DNA. The primers also have a restriction site in a non-complementary 
sequence that lies at one end of the complementary sequence to allow ligation of the 
amplified product into a suitable vector. The primers made had the sequences
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shown in Figure 2 .6 .1. The complementary sequences are shown in bold type, the 
non-complementary sequences in plain type and the restriction sites are underlined. 
The 4 b.p. “tails” are to prevent exonucleolytic degradation during the course of the 
PCR process.
A. 3' AGAGGAATTCAAAATTTAAAGTGCAACCAAT 5*
A
Eco R1 restriction site
B. 5' ACATGGATCCCCTCAGATCACTCTTTGCCAA3'
A
Bam HI restriction site 
Figure 2.6.1: The PCR primers
The PGR reaction amplifies the sequence lying between the two primers in an 
exponential fashion, resulting in a vast excess of the required sequence over other 
sequences. The basis of the amplification lies in a cycle of dénaturation, annealing 
and extension. In the first cycle the DNA and primers mixture is heated to 94°C to 
denature the double helix, then cooled to 55°G to allow the primers (present in a 
large excess over the template DNA) to anneal to the template. Heating to 72°G 
allows the thermostable DNA polymerase to extend the primer as shown below. The 
second cycle proceeds as the first, except that there are now extended strands from 
the first cycle for the primers to anneal to, as well as the original template. Repetition 
for 25-30 cycles results in a large amount of amplified DNA.
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1. Primer 1
« «TAACCAACGTGAAATTTAAAA...
 < GCTGAGATCCTTTGCCAA..................-ATTGGTTGGAGTTTAAATTTT---------->
 < GGAGTGTAGGAAAGGGTT  TAAGGAAGGTGAAATTTAAAA >
...GGTGAGATGGTTTGGGAA»»
Primer 2
2 .
« «TAAGG AAGGTG AAATTTAAAA...
GGTGAGATGGTTTGGGAA --ATTGGTTGGAGTTTAAATTTT >
<- GGAGTGTAGGAAAGGGTT-----------TAAGGAAGGTGAAATTTAAAA
... GGTGAGATGGTTTGGGAA» »
3.
««TAAGGAAGGTGAAATTTAAAA...
GGTGAGATGGTTTGGGAA  ATTGGTTGGAGTTTAAATTTT
GGAGTGTAGGAAAGGGTT---------------TAAGGAAGGTGAAATTTAAAA
. ..GGTGAGATGGTTTGGGAA» »
»» - Direction of replication by the DNA polymerase.
Scheme 2.6.2: The PCR reaction
There are also competing reactions where the primers re-anneal to the longer 
templates, but the amount of DNA produced by these reactions only increases 
linearly with the number of denaturation-annealing-extension cycles. The amount of 
DNA from the region flanked by the primers, however, increases exponentially with 
the number of cycles, resulting in a DNA preparation that is essentially homogenous. 
This DNA was then digested with the appropriate restriction enzymes, prior to 
ligation Into the cloning vector, pGEX-2T. The recombinant plasmid so produced was
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designated pGEX-HPR. PGR from the plasmid template proceeded smoothly, but 
PGR from baculovirus derived pol DNA was very unreliable and was therefore 
abandoned.
2.6.2 The cloning and transfection process
The pGEX-2T plasmid (see Appendix B) contains the restriction sites for Bam H1 
and Eco R1 in a short multiple cloning site (MGS). The MGS lies at the 3' end of the 
coding region for the glutathione-S-transferase enzyme (GST) from S. japonicum.^'^^ 
Gleaving the plasmid and the amplified protease gene with the same restriction 
endonucleases (Bam H1 and Eco R1) gives pairs of complementary ends on the 
plasmid and the gene. The placement of the restriction sites is such that a gene 
ligated into the sites will be in the same reading frame as the GST gene. Therefore, 
cloning the protease gene into pGEX-2T creates a fusion protein between the GST 
and the HIV protease, of mass 37 kDa (GST is 26 kDa, the protease 11 kDa).
There are a number of advantages to using these two restriction enzymes over any 
others contained in the MGS of pGEX-2T. As they have different sequence 
specificities and both produce overhanging ends (see Figure 2.6.2) cloning into the 
MGS with these enzymes will force the cloned gene to be only in one orientation and 
in the same reading frame as the GST.
Bam H1 - G // GATGG Eco R1 - G//AAGGG
GGTAG//G GTTGG//G
// - site of cleavage
Figure 2.6.2: Cleavage sites for the restriction endonucleases Bam H1 and Eco R1
Using two restriction enzymes also eliminates the need to prevent the plasmid 
re ligating without having incorporated the gene to be cloned. As the overhanging 
ends produced by the two enzymes are incompatible they will not base pair (the 
necessary step prior to ligation) in the absence of a linker with the correct 
complementary ends (the gene to be cloned). Thus, ligation will not occur in the 
absence of the gene to be cloned. Also, the enzymes have sim ilar buffer
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requirements for activity so the digestions can be performed simultaneously, rather 
than sequentially.
In pGEX-2T the GST gene is under the control of the tac promoter. The tac 
promoter is a hybrid of sequences from the trp and lac p romoters . ' ^ I t  has an 
upstream sequence (the so-called -35 sequence) from the trp promoter and the 
sequence closer to the transcription start point (the TATA or Pribnow box) is from the 
lac UV5 promoter. As it is such a strong promoter it is necessary to keep it repressed 
or the gene(s) under its control will be expressed before induction i.e. constitutively.
In pGEX-2T repression is achieved by the lac repressor protein, which is expressed 
constitutively in amplified amounts by the lacR gene. This represses transcription 
from the tac promoter in the absence of inducer, by binding to the promoter region. 
Induction is achieved with isopropyl-p-D -th ioga lactoside (IPTG), a non- 
metabolizable analogue of galactose. Once induced with IPTG the tac promoter will 
give high levels of transcription of proteins under its control and thus high levels of 
expressed protein.
As the protease is fused to GST in pGEX-HPR the fusion protein is also under tac 
control. Between the 3' end of the GST gene and the MGS there are two codons 
coding for the cleavage site of the serine protease thrombin, Arg-Gly (see Scheme 
2 .2 .12). Therefore, the thrombin cleavage site will be near the junction of GST and 
the protease in the fusion protein. Induction of expression from this promoter will 
result in the synthesis of a fusion protein, consisting of GST fused to the protease 
through the thrombin cleavage site. Thus, at a suitable stage in the purification, the 
protease can be released from the fusion by treatment with thrombin.
Many proteins have been isolated using GST fusion proteins.^^"^ The ease of 
binding of specific proteins to a glutathione agarose column means that the binding 
and elution conditions are extremely mild. A further advantage of the fusion protein 
protocol is that the yields of protease are often much higher than those obtained for 
expressing the “bare” protease.^"*^
Just after the Eco R1 restriction site in pGEX-2T lie stop codons (TGA) in all three 
reading frames (Figure 2.6.3). Thus, transcription of the protease gene will stop, 
regardless of what reading frame is being transcribed, just after the end of the 
inserted gene. After the manipulations (ligation, expression and cleavage with 
thrombin) are complete the fusion protein will have the junction sequences shown in 
the Figure. Bases in bold type arose from the amplified protease gene, bases in ft
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ordinary type from the plasmid pGEX-2T. Amino acids in bold type are part of the 
native protease sequence, those in ordinary type are from the plasmid. The numbers 
refer to the number of the amino acids in the protease sequence.
5’ end of the protease sequence
5'...GTGGTTCGGCGTGGA TTCCCT GAG  3'
Leu Val Pro Arg Gly Ser Pro Phe.......
A 1 2
Thrombin cleavage
3’ end of the protease sequence
5’ ...AAT TTT GAA TTG ATG GTG AGT GAG TGA 3‘
Asn Phe Glu Phe Met Val Thr Asp STOP 
98 99
Figure 2.6.3: The 5' and S'junctions of the protease fusion 
The stop codons are underlined.
The recombinant protease will therefore be isolated with 2 extra residues at its N 
terminus (glycine and serine) and six extra residues at its G terminus (glutamate to 
aspartate above). This was not expected to affect any of the functions of the enzyme 
in any way and it may have had a beneficial effect in helping to increase the 
solubility of the protein. A fusion protease has been produced with extra amino acids 
at the N (Pro-Gln-lle-Thr-) and G termini (-Val-Lys-Gln-Trp) and this did not appear to 
affect the activity of the protease.'^^^^
Transfection of the pGEX-HPR plasmid into E. coli strain JM 101 was achieved 
using the method of Hanahan"^^® or a method using rubidium salts (the MOPS 
method). The Hanahan method uses a complex mixture of metal ions and DMSO 
(see Experimental section) to make the bacteria competent to take up exogenous 
DNA. The mechanism of DNA uptake into E.coli \s unclear, but seems not to involve 
passive diffusion through pores in the membrane, as no sharp cuto ff in 
transformation probability versus size is seen (the probability of transformation 
decreases linearly with size of plasmid).'^^^ The Hanahan method was found to be 
unreliable, though when it worked well the levels of transformation found were very
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high (around 1 x 10^ transformants  ^DNA). Therefore, it was abandoned in favour 
of the more reliable MOPS method which gave around 5 x 1 0 ^  transformants ^g 'i 
DNA.
2.6.3 Isolation and analysis of cioning products
Once transformed bacteria were identified by their ampicillin resistance it was 
necessary to determine which of them carried the recombinant plasmid, which 
should have been most of them, for the reasons outlined above. Colonies were 
picked from ampicillin LM agar plates and grown up in 10 ml LB broth containing 100 
pg ml'"* ampicillin, induced and harvested after 3 hours. Total cell protein was 
examined by running PAGE gels on soluble protein from bacteria lysed by boiling in 
running buffer for 5 mins. Those bacteria that gave a band of the correct mass (37 
KDa) were picked, as they were expressing the protease-GST fusion (these were 
designated JM 101/HPR). The recombinant protein was also identified by 
comparison to induced bacteria carrying the parent pGEX-2T plasmid, uninduced 
recombinant bacteria and JM 101. The recombinant bacteria gave a very strong 
band at 37 kDa that is heavier than the protein (26 kOa) from bacteria carrying only 
pGEX-2T (JM 101/pGEX) and is not contained in JM 101. This is shown in the gel 
below.
A
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Column Sample
1 M. W. standards
2 Soluble protein from JM 101/HPR
3 Insoluble material from JM 101/HPR
4 JM 101 total cell protein
5 & 6 Total cell protein from JM 101/HPR
7 Total cell protein from JM 101/ pGEX
Comparison of lanes 2 , 5 and 6 with 7 shows the expected increase in mass on 
forming the fusion protein. This band is absent in the parent bacteria (lane 4) so must 
have come from the transformed bacteria. The masses of the standards are 76 kDa, 
66.25 kDa, 42.7 kDa, 30 kDa and 17.2 kDa.
Various checks were carried out to ensure that the plasmid isolated from the 
bacteria selected contained the protease gene. The simplest approach is to perform 
a comparative restriction analysis on the recombinant and parent plasmids. In this 
approach the plasmids are digested with two restriction endonucleases that each 
have one unique site in the plasmid and the size of the fragments produced are 
compared by agarose gel electrophoresis. A partial restriction map for the two 
plasmids is given in Appendix B. It can be seen that digestion of the plasmids with 
Sma 1 and Eco RV will give two bands from both plasmids. The recombinant plasmid 
will give one of these bands about 300 bp heavier due to incorporation of the HIV-1 
protease gene (297 bp). These two enzymes were chosen as they can be used in 
the same buffer system without either of them losing much activity. This eliminates 
the need to perform the digests consecutively.
Sequencing of the insert will ensure that the protease is in the correct reading 
frame and that it is inserted in the correct place in the MCS. Isolation and purification 
of the plasmid for sequencing proved to be problematic, with the usual protocol 
giving low yields of the plasmid, heavily contaminated with chromosomal DNA.
Small scale preparations, using the Stratagene Plasmid Quik™ kit, were also 
performed and also gave heavily contaminated plasmid. A modification of the 
described purification was tried, using benzoylated napthoylated DEAE cellulose 
(BND cellulose) to purify the plasmid DNA from the chromosomal DNA, tRNA and 
residual bacterial protein. This also proved problematic, due to the very low yields of
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plasmid.
The reason for the low yield is not clear as the parent plasmid (pGEX-2T) is a high 
copy number p l a s m i d , s o  pGEX-HPR should also have a high copy number 
(plasmid copy number is determined by a DNA sequence carried on the plasmid 
itself). In order to overcome this difficulty the amount of plasmid was amplified by 
chloramphenicol treatment. When this is added to the bacterial culture host protein 
synthesis stops but plasmid replication continues as it is dependent on proteins that 
turn over slowly e.g. DNA polymerases I and III. However, chromosomal DNA 
replication requires newly synthesised proteins, so it is also halted by 
chloramphenicol treatment. Thus, the amount of plasmid is amplified over 
chromosomal DNA and host protein by chloramphenicol treatment, which makes the 
purification much easier. This strategy was found to be effective, increasing the yield 
of plasmid around 50-fold (to around 300-500 pg per litre of culture).
It was possible that a reason for the low yield of plasmid was that after a few hours 
culturing the ampicillin in the medium had been degraded by 3-lactamases secreted 
into the medium by the resistant bacteria. After this point any bacterium that 
spontaneously lost the plasmid would be able to grow, and grow much more quickly 
than those bacteria that still retained the plasmid. These non-transformed bacteria 
would quickly dominate the bacterial population and result in very low yields of 
plasmid. To check this hypothesis a viable cell count was performed. A fresh culture
was plated out on LB plates containing ampicillin (100 pg ml""*), the rest of the culture 
was incubated overnight and then plated out as before. The number and size of the 
colonies on the plates after 24 hours growth were assessed and found to be 
equivalent. This indicates that the plasmid is well maintained over long growth 
periods. The low yields of plasmid in the absence of chloramphenicol amplification 
therefore remains unexplained.
When plasmid preparations were performed to isolate further amounts of pGEX-2T 
for cloning the purity of the plasmid was checked by agarose gel electrophoresis on 
the intact plasmid and on the plasmid restricted with Sma 1 and Eco RV. These were 
run against similarly treated samples of the pure plasmid.
Once isolated and purified attempts were made to sequence the plasmid DNA. 
Unfortunately, sequencing proved extremely difficult. The dideoxy method,^*'^ was 
used, with ^ ^ 8  as the radiolabel. There seemed to be impurities in the plasmid 
preparation that interfered with the DNA polymerase used in sequencing and so at 
best only partial sequences of the pGEX-HPR around the MCS were obtained. An
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alternative explanation is that the dénaturation protocol of the double strand plasmid 
DNA (heating in the presence of sodium hydroxide) used was not working well.
In an effort to circumvent the problems encountered in sequencing double 
stranded plasmid DNA, single strand sequencing was examined instead as 
sequencing single strand DNA is usually much easier. Two alternative approaches to 
obtaining single strand DNA were investigated.
i) Clone the protease gene into the bacteriophage M13. M13 produces single 
strand DNA when it infects bacteria, such as JM 101, that express the appropriate 
cell surface receptor.
ii) Make pGEX-HPR into a phagemid by cloning the origin of replication (oh) from 
the bacteriophage Ml 3 into it. This will make a bacterial cell transfected with the 
phagemid produce large quantities of single strand DNA. The ori will be amplified by 
PCR from a suitable Ml 3 vector.
Approach (I) was taken first. Cloning into Ml 3 was carried out in a very similar way 
to the cloning into pGEX-2T discussed above. The M13mp18 vector^'*^ was used as 
the double stranded replicative form (RF). This was handled exactly as if it were a 
plasmid. Like pGEX-2T M13mp18 RF has a multiple cloning site (MCS) containing, 
amongst others, unique Bam HI and Eco R1 sites. The MCS is located within two 
genes required for lactose metabolism. Thus, following the same procedure as for 
the cloning of the protease, the PCR amplified protease gene was ligated into the 
MCS of M13mp18. The recombinant Ml 3 vector was then transfected into competent 
JM 101 in the same way as pGEX-HPR was.
Care was taken to ensure that the competent bacteria used in the transfection 
retained the receptor for M l3, the sex pili, which is encoded by a bacterial plasmid 
known as the F’ episome. This episome also contains two genes (pro A and B) 
involved in proline biosynthesis. JM 101 does not contain these genes, so growing 
JM 101 on a minimal medium, such as M9, that does not contain proline will ensure 
that the F' episome is retained. Thus, the bacteria that were made competent for this 
procedure were grown from colonies picked from an M9 minimal agar plate.
Transformation was carried out exactly as above and the cells plated out in semi­
solid medium (top agar) on LB agar plates. The screening was carried out by 
identifying clear plaques on a bacterial lawn from the transformation. Ml 3 slows the 
growth of infected bacteria, resulting in areas of low bacterial growth that show up as 
clear plaques against the lawn of quickly growing, uninfected bacteria. Metabolism of
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BCIG (X-gal) in the top agar by lactose metabolising bacteria will result in a blue by­
product, which makes the bacterial plaque blue. JM 101 is unable to metabolise 
lactose, having had two of the genes required deleted. However, these two genes 
are carried on the F’ episome. Thus, those plaques that have a blue colour arise from 
JM 101 infected with M l3 that contains functional lactose metabolising genes. 
Successful cloning of a gene into the M13 MCS will result in insertional inactivation 
of the two lactose metabolising genes it carries, which means no metabolism of the 
BCIG to the blue compound. Thus, clear plaques arise from bacteria infected with 
Ml 3 that contains the gene to be cloned. Once clear plaques were identified single 
strand DNA was prepared from them and sequenced. Similar problems were 
encountered in sequencing this DNA as were found for sequencing double strand 
plasmid DNA. Only a partial sequence was obtained by this method (see Figure
2.6.4).
The phagemid approach was explored initially but several problems were 
encountered early on and so the route was set aside in favour of the Ml 3 procedure. 
The PCR amplified origin of replication (ori) from M l3 was cloned into the Aat II site 
of pGEX-2T. The recombinant bacteria harbouring the plasmids required were 
identified after plating transformed bacteria onto agar plates containing ampicillin. 
Since the recombinant plasmid contains the Ml 3 ori it is slightly larger than the non­
recombinant plasmid. The difference in the size of the intact plasmids is too small to 
reliably detect by gel electrophoresis (the M l3 ori is 123 b.p. and pGEX-2T is 4948 
b.p.). However, restriction analysis of plasmid isolated from ampicillin resistant 
bacteria should have allowed those plasmids containing the ori to be easily 
identified. Several possible restriction digests were considered, but none gave 
reliable results and so the route was abandoned. This may be due to the method 
used to isolate the plasmid, ST ET preparations, instead of the much more time- 
consuming alkaline lysis/cesium chloride banding procedure, which gives much 
purer plasmid, used for large-scale preparations. The impurities in the plasmid 
isolated by the ST ET procedure may interfere with the action of the restriction 
enzymes and result in poor reproducibility of the digests.
Unfortunately, only partial sequences were ever obtained from the above efforts at 
sequencing. The most extensive sequence obtained gave the 3' 96 nucleotides of 
the protease gene but this did not show the site of insertion as it was obtained using 
the 3' PCR primer.
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5’...ATA/GAA7rCT/GTG/GAC/ATA/AAG/CTAn‘AG/TAG/GAC/CTA/CAC/CTT/GTC/AA 
G/ATA/ATT/GGA/AGA/AAT/CTG/TTG/AGTCAG/ATT/GGT/rGC/AGT/TTA/AAT/TTT 3’
Figure 2.6.4: Partial sequence of HIV-1 protease cloned into pGEX-2T
2.6.4 Expression and purification strategy
Once the fusion protein had been expressed in the recombinant E. coil it was 
thought that it could be very easily be purified by affinity chromatography. Simply 
passing the crude cell extract over a glutathione agarose column should result in 
extensive purification of the HIV protease-GST fusion protein. The active site of 
glutathione-S-transferase (GST) clearly has a high affinity for the glutathione and will 
bind to it and the remainder of the cellular proteins will pass through the column. 
Elution with a glutathione solution releases substantially pure fusion protein. 
Treatment with thrombin will then release the protease, which can then be further 
purified by affinity chromatography over a pepstatin agarose column, as has been 
used before.^'*^ Pepstatin is a generalised aspartic protease inhibitor, and so will be 
bound specifically by the protease. Any residual cellular proteins and the GST will 
pass through unhindered and the protease will be retained. Elution should give 
essentially homogenous protein.
An inherent problem with the use of a fusion protein approach for expression and 
purification of the HIV protease is that the protease may not be active as a fusion. 
The enzyme is an obligate dimer (see Section 1.10.2.3), with the dimérisation 
Interface lying at the N and G-termini. The N-terminus of the protease will be 
occluded by the presumably folded GST, thus preventing dimérisation. Prevention of 
dimérisation will prevent expression of activity. This means that the purification 
cannot be followed in the usual way, by assessing protease activity in fractions 
collected from columns and so forth. Purification therefore has to be followed by gel 
electrophoresis. Most attempts to express the protease as a fusion have resulted in 
active protein^^^'»*^ while others have not.^"*® In this case activity could only be 
restored by dénaturation in urea and refolding. It would be expected that the 
protease would be active as a fusion protein as it is expressed in vivo as a fusion 
with the rest of the gfag-po/polyprotein. Kotler et al.^^^ have found that the protease
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is active when its N-terminus is fused with parts of the gag polyprotein. Thus, the 
factors that determine the activity of a protease fusion are manifold and difficult to 
determine.
During the initial stages of the purification the distribution of the fusion protein 
between the supernatant from sonication and the cell debris was checked by SDS- 
PAGE. It was found that some of the fusion remained in the cell debris, i.e. it was 
produced as an insoluble aggregate. In an attempt to maximise the level of soluble 
protein a series of experiments on the effect of different induction conditions were 
undertaken.
Lower concentrations of IPTG will reduce the rate of production of the fusion protein 
and thus reduce the chances for aggregation. Concentrations from 20-150 pM IPTG 
were tried and the proportion of the insoluble protein did not seem to alter greatly 
over this range. Hartmann et ai.^ '^  ^ have reported that low growth temperatures also 
result in reduced amounts of recombinant proteins being formed as inclusion bodies. 
However, downshifting the growth temperature to 25 °C did not reduce the amount of 
insoluble protein. Lastly, the effect of induction time (from 1-5 hours) was examined 
for its effect both on the proportion of insoluble protein, the level of expression.and 
the cell density.
To assess the effect of the expression of the protease on the growth rate of JM-101 
the optical density at 600 nm of the culture was monitored. The results are presented 
graphically below. It can easily be seen that the expression of the protease does not 
cause the saturation density of the culture to be lowered significantly i.e. the 
expression of protease is not toxic to the cell. This is unusual, as most groups have 
observed extremely deleterious effects on cell growth occurring on induction of 
protease e xp re ss io n .S a tu ra tio n  density is reached approximately 2 hours post­
induction. However, since no activity could be obtained in crude preparations the 
effect of induction time on the level of activity produced could not be assessed.
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To select the optimal time post-induction for harvesting the cells the level of fusion 
protein was monitored at various times (30 mins.-3.5 hours) by denaturing PAGE. 
The levels in both total cell protein and in supernatants of lysozyme lysates of 1.5 ml 
aliquots of the culture were examined. The level of protein expressed was estimated 
from the intensity of the band corresponding to the fusion protein when the gels were 
loaded under identical conditions. Maximal expression was achieved 2-2.5 hours 
post-induction.
Once optimal growth conditions had been established the transformed cells were 
grown, harvested, sonicated and centrifuged to remove insoluble cell debris. The 
supernatant, containing most of the HIV PR-GST fusion, was applied to a glutathione 
agarose column and the wash-through collected. The GST fusion was eluted by 
washing with 2 column volumes of 5 mM glutathione. However, no protein was 
eluted from the column.
When the effluent from column loading and the column washing were run on 
denaturing polyacrylamide gels there was a strong band from both sets of fractions of 
a molecular weight around 29 kDa. When the total cell protein was run on PAGE gels 
the major band was observed, as expected, at 37 kDa. Thus there is a loss of around 
8 kDa from the recombinant fusion protein on sonication. This implies that the fusion 
protein was being cleaved on sonication to give the smaller form observed, and this 
form was not binding to the glutathione column. If the fusion protein were truncated 
before expression i.e. at the gene level, then the gene has been cleaved before
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expression. This is unlikely as the host strain JM 101 contains only one restriction 
endonuclease, Eco K, which has an 8 b.p. cleavage site. This sequence is not 
contained in the GST or the protease genes. Also, if the plasmid were to be cleaved 
in JM 101 then it would not be maintained from generation to generation in the JM 
101 , thus there would be no source of ampicillin resistance and the bacteria would 
die in culture.
The cleavage therefore takes place at the protein level and could be due to either 
cellular protease(s) or the HIV-1 protease. As the cleavage takes place over a very 
short period of time and only after sonication it is unlikely that a cellular protease is 
the cause. Also, expression of non-proteolytic enzymes as GST fusions in JM101 
does not result in any detectable cleavage of the f u s i o n , a g a i n  supporting the 
fused protease as the source of the cleavage. Since cleavage is not seen in the total 
cell protein, sonication must somehow activate the protease, perhaps by breaking up 
aggregations of the fusion protein in solution (or perhaps even solid inclusion 
bodies).
The cleavage was almost defin ite ly  not occurring in the protease, as 
autoproteolysis of the protease does not release a fragment of the correct size,^®® 
and autoproteolysis occurs on a much slower time-scale than that observed here. 
The protease therefore cleaves the GST. The observed loss in mass on cleavage of 
the fusion protein (around 8 kDa) is consistent with cleavage at a putative good 
protease site in GST, Phe 53-Pro 54, which results in the loss of 7.5 kDa. It has been 
shown that the main determinant of cleavage by the protease is not the sequence but 
the conformation of residues in the vicinity of the scissile bond (see Section 1.8.3). 
Thus, the possibility of the Phe 53-Pro 54 site being cleaved was investigated by 
examining the predicted secondary structure of the 20 amino acid region around the 
putative cleavage site with that around known Phe-Pro cleavage sites from the gag- 
po l polyprotein. Secondary structure prediction was undertaken using the 
GeneWorks^^ program and the PepPlot and Peptide Structures routines from the 
UWGCG p a c k a g e . N o  definite secondary structure prediction was made which is 
consistent with studies on peptide substrates for the HIV protease that show they 
have only random conformation in solution.^^2
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The recent solution of the crystal structure of GST from rat^^^ shows that the Phe- 
Pro residues are in the glutathione-binding domain. The equivalent residues to Phe- 
53 and Pro-54 in the rat GST are contained in a c/s-Pro bend, which is on the 
exterior of the protein. This means that the putative cleavage site is accessible to the 
protease, which is consistent with Phe-53-Pro-54 being the actual site of cleavage.
This could be demonstrated by isolating the small fragment and sequencing its N- 
terminus.
In an effort to suppress the cleavage by inhibiting the break-up of the putative 
protein aggregates sonications were carried out on cells suspended in decreasing 
volumes of sonication buffer. This also mimics conditions in the cell as closely as 
possible, which would be helpful if some cellular factor were either inhibiting the 
protease or promoting its aggregation. This approach was not fruitful, which is not î
unexpected as the cleavage is an intermolecular reaction, so would be expected to 
proceed faster in higher concentrations. Sonications were also tried using very large 
volumes of buffer to reduce the rate of this intermolecular reaction. This proved 
ineffective. The use of raised pH (from 7.5 to 9 in 0.5 unit steps) to reduce the activity 
of the protease (which has a pH optimum around 5.5, see Section 1.8,3) was also 
ineffective.
Sonication in the presence of 20 juM pepstatin, which is a general inhibitor of 
aspartic proteases including the HIV protease (Kj = 1.4 p.lVI^^^), should have 
prevented this cleavage. This was not the case, however, and so the source of the 
cleavage remained unclear. It may be that the reaction occurs too rapidly for the 
pepstatin to interact with the protease and inhibit it, perhaps because pepstatin has a 
two-stage interaction with the HIV protease as it does with other aspartic 
proteases.^^^ The second stage of the interaction occurs over the course of several 
minutes, so if pepstatin interacts with the protease in this way then a high level of 
inhibition will only be achieved after a considerable period of time. This delay in 
achieving good inhibition will mean that the cleavage reaction will have finished 
before the enzyme is inhibited. In order to overcome this it was decided to incubate 
the cells in the presence of 50 )iM pepstatin for 20 minutes before sonication in the 
presence of 20 pM pepstatin. This also had no observable effect on the cleavage.
Thus, it appears that while the cleavage is not caused by a cellular protease, 
inhibiting the HIV protease is problematic.
The difficulties discussed above meant that no uncleaved protease fusion was 
isolated from the recombinant bacteria. Attempts were made to purify the cleaved
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fragment and thrombinise off the cleaved GST after purification. Precipitation of the 
cleaved fusion was efficiently achieved with ammonium sulfate at 20% saturation, 
with few contaminating proteins (purity was estimated to be around 80%). There was 
still no measurable protease activity. Subsequent size exciusion chromatography on 
Sephadex G-75 also gave no activity. The purity of the protein is shown in the PAGE 
gel below.
The rightmost lane contains the molecular weight markers, the adjacent lane shows 
a sample of the protease after elution from the G-75 Sephadex column. The masses 
of the standards are 76 kDa, 66.25 kDa, 42.7 kDa, 30 kDa and 17.2 kDa.
It has recently been brought to our attention that similar attempts in other groups to 
express the HIV-1 protease as a GST fusion have all failed, with no or very low 
amounts active protein i s o l a t e d . T h e  inconsistency between the lack of protease 
activity against the peptide substrate used in the in vitro assays and the proposed 
high level of activity against GST remains unexplained.
2.6.5 Future Work
A solution to the problem of cleavage is to use site-directed mutagenesis to mutate 
away the cleavage site in the GST. Since the proline at position 54 causes a bend in 
the protein chain, mutation of this residue is likely to cause gross changes in the 
folding of the GST, probably resulting in a protein that will not bind to glutathione. 
Thus, it was decided to mutate the phenylalanine to glutamine as this residue is of
142
approximately the same size as the phenylalanine side-chain, so will not perturb the 
side-chain packing greatly. It is also known that the GIn-Pro linkage is not cleaved by
the HIV-1 protease.^^^ The protease may also be expressed as a fusion with a 
different protein. In order to observe activity it may be necessary to express the 
protease as an insoluble fusion protein (in inclusion bodies) and return activity by 
refolding solubilised inclusion bodies from urea.
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3.0 Experimental
Optical rotations were measured at room temperature on Optical Activity AA-100 and 
AA-1000 polarimeters.
Elemental analyses were performed in the departmental microanalytical laboratory 
and by the University College, London laboratory.
N.m.r. spectra were taken on Bruker AM-360 (360 MHz, f.t. '•H-n.m.r. and 89.71 MHz 
^^C-n.m.r.), Bruker AM-300 (300 MHz, f.t. ^H-n.m.r., 121.49 MHz, P-n.m.r. and 
74.76 MHz, ’•^C-n.m.r,), Jeol JNM-GX270 (270 MHz, f.t., ^H-n.m.r.), Varian Gemini 
200 (200 MHz, f.t. ^H-n.m.r. and 50.31 MHz.l^C-n.m.r.) and Jeol FX-90Q (90 MHz, f.t. 
’’ H-n.m.r.) spectrometers. H-N.m.r. spectra are described in parts per million 
downfield shift from TMS and are reported consecutively as position (8^), relative 
integral, multiplicity (s.-singlet, d.-doublet, t.-triplet, q.-quartet, m.-multiplet, d.d.- 
double doublet and br.-broad), coupling constant and assignment (numbering 
according to the lUPAC nomenclature for that compound^^^). For compounds run in 
C^HCIg, the spectra were referenced to the internal CHGI3 signal at 7.27 p.p.m. and 
for compounds run in 2H2O the spectra were referenced to the internal HO^H peak at 
4.60 p.p.m., or dioxan at 3.66 p.p.m.
H}'*^C-Nuclear magnetic resonance spectra were referenced to chloroform (at
77.20 p.p.m.), dioxan (67,40 p.p.m.) or dimethyl sulfoxide (at 39.70 p.p.m.). and are 
reported consecutively as position (8^), multiplicity (d.-doublet), coupling constant 
and assignment (quat.- quat.).
Conformational effects are indicated by the symbol t  appearing after the chemical 
shift of the atom(s) concerned.
l.r. spectra were taken on Perkin-Elmer Series 1500 and Perkin-Elmer 1710 f.t. i.r. 
spectrometers. The samples were prepared as Nujol mulls, solutions in chloroform or 
thin films between sodium chloride discs. Absorption maxima are given in 
wavenumbers (cm""*) relative to a polystyrene standard.
Mass spectra and accurate mass measurements were recorded on a VG 70-250 BE, 
a Kratos MS-50 or by the SERC service at Swansea using a VG AZB-E. Fast atom 
bombardment spectra were recorded using glycerol as a matrix. Major fragments are
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given as percentages of the base peak density (100%).
UV/ Vis spectra were recorded on Pye-Unicam SP8-500 or SP8-100 spectrometers. 
Flash chromatography was performed according to the method of StilH^^ using 
Sorbsil C 60 (40-60 pm mesh) or Machery-Nagel silica gel N.
Analytical thin layer chromatography was carried out on 0.25 mm precoated silica 
gel plates (Macherey-Nagel SIL G/UV254) and compounds were visualised using UV 
fluorescence, iodine vapour, aqueous potassium permanagnate or ninhydrin.
Melting points were taken on an Electrothermal melting point apparatus and are 
un corrected.
All solvents were distilled before use and light petroleum refers to that portion boiling 
between 40 and 60°C. Solvents were dried according to the lite ra tu re  
p r o c e d u r e s . '^ ^ a  Agarose gel electrophoresis was carried out on 1% agarose gels 
containing 1 pg mi'i ethidium bromide with TBE buffer at 100 mA unless otherwise 
specified. Sonications were carried out on a MSE Soniprep 150 sonicator at full 
power. Centrifugations were carried out on a Beckman JA-2000 centrifuge in JA-14 
or JA -6 rotors and ultracentrifugations on a Beckman TL-100 in a J-2 rotor. 
O ligonucleotides were synthesised on an Applied Biosystems 381A DNA 
synthesiser. DNA concentrations were measured by absorbance at 260 nm. 
Common broths, buffers and stock solutions were made as described by Sanbrook 
et
Molecular modelling calculations were carried out on a Silicon Graphics IRIS 
4D/85GT and an Indigo Elan R4000. Macro mode I V . 3 . 1 X ^ 3 0  and INSIGHT 2.1.2^^^ 
were used to perform these calculations and display the results. Crystal structures 
were obtained from the Protein Data Bank.432
N-ferf-Butoxycarbonyl-(2S)-phenylaianine phenylhydrazide (1).-
To a stirred solution of N-fe/t-butoxycarbonyl-(2S)-phenyalanine (265 mg, 1 mmol) 
in dry DMF (10 ml) at 0 °C was added N-methylmorpholine (109 pi, 1 mmol), 
fol lowed by 2 -me thy lp ropy lch io reform ate (136 pi, 1 mmol). A fter 1.5 h. 
phenylhydrazine (98.3 pi, 1 mmol) and N-methylmorpholine (109 pi, 1 mmol) were 
added in DMF (10 ml) and the mixture stored at 4 °C overnight. The solution was 
then partioned between ethyl acetate (40 ml) and water (10 ml), the ethyl acetate
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layer was separated and washed with 1 M HCl (3 x 10 ml), water (10 ml), 5% sodium 
bicarbonate solution ( 3 x 1 0  ml) and water (10 ml). The organic layer was dried 
(IVIgSO^) and the solvent removed under reduced pressure to give a yellow oil which 
was crystallised from methanol/ water to give cream crystals (173 mg, 48%) of m.p 
135-137 °C. [a]o22 -16.1° (c 1 in MeOH); v^ax (CHCI3) 3429 (NH), 3300 (amide NH), 
1750-1650 (CO) and 756 cm""* (aromatic); (MeOH) 283 nm (e 2060); 8^ (90 
MHz, C2HCI3) 1.40 (9H, s., (CH3)3C), 3.03 (2H, d., J 8.1 Hz, CHg), 4.48 (1H, m., CH),
5.26 (1H, d., J  6.9 Hz, PhNH), 6.58 (1H, d., J 6.9 Hz, amide NH), 7.1-7.4 (10 H, m., 
aromatic) and 8.2 (1H, br.s., urethane NH); m/z(C\) 356 ([M+H]+, 5.1%), 299 ([M+H- 
(CH3)3C]+, 25.9), 282 ([M-(CH3)3CO]+, 68.4), 256 ([M-(CH3)3C0 C(0 )]+, 100) and 
120 (NH2CH(NH)CH2Ph+, 98.1).
N“ferf-Butoxycarbonyl-(2S)-phenylalanlne nitrophenylhydrazide (2).-
This was prepared in an identical manner to the phenylhydrazide (1), using 
nitrophenylhydrazine (153 mg, 1 mmol). The product was obtained as beige 
amorphous crystals, after recrystallisation from methanol/ water (192 mg, 48%) of 
m.p. 208-209 °C (dec.), -8.9° (c 1 in MeOH); v^ax (Nujol) 3340-3250 (NH),
1689 (urethane CO), 1653 (amide CO), 1531 (NO2), 1329 (NO2), 843 (p-substituted 
aromatic) and 724 cm'^ (mono-substituted aromatic); (MeOH) 353 nm (e 
56,800); 8h (360 MHz, C2HCI3) 1.46 (9H, s., (CH3)3C), 3.06 (2 H, m., CHg), 4.36 (1H, 
m., CH), 6.65 (2H, d., J 8.9 Hz, nitroaromatic), 7.42 (5H, s., Ph), 8.04 (2H, d., J  8.9 
Hz, nitroaromatic), 9.20 (1H, s., amide NH) and 10.37 (1H, s., urethane NH); m/z 
(FAB) 401 ([M+H]+, 12.3%), 300 {[M+H - (CH3)3C0C(0)]+, 30.7), 91 (PhCH2+, 13.6) 
and 57 ((CH3)3C+, 100).
Benzylhydrazine (3).-
Benzylhydrazine dihydrochloride (1.37 g, 7 mmol) was added to a stirred solution 
of 1 M sodium hydroxide solution (15 ml) at room temperature. After 1 h. and the 
aqueous phase was extracted with chloroform (3 x 20 ml). The extracts were 
combined, dried (MgSO^), filtered and the solvent removed under reduced pressure 
to give a yellow oil (702 mg, 82%). v^ax (CHCIg) 3018 (NH) and 754 cm"^ (aromatic);
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ÔH (90 MHz, C^HCIg) 2.81 (2H, s., CHgPh) and 7.31 (5H, s., aromatic).
N-ferf-Butoxycarbonyl-(2S)-phenylalanine benzyihydrazide (4).-
This was prepared as for the phenyl analogue (1), using benzylhydrazine (122 mg, 
1 mmol). Recrystallisation from methanol/ diethyl ether gave the product as a white 
solid (122 mg, 49%) of m.p. 121-123 °C. [ay^-7 .2^  (c 2 in CHCI3); v^ax (CHCI3) 
2981 (amide NH), 1705 (urethane CO), 1680 (amide CO) and 710-750 .cm*'  ^
(aromatic); X^ax (MeOH) 283 nm (e 2240); 8^ (270 MHz, C^HCIg) 1.40 (9H, s., 
(CH3)gC), 3.04 (2 H, d., J 7.5 Hz, CHgNH), 3.83 (2 H, m., CHCJI2), 4.27 (1H, m., C-2 
H) and 7.06-7.39 (10H, m., aromatics); m/z (Cl) 370 ([M+H]+, 4.2%), 314 ([M+H- 
(CH3 )gC]+, 25.4), 296 ([M -((CH3)3C+HgO)]+, 100), 270 ([M -(CH3)3CC02]+, 49.1) 
and 108 (PhCH2NH3+ 17.3).
Methyl (2S)-tyrosinate hydrochloride
(2S)-Tyrosine (1 g, 5.5 mmol) was dissolved in dry methanol (15 ml) at 0 °C and 
distilled thionyl chloride (1.69 g, 14 mmol) was added drop wise with stirring, keeping 
the temperature at 0 °C. The mixture was then refluxed for 90 min. The solvent was 
removed under reduced pressure to give an off-white solid, which was recrystallised 
from methanol/ diethyl ether to give the product as white crystals (1.21 g, 95%) of m.p 
189-191 °C (lit.433 190 °C). m/z (Found: {M + H+) 196.0973. C10H14NO3 requires 
196.0973); [o.]q^  +65.2° (c 2.4 In HjO) (lit."33 +74° (c 3 in pyridine)); v^ax
(Nujol) 3338 (NH), 1743 (CO) and 750 cm-1 (aromatic); 8 ,^ (90 MHz, ^H^O) 2.97 (2H, 
d., J  6.5 Hz, CHg), 3.64 (3H, s., OCH3), 4.15 (1H, t., 0-2 H), 6.65 (2 H, d., J  8.2 Hz, 
aromatic), 6.92 (2H, d., J  8.2 Hz, aromatic); (50.31 MHz, ^HgO) 37.56 (CHgPh), 
56.34 (CHNH3+), 56.99 (CH3O), 118.77 (ortho aromatic), 128.18 (para aromatic), 
133.64 (meta aromatic), 158.03 (ipso aromatic) and 172.93 (ester CO); m/z (El) 195 
([M-HCI]+, 6.5%), 136 ([M-HCI-C0 2 Me]+, 33.9), 107 (C7H6OH+, 100) and 77 (CgHs^,
16.4).
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(2S)-Tyrosine methyl ester (6).-
(2S)-Tyrosine methyl ester hydrochloride (695 mg, 3 mmol) was dissolved in 
saturated sodium bicarbonate solution (20 ml). The solution was then extracted with 
chloroform (4 x 15 ml), the organic layer was dried (Na2S0 4 ) and the solvent 
removed under reduced pressure to give a white solid (421 mg, 72%) of m.p. 132- 
134 °C (lil.434 133-135 °C). [a][,32 +24° (c 4 in MeOH); v^gx (CHCI3) 3353 (NH), 
2850-2640 (aromatic) and 1743 cm  ^ (CO); By (90 MHz, C2HCi3) 2.94 (2H, app. d., J
6.8 Hz, CHg), 3.65 (3H, s., OCH3), 4.13 (1H, m., C-2 H), 6.65 (2H, d., J  7.9 Hz, 
aromatic) and 6.95 (2 H, d., J  7.9 Hz, aromatic); m/z (Ei) 195 4%), 136 {[M-
C0 2 Me]+, 16), 107 (C7H7OH+, 42) and 77 (CgH5+, 100).
Methyl N-ferf- butoxycarbonyl-(2S)-phenylalanyi-(2S)-tyros[nate (7).-
N-ferf-Butoxycarbonyl-(2S)-phenylalan ine (133 mg, 0.5 mmol) and N- 
methylmorpholine (55 pi, 0.5 mmol) were dissolved in dry DMF (10 ml) and 2- 
methylpropylchloroformate (65 pi, 0.5 mmol) added. The reaction was stirred at 0 °C 
for 1.5 h., methyl ester (6 ) (98 mg, 0.5 mmol) added in dry DMF (5 ml) and the 
reaction stirred overnight at 4 °C. Water (15 ml) was added and the mixture extracted 
into ethyl acetate (40 ml). The ethyl acetate layer was separated and washed with 1 
M HCl (3x10  ml), water (10 ml), saturated sodium bicarbonate (3x10  ml) and water 
(10 ml), dried (MgS0 4 ) and the solvent removed under reduced pressure to give a 
yellow oil. This was twice recrystallised from ethyl acetate/ light petroleum to give a 
white solid (73 mg, 15.8%) of m.p. 142-143 °C. v^ax(GHCl3) 1748 (ester CO) cm"'*; 
Bh (90 MHz, C^HCig) 1.40 (9H, s., (CH3)3C), 3.0 (4H, m., CHg x2), 3.68 (3H, s., 
OCH3), 4.34 (1H, m., Phe CH), 4.76 (1H, m., Tyr CH), 5.27 (1H, d., J 7.8 Hz, amide 
NH), 6.66 (2 H, d., J 7.5 Hz, tyrosine aromatic), 6.87 (2H, d., J 7.5 Hz, tyrosine 
aromatic), 7.26 (5H, s., Ph) and 8,26 (1H, br., urethane NH).
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%(2S)-Tyrosine amide (8)-
Methyl ester hydrochloride (5) (0.8 g, 3.25 mmol) was dissolved in saturated 
methanolic ammonia solution (15 ml) and stirred at room temperature for 96 h. The 
ammonia was blown off in a stream of nitrogen and the solvent removed under 
reduced pressure to give a cream solid, which was recrystallised from ethanol/ light 
petroleum to give white crystals (0.52 g, 69%) of m.p. 240-243 °C. m/z (Found: {M + 
H )+181.0977. C9H13N2O2 requires 181.0977); +21° ( c l  in H2O); v^ax (Nujol)
3330 (amide NH), 3175 (amine NH), 1703 (CO), 1458 (amide II) and 793 cm'i 
(aromatic); 5h (90 MHz, 2H2O) 3.12 (1H, d.d., 7.4 Hz, 13-8 Hz, 1 of CH2),
3.21 (1H, d.d., Jgx 5.8 Hz, Jab 13.8 Hz, 1 of CH2), 4.22 (1H, d.d., Jax^.S Hz, Jgy 5.8 
Hz, CH), 6.91 (2H, d., J 8.8 Hz, aromatic) and 7.23 (2H, d., J 8.8 Hz, aromatic); Ôq 
(50.31 MHz, dg-DMSG) 36.23 (CH2Ph), 53.92 (CH-NH), 115.53 (orf/?o aromatic),
125.26 {para aromatic), 130.74 {meta aromatic), 156.79 {Ipso aromatic) and 170.16 
(amide CO); m/z (El) 180 {M*, 2 .1%), 163 ([M-OH]+, 58.5), 136 ([M-CONH;]*, 95.5), 
107 (CH2C6H4OH+, 100) and 74 (NH3CONH2+, 72.6).
N-ferf-Butoxycarbonyl-(2S)-leucine hydrate (9).-
To a stirred solution of (2 S)-leucine (1.12 g, 10 mmol) in 1 M sodium hydroxide (10 
ml) and distilled /sopropanol (10 ml) was added di-tertiary butyl dicarbonate (2.9 g, 
13 mmol) in /sopropanol (5 ml). The resulting precipitate was dissolved in 1 M 
sodium hydroxide (7 ml). After 1 h., the alcoholic layer was removed under reduced 
pressure, the aqueous layer washed with light petroleum (15 ml) and acidified to pH 
3 with 1 M sulphuric acid. The resulting solid was filtered and carefully dessicated 
over phosphorous pentoxide to give the product as white crystals (1.66 g, 81%) of 
m.p 68-71 °C (lit.435 67-71 °C). m/z (Found: {M + H)+ 232.1549. C11H22NO4 
requires 232.1549); [aj^^o _21° (c 2 in AcOH) (lit.435 [aj^zo _25° (c 2 in AcOH)); v^ax 
(CHCI3) 3442 (NH), 3019 (CH), 1714 (carboxyl CO) and 1694 cm'^ (urethane CO); 
ÔH (270 MHz, C^HCIg) 0.96 (6 H, d., J 6.5 Hz, (CÜ3)2CH), 1.45 (9H, s., (CHg)3C), 
1.47-1.83 (3H, m., (CH3)2CH and CH2), 4.36 (1H, m., CJHNH), 4.97 (1H, d., J 7.9 Hz, 
NH) and 9.22 (1H, br. s., CO2H); Ôq (50.31 MHz, C^HCIg) 22.23 & 23.32 (CH(C.H3)2),
25.31 (£H(CH3)2), 28.76 ((^H3)3C), 41.92 (CH2), 52.61 (CHNH), 80.61 {{CHq) ^ ^ ,  
156.19 (urethane CO) and 178.37 (acid CO); m/z (Cl) 249
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([M + N H ^r, 38%), 232 ([M+H]+, 1.8), 186 ([M -C02H]+, 20.04), 130 { [ M - 
(CH3)3C0 C0 ]+, 49.04), 86 (NHCH(CH2)C0 2 H+, 53.4) and 57 ((CH3)3C+, 100).
N-ferf-Butoxycarbonyl-(2S)-leucyl-(2S)-tyrosine amide (10).-
N-fe/t-Butoxycarbony!-(2S)-leucine hydrate (9) (231 mg, 1 mmol) was dissolved in 
ethyl acetate (10 ml), dried (IVIgSO^) and the solvent evaporated to give a clear oil. 
The oil was then dissolved in dry DMF (10 ml), containing N-methyl morpholine (109 
pi, 1 mmol) at 0 °C, and 2 -methylpropylchloroformate (136 pi, 1 mmol) added with 
stirring. The reaction mixture stirred for 90 min. at 0 °C. A solution of amide (8 ) (165 
mg, 1 mmol) and N-methyl morpholine (109 pi, 1 mmol) in DMF (3 ml) was added 
dropwise and the reaction stirred overnight at 4 °C. The reaction was partitioned 
between water (15 ml) and ethyl acetate ( 3x10  ml), which was then washed with 1 
M HCl ( 3 x 1 0  ml), water (10 ml), 5% sodium bicarbonate solution ( 3 x 1 0  ml) and 
water (10 ml). The organic layer was dried (MgSO^) and the solvent removed under 
reduced pressure to yield a white solid, which was recrystallised from ethyl acetate/ 
light petroleum to give the product as white crystals (66 mg; 16.5%) of m.p. 119-122 
°C. m/z (Found: (W+ H)+394.2342. C20H32N3O5 requires 394.23417); [a][)20+i8.8° 
(c 1 in MeOH); v^gx (Nujoi) 3541 (OH), 3470-92 (NH), 1699 (urethane CO), 1685 & 
1669 (amide CO) and 753 cm‘  ^ (aromatic); 5y (270 MHz, dg-DMSO) 0.89 (6 H, m., 
(CH3)2CH), 1.37 (9H, s., (CHg)3C), 1.55 (2 H, m., CHCÜ2), 162 (1H, m., CMOH2),
2.57 (1H, d.d., Jab 14.2 Hz, 6.9 Hz, 1 of CH2Ph), 2.88 (1H, d.d., 14.2 Hz, Jgx
5.5 Hz, 1 of CH2Ph), 3.81 (1H, m., NHCH Tyr), 4.33 (1H, m., NHCH Leu), 6.62 (2H, d., 
J 8 Hz, aromatic), 6.90 (2H, d., J 8 Hz, aromatic), 7.01 (1H, d., J 7.5 Hz, amide NH),
7.06 (1H, s., 1 of 1° amide NH), 7.35 (1H, s., 1 of 1° amide NH), 7.57 (1H, d., J  7.2 
Hz, urethane NH) and 9.07 (1H, s., aromatic OH); (75.74 MHz, cfg-DMSO) 20.51 & 
22.72 ((CHg)2), 24.12 (^lH(CHg)2), 28.09 ((CH3)3C), 36.83 (CHg Leu), 40.65 (CHg 
Ar), 53.6 (Tyr CH), 56.1 (Leu CH), 78.14 ((CHg)3£ ), 114.74, 127.55 & 129.99 
(aromatic), 152.71 (urethane CO) and 171.83 & 172.68 (CO); m/z (Cl) 394 ([/W+H]+, 
14%), 338 ([(M-(CH3)gC0 ) + NH4]+, 58), 294 ([(M-Boc) + NH4]+, 100) and 107 
(CH2CgH4 0 H+, 12).
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(2S)-Leucyl-(2S)-tyrosyl amide hydrochloride (11).-
Peptide (10) (100 mg, 0.254 mmol) was dissolved in ethyl acetate (10 ml), cooled 
to 0 °C and dry hydrogen chloride gas bubbled into the solution for 10 min. The 
solution was stirred at 0 °C for 1 h. and then allowed to warm to room temperature 
over 15 min. The solvent was removed under reduced pressure to give a white solid 
that was washed with diethyl ether ( 2 x 5  ml) and dried under vacuum to give the 
product as a white solid (65.3 mg, 79%) of m.p. 110-112 °C. m/z (Found: {M + H)+ 
294.1810. C15H23N3O3 requires 294.1817); -23.1°(c 2 in MeOH); v^ax (Nujol)
3541 (OH), 3470-3210 (NH), 1683 & 1676 (amide CO) and 758 cm-"* (aromatic); Ôh 
(270 MHz, dg-DMSO) 0.83 (3H, d., J  6.0 Hz, 1 of (CH3 )2CH), 0.87 (3H, d.. J  5.6 Hz, 
1 of (CH3)2CH), 1.53 (2H, m., CHCH2). 161 (1H, m, CJICH2), 2.60 (1H, d.d.,
14.1 Hz, Jax 8.5 Hz, 1 of CH2Ph), 2.88 (1H, d.d., J^B 14.1 Hz, Jgx 5.4 Hz, 1 of 
CH2Ph), 3.73 (1H, t„  J 6.8 Hz, NHCH Leu), 4.29 (1H, m., NHCH Tyr), 6.60 (2H, d., J
7.5 Hz, aromatic), 7.03 (2H, d., J 7.5 Hz, aromatic), 7.04 (1H, s., 1 of 1° amide NH2), 
7.55 (1H, s., 1 of 1° amide NH2), 8.09 (2H, s., amine NH2), 8.68 (1H, d., J 8.14 Hz, 2° 
amide NH) and 9.07 (1H, s., aromatic OH); 6q (50.31 MHz, ^H2 0 ) 21.66 & 22.35 
((&H3)2), 24.48 (G.H(CH3)2), 36.82 (CH2 Leu), 41.01 (CH2 Tyr), 53.62 (Tyr CH),
56.14 (Leu CH), 116.66, 128.90 & 131.55 (aromatic), 155.23 (urethane CO) and 
170.81 & 175.94 (amide CO); m/z (FAB) 293 ([M-HCI]+, 1.8%), 208 ([M+H- 
NH2 CHC H 2CH(CH3 )2l+, 2.8), 187 ([M +H-CH2C6H40H]+, 5.2), 136
(NH3CHCHC6H4OH+. 6.3) and 86 (NH3CHCH2(CH3)2"^ , 100).
N-Acetyl-(2S)>phenylalanlne (12).- Method 1
(2S)-Phenylalanine (2.25 g, 13.8 mmol) was dissolved in water (30 ml) and the pH 
adjusted to 11.5 with 2 M sodium hydroxide. Acetic anhydride (3.6 ml) was dissolved 
in benzene (30 ml), the aqueous phase added and the two phase mixture shaken 
vigorously for 15 min., then stirred at room temperature for 2 h. Ethyl acetate (15 ml) 
was then added and the two phases separated, the pH of the aqueous phase 
adjusted to 2 with 2 M HCl and extracted with ethyl acetate ( 3 x 1 5  ml). The organic 
extracts were combined, dried (MgS0 4 ) and the solvent removed under reduced 
pressure to give a white solid, (1.77 g, 62%). This was identical in all respects to the
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sample produced by method 2 .
Method 2^88
N-Methoxydiacetamide, the acetylating agent, was prepared as follows; 
Triethylam lne (12 g, 120 mmol) was mixed with 0-m ethy l hydroxylam ine 
hydrochloride (2.5 g, 30 mmol) in dichloromethane (25 ml) with cooling in ice. Acetic 
anhydride (7.6 g, 75 mmol) was then added dropwise during 30 min. and the 
reaction mixture stirred overnight. The solution was then filtered and the filtrate 
washed with 5% sodium bicarbonate solution ( 3 x 1 5  ml), dried (MgSO^) and the 
solvent removed under reduced pressure to give an oil. Distillation under reduced 
pressure gave the product as a colourless oil (72-74 °C, 12 mm Hg) (2.91 g, 74%).
Vmax (Nujol) 1720 cm'l (amide CO); Ôh (90 MHz, C^HCIg) 2.31 (6 H, s., CH3CO) and
3.74 (3H, s., OCH3); m/z (El) 131 (/VT, 1.9%), 89 ([M+H-CH3CO]+, 38.2) and 43 
(CH3CO+, 100).
To a stirred solution of (2S)-phenylalanine (169 mg, 1 mmol) in dioxane (4 ml) was 
added 2 M sodium hydroxide (0.5 ml), followed by N-methoxydiacetamide (262 mg,
2 mmol) at room temperature. After 27 h. the reaction was diluted with water (4 ml), 
the pH adjusted to 4 with glacial acetic acid and the aqueous phase extracted with 
ethyl acetate (3 x 20 ml). The organic extracts were combined, dried (MgSO^) and 
the solvent removed under reduced pressure to give a white solid. The solid was 
suspended in diethyl ether, filtered, washed with diethyl ether (15 ml) and dried to 
give the product as a white solid (158 mg, 71%) of m.p. 170-172 °C (lit/^G -j 7 -1-3 qq). 
m/z (Found: (M+  H)+ 208.0974. C11H14NO3 requires 208.0974); [ajp^o +4 3 ° 1 |n
MeOH) (lit.436 [a]D20+46.5° (c 2 in EtOH)); v^ax (Nujol) 3329 (NH), 1688 (acid CO),
1617 (amide CO), 1552 (amide II) and 752 cm""* (aromatic); Ôh (90 MHz, dg-DMSO)
1.82 (3 H, s., CH3CO), 3.02 (1H, d.d., 7.9 Hz, 14.05 Hz, 1 of CHgPh), 3.05
(1H, d.d., Jbx 6.7 Hz, J^b 14.05 Hz, 1 of CHgPh), 4.42 (1H, m., CH), 7.29 (5H, s., 
aromatic) and 8.20 (1H, d., J  8.2 Hz, NH); Ôq (50.31 MHz, C^HCIg) 23.59 (CH3),
38.29 (CHg), 53.64 (CH), 127.63-129.72 (aromatic), 136.35 (quat. aromatic) and 
170.32 & 172.68 (CO); m/z (El) 207 (A/T, 1.62%), 163 ([M+H-C0 2 H]+, 4.3), 148 ([M- 
CHgCONHgr, 100), 91 (PhCHg+, 71.55) and 74 (HO2CCHNH2+, 38.0).
1
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Methyl (2S)-phenylalaninate hydrochloride (13)-
To a stirred solution of (2 S)-phenylalanine (4.20 g, 25 mmol) in dry methanol (20 
ml) at 0 °C was added thionyl chloride (4.02 ml, 55 mmol) dropwise with stirring. The 
solution was then refluxed for 2 h. and the solvent removed under reduced pressure 
to give a cream solid. Recrystallisation from methanol/ diethyl ether gave the product 
as white crystals (4.09 g, 76.5%) of m.p. 159-162 °C (lit.437 158-162 °C), m/z 
(Found: {M + H)+ 180.1024. C10H14NO2 requires 180.1024); -6.4° (c 1 in
H2O) (lit.437 [a]p20 .4.6 (c 5 in H2O)); v^ax (Nujol) 3153 (NH), 1745 (ester CO), 1583 
(NH bend) and 763 cm'i (aromatic); ôj_j (90 MHz, ^H2 0 ) 3.04 (1H, d.d., Jab 14.1 Hz 
and Jfix5.5 Hz, CH2Ph), 3.10 (1H, d.d.. Jab 14.1 Hz and Jgy 7.6 Hz), 3.69 (3H, s.,
OMe), 4.38 (1H, d.d., Jgx 7.6 Hz, ^ ^ 5 .5  Hz, NHCH) and 7.28 (5H, m., Ph); m/z {B)
179 ([M-HCI]+, 1.4%). 120 ([M-C0 2 Me]+, 89.3), 91 (PhCH2+, 31.7) and 87 {[M- à 
PhCH2-HCI]+, 100).
Methyl N-acetyl-(2S)-phenylalaninate (14) . - M e t h o d  1 4 3 8
N-Acetyl (2S)-phenylalanine (1 2) (207 mg, 1 mmol) was suspended in diethyl ether 
(10 ml) and cooled to 0 °C. Excess ethereal diazomethane (0.2 g, 4.8 mmol) was 
added with stirring and the mixture stirred at room temperature for 1 h. Excess 
diazomethane was then removed in a stream of nitrogen and the solvent removed 
under reduced pressure to give a yellowish solid, which was recrystallised from 
diethyl ether/ light petroleum to give the product as white crystals (175 mg, 79%). In 
all respects it was identical with the sample from method 3.
Method 2
The ester (13) (431 mg, 2 mmol) was dissolved in glacial acetic acid (10 ml) and 
distilled acetic anhydride (224 mg, 2.2 mmol) added. The mixture was stirred at room 
temperature for 96 h., the solvent was removed under reduced pressure to give a 
white solid that was recrystallised from ethyl acetate/ light petroleum to give the 
product as a white solid (350 mg, 68%). This was identical in all respects with the 
sample from method 3.
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Method 3
Ester (13) (1.35 g, 6.25 mmol) was suspended in chloroform (35 ml), triethylamlne 
(871 pi, 6.25 mmol) added with stirring and the solution cooled to -40 °C. Acetyl 
chloride (440 pi, 6.25 mmol) was added dropwise over 20 min., and the solution 
stirred for 40 min. at room temperature. The solvent was removed under reduced 
pressure and the residue triturated with ethyl acetate (50 ml). The resulting solution 
was washed with 0.5 M HCl (20 ml), 5% sodium bicarbonate solution (20 ml), water 
(20 ml) and brine (20 ml). The solution was dried (MgSO^) and the solvent removed 
under reduced pressure to give a white solid that was recrystallised from ethyl 
acetate/ light petroleum to give the product (1.14 g, 83%) as white crystals of m.p. 90- 
91 °C (lit.438 90-91 °C). (Found: C, 64.89; H. 6 .68 ; N, 6.28. Calc, for C12H15NO3 : C, 
65.15; H, 6.79; N, 6.28); +14.2° (c 2 in MeOH) (lit.438 [a]^20 +16,50 2 in
MeOH)); v^ax (Nujol) 3328 (NH), 1699 (ester CO), 1621 (amide CO), 1533 (amide II), 
1243 (C-O) and 746 cm  ^ (aromatic); Ôh (360 MHz, C^HCIg) 1.99 (3H, s., CH3CO),
3.06 (1H, d.d.. Jab 13 9 Hz and Jax5.8 H z , 1 of CH2Ph), 3.12 (1H, 6.6., Jab 13.9 Hz 
and Jbx8.1 Hz, 1 of CHgPh), 3.73 (3H, s., OCH3), 4.88 (1H, d.d.d., Jgx 8.1 Hz, J^h 
7.2 Hz, Jax5.8 H z  , NHCH), 6.02 (1H, br. d., J 7.2 Hz, NH) and 7.05-7.35 (5H, m., 
Ph); ÔC (90.56 MHz, C2HCI3) 23.2 (jQH3C0 ), 37.9 (CHgPh), 52.3 (OCH3), 53.2 
(CHNH), 127.2, 128.7 & 129.3 (aromatic), 135.9 (quat. aromatic) and 169.7 & 172.2 
(CO); m/z (El) 221 (A^, 3.1%), 178 ([M-CH3C0 ]+, 2.2), 162 ([M-C0 2 Me]+, 100), 131 
([A4+H-CH2Ph]+, 33.6), 120 (NH2CHCH2Ph+, 45.0), 88 (NH2CHC0 2 Me+, 64.5) and 
43 (CH3CO+, 43.8).
N-ferf-Butoxycarbonyl-(2S)-leucinol (15).- Method 1
N-ferf-Butoxycarbonyl-(2S)-leucine hydrate (9) (400 mg, 1.75 mmol) was dried as 
for compound (10) and dissolved in dry THF (10 ml). The solution was cooled to -20 
°C and triethylamlne (156 mg, 1.75 mmol) and 2-methylpropylchloroformate (228 pi,
1.75 mmol) were added consecutively. The solution was stirred for 15 min., then 
filtered directly into a 0 °C solution of sodium borohydride (100 mg, 2.5 mmol) in 
water (10 ml). The solution was allowed to warm to room temperature and stirred for 
3 h. The mixture was acidified to pH 3 with 2 M HCl and extracted with diethyl ether 
( 4 x 1 0  ml). The ethereal extracts were combined, dried (MgSO^) and evaporated
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under reduced pressure. The resulting yel low oil was purified  by flash 
chromatography (diethyl ether/ light petroleum, 7:3) to give the product as a clear oil 
(273 mg, 72%). v^ax (thin film) 3349 (OH), 2956 (NH), 2790-2650 (CH), 1685 
(urethane CO) and 1173 cm'l (amide II): Ôh (270 MHz, C^HCIg) 0.91 (6H, d., J 7 Hz. 
(CÜ3)2CH), 1.34 (2 H, m., CJdaCH), 1.47 (9H, s., (CH3)gC), 1.49 (1H, m., CJbiCHg), 
3.54 (1H, m., CH2OH), 4.30 (1H, m., NHCH), 4.62 (1H, s., OH) and 4.94 (1H, d., J  7.7
Hz, NH); m/z (El) 217 (M+, 1.5%), 186 ([M-CH2 0 H]+, 3.9), 130 ([M+H-CH2OH- 
(CHg)3C)+, 33.8), 86 ([M+H-CH2 0 H-Boc]+, 21.4) and 57 ((CH3)gC+, 100).
Method 2489
N-te/t-Butoxycarbonyl-(2S)-leucine hydrate (9) (205 mg, 0.887 mmol) was dried as 
for compound (10), dissolved in dry THF (4 ml) and cooled to -10 °C. N-methyl 
morpholine (89.6 mg, 0.887 mmol) and ethyl chloroformate (95.8 mg, 0.887 mmol) 
were added and the solution stirred for 10 min. Sodium borohydride (100 mg, 2.66 
mmol) was then added in one portion and dry methanol (8 ml) added dropwise over 
the next 10 min. at 0 °C. After 10 min. the reaction was neutralised with 1 M WCI. The 
organic solvents were removed under reduced pressure and the resulting aqueous 
layer extracted with ethyl acetate ( 3 x 8  ml). The organic layer was washed 
successively with 1 M HCl (3 ml), water ( 2 x8  ml), 5% sodium bicarbonate (4 ml) and 
water ( 2 x 8  ml) and then dried (MgSO^). The solvent was evaporated under reduced 
pressure to give a clear oil, which was further purified by chromatography on flash 
silica (diethyl ether/ light petroleum, 7:3) to give a clear oil (133 mg, 69%) identical to 
the sample prepared by Method 1.
(2S)-Leucinol hydrochloride (16).-
This was synthesised in an identical manner to the hydrochloride (11 ), starting with 
(15) (217 mg, 1 mmol), to give the product as a white solid (125 mg, 82%) of m.p. 
156-8 “C. Mo^O+0.9" (c 3 in MeOH); v^gx(Nujol) 3375 (OH), 3100 (NH3+) and 1375 
cm-1 (OH bend). 5^ (270 MHz, ^HgO) 0.71 (3H, d., J  6.2 Hz, 1 of (CH3 )2CH), 0.73 
(3H, d„ J  6.2 Hz, 1 of (CH3)2CH), 1.27 (1H, m., CH(CH3)2), 1.54 (2H, m„ C II2CH), 
3.37 & 3.58 (2H, m., CH2OH) and 3.79 (1H, t., J 7.8 Hz, CH); m/z (El) 157 ([M+H]+, 
5.8%), 86 ([M-HCI-CH2 0 H]+, 100), 60 (NH2CHCH2OH+, 19.6) and 44 (CHCH2OH+,
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M e th y l (2 S )-v a lln a te  h y d ro c h lo r id e  (1 7 ).-
This was made in an identical manner to (13), using (2S)-valine (1.17 g, 10 mmol). 
Recrystallisation from methanol/ diethyl ether gave the product as white crystals 
(1.09 g, 69%) of m.p. 164-166 °C (lit.440 166-168 °C). m/z (Found: (M + H)+ 
207.0896. C11H13NO3 requires 207.0895); [alo^O+IS.O® (c 1 in HgO) (lit.440 [a]p20 
+15.5° (c 1 in HgO)); v^ax (Nujol) 3324 (NH), 1738 (ester CO), 1506 (NH bend) and 
1243 cm-1 (C-O); 0^ (90 MHz, ^HgO) 0.91 (6 H, d., J 7.5 Hz, (CH3)2CH), 2.25 (1H, m., 
(CH3)2CH), 3.69 (3H, s., OCH3) and 3.89 (1H, d., J 7.2 Hz, CHNH); m/z (El) 131
1.2%), 88 ([M-CH(CH3)2)]+, 12.3), 72 ([/W-COgMe^, 100) and 36 (NH2CHCH2+, 
34.6).
M e th y l N -a c e ty l-(2 S )-p h e n y la la n y l-(2 S )-v a lln a te  (1 8 ).-
N-Acetyl-(2S)-phenylalanine (12) (208 mg, 1 mmol) was dissolved In dry DMF (5 
ml) at -5°C and N-methyl  morphol ine (110 pi, 1 mmol) and 2 - 
methylpropylchloroformate (130 pi, 1 mmol) added with stirring. The mixture was 
maintained at -5 °C for 20 min. and the ester (17), (131 mg, 1 mmol) added iri DMF 
(5 ml) containing N-methyl morpholine (110 pi, 1 mmol). The mixture was then 
allowed to warm to room temperature and stirred overnight. Water (10 ml) was added 
and the mixture extracted with ethyl acetate (3x10 ml), which was then washed with 
0.5 M HCl ( 3 x 5  ml), 5% sodium bicarbonate solution ( 3 x 5  ml) and saturated brine 
(10 ml). The organic extract was dried (MgSO^) and the solvent removed under 
reduced pressure to give a clear oil, which was crystallised from methanol/ light 
petroleum to give the product as white crystals (158 mg, 49%) of m.p. 127-130 °C. 
m/z (Found: (M +H )* 321.1814. C17H25N2O4 requires 321.1814); ^ [ , 20 .9 .2° (c2 in 
CHCI3); Vmax (Nujol) 3019 (NH), 1738 (ester CO), 1695 (acetyl amide CO), 1656 (2° 
amide), 1516 (NHbend) and 1223 cm-l (C-O); 8,4 (360 MHz, C ^H C y 0.81 (6 H, d., J  
8.4 Hz, (CJd3)2). 1.94 (3H, S., CH3CO), 2.12 (1H, m„ Cji(CH3)2), 2.78 (1H, d.d., J^b
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12.8 Hz, 7.6 Hz, 1 Of CHgPh), 2.97 (1H, d.d., 1 2 .8  Hz, Jgx 5-3 Hz, 1 of
CHgPh), 3.69 (3 H, s.. OCH3 ), 4.40 (1H, m., Phe NHCH), 4.92 (1 H, m., Val NHCH),
6.94 (1H, d., J 8.2 Hz, Val NH), 7.12 (1H, d., J 8.4 Hz, Phe NH) and 7.31 (5H, m., 
aromatic); 8c (50.31 MHz, C^HCIg) 15.3 & 16.7 ((CHala), 20.7 (GHaCO), 28.8 
(£H(CH3 )2 ), 36.4 (CHgPh), 49.7 (Val NHCH). 52.2 (Phe NHCH), 55.3 (CH3O), 124.8,
126.7 & 127.2 (aromatic) and 172.8, 174.5 & 175.2 (CO); m/z(EI) 320 {M*, 18.9%),
261 ([M-COaMer. 34.3), 187 ([M-CH3 CO-CH2 Ph]+. 34.4), 120 (NHaCHCHaPh»,
100) and 91 (PhCHa' ,^ 23.6).
N-Acetyl-(2S)-pheny lalanyl-(2S)-valine (19).-
Methyl ester (18) (200 mg, 0.625 mmol) was dissolved in a 5% solution of water In 
methanol (10 ml), containing potassium carbonate (95 mg, 0.68 mmol). The mixture 
was stirred at room temperature for 48 h. The solution was then washed with 
chloroform (5 ml), acidified to pH 2  with 0.5 M HCi and extracted with chioroform (3 x 
5 mi). The organic extract was washed with water (8  ml), dried (MgSO, )^ and the 
solvent removed under reduced pressure to give a cream solid, which was 
recrystailised from methanol/ diethyl ether to give the product as white crystals (155 
mg, 81%) of m.p. 103-107 °C. v^ gx (Nujol) 3419 (NH), 3013-2850 (COOH),1708 
(acid CO), 1695 (acetyl amide CO), 1656 (2° amide), 1516 (NH bend) and 754 cm"' 
(aromatic); 5h (90 MHz. C2 HCi3 ) 0.85 (6 H, m., (CM3 )2CH), 1.88 (3H, s., CH3CO).
2.01 (1H, m., CM(CH3 )2 ), 2.68 (1 H, d.d., '3.2 Hz, 7 4 Hz, 1 of CH2 Ph), 2.93
(1 H, d.d., Jab '3.2 Hz, Jgx 5.2 Hz, 1 of CHgPh), 4.42 (1 H, m., Phe NHCH), 5.01 (1 H, 
m., Val NHCH), 7.31 (5H, m., aromatic), 7.43 (1H, m., Vai NH) and 8.84 (1H, br. s.,
CO2 H); 5c (50.31 MHz, C^HCIg) 18.38 & 19.32 (Val CH3 ), 23.21 ((IH3 CO), 31.32 4
(C,H(CH3 )2 ), 55.04 & 58.16 (NHCH x2), 127.42, 129.01 & 129.88 (aromatic) and 
171.50, 172.35 & 173.93 (CO).
Methyl (2S)-alanlnate hydrochloride (20).-
This was prepared exactly as for (13), using (2S)-aianine (2.25 g, 25 mmol). 
Recrystallisation from dry ethanol/ dry diethyl ether gave the product as hygroscopic
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white crystals (3.12 g, 89%) of m.p. 108-110 °C  (iit.'*''i 109-111 °C). m/z (Found; (M 
+ H)+ 104.0711. C4 H1 0 NO2  requires 104.0711); [alp^O +6.1° (c 2 in MeOH); v„,ax 
(Nujoi) 3418 (NH) and 1742 cm"' (ester CO); 6^ , (90 MHz, ^HgO) 1.43 (2H, d., J  7.5 
Hz, CHCJI3 ), 3 72 (3H, s., OCH3 ) and 4.08 (1H, q., J  7.5 Hz, CH); 6^ (50.31 MHz, 
2 H2 O) 17.87 (jCHgCH), 51.84 (CH), 56.95 (OCH3 ) and 174.89 (CO); m/z (El) 103 
1.1%), 88 ([W-CH3 I+, 3.02), 44 (H2 NCHCH3 +, 100) and 36 (HCI, 23.77).
Methyl (2S)-leucinate hydrochloride (21).-
This was prepared in an identical manner to the (2S)-phenyalanine analogue (13), 
using (2S)-leucine (655 mg, 5 mmol). The product was obtained as white crystals, 
after recrystallisation from methanol/ diethyl ether, of m.p. 150-153 °C (lit.^"^  ^ 148- 
150 °C). m/z (Found: {M + H)+ 146.1181. CyHigNOg requires 146.1181); [aJp^O . 
15.2° (c 2 in MeOH) (lit.442 [a]^20 . 13,40 5 HgO)); v^ax (Nujol) 3484 (NH), 1737
(ester CO) and 1591 cm'l (NH3+); 0^ (90 MHz, ^HgO) 0.82 (6 H, d., J  5.7 Hz, (0 ^ 3 )2), 
1.3-1.8 (1H, m., CHgCH), 3.68 (3H, s., OMe) and 4.01 (1H, t., J 6 Hz, H3NCJI); Ôq 
(50.31 MHz, ^HgO) 23.72 & 24.28 ((D.H3)2CH), 26.72 ((CH3)2^H), 41.58 (ÜHgCH),
54.20 (CHNH3), 56.27 (CH3O) and 174.16 (ester CO); m/z (El) 146 {M^, 17.8%) and 
86 ([M-COgMe]+, 100).
(2S)-3-Methyloxlranemethanol (22).-^09
Crushed, activated 3 Â molecular sieves (3.0 g) were added to a flame-dried flask 
under nitrogen, followed by dry dichloromethane (200 ml). The flask was then cooled 
to -20  °C with stirring and (2S)-(+)-diisopropyl tartrate (1.42 g, 6 mmol), E -2 -buten-1- 
ol (7.21 g, 100 mmol, stored over 3Â molecular sieves) and titanium isopropoxide 
(1.42 g, 5.0 mmol) were added sequentially. Stirring was maintained for 15 min. at - 
20 °C, then a 3.0 M solution of fe/t-butyl hydroperoxide (67 ml, 200 mmol) in dry 
dichloromethane (200 ml) was added and the mixture stirred at -20 °C for 2 h. The 
reaction was quenched by the slow addition of tributylphosphine (20.2  g, 100 mmol) 
at -20 °C. The mixture was checked by t.I.c. (40 % ethyl acetate: light petroleum) to 
ensure all the hydroperoxide had been reduced. Citric acid mbnohydrate (1.05 g) in 
10% acetone in diethyl ether (150 ml) was added and the mixture stirred at room
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temperature for 30 min. After filtration through a pad of Celite the mixture was 
concentrated under reduced pressure to yield a yellow viscous oil, which was 
distilled under reduced pressure (18 mm Hg, 81-83 °C) to yield a clear colourless oil,
which proved to be very difficult to purify any further. 8  ^(300 MHz, C^HCIg) 1.36 (3H, 
d., J 5.6 Hz, CH3CJI), 2.91 (1 H, d.d.d., J2.9, 3.0, 3.9 Hz, CHCHgOH), 3.04 (1 H, d.q., 
J 2.9, 5.6 Hz, CH3CH), 3.61 (1H, d.d., J3 .7 ,12.9 Hz, 1 of CHgOH) and 3.89 (1H, d.d., 
J3 .0 ,12.9 Hz, 1 of CHgOH).
N-9-Fluorenylmethyloxycarbonyl-(2S)-threonlne (23).-443
To a stirred suspension of (2S)-threonine (2.26 g, 19 mmol) in 10% sodium 
carbonate solution (30 ml) and dioxan (20 ml) at 0 °C was added dropwise 9 - 
fluorenylmethylchloroformate (4.9 g, 19 mmol) in dioxan (20 ml). After 1 h. the 
solution was warmed to room temperature and stirred for 4 h. The mixture was then 
poured into ice-water (250 ml) and extracted with diethyl ether (3 x 120 ml). The 
aqueous layer was cooled in an ice-bath during acidification to pH 2, causing a 
yellow oil to separate that was taken up in ethyl acetate (250 ml). The organic layer 
was washed with 0.1 M HCI (50 ml), water (50 ml) and brine (50 ml). The organic 
layer was dried (MgSO^) and the solvent removed under reduced pressure to give 
an off-white solid. Trituration with light petroleum gave the product as a cream solid 
(4.79 g, 74%) of m.p. 102-106 °C that was refractory to recrystallisation, m/z (Found: 
(M+ H)+342.1341. C19H2 0NO5 requires 342.1341); -6.4° (c 2 in CHC^jv^ax
(CHCI3 ) 3587-3340 (OH), 3432 (NH), 3020-2930 (aromatic), 1742 (carboxyl CO), 
1723 (urethane CO) and 1520 cm-^  (amide II); 8  ^ (90 MHz, C2 HCI3 ) 1.21 (3 H, d., J
7.1 Hz, CH3 ), 4.18 (1 H, t., J 7.5 Hz, Fmoc CH), 4.21 (4H, m., Fmoc CHg, C-3  and C-2  
H), 5.94 (1H, d., J 8.4 Hz, NH) and 7.24-7.7 (aromatic); 8  ^ (50.31 MHz, C^HCy 
20.41 (G.H3 CH), 47.61 (CH2 ), 59.92 (CHOH), 67.73 (Fmoc CH), 68.2 (CHNH), 
120.55, 125.69, 127.65 & 128.29 (aromatic), 141.8 & 144.21 (quat. aromatic), 157.54 
(urethane CO) and 172.45 (carboxyl CO); m/z (Cl) 359 ([M+NH, ]^+, 89%), 342 {[M 
+H]+, 96), 178 ([9-fluorene]+, 100) and 120 ([threonine+H]+, 47).
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Methyl 9-Fluorenylmethyloxycarbonyl-(2SHhreonlnate (24).-
To a stirred solution of Fmoc (2S)-threonine (23), (1.62 g, 4.75 mmol) in diethyl 
ether (50 ml) at 0 °C was added excess ethereal diazomethane (0.5 g, 12 mmol) and 
the solution stirred at room temperature for 1 h. Un reacted diazomethane was 
removed in a stream of nitrogen and the solvent removed under reduced pressure to 
give a yellowish solid. Low pressure column chromatography on t.I.c. silica (ethyl 
acetate) gave a white solid. Recrystallisation from diethyl ether/ light petroleum gave 
the product as a white solid (1.21 g, 72%) of m.p. 118-119 °C. m/z (Found: {M + H)+ 
356.1498. C11H13NO3 requires 356.1498); [alp^O _12.8° (c 1 in CHCI3 ); v^ax 
(CHCI3) 3495 (OH), 1758 (ester CO), 1723 (urethane CO), 1493 (aromatic) and 1212 
cm-1 (aromatic); 5h (300 MHz, C2HCI3) 1.22 (3H, d., J 7.1 Hz, CH3), 3.72 (3H, s., 
OCH3), 4.21 (1H, t., J 7.4 Hz, Fmoc CH), 4.3-4.5 (4H, m., Fmoc CHg, C-2 and C-3 H), 
5.90 (1H, d., J 9 Hz, -NH) and 7.1-7.7 (8H, m., aromatic); Ôq (75.47 MHz, C^HCIg)
20.15 (CH3), 47.53 (CHg), 52.91 (OCH3), 59.48 (CHOH), 67.52 (Fmoc CH), 68.21 
(CHNH), 120.41, 125.12, 127.24 & 127.66 (aromatic), 142.77 & 144.12 (quat. 
aromatic), 156.80 (urethane CO) and 174.98 (ester CO); m/z (Cl) 356 ([M +H]+, 
6 .8%), 179 ([9-fluorene+ H]+, 97) and 134 ([M-Fmoc+H]+, 100).
M e th y l (2 R ,3 S )- (9 -F lu o re n y lm e th y fo x y c a rb o n y l) -2 -a m ln o -3 -  
bromobutyrate (25).-^06
Carbon tetrabromide (3.36 g, 10.1 mmol) and triphenylphosphine (2.66 g, 10,1 
mmol) were dissolved in dry benzene (60 ml) at room temperature and the methyl 
ester (24) (2.5 g, 7 mmol) added in portions over 30 min. The mixture was stirred for 
a further 90 min., filtered and the pad washed with dry benzene (30 ml). The 
benzene was removed under reduced pressure to give a yellow oil which was 
purified by flash column chromatography (ethyl acetate/ chloroform (3:1)), to give an 
oil. Further flash column chrom atography (chloroform) gave a c lear oil. 
Crystallisation from diethyl ether/ light petroleum gave the product as a white solid 
(2.6 g, 61%) of m.p. 147-150 °C. [a]p20 +7 .3  ° (c 2 in CHCI3); v^ax (Nujol) 3415 (NH), 
1745 (ester CO), 1718 (urethane CO) and 1507 cm"^ (aromatic); (300 MHz, 
C ^H C y 1.77 (3H, d., J 7.0 Hz, CH3), 3.72 (3H, s., OCH3), 4.21 (1H, t., J  7.2 Hz, 
Fmoc CH), 4.37 (3H, m., Fmoc
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CHg and C-2 H), 4.59 (1H, m., C-3 H), 5.72 (1H, d., J  8.9 Hz, NH) and 7.1-7.7 (8 H, 
m., aromatic); Sg (75.47 MHz, C^HCig) 23.68 (CH3), 48.02 (CHg), 50.12 (OCH3), 
53.61 (C-2 ), 60.65 (3-CH), 68.22 (Fmoc CH), 120.94, 125.96, 127.95 and 128.60 
(aromatic), 142.23 & 144.53 (quat. aromatic), 156.41 (urethane CO) and 169.98 
(ester CO).
Methyl N-tei't-butoxycarbonyl-(2S)-leucyl-(2S)-leucinate (26).
To a stirred soiution of N-fert-butoxycarbonyl-(2 S)-ieucine hydrate (9) (2.31 g, 10 
mmoi), dried as for (1 0 ), in dry THF (25 ml) was added N-methyimorphoiine (1.10 ml, 
10 mmoi) and the soiution cooled to -15 °C. 2-methyipropyichioroformate (1.36 ml, 
10 mmoi) was added with stirring and the solution stirred for 1 min. Methyl ester (21 ) 
(1.81 g, 10 mmol) in DMF (15 mi) containing N-methylmorpholine (1.12 ml, 10 mmol) 
was then added in one portion. After 1 min. at -15 °C and 5 min. at room temperature 
the hydrochlorides were filtered off and the THF removed under reduced pressure. 
Addition of water to the residual liquid precipitated a white solid, which was 
recrystallised from methanol/ water to give the product as a white solid (2.83 g, 79%) 
of m.p. 134-136 °C (iit.445 132-133 °C). m/z (Found: (M + H)+ 359.2547. 
C18H35N2O5 requires 359.2546); [a]o^°-48.9° (c 1 in MeOH) (lit.445 (c
1 in MeOH)); v^gy (CHCI3) 3020-2960 (CHg, CH), 1741 (ester CO), 1705 (urethane 
CO), 1679 (amide CO) and 1215 cm ' (C-0); Sh (360 MHz, C^HCig) 0.97 (12H, m., 
(0113)2 X 2), 1.44 (9H, s., (CH3)3 0 , 1.46-1.80 (6 H, m., CH2CJI x 2), 4.10 (1H, m., 
NHCH Leu2 ), 4.62 (1H, m., NHCH Leui), 4.89 (1H, d., J 7.3 Hz, NH Leu2 ) and 6.47 
(1H, d., J  8.1 Hz, NH Leui); Ôq (50.31 MHz, C2HCI3) 22.48 & 23.42 ((CH3)2 x2),
25.31 (CH), 28.85 ((£H3)3C), 41.52 and 42.14 (CH2 x2 ), 51.26 (NHCH Leu 1), 52.7 
(OCH3), 54.55 (NHCH Leu 2), 80.13 ((CH3)3Ü) and 172.81 & 173.6 (CO x2); m/z(Ei) 
358 (M+, 0.33%), 302 ([/M+H-(CH3 )3C]+, 4), 299 ([M -COzMe]*, 0.5), 130 
([CH(C0 2 Me)CH2(CH3)2+H]+, 79.1), 86 (NH2CHCH2CH(CH3)2+, 100) and 57 
((CH3)3C+, 66.3).
161
r. .  ' :
N - fe r f-B u to x y c a rb o n y i- (2 S )- le u c y l- (2 S )- le u c in e  (27).-^^®
The methyl ester (26) (3.58 g, 10 mmol) was dissolved in methanol (20 ml), the 
flask surrounded by a water bath at room temperature and 1 M sodium hydroxide (12 
ml) added with stirring. The resulting precipitate was dissolved in the minimum 
quantity of methanol and the solution stirred at room temperature for 2 h. The 
methanol was removed under reduced pressure and the aqueous solution stirred in
an ice-bath during acidification to pH 2 . The solution was kept at 0 °C for a further 2 *
.!■min. and the resulting white solid collected by filtration. Recrystallisation from ^
methanol/ water gave the product, after drying over phosphorous pentoxide, as a 
white solid (3.09 g, 90%) of m.p. 137-138 °C. m/z (Found: (M + H)+ 345.2387. I
C17H33N2O5 requires 345.2389); -18.2° (c 2 in CHCI3); y^ax (Nujol) 3431
(NH), 3336 (NH). 1705 (acid CO), 1684 (urethane CO), 1637 (amide CO), 1536 
(amide II) and 1275 cm-l (C-0); 5h (360 MHz, C2HCI3) 0.95 (12H, m., (CH3)g x 2),
1.47 (9H, s., ((CH3)3C), 1.50-1.80 (6 H, m., CH2CH x 2), 4.06 (1H, app. d. oft., J 8.1 
and 8 Hz, NHCjH Leui) 4.32 (1H, d.d.d., J 8 .6 , 8 and 8 Hz, NHCH Leu2 ), 6.96 (1H, 
d., J  8.6  Hz, NH Leu2) and 8.02 (1H, d., J 8.1 Hz, NH Leui); Ôq (90.56 MHz,
C2HCI3) 23.7 & 24.9 ((CH3)2 x2), 26.7 (CH x2), 30.2 ((ÜH3)3C), 42.8 & 43.3 (CHg 
x2 ), 52.7 (Leu 1 NHCH), 54.8 (Leu 2 NHCH), 82.2 ((CH3)3Q.), 158.0 (urethane CO) 
and 174.8 & 177.6 (amide CO); m/z (Cl) 362 ([M+NH^^, 10.6%), 345 ([M+H]+, 100),
306 ([/lf+NH4-(CH3)3C]+, 28.0), 289 ([M+H-(CH3)3C]+, 40.1), 245 ([M+H-Boc)+, 84.6) 
and 86 (NH2CHCH2CH(CH3)2+, 45.1).
(2S)-LeucyI-(2S)-leucine trifluoroacetate (28).-
Dipeptide (27) (686 mg, 2 mmol) was dissolved in dichloromethane (10 ml) at 0 °C 
and trifluoroacetic acid (2 ml) added with stirring. After 1.5 h. at 0 °C the solvent was 
removed under reduced pressure to give a yellow oil which was crystallised from 
methanol/ light petroleum to give the product as a white solid (406 mg, 84%) of m.p.
250-252 °C (lit.447 259-261 °C). [a lo ^O -ia .r (c 1 in MeOH) (lit.447 [a]^20  . 13.40 (c 1 
in MeOH)); Vg,ax (Nujoi) 1745 (acid CO), 1708 (amide CO) and 1480 cm ' (amide li);
Sh (300 MHz, dg-DMSO) 1.03 (6 H, d., J 6.5 Hz, (CHg);), 1.05 (6 H, d., J  6.5 Hz,
(CH3)2), 1.67 (4H, m., CHg x2), 1.75 (2 H, m., CH x2), 3.88 (1H, t., J  7 Hz, Leui
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NHCH), 4.38 (1H, m., Leu2 NHCH) and 8.83 (1H, d., J 7.5 Hz, NH); 5q (90.56 MHz, 
dg-DMSO) 23.78 ((CHg)^), 24.92 ((CHg)2), 25.41 & 26.20 (Leu CH's), 42.02 & 43.84 
(CH2), 52.16 & 53.65 (NHCH x2), 173.25 (acid CO) and 176.80 (amide CO).
Methyl N -ferf-bu toxycarbony!-(2S )> ieucyl-(2S )-leucyi-(2S )-ieucinate  
(29).-
Dipeptide (27) (688 mg, 2 mmol) was dissolved in dry THF (15 ml), N-methyl 
morphotine (218 pi, 2 mmol) added and the solution cooled to -15 °C. 2 - 
methylpropylchloroformate (272 pi, 2 mmol) was added and the solution stirred for 1 
min. Methyl (2S)-leucinate hydrochloride (21) (362 mg, 2 mmol) in DMF (3 ml) 
containing N-methylmorpholine (218 pi, 2 mmol) was added in one portion. The 
solution was stirred at -15 °C for 1 min. and at room temperature for 5 min. The 
hydrochlorides were then filtered off and the THF removed under reduced pressure. 
Addition of water precipitated a white solid, which was recrystallised from methanol/ 
water to give the product as a white solid (740 mg, 79%) of m.p. 150-152 °C (lit.'^^^ 
156-159 °C). m/z (Found: (M + H)+ 472.3387. C24H46N3O6 requires 472.3386); 
[alo^o -20.3° (c 1 in CHCI3) (llt.448 [aj^zo .21 .7° (c 1 in CHCI3)); Vg,gx (Nujol) 3392 
(NH), 1751 (ester CO), 1693 (urethane CO), 1668 (amide CO), 1643 (amide CO), 
1541 (amide ii) and 1167 cm"' (C-O); 6^ (360 MHz, C^HCig) 0.95 (18 H, m., (0 13 )2  x 
3), 1.44 (9H, s., (CH3)3C), 1.45-1.70 (9H, m., CHgCH x3), 3.73 (3H, s., OCH3), 4.10 
(1H, m.. Leu 3 NHCJH, 4.46 (1H, m.. Leu 1 NHCJl), 4.57 (1H, m.. Leu 2 NHCJl), 4.76 
(1H, d., J  7.4 Hz, Leu 2 NH) and 6.63 (2H, m.. Leu 1 and 3 NH); Sq (90.56 MHz, 
C2HCI3) 21.9, 22.1, 22.9 & 23.0 (CH3 x 6), 24.7 & 24.9 (CH x2), 28.4 ({Q.Hq)3C), 40.7,
41.5 & 42.0 (CHg x3), 50.8 (Leu 1 NHCH), 51.7 (NHCH), 52.4 (CH3O), 53.2 (NHCH),
80.3 ((CH3)3G) and 171.6, 172.8 & 173.2 (CO); m/z (FAB) 472 ([M+H]+, 30%), 416 
([/W+2 H-(CH3)3C]+, 22.5), 327 (Boc.Leu.Leu.CO+, 4.4), 227 (H2NLeu.Leu.CO+, 8 .6), 
199 (H 2 NLeu.Leu+, 5.5), 146 (H3 NLeuC0 2 Me+, 35.7) and 86
(H3NCHCHCH(CH3)2+, 100).
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N - ferf-Butoxycarbonyl-(2S)-leucyl-(2S)-leucyl-(2S)-leucine (30).-
This was prepared as for (27), using (29), (471 mg, 1 mmol) and 1 M sodium 
hydroxide (1.1 ml). Work-up gave the product as a white solid (393 mg, 86%) of m.p. 
146-148 °C (lit.448 1 46-147 °C) after recrystallisation from methanol/ water, m/z 
(Found: (M + H)+ 457.3152. C23H43N3O6 requires 457.31516); [alp^O -28.6 (c 1 In 
MeOH); v^g^ (Nujoi) 3311 (NH), 3150-2550 (OH), 1724 (acid CO) and 1691, 1669 & 
1641 cm-' (amide CO); 5^ (300 MHz, dg-DMSO) 0.89 (18H, m., ((CHg)2 x3), 1.43 
(9H, s., ((CH3)3C) 1.65 (6 H, m., CHg x3), 1.72 (3H, m., CH x3), 3.87 (1H, t., J 7.3 Hz, 
Leui NHCH), 4.37 (1H, m., Leu3 NHCH), 4.55 (1H, m., Leu2 NHCH), 8.34 (1H, d., J
6.4 Hz, NH) and 8.72 (1H, d., J 6.8 Hz, NH); 5c (50.31 MHz, C^HCIg) 21.9, 22.1, 22.9 
& 23.0 (CH3 X 6 ), 23.1 & 24.3 (CH), 28.3 ((HH3)3C), 40.4, 41.5 & 42.0 (CHgxO), 50.4,
50.7 & 52.1 (NHCH's), 78.2 ((CH3)3Û), 155.6 (urethane CO) and 172.0, 172.2 &
174.1 (amide and acid CO); m/z (FAB) 458 [M*, 10.9%), 402 ([M+2 H-(CH3)3C]+,
12.5), 327 (Boc.Leu.Leu.CO+, 4.4), 227 (H2 N Leu.Leu.C 0 +, 7.4), 142 
(H3NLeuC0 2 H+, 6 .8 ) and 86 (H3NCHCHCH(CH3)2+, 100).
(2S)-Leucyl-(2S)-leucyl-(2S)-leucine trifluoroacetate (31).-
This was prepared in an identical manner to (28), using (30), (365 mg, 0.8 mmol) 
to give the product as a white solid (328 mg, 92%) of m.p. 203-205 °C. m/z (Found: 
([M + H -CF3C0 2 H)+ 357.2625. C18H35N3O4 requires 357.2627); [aJc^O -12.4° (c 2 
in MeOH); Vmgx (Nujol) 3274 (NH), 3050 (CH, CHg), 1730 (acid CO), 1688 & 1676 
(amide CO) and 1559 cm"' (amide il); 5^ (300 MHz, dg-DMSO) 0.89 (18 H, m., 
(CH3)g x3), 1.61 (6 H, m., CHg), 1.74 (3H, m., CH x3), 3.83 (1H, app. t., J  7.3 Hz, Leu1 
NHCH), 4.36 (1H, m., Leu3 NHCH), 4.55 (1H, m., Leu2 NHCH), 8.32 (1H, d., J 7.1 
Hz, NH) and 8.72 (1H, d., J 6.9 Hz, NH); (90.56 MHz, C^HCig) 20.9-24.1 (CH3 
x6 ), 24.91 & 25.24 (^HCHg x3), 40.98, 42.07 & 43.12 (CHC.H2 x3), 49.94 (Leu 1 
NHCH), 50.86 (Leu3 NHCH), 51.10 (Leu2 NHCH), 168.92 (carboxyl CO), 171.26 
(Leu 2 CO) and 173.76 (Leu 1 CO); m/z (FAB) 358 ([M+H]+, 23.9%), 227 
(H2NLeu.Leu.CO+, 19.8), 199 (HgNLeu.Leu-*-, 17.0), 131 (HgNLeu-^, 4.6) and 86 
(H2NCHCHCH(CH3)2+, 100).
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(2S)-Leucyl-(2S)-leucyl-(2S)-tyrosyl amide trlfluroacetate (33).-
This was prepared exactly as for (28), using (32) (1 g, 1.98 mmol) and trifluroacetic
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N -te rf-B u to x y c a rb o n y l-(2 S )-le u c y i-(2 S )-ie u c y l-(2 S )-ty ro s in e  am ide  
(32).-
The dipeptide (27), (1.72 g, 5 mmol) was dissolved in THF, N-methyl morpholine 
(550 pi, 5 mmol) added and the solution cooled to -15°C. 2 - 
methylpropylchloroformate (680 pi, 5 mmol) was added with stirring, the mixture 
stirred for a further 1 min. and (2S)-tyrosine amide (8 ) (905 mg, 5 mmol) in DMF (10 
ml) containing N-methyl morpholine (550 pi, 5 mmol) added in one portion. The 
mixture was stirred at -15 °C for 1 min., then at room temperature for a further 5 min.
The hydrochlorides were filtered off and the THF removed under reduced pressure to 
give an oil. Addition of water (10 ml) to the oil caused the precipitation of a white 
solid that was recrystallised from ethanol/ water to give the product as a white solid 
(1.87 g, 74%) of m.p. 189-192 °C (dec.), m/z (Found: (M + H)+ 507.3181. 
C26H43N4O6 requires 507.3182); [alo^o +19,30 (c 3 in CHCI3); v^g^ (Nujol) 3336 (1° 
amide NH), 3260-3050 (2° amide and urethane NH), 1688 (urethane CO), 1672-76 
(2 ° amide GO), 1657 (1° amide GO), 1557 (amide II) and 1518 cm""* (aromatic); 614 
(300 MHz, dg-DMSO) 0.93 (12 H, m., (GH3)2 x2), 1.45 (9H, s., (GH3)3G), 1.56 (4H, 
m., GH2CH x2), 1.69 (2H, m., GMGH2 x2), 2.72 (1H, d.d.'s, Jj^ q 13.5 Hz, Hz, 1
of Tyr GH2), 2.84 (1H, d.d.'s, 13.5 Hz, Jgy 7.5 Hz, 1 of Tyr GH2), 3.91 (1H, m., Leu
1 NHGH), 4.13 (1H, m., Leu 2 NHGH), 4.22 (1H, m., Tyr NHGH), 6.52 (2 H. d., J 7.3 
Hz, aromatic), 6.96 (2H, d., J  7.3 Hz, aromatic), 6.94 (1H, s., 1 of NH2), 7.01 (1H, s.,
OH), 7.28 (1H, s., 1 of NHg), 7.68 (1H, d.. J 7.1 Hz, NH) and 7.80 (1H, d., J  6.2 Hz, 1 
NH); ÔQ (74.47 MHz, dg-DMSO) 25.52, 25.66, 26.98 & 27.12 ((^H 3)2 x2 ), 27.91 &
28.22 (ÜH(GH3)2 x2), 32.14 ((ÜH3)3G), 40.76 (ArGH2), 44.60 & 44.87 (GHG.H2 x2),
55.03, 56.70 & 57.77 (NHGH x3), 79.04 ((GH3)3Q , 118.86, 131.61 & 134.06 
(aromatic), 159.71 (urethane GO) and 175.58, 176.43 & 176.67 (amide GO); m/z 
(FAB) 507 ([M+H]+, 34.6%), 407 ([M+2H-Boc]+, 8 .8), 327 ([M+H-TyrNH2f ,  6.9), 136 
(H3NGHGH2G6H4OH+, 35.0), 227 (H2N.Leu.Leu.G0 +, 9.1), 214 (BocLeuGO+, 4.2),
199 (H2NLeu.Leu+, 6.3), 181 (TyrNH3+, 34.8) and 86 (H3NGHGHGH(GH3)2+, 100).
acid (2 ml) to give the product as a white solid (700 mg, 87%) of m.p. 207-211°C 
after recrystallisation from methanol/ light petroleum. [ajQ^o +12.9° (c 1 in MeOH); 
W  (Nujol) 3321 (1° amide NH), 1674-80 (2° amide CO), 1652 (1° amide CO), 1551 
(amide II) and 1519 cm"^ (aromatic); ô|_| (300 MHz, dg-DMSO) 0.89 (12H, m., (CH3)2),
1.14 (2H, m.. CH x2), 1.4-1.7 (4H, m., Leu CHg x2), 2.76 (1H, d.d.'s, J^b 14.1 Hz, J 
AX 6.8 Hz, 1 ofTyr CHg), 2.88 (1H, d.d.'s. Jab 14.1 Hz, Jgx 7.7 Hz, 1 of Tyr CH2), 3.72 
(1H, m., Leui NHCH), 4.08 (1H, m., Tyr NHCH), 4.37 (1H, m., Leu2 NHCH), 6.62 
(2H, d., J 7.6 Hz, aromatic), 6.93 (2 H, d., J 7.6 Hz, aromatic), 7.21 (1H, s., OH), 7.73 
(1H, d., J 8.4 Hz, NH), 8.05 (2 H, br., Leui NH2), 8.48 (1H, d., J 7.6 Hz, NH); 6^ 
(74.47 MHz, dg-DMSO) 21.60, 21.77, 22.60, & 23.42f ((CH3)2 x2), 26.76 & 28.37 
((CH3)3ÜH), 43.72, 44.11 & 44.53t (CH2 x3), 54.55, 55.81 & 56.15 (NHCH), 114.82,
127.64 & 129.92 (aromatic), 158,03 (urethane CO) and 168.74, 170.82 & 172.65 
(amide CO).
Diphenyl [1-(N-benzyloxycarbonyl)-amlno]benzyiphosphonate (34).-^^^
o
PO(OPh)2
Triphenyl phosphite (31.0 g, 0.1 mol), phenylacetaldehyde (18 g, 0.15 mol) and 
benzyl carbamate (15.1 g, 0.1 mol) were dissolved in glacial acetic acid (15 ml) and 
stirred at room temperature until the exothermic reaction had ceased (about 1 h.). 
The mixture was heated to 80 °C for a further 1 h., then the volatile products were 
removed under reduced pressure on a boiling water bath. The yellow residue was 
dissolved in methanol (150 ml) and left to crystallise at -10 °C for 3 h. The crystalline 
product was then collected by filtration, dissolved in the minimum quantity of hot 
chloroform and a 4 fold excess of methanol added to give the product as a white
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solid (14.1 g, 29%) of m.p. 120-2 °C (llt.332 119-120 °C). (Found C, 68.75; H 5.44; N, 
2.71. Calc, for CggHggNOgP: 0, 68.97; H, 5.38; N, 2.87); m/z (Found: (A4 + H)+ 
487.1549. CggHggNOgP requires 487.1549); v^gx (Nujol) 3287 (NH), 1720 (uretfiane
CO), 1590 (amide II), 1262 (PC) and 1212 cm-' (P-OPti); 5h (300 MHz, C^HCIg) 3.1 -
3.5 (2 H, m., CJlg-CH), 4.75-4.9 (1H, m., CH), 5.12 (2H, s., PfiCHgO), 5.34 (1H, d., J
10.5 Hz, NH) and 7.02-7.40 (20 H, m., aromatic); 5p (121.5 MHz, C^HCIg) 17.17
(88%) and 16.74 (12%); 5c (50.31 MHz, C^HCIg) 36.50 (PhfiHgCH), 48.22 & 51.35 
(d., PhCHgC,H, Jpc 158.1 Hz), 67.7 (PhCHgO), 120.86-121.25 (para aromatic),
125.81-130.37 (aromatic), 136.16 & 136.77 (quat. aromatic) and 150.47 (urethane
CO); m/z (El) 487 ( # ,  5.4%), 394 ([M-OPh]+, 32), 379 ([M-PhCH2 0 H]+, 15.2), 336
([M-H2NCOOCH2Ph]+, 100), 234 (PO(OPh)2+, 12.9), 145 (PhCH2CHNHCO+, 37), 94 
(PhOH, 65) and 77 (Ph+, 14.9).
Dimethyl [1-(N-benzyloxycarbonyl)-amino]benzylphosphonate
o
(35).
PO(OMe)2
The diphenyl compound (34) (15.4 g, 31 mmol) was dissolved with warming in dry 
methanol (200 ml) and sodium (1.47 g, 64 mmol) dissolved in dry methanol (30 ml) 
added dropwise with stirring. The solution was stirred at room temperature overnight, 
then the volume reduced to 20 ml on a rotary evaporator and dichloromethane (200 
ml) added. The solution was washed with 5% sodium hydrogen carbonate (3 x 80 
ml), 0.1 M HCI (80 ml), water (80 ml) and brine (80 ml). The solution was dried 
(MgSO^) and the solvent removed under reduced pressure to give a yellow oil. 
Purification by flash chromatography (ethyl acetate) gave a clear oil, which
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crystallised on standing. Recrystallisation from ethyl acetate/ light petroleum gave the 
product as a white solid of m.p. 67-69 °C (7.56 g, 67%). m/z (Found: {M + H)+ 
364.1314. C18H22NO5P requires 364.1315); v^ax (Nujol) 3224 (NH), 1710 (urethane 
CO). 1586 (amide II), 1258 (P=0) and 1057 cm’' (P-OMe); 8^ (200 MHz, C^HCIg) 
2.84-3.3 (2H, m., PhCJdgCH), 3.62 (3H, d., JpH 10.6 Hz, P(0 )(0 CH3)2), 3.68 (3H, d., 
JpH 10.6 Hz, P(0 )(0 CH3)2), 4.40 (1H, d.t., J  7.0 Hz and 8.6 Hz, PhCH2CH), 4.97
(2H, s., PhCH2 0 ), 5.81 (1H, d., J  7.1 Hz, NH) and 7.20 (10H, m„ Ar); 5p (121.5 MHz,
C2HCI3) 26.83 (91%) and 26.21 (9%); 8c (50.31 MHz, C2HCI3) 34.51 (Ph£.H2CH), 
47.44 & 50.59 (d., PhCH2&H, Jpc 156.4 Hz), 52.82 (d., Jpc 27.1 Hz, -OCH3), 65.51 
(PhCH2 0 ), 126.79-129.36 (aromatic), 137.48 & 137.75 (quat. aromatic) and 156.14 
(urethane CO); m/z (Cl) 364 ([M+H]+, 100%), 259 ([A/f+2 H-PhCH2 0 ]+, 12.1), 230 
([M+H-PhCH2 0 C0 ]+, 2.4), 120 (PhCH2CHNH2+ 16.6), 108 (PhCH2 0 H, 11.2) and 
91 (PhCHg+, 13.3).
Methyl hydrogen [1-(N-benzyioxycarbonyl)-amino]-benzyiphosphonate 
(36).-
o
.OMe
The dimethyl compound (35) (3.63 g, 10 mmol) was dissolved in methanol (30 ml) 
and 2 M sodium hydroxide (15 ml) added with stirring. The solution was stirred at 
room temperature for 12 h., the solution diluted with water (60 ml) and washed with 
dichloromethane (100 ml). The aqueous layer was acidified to pH 2 with 6 M HCI 
and extracted with dichloromethane (3 x 70 ml). The organic extracts were dried 
(MgSO^) and evaporated under reduced pressure to give a white solid.
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Recrystallisation from ethyl acetate/ light petroleum gave the product as a white solid 
(2.69 g, 77%) of m.p. 126.5-127.5 °C. m/z (Found: (M+ H+) 350.1152. C17H21NO5P 
requires 350.1154); v^ax (Nujol) 3289 (OH), 2665 and 2320 (P-OH), 1687 (urethane 
CO), 1546 (amide II), 1219 (P=0), 1041 (P-OH) and 982 cm"' (PO-C); 8^ (200 MHz, 
C^HCIg) 2.93 (2H, m., PhCHgCH), 3.62 (3H, d., Jpy 10.6 Hz, P(0 )OCH3), 4.40 (1H, 
d.t., Jnh 7.1 Hz, JcH 6.3 Hz, PhCHaCJJ), 4.97 (2H, s., PhCHgO), 5.64 (1H, br., OH),
5.81 (1H, d., J  7.1 Hz, NH) and 7.15 (10H, m., Ar); 8p (121.5 MHz, C^HCIg) 22.55 
(9.5%) and 23.11 (90.5%); 8c (50.31 MHz, C ^H C y 38.55 (Ph^HgCH), 52.34 &
54.31 (d., Jpc 103 Hz, PhCHgOH), 56.37 (d., Jpc 21.1 Hz, OMe), 69.21 (PhCHgO), 
126.71-129.36 (aromatic), 141.34 & 142.40 (quat. aromatic) and 156.17 (urethane 
CO); m/z (El) 350 {[M + H]+, 5.4%), 320 ([A4-OMe+2H]+, 100), 242 ([M-OMe- 
PhCH2 0 +2 H]+, 18.3) and 91 (PhCHg^, 49.2).
Diethyl 1-(N-benzyloxycarbonyl)-aminobenzylphosphonate (37).-
This was prepared exactly as for (35), using the diphenyl compound (34) (2.44  g, 
5 mmol) in dry ethanol (30 ml) and sodium (0.286 g, 12.5 mmol) dissolved in dry 
ethanol (10 ml). Work-up as for (35) gave the product as a white solid (1.08 g, 56%). 
ÔH (200 MHz, C^HCIg) 2.84-3.3 (2H, m., PhCHgCH), 3.62 (3H, d., Jp^ 10.6 Hz, 
P(0 )0 CH3), 4.40 (1H, app. d.t., 7.1 Hz, Jqh 6.4 Hz, PhCH2CH ), 4.97 (2H, s.,
PhCH2 0 ), 5.64 (1H, br., OH), 5.81 (1H, d., J 7.1 Hz, NH) and 7.15 (10H, m., Ar); Ôq 
(50.31 MHz, C^HCIg) 16.87 (d., Jpc 7.1 Hz, OCH2^1H3), 36.36 & 36.43 (PhC.H2CH), 
47.61 & 50.78 (d., Jpc 156.8 Hz, PhCHgHH), 62.92-63.51 (OI1H2CH3), 67.36 
(Ph£H2 0 ), 127.22-129.74 (aromatic) and 156.16 (urethane CO).
N- ferf-Butoxycarbonyl-(2S)-prollne (38).-'^ '^ ®
(2S)-Proline (11.5 g, 0.1 mol) was added with stirring to a 1 M sodium hydroxide 
solution (100 ml). The suspension was diluted with fe/t-butanol (75 ml) and dl-te/t- 
butyi dicarbonate (22.3 g, 0.1 mol) in ferf-butanol (10 ml) added dropwise in the 
course of 1 h. The reaction was stirred at room temperature for 12 h. after the 
exothermic reaction had subsided. The reaction mixture was then extracted with light
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petroleum (2 x 40 ml) and this organic phase was then extracted with saturated 
aqueous sodium bicarbonate (3 x 30 ml). The aqueous layers were combined, 
cooled in an ice bath and acidified to pH 1.5 with 1 M HCI, causing the precipitation 
of a white solid, which was filtered and dried. The aqueous filtrate was then extracted 
with ethyl acetate (3 x 50 ml) and the combined organic layers were washed with 
water (2 x 40 ml), dried (IVIgSO^) and filtered. The solvent was removed under 
reduced pressure and the resulting yellowish oil dissolved in light petroleum (15 ml) 
and kept at -10 °C overnight to give a white solid. The two solids were combined and 
recrystallised from diethyl ether/ light petroleum to give the product as a white solid 
(18.9 g, 8 8 %) of m.p. 134-136 °C (lit.‘'5° 136-7 °C). m/z (Found: {M+  H)+ 216.1236. 
C10H17NO4 requires 216.1238); [aJo^O . 5 8 ° ( 0  2 in AcOH) (iit.449 -60 .6° (c 2 in 
AcOH)); (Nujoi) 1737 (urethane CO), 1720 (acid CO) and 1554 cm ' (amide li); 
5h (300 MHz, C^HCIg) 1.44 & 1 .45 f (9H, s., ((CHg)3 C), 1.7-2.3 (4H, m., CHgCHg), 
3.35-3.6 (2H, m., CHgN), 4.19 (1H, m., CH) and 8.94 (1H, br.s., COgH); Sg (50.31 
MHz, C^HCIg) 24.13 & 2 4 .7 8 f (C-4), 28.74 & 2 8 .8 6 t ((£Hg)gC), 29.42 & 31.3 t  (C-3),
46.81 & 47.37T (C-5), 59.43 (C-2 ), 80.84 & 81.55+ ((C H g)g il), 154.25 & 156.73+ 
(urethane CO) and 176.59 & 179.46+ (acid CO); m/z (Ci) 216 ([M+H]+, 26.5% ), 160 
([M + 2 H-(CHg)gC]+, 59.8), 116 ([M +2 H-(CH 3 )gC-OCO]+, 51.5), 70 (C 4 H9 N+, 100) and 
57 ((CHg)gC+, 100).
N-Benzyloxycarbonyl-(2S)-leucine (39).-
To a vigorously stirred solution of (2S)-leucine (1.31 g, 10 mmoi) in 5% sodium 
bicarbonate solution (40 ml) was added benzyloxychloroformate (1.87 g, 11 mmol) 
dropwise. After 3 hr. the mixture was washed with diethyl ether (2 x 25 ml), acidified 
to pH 2 with 2 M HCI and extracted with diethyl ether (3 x 30 ml). The ethereal 
extracts were washed with water (2 x 30 mi), dried (MgS0 4 ) and the soivent removed 
under reduced pressure to give a thick straw coloured oil (1.835 g, 69%). m/z 
(Found: (M + H)+ 266.1390. C ,4H,gN0 4  requires 266.1392); -18° (c 2 in
ethanoi); 8^  (200 MHz, C^HCig) 0.96 (6 H, d., J 4.6 Hz, (CHg)gCH), 1.68 (3H, m., 
CHCHg), 4.42 (1H, m., CHNH), 5.12 (2 H, s., CHgOAr), 5.32 (1H, d., J 6.8  Hz, NH) 
and 7.34 (5H, s., aromatic); 8c (50.31 MHz, C^HCIg) 22.08 & 23.36 (CH(£Hg)2),
25.23 (£lH(CHg)2), 41.89 (CHg), 52.87 (CHNH), 68.18 (CHgOAr), 156.78 (urethane
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CO) and 178.43 (acid GO); m/z (01) 283 ([M + H]+, 32.1%), 266 ([M + H]+, 85), 222 
([M + H - 002]+ , 85), 176 ([M +H-PhOH2]+, 18.3), 132 (HgN- 
OH(0 0 2 H)OH2 0 H(OH3)2+, 23.4) and 91 (PhOH2+, 59.9).
p-Methoxyphenethanol (40).-
p-Methoxyphenylacetic acid (8.4 g, 50 mmol) was dissolved in dry THF (50 ml) and 
cooled to -20 °0. Triethylamine (5.49 g, 50 mmol) and ethyl chtoroformate (5.49 g, 50 
mmol) were added with stirring, then the solution was filtered into a solution of 
sodium boro hydride (2.88 g, 75 mmol) in water (60 ml) cooled to 0 °0. The solution 
was stirred for 3 h. at room temperature, then acidified to pH 2 with 5 M HOI and 
extracted with diethyl ether (3 x 80 ml). The ethereal extract was dried (IVIgSO^) and 
the solvent removed under reduced pressure to give a light yellow oil. Distillation 
under reduced pressure gave a clear oil that solidified on standing to give a white 
solid (5.01 g, 66%) identical to that produced by method 2 .
Method 2
p-Methoxyphenylacetic acid (8.3 g, 50 mmol) was dissolved in dry diethyl ether 
(100 ml) and added slowly to lithium aluminium hydride (2.09 g, 55 mmol) 
suspended in dry diethyl ether (50 ml) at room temperature. The solution was stirred 
for 15 min., then excess water was cautiously added, followed by 1 M sulphuric acid 
(25 ml). The layers were separated and the aqueous layer further extracted with 
diethyl ether (2 x 50 ml). The organic extracts were combined, dried (MgSO^) and 
the solvent removed under reduced pressure to give a yellow oil. Bulb to bulb 
distillation under reduced pressure (141-143 ° 0 ,15 mmHg) (lit. 154.5-155 °0, 21 
mm Hg)) gave the product as a clear oil that crystallised on standing to give white 
crystals of m.p. 30-32 °0 (5.28 g, 70%). m/z (Found: (M + H)+ 152.0837. O9H12O2 
requires 152.0837); (OHOI3) 3436 (OH), 3018 (aromatic) and 1613 & 1512 cm"^ 
(aromatic 0-H); Ôh (200 MHz, O^HOIg) 1.77 (1H, s., OH), 2.82 (2H, t., J 6.7 Hz, 
OHgPh), 3.80 (3H, s., OOH3), 3.82 (2H, t., J 6.7 Hz, OH2OH), 6.86 (2H, d., J 8.7 Hz, 
aromatic) and 7.15 (2H, d., J 8.7 Hz, aromatic); Ôq (50.31 MHz, 0 2 HOI3) 38.75 
(OHgAr), 55.76 (OH2OH), 64.29 (OH3O), 114.54 (aromatic, ortho Xo OH3O), 130.45
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(aromatic, para to CH3 O), 130.96 (aromatic, metaXo CH3 O) and 158.76 (aromatic, 
ipsoXo CH3 O); m/z (Cl) 152 ([M + H]+, 2 1 .6 %), 134 (CH3 OC6 H4 CHCH2 , 5.2), 121 
([CH3 OC6 H4  + NH4 ]+, 100) and 91 (PhCH2 +, 14.2).
Bis(triphenylphosphine)tetrahydroboratocopper (41).-452
Triphenylphosphine (36 g, 137 mmol) was dissolved in chloroform (200 ml) and 
cuprous chloride (6 . 6  g, 6 6  mmol) added slowly. After the solution became 
homogeneous a slurry of sodium borohydride (2.54 g, 6 6  mmol) in 95% ethanol (30 
ml) was added slowly and the resulting mixture stirred for 15 min. The mixture was 
then poured into water (60 ml), the organic layer separated and washed with water 
(2 X 50 ml), dried (MgS0 4 ) and filtered. The resulting yellow solution was treated with 
diethyl ether (400 ml) and the resulting precipitate collected and dissolved in 
chloroform (300 ml). To this solution was added triphenylphosphine (8.34 g, 32 
mmol) and sodium borohydride (2.14 g, 55 mmol) in 95% ethanol (25 ml) and the 
solution stirred for 20 min., after which time ethanol (90 ml) was added. The mixture 
was filtered and the resulting solution evaporated under reduced pressure until 
crystals began to form. The solution was cooled and the white precipitate collected, 
washed with diethyl ether and dried in air to give the product as a white solid of m.p. 
175-177 °C (lit.452 177 «C).
p-Methoxyphenylacetyl chloride (42).-
p-Methoxyphenylacetic acid (1.66 g, 10 mmol) was dissolved in dry benzene (15 
ml), a drop of DMF was added and the mixture cooled to 0 °C. Oxalyl chloride (1.92 
g, 2 2  mmol) was added dropwise, the cooling bath removed and the solution stirred 
at room temperature for 30 min. The volatiles were then removed to give a brown oil 
that was distilled under reduced pressure to give the product as a colourless liquid 
(1.25 g, 6 8 %) that was used immediately. 8 ^ (300 MHz, C2 HCI3 ) 3.81 (3H, s., OCH3 ),
4.08 (2H, s., CH2 ), 6.89 (2H, d., J 7.2 Hz, aromatic) and 7.17 (2H, d., J 7.2 Hz, 
aromatic); Ôq (50.31 MHz, C^HCIg) 52.7 (CHg), 55.8 (OCH3 ), 114.9 (aromatic, ortho 
to MeO), 125.8 (aromatic, para to MeO), 131.1 (aromatic, metaXo MeO), 159.9 (ipso
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to MeO) and 172.8 (CO).
Pyridlnium chlorochromate (43).-^83
Chromium trioxide (10 g, 100 mmol) was added to 6 M HCI (18.4 ml, 110 mmol) 
rapidly with stirring. After 5 min. the solution was cooled to 0 °C and pyridine (7.91 g, 
100 mmol) added slowly over 10 min. Recooling to 0 °C gave the product as an 
orange solid which was collected by filtration and dried in vacuo overnight (17.1 g, 
80%).
Cyclohexylacetaldehyde (44).-^ "^ °
2-Cyclohexylethanol (5.08 g, 40 mmol) was dissolved in dry dichloromethane (20 
ml) and added in one portion to a suspension of pyridinium chlorochromate (4 3 ) 
(12.8 g, 60 mmol) in dry dichloromethane (100 ml). The mixture was stirred for 2 h. at 
room temperature, then dry diethyl ether (100 ml) added and the solution decanted. 
The residue was washed with dry diethyl ether (3 x 50 ml), the organics combined 
and filtered through a pad of Florisil. Evaporation of the solvent gave a light green oil 
that was purified by distillation under reduced pressure (68-70 °C, 25 mm Hg) to give 
the product as a colourless oil (3.3 g, 67%). (thin film) 3021, 2927 & 2855 (C-H) 
and 1721 cm"'* (aldehyde CO); 5^ (200 MHz, C^HCIg) 0.9-2.0 (10H, m., cyclohexyl 
CHg), 2.31 (1H, m., CH-CHg), 4.14 (1H, m., CH2-CHO) and 9.78 (1H, t., J  2.4 Hz, 
CHO); ÔQ (50.31 MHz, C^HCIg) 26.51-26.79 (cyclohexyl CHg x4), 33.10-33.72 
(cyclohexyl CHg x2 , CH), 51.83 (ÜHg-CHO) and 203.45 (CHO).
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Diphenyi[1-(N-benzyloxycarbonyi)-amino]cyclohexylmethylphosphonate
(45).-
P0(0Ph)2
This was synthesised exactly as for the benzylphosphonate analogue (34), using 
aldehyde (44) (20 mmol, 2.5 g). The product, after recrystallisation from chloroform/ 
methanol, was'obtained as a white solid of m.p.136-138 °C (4.7 g, 48%). m/z  
(Found: (M+H)+ 494.2095. C28H33NO5 P requires 494.2098); v^iax (Nujol) 3273 
(NH), 1718 (urethane CO), 1543 (amide II), 1244 (P=0), 954 (P-0) and 763 cm"^ 
(aromatic); 8^ (200 MHz, C2HCI3) 0.7-1.9 (11H, m., cyclohexyl), 4.39 (1H, m., CH-P),
5.13 (2H, s., PhCH2 0 ), 7.07-7.15 (15H, m., aromatic) and 8.04 (1H, d., J 8.4 Hz, NH); 
8p (121.49 MHz, C2HCI3) 17.92; 8q (75.47 MHz, dg-DMSO) 25.2-25.82 (cyclohexyl 
CH2 x5), 37.17 (d., JpQ 10.9 Hz, cyclohexyl CH), 39.50 (d., JpQ 46.8 Hz, 
CHC.H2CHP), 44.75 (d., Jpc 158.6 Hz, CHP), 69.75 (benzyl CH2), 124.3-131.12 
(aromatic), 136.91 (quat. aromatic) and 160.22 (urethane CO); m/z (Cl) 494 ([M+H]+, 
100%), 400 ([M-OPh]+, 15.5), 360 ([A4+2H-Cbz]+, 1.2), 260 ([M-PO(OPh)2]+, 9.6), 126 
(H2NCH2C6H11+, 39.4) and 91 (PhCH2+, 70.4).
Dimethyl 1 -(N-benzyloxycarbonyi)-amlno cyclohexylmethylphosphonate 
(46).-
This was prepared exactly as for the benzyl analogue (35), using diphenyl ester 
(45) (4.69 g, 10 mmol) in dry methanol (75 ml) and sodium (0.506 g, 22 mmol) in dry
174
methanol (25 ml). The same work-up gave the product as a white solid of m.p. 83.5-
84.5 °C after recrystallisation from chloroform/ light petroleum (2.59 g, 68%). m/z 
(Found: (M+ H)+ 369.1701. CigHggNOgP requires 369.1698); v^ax (Nujol) 3271 
(NH), 3062 (aromatic CH), 1714 (urethane CO), 1548 (amide II), 1247 (P=0) and 
1223 cm"l (P-0); Ôh (300 MHz, C^HCIg) 0.7-1.75 (10H, m., CHg x5), 1.83 (1H, m., 
CH), 3.67 (3H, d., JpH 10.9 Hz, OCH3), 4.20 (1H, m., POCH), 5.10 (2H, s., benzyl),
5.15 (1H, d., Jnh 9.6 Hz, NH) and 7.29 (5H, s., aromatic); 6p (121.49 MHz, C^HCIg)
27.82; ÔQ (75.4 MHz, C2HCI3) 26.7-27.1 (cyclohexyl CHg), 32.42, 34.74 & 37.61f 
(obscured d., CHC.H2CH), 34.48 (d., JpQ 13.1 Hz, cyclohexyl CH), 46.7 (d., JpQ 154.7 
Hz, P(O)CH), 53.9 (d., JpQ 28.2 Hz.OCHg), 68.1 (CH2Ph), 128.7-129.22 (aromatic),
137.21 (quat. aromatic) and 156.72 (urethane CO); m/z (El) 370 ([/W+H]+, 5.4%), 260 
([/W-PO(OMe)2l+, 65.4), 110 ([P0 (0 Me)2+ H]+, 68 .8) and 91 (PhCH2+, 100).
M e th y l h y d ro g en  [1 - (N -b e n z y lo x y c a rb o n y [)-a m ln o ] c y c lo h e x y l 
methylphosphonate (47).-
This was synthesised exactly as for the benzylphosphonate analogue (36), using 
compound (46) (3.69 g, 10 mmol) in methanol (40 ml) with 2 M sodium hydroxide 
(15 ml). Recrystallisation from chloroform/ light petroleum gave the product as a 
white solid of m.p. 126-128 °C (2.76 g, 77%). m/z (Found: (M + H)+ 356.1628. 
C17H27NO5P requires 356.1626); v^ax (Nujol) 3305 (OH), 2662 and 2350 (P-OH), 
1686 (urethane CO), 1546 (amide II), 1216 (P=0), 1041 (P-OH) and 982 cm"' (PO- 
0); Sh (200 MHz, C^HCIg) 0.7-1.7 (10H, m., CHg x5), 1.83 (1H, m., CH), 3.71 (3H, d., 
JpH 12.9 Hz, OCHg), 4.21 (1H, m., CHPO), 5.22 (2 H, s., PhCHgO), 6.82 (1H, br., NH),
7.31 (5H, s., aromatic) and 9.88 (1H, br.s., P(O)OH); 5p (121.49 MHz, C^HCIg) 27.92 
& 28.69 (diastereomers, 1:5.2); Sg (75.47 MHz, C^HCIg) 26.78-27.15+ (cyclohexyl 
CHg), 32.82, 35.11 & 37.42+ (obscured d., cyclohexyl CHg), 34.74 (cyclohexyl CH), 
45.16 (d., Jpc 154 Hz, CH-PO) 53.78 (d., JpQ 27.2 Hz, OCHg), 67.41 (benzyl CHg),
111.4-111.95 (aromatic), 134.89 & 134.85+ (quat. aromatic) and 156.47 (urethane 
CO); m/z (Cl) 356 ([M+ H]+, 100).
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Diphenyl 1-(N-Benzyloxycarbonyl)-amlno-n-butylphosphonate (48).
O
H- ■P0(0Ph)2
vv
This was prepared exactly as for the benzyl analogue (34), using pentanal (12.9 g, 
150 mmol). The usual work-up gave the product as a white solid (23.8 g, 53%) of 
m.p. 102-3 °C. (Found: C, 66.25; H, 6.39; N, 3.12. Caic. for CgsHggNOgP: C, 66 .2 0 ; 
H, 6.18; N, 3.09%); m/z (Found: [M  + H)+ 453.1701. CggHggNOgP requires 
453.1698); v^gx (Nujol) 3267 (NH), 1710 (urethane CO), 1589 (amide II), 1253 
(P=0), 950 (P-O) and 759 cm"' (aromatic); 5^ (300 MHz, C^HCig) 0.88 (3H, t., J 7.4 
Hz, CHg), 1.1-1.5 (4H, m., CHg-CJdg), 1-71 (1H, m., 1 of CHg-CH-P), 1.97 (1H, m., 1 
of CHg-CH-P), 4.44 (1H, m., CHg-CH-P), 5.04 (1H, AB d., J 11.8 Hz, 1 of PhCHgO), 
5.10 (1H, AB d., J 11.8 Hz, 1 of PhCHgO), 5.52 (1H, br., NH) and 6.92-7.31 (15H, m., 
aromatic); 5p (121.49 MHz, C^HCig) 18.23 (93%) and 17.92 (7%); Sg (75.47 MHz, 
C^HCIg) 13.62 (CHg), 21.95 (C-4 CHg), 27.50 (d., Jpc 2.9 Hz, C-3 CHg), 29.44 (d., 
Jpc 13.3 Hz, C-2 CHg), 47.52 (d., Jpc 157.7 Hz, C-1 CH), 66.91 and 67.21 
(PhCHgO), 120.14-129.88 (aromatic), 136.0 (quat. aromatic), 149.82-150.18 (quat. 
aromatic ArC-0) and 155.82 & 155.90 (urethane CO); m/z (Cl) 454 ([M+H]+, 100%), 
363 ([/W-PhCHg]+, 25.3), 346 ([M-PhCHgOH]+, 41.5), 235 (PO(OPh)g+, 4.2), 220 
(CbzNHCH(CHg)gCH3+, 6.3) and 108 (PhCHgOHg+, 40.8).
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D ipheny l 1 -(N -b e n zy io xyca rb o n y i)-a m in o -2 -m e th y lp ro p y ip h o sp h o n a te
(49).-
O
H- •PO(OPh)2
This was prepared exactiy as for the benzyl analogue (34), using 3-methyl butanal 
(12.9 g, 150 mmol). The usual work-up gave the product as a white solid (20.1 g, 
44.3%) of m.p. 123-4 °C ( i i t .3 3 2  122-3 °C). (Found; C. 66.45; H, 6.45; N, 3.09. Calc, 
for CgsHgaNOgP: C, 66.20; H, 6.18; N, 3.09%); m/z (Found: {M + H)+ 454.1776. 
C25H29NO5P requires 454.1778). v^ ^gy (Nujol) 3269 (NH), 1713 (urethane CO), 
1592 (amide II), 1270 (P=0), 946 (P-O) and 756 cm"' (aromatic); 8,+ (300 MHz, 
C^HCIg) 0.91 (6 H, d., J 5.4Hz, (CHg)2), 1.62-1.74 (3H, m., CHgCH), 4.51 (1H, m., 
CH-PO), 5.12 (2H, s., PhCHgO), 5.19 (1H, obscured d., NH) and 6.87-7.38 (15H, m., 
aromatic); 5p (121.49 MHz, C^HCIg) 18.23 (14.4%) and 18.57 (85.6%); Sg (75.47 
MHz, C^HCIg) 21.62 (CHg), 23.71 (CHg), 24.80 & 25.03+ ((CHg)2(IH), 39.02 & 
39.98+ (d., Jpc 48.2 Hz, (CHg)2CHGH2), 47.43 (d., Jpc 158.4 Hz, CH-P), 67.67 &
68.03 (GHgOAr), 120.87-130.31 (aromatic), 136.7 (quat. aromatic Ar£-C), 150.6- 
150.97 (quat. aromatic Ar£.-0) and 154.45 & 156.38+ (urethane CO); m/z (Cl) 454 
([M+H]+, 100%), 363 ([M-PhCH2]+, 12.6), 346 ([M-PhCH20H]+, 10.8), 320 ([M+H- 
Cbz]+, 2.1), 220 (CbzNHCHCH2CH(CHg)2+, 6 .6) and 108 (PhCH2 0 H2+, 40.8).
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Diphenyl 1-(N>benzyloxycarbonyl)-amino-/sopropyiphosphonate (50).
O
H- •PO(OPh)2
This was prepared exactly as for the benzyl analogue (34), using 2-methyl 
propanal (10.8 g, 150 mmol). The usual work-up gave the product as a white solid 
(24.8 g, 56.5%) of m.p. 108-9 °C (lit.332 104-5 °C). (Found: C, 65.7; H, 5.92; N, 3.23. 
Calc, for Cg^HggNOgP: C, 65.6; H, 5.92; N, 3.19); m/z (Found: (M + H)+ 439.1546. 
C25H28NO5P requires 439.1548); (Nujol) 3305 (NH), 1716 (urethane), 1591 
(amide II), 1245 (P=0), 946 (P-0) and 746 cm"' (aromatic); 8+, (200 MHz, C^HCIg)
1.14 (6 H, d., J  7.3 Hz, (CMg)2CH), 2.51 (1H, m, (CHg)2CÜ).4.44  (1H, d.d.d.,
Jnh 10.9, JpH 19.1 Hz, CH-PO), 5.13 (1H, AB d., J 11.8 Hz, 1 of PhCHgO), 5.16 (1H, 
AB d., J 11.8 Hz, 1 of PhCHgO), 5.29 (1H, d., J 10.9 Hz, NH) and 7.03-7.43 (15H, m., 
aromatic); 8p (121.49 MHz, C^HCig) 17.86 (18.6%) and 18.21 (81.4%); 8c (75.47 
MHz, C^HCig) 17.55 & 17.60+ ((£Hg)2CH), 20.1 & 20.28+ ((£.Hg)2CH), 29.12 (d., Jpc
8.1 Hz, (CHg)2£.H), 52.59 (d.. Jpg 154.2 Hz. CH-P), 67.24 & 67.45+ (PhCHgO), 
120.25-129.46 (aromatic), 135.96 (quat. aromatic ArH-C), 149.8-150.15 (quat. 
aromatic, ArC-O-P) and 156.05 & 156.14 (urethane CO); m/z (Cl) 440 ([M+H]+, 
100%), 349 ([M-PhCH2]+, 12), 206 ([M-P0 (0 Ph)2]+, 9.3) and 108 (PhCH2 0 H2+,
45.5).
Dimethyl
Method 1
1-(N>benzyloxycarbony[)-aminon-*butyiphosphonate (51).-
This was prepared exactly as for the benzylphosphonate analogue (34), using 
(48) (4.53 g, 10 mmol). The product was isolated as a clear oil after flash
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chromatography, identical in all respects to that obtained from method 2 , (2.86 g, a
79%) (ethyl acetate) that proved refractory to crystallisation.
Method 2^34
The diphenyl phosphonate (48) (4.53 g, 10 mmol) was dissolved in methanol 
(30 ml) and potassium difluoride dihydrate (8.0 g) and 18-crown-6 (20 mg) added.
The mixture was heated to boiling for 5 min. then stirred at room temperature 
overnight, then the solvent was removed under reduced pressure. The resulting solid 
was suspended in ethyl acetate (40 ml), washed with water (2 x 20 ml), 5% sodium 
bicarbonate solution (3 x 20 ml) and brine (20 ml). The organic layer was dried 
(MgSO^) and the solvent removed under reduced pressure to give a light yellow oil.
Flash column chromatography (ethyl acetate) gave a clear oil (2.11 g, 64%) that 
could not be crystallised, v ^  (Nujol) 3327 (NH), 1721 (urethane CO), 1586 (amide 
II), 1243 (P=0), 941 (P-0) and 749 cm"' (aromatic): (200 MHz, C^HCIg) 0.89 (3H,
t., J  6.9 Hz, CH3CH2), 1.12-1.63 (4H, m., CH2CH2), 1.81 (2 H, m., POCHOilg), 3.61 
(3H, d., JpH 10.5 Hz, 1 of P0 (0 CHg)2), 3.64 (3H, d., Jpp, 10.5 Hz, 1 of PO(OCH3)2),
4.09 (1H, m., POCJICH2), 5.01 (1H, AB d., J 12.3 Hz, 1 of PhCH2 0 ) and 5.08 (1H,
AB d., J  12.3 Hz, 1 of PhCHgO), 5.82 (1H, d., J 9.7 Hz, NH) and 7.34 (5H, s., 
aromatic); Bp (121.49 MHz, C^HCIg) 27.06; Bg (50.31 MHz, C^HCIg) 14.28 (CHg),
22.59 (CHg^Hg), 28.32 (d., Jpc 12.8  Hz, IlHgCH), 29.58 (d., Jpc 2 .8  Hz, 
CHgCHgüHg), 49.20 and 46.09 (d., Jpc 156.4 Hz, CHPO), 53.28 (d.. Jpg 6.7 Hz, 1 of 
P0 (0 CHg)2), 53.61 (d.. Jpg 6.7 Hz, 1 of PO(OCHg)2), 128.36-128.86 (aromatic),
136.90 (quat. aromatic) and 156.80 (urethane CO).
Dimethyl 1-(N-Benzy!oxycarbony[)-am ino-2-m ethyipropylphosphonate
(52).-Method 1
This was synthesised exactly as for the benzyl analogue (35) using (49) (4.53 g, 
10 rnmol), giving the product as a clear oil (2.59 g, 71%) after flash chromatography 
(ethyl acetate). The oil could not be crystallised.
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Method 2331
To a stirred suspension of lead tetraacetate (4.48 g, 10.1 mmol) in dry DMF (10 ml) 
at 0 °C was added dropwise a solution of N-benzyloxycarbonyl-(2S)-leucine (39) 
(2.65 g, 10 mmol) in dry DMF (10 ml). After 30 min., cooling was removed and the 
reaction stirred for an additional 3.5 h., and then saturated sodium carbonate 
solution (75 ml) was added. The mixture was extracted with ethyl acetate (4 x 60 ml) 
and the organic extracts washed with saturated sodium carbonate solution (100 ml) 
and then brine (60 ml), dried (MgSO^) and evaporated under reduced pressure to 
give the crude product as a yellowish oil. A solution of this oil in dry dichloromethane 
(50 ml) was then added to trimethyl phosphite (1.49 g, 11 mmol) and the mixture 
cooled to -78 °C under an argon atmosphere. Titanium tetrachloride (2.09 g, 
11 mmol) in dry dichloromethane (10 ml) was added dropwise over 10 min. and the 
resulting yellow solution allowed to warm to room temperature overnight. Sodium 
carbonate decahydrate (5 g, 17.5 mmol) suspended in dichloromethane (60 ml) was 
then added and the mixture stirred for a further 30 min., filtered, dried (MgSO^) and 
evaporated under reduced pressure to give a yellow oil. Purification by flash column 
chromatography (ethyl acetate) gave the product as a clear oil that crystallised on 
standing to give white crystals (1.71 g, 54 %) of m.p. 44-6 °C. v^gy (Nujol) 3321 (NH), 
1728 (urethane CO), 1584 (amide II), 1247 (P=0), 941 (P-O) and 744 cm"' 
(aromatic); 6^ (200 MHz, C^HOIg) 0.90 (6H, d., J 6.6 Hz, (CHg)2 0 H), 1.32-1.78 (3H, 
m., -CHgCh.-), 3.61 (3H, d., JpH 9.8 Hz, 1 of P0 (0 CJdg)2) 3.65 (3H, d., Jpp, 9.8 Hz, 1 of 
P0 (0 CH3)2), 4.14 (1H, m, POCHGH2). 5.06 (1H, AB d., J 12.3 Hz, 1 of PhCH2 0 ),
5.09 (1H, AB d., J  -12.3 Hz, 1 of PhCH2 0 ), 5.15 (1H, d., J 10.8 Hz, NH) and 7.34 (5H, 
s., aromatic); 5p (121.49 MHz, G^HCIg) 27.06; 5g (75.47 MHz, G^HGIg) 21.73 (GHg),
23.86 (GHg), 24.95 (d.,Jpg 11.6 Hz, (GHg)2(lH ), 39.58 (d.. Jpg 48.1 Hz, 
(GHg)2GHG.H2), 46.81 (d.. Jpg 158.4 Hz, GH-PO), 53.75 (d.. Jpg 7.2 Hz, 1 of 
P0 (0 GHg)2), 53.98 (d.. Jpg 7.2 Hz, 1 of PO(OGHg)2), 66.54 (OGHgAr), 125.36-
128.86 (aromatic), 136.90 (quat. aromatic) and 156.60 (urethane CO).
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Dimethyl 1-(N-benzyloxycarbonyl)-amlno/sopropylphosphonate (53).-
This was prepared exactly as for the benzyl analogue (35), using (4.39 g, 10 mmol) 
of (50). Crystallisation of the clear oil (1.96 g, 62%) obtained from flash
chromatography (ethyl acetate) proved impossible, (Nujol) 3342 (NH), 1721
(urethane CO), 1580 (amide II), 1240 (PO), 941 (P-0) and 752 cm'"* (aromatic); 5^
(200 MHz. C^HCIg) 0.97 (6 H, d., (CÜ3)2CH), 2.20 (1H, m., (CHg)2Cji), 3.71 (3H, d., 
JpH 6.4 Hz, P0 (0 CH3)2). 3.74 (3H, d., JpH 6.4 Hz, P0 (0 CHg)2), 4.11 (1H, m., 
CHPO), 5.12 (2 H, s., PhCH2 0 ) and 7.32 (5H, s., aromatic); 5p (121.49 MHz, C^HCIg) 
28.14.
Methyl hydrogen 1-(N-benzyloxycarbonyl)-am i non-butyl phosphonate
(54).-
This was produced exactly as for the benzyl analogue (36), using dimethyl 
phosphonate (51) (3.29 g, 10 mmol). The resulting solid was recrystallised from 
chloroform/ light petroleum to give the product as a white powder (2.58 g, 82%) of 
m.p. 125-127 °C. m/z (Found; (M+ H)+ 316.1310. C^^H23N0gP requires 316.1308). 
Vmax (Nujol) 3302 (NH), 3140-2810 (br., OH), 1718 (urethane CO), 1585 (amide II), 
1240 (P=0), 931 (P-O) and 745 cm’ ' (aromatic); 5h (300 MHz, C^HCIg) 0.88 (3H, t., 
J  6.9 Hz, CHg), 1.14-1.62 (4H, m.. CHgCHg), 1.71 (1H, m., 1 of CHg-CHP), 1.97 (1H, 
m., 1 of CH2-CH-P), 3.70 and 3.71 (3H, d., JpH 10.8 Hz, diastereomers of CH3O-PO),
4.09 (1H, m., CHg-CHP), 5.17 (2H, s., PhCHgO), 5.19 (1H, d., obscured, NH), 7.31 
(5H, m., aromatic) and 10.83 (1H, br., PO-OH); Ôp (121.49 MHz, C3HCI3) 28.11 
(76.2%) and 27.39 (23.8%); Ôq (75.47 MHz, C ^H C y 14.94 (CH3). 26.46 (CH3C.H2),
27.94 (d., Jpc 12.1 Hz, C.H2CH), 29.02 (d., Jpc 2.8 Hz, CH3CH2ÜH2), 47.42 & 50.53 
(d., JpQ 156.4 Hz, CHPO), 55.28 (d., JpQ 8.6 Hz, PO(OCH3)g), 67.94 (CHgO), 
127.36-130.32 (aromatic), 137.87 (quat. aromatic) and 156.67 (urethane CO); m/z 
(Cl) 316 {[M+ H]+, 29.5%), 298 ([AfCH3(CH2)3)+, 4) and 108 (PhCH2NH3+, 21).
181
M ethyl hydrogen 1 -(N -b e n zy to x y c a rb o n y l)-a m ln o -2 -m e th y lp ro p y i 
phosphonate (55).-
This was produced exactly as for the benzyl analogue (36), using dimethyl 
phosphonate (53) (3.29 g, 10 mmol), giving the product, after recrystallisation from 
chloroform/ light petroleum, as a white solid of m.p. 119-121 °C (2.24 g, 71%). m/z 
(Found: {M + H)+ 316.1309. C^^HggNOgP requires 316.1308). (Nujol) 3302 
(NH), 3140-2850 (br., OH), 1718 (urethane CO), 1585 (amide II), 1240 (P=0), 931 (P- 
O) and 745 cm"'' (aromatic); 5h (300 MHz, C^HCIa) 0.91 (6 H, d., J  6.5Hz, 
CH2CH(C il3)2). 1.58 (2H, m, CM2CH(CH3)2), 1.74 (IN. m., CH2CH(CH3)2), 3.71 
(3 H, d., JpH 10.8 Hz. CH3O-P), 4.19 (1H, m., CH-PO), 5.09 (1H, obscured d., NH), 
5.12 (2 H, s., PhCH2 0 ), 7.34 (5H, m., aromatic) and 10.83 (1H, br.s., PO-OH); 5p 
(121.49 MHz, C2HCI3) 27.62 (18%) and 28.32 (82%); Sq (75.47 MHz, C2HCI3)
20.81-92t ((£H3)2CH), 24.21 (d., Jpc 13.1 Hz, (CH3)2£H), 37.85 (d., Jpc 34.2 Hz, 
CHgCH), 43.97 & 47.12 (d., JpQ 158.5 Hz, PO-CH), 52.08 (d., Jpc 10.4 Hz, P-OCH3),
67.03 & 67.50 (PtiCH2 0 ), 127.8-128.4 (aromatic), 136.12 (quat. aromatic) and 
155.27 & 156.06 (urethane CO); m/z (Ci) 333 ([M+ NH^^, 18%), 316 ([M+ H]+, 100) 
and 91 (PhCH2+, 58).
Methyl hydrogen 1-(N-benzyloxycarbonyl)-amino/sopropylphosphonate
(56).-
This was prepared exactly as for the benzyl analogue (36), using dimethyl 
phosphonate (53), (3.15 g, 10 mmol), giving the product, after recrystaliisation from 
chloroform/ light petroleum, as a white solid of m.p. 102.5-105 °C (1.96 g, 65%). m/z 
(Found: {M + H)+ 302.1160. C ,3H2 iNOgP requires 302.1158). v^ax (Nujol) 3302 
(NH), 3140-2410 (PO-OH), 1718 (urethane CO), 1585 (amide II), 1240 (P=0), 931 
(P-O) and 745 cm''' (aromatic); 5h (300 MHz, C2HCI3) 0.97 & 0.98 (6 H, t., J  6.9 Hz, 
diastereomers of (CJl3)2CH), = 6:1), 2.20 (1H, m., (CH3)2CH)), 3.68 (3H, d., Jpp, 10.9 
Hz, PO-OCH3), 4.07 (1H, d.d.d., JpH 19.0 Hz, 10 5 Hz, Jqh 4-3 Hz, PO-CH), 5.12 
(2 H, s., PhCHgO), 5.22 (1H, d., J  10.5 Hz, NH), 7.37 (5 H, s., aromatic) and 10.83 (1H, 
br.s., PO-OH); 8p (121.49 MHz, C^HCig) 27.03 (14%) and 27.78 (86%); 5c (75.47
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MHz, C^HCIg) 17.48 (d., Jpc 2.5 Hz, (£.H3)2CH, 1 diastereomer), 20.19 (d., JpQ 5.7 
Hz, (C.H3)2CH, 1 diastereomer), 28.62 (d., Jpc 10.6 Hz, (CH3)2ÛH), 51.16 & 53.22 
(d., PO-CH. Jpc 155.5 Hz), 52.42 & 53.15 (d., JpQ 15.8 Hz, PO-OCH3 , 
diastereomers), 67.15 & 67.43 (PhCH2Û, diastereomers), 127.77-128.38 (aromatic),
136.07 (quat. aromatic) and 156.27 & 156.36 (urethane CO); m/z (Cl) 302 {[M + H]+, 
43%), 284 ([M-OH]+, 28.1) and 91 (PhCH2+, 56).
Dimethyl phthalimidomethylphosphonate (57).- Method 1
To a 50% dispersion of sodium hydride in mineral oil (1.58 g, 33 mmol) in dry THF 
(10 ml) under nitrogen was added dimethyl phosphite (3.3 g, 30 mmol) in dry THF 
(30 mi). The mixture was stirred at room temperature for 45 min., until effervescence 
had ceased, and allowed to settle. The solution was then added dropwise to N- 
bromomethylphthalimide (7.2 g, 30 mmol) in dry toluene (50 ml) under nitrogen at 0 
°C. The reaction was refluxed for 8 h., filtered and the pad washed with ethyl acetate. 
The THF was removed under reduced pressure and the solution washed with water 
(40 ml) and brine (40 ml), dried (MgSO^) and evaporated under reduced pressure to 
give a white solid. Crystallisation from ethyl acetate/ light petroleum gave the product 
as white amorphous crystals (6.72 g, 83%) of m.p. 103-6 °C. m/z (Found: (M + H)+ 
270.0530. C11H13NO5P requires 270.0528); v^^x (Nujol) 1718 (imide CO), 1254 
(P=0), 1020 (P-OMe) and 835 cm'i (aromatic): 6^ (200 MHz, C ^H C y 3.87 (6 H, d., J
11.3 Hz, P(OCH3)2), 4.13 (2H, d., JpH 9.8 Hz, CM2-PO(GMe)2) and 7.71-8.0 (4H, m., 
aromatic); ôp (121.49 MHz, C ^H C y 22.50; 8^ (50.31 MHz, C^HCIg) 29.78 & 32.81 
(d., Jpc 151 Hz, CH2-P), 52.12 (d., JpQ 5.7 Hz, PO(OCH3)2). 122.21 (aromatic),
130.82 (quat. aromatic), 133.82 (aromatic) and 165.84 (CO); m/z (El) 269 (M+,
18.8%), 160 ([M-PO(OMe)g]+, 100), 133 ([CeH4(CO)2 + H]+, 12.5) and 76 (C6H4+
18.8).
Method 2^^®
N-bromomethylphthaiimide (2.4 g, 10 mmol) was dissolved in 5 ml xylene and 
trimethyl phosphite (1.36 g, 11 mmol) added. The reaction flask was swept with
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1argon and heated slowly to near reflux, when the mixture reacted exothermically. 
Heating was discontinued until the exotherm had subsided, then the mixture was 
refluxed for 5 h. Most of the solvent was then removed under reduced pressure and 
the remainder allowed to cool overnight. The resulting yellow solid was collected, 
heated in dry diethyl ether (15 ml) for 3 h., filtered and evaporated to give the crude 
product. Recrystallisation from ethyl acetate/ light petroleum gave the product as a 
white solid (1.29 g, 48%) identical in all respects to that produced by method 1.
Diethyl phthalimidomethylphosphonate ( 58 ) . - ^ 2 3
N-bromomethylphthalimide (4.8 g, 20 mmol) and triethyl phosphite (3.32 g, 
20 mmol) were stirred together in a flask fitted with a reflux condenser, and heated 
gently to initiate the exothermic reaction. When the exotherm had subsided the 
mixture was heated for 1 h., then dichloromethane (20 ml) was added. The resulting 
solution was then washed with water ( 3 x 1 0  ml), brine (10 ml), dried (MgSO^) and 
evaporated under reduced pressure to give a yellow oil which crystallised on 
standing. Recrystallisation from dichloromethane/ light petroleum gave the product
as a white solid (4.69 g. 79%) of m.p. 68-70°C (lit.323 67°C). v^ax (Nujol) 1719 (CO), 
1240 (P=0), 1045 (P-O) and 782 cm ' (aromatic); 8^ (200 MHz, C^HCIg) 1.24 (6 H, 
app. t., J Hz, CJdgCHg x2), 4.04 (2H, d., J Hz, PO-CHg-N), 4.15 (4H, m., CÜ2CH3) 
and 7.79 (4H, m., aromatic).
Diphenyl (N-benzyloxycarbonyl) aminomethanephosphonate (59).-^^^
A mixture of benzyl carbamate (1.53 g, 10 mmol), paraformaldehyde (300 mg, 
10 mmol), acetic anhydride (1.19 ml, 12.5 mmol) and acetic acid (5 ml) was stirred at 
65 °C for 3 h. Triphenyl phosphite (3.1 g, 10 mmol) was added and the mixture 
stirred at 120 °C for 2 h. Acetic acid and un reacted acetic anhydride were then 
removed under reduced pressure. The residue was dissolved in hot methanol and 
stored at -20 °C overnight. The resulting white solid was filtered, washed with 
methanol and recrystallised from chloroform/ methanol to give the product as a white 
solid (1.58 g, 32%) of m.p. 113-114 °C (lit.335 114-116 °C). m/z (Found: (M + H)+
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398.1155. C21H21NO5P requires 398.1152); v^ax (Nujol) 3273 (NH). 1721 (urethane 
CO), 1558 (amide ii), 1226 (P=0), 953 (P-OPh) and 766 cm ' (aromatic); 5h (200 
MHz, C^HCig) 3.98 (2 H, d., J 6.2 Hz, CH2PO), 5.13 (2 H, s., PhCH2 0 ), 5.32 (1H, br., 
NH) and 7.08-7.41 (15H, m., aromatic); 5p (121.49 MHz, C^HCig) 15.24 (3.8%) and
15.82 (96.2%); (50.31 MHz, C^HCig) 35.97 & 39.15 (d., JpQ 160.3 Hz, CHg-PO),
67.91 (PhCH2 0 ), 120.9-130.3 (aromatic) and 163.1 (urethane CO); m/z (01) 415 ([M 
+ NH4)+, 1.3%), 290 ([OCNCH2PO(OPh)2 + H]+, 100), 264 ([M+H-Cbz]+, 6 .6 ), 94 
(PhOH, 16.3) and 91 (PhCH2+, 33.1).
Diphenyl 1-aminomethanephosphonate hydrobromide (60).-
Gompound (59) (7.94 g, 20 mmol) was dissolved in 30% hydrogen bromide in 
acetic acid (8 ml). The solution was stirred at room temperature for 1 h. and the 
solvent and volatiles were then removed under reduced pressure. The oily residue 
was crystallised from methanol and diethyl ether. Recrystallisation from methanol/ 
diethyl ether gave the product as white, hygroscopic crystals of m.p. 147-149°G 
( i i t3 3 5  147.149»C). 5 h  (200 MHz, 2H2O) 4.43 (2H, d., 10.3 Hz, CH2) and 7.52-
7.90 (10H, m., aromatic).
Diphenyl 1-amlnobenzylphosphonate hydrobromide (61).-
N-Benzyloxycarbonyl protected (34) (4.87 g, 10 mmol) was dissolved in 30% 
hydrogen bromide in acetic acid (8 ml) and the solution stirred at room temperature 
for 1 h. After this time the volatiles were removed under reduced pressure to give an 
oily residue that was crystallised from methanol/ diethyl ether. Recrystallisation from 
methanol/ diethyl ether gave the product as white crystals (4.15 g, 96%) of m.p.
163.5-164.5 °C (lit.332 164-166 °C). 8^ (200 MHz, C^HgO^H) 3.20 (1H, m., 1 of 
CHgPh), 3.47 (1H, m., 1 of CJl2Ph), 4.36 (1H, d.d.d., 6 8 and 8.3 Hz Jpp, 14.6 Hz,
CHPO) and 6.92-7.46 (15H, m., aromatic); 8c (50.31 MHz, C^HgO^H) 35.81 
(CHgPh), 51.66 (d.,Jpc 151.2 Hz, CH-P), 121.91-131.45 (aromatic) and 135.2-136.1 
(quat. aromatic).
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Diphenyl 1-aminobenzyiphosphonate (62).-
Hydrobromide (61) (4.33g, 10 mmol) was suspended in chloroform (40 ml) and 
2 M sodium hydroxide (40 ml) added. The mixture was shaken until all the solid had 
dissolved, the layers were separated and the organic layer dried (MgSO^). The 
solvent was removed under reduced pressure to give a clear oil that solidified on 
standing. Recrystallisation from dichloromethane/ light petroleum gave the product 
as a white solid (3.20 g, 91%) of m.p. 61.5-62 °C. m/z (Found: (M + H)+ 354.1259. 
C20H21NO3P requires 354.1259); v^ax (Nujol) 3285 (NH), 1278 (P=0), 932 (P-O) 
and 761 cm"^ (aromatic); 8^ (200 MHz, C^HCIg) 1.59 (2H, br.s,, NHg), 2.91 (1H, m., 1 
of CHgPh), 3.45 (1H, m., 1 of CHgPh), 3.65 (1H, app. t. of d., Jch 3.4 Hz JpH 10.7 Hz, 
CH-PO) and 7.30 (15H, m., aromatic); 8p (121.49 MHz, C^HCIg) 21.61; 5q (50.31 
MHz, C^HCIg) 38.32 (CH2Ph), 49.67 & 52.71 (d., CH-PO, JpQ 153.1 Hz), 121.09-
130.31 (aromatic) and 137.70 (quat. aromatic); m/z (Cl) 354 {[M + H]+, 4.6%), 235 
([H2PO(OPh)2]+ , 47.5) and 120 { [M -PO(OPh)2]+, 100).
Dibenzoyl (2S)-tartaric anhydride (63).-
To a stirred solution of freshly recrystallised dibenzoyl (2S)-tartaric acid (7.06 g, 
20 mmol) in dry THF (50 ml) at 0 °C was added dropwise trifluoroacetic anhydride (2 
ml) over 5 min. The mixture was then stirred at room temperature for 30 min., with the 
formation of white crystals. Removal of the solvent under reduced pressure gave 
white fluffy crystals which were recrystallised from ethyl acetate/ light petroleum to 
give the product as white crystals (6.32 g, 94%) of m.p. 194-6 °C. (Nujol) 1824 & 
1740 (anhydride CO), 1707 (ester CO) and 713 cm'"* (aromatic); 8^ (200  MHz, 
C^HCIg) 5.98 (2 H, s., CH x2), 7.42-7.75 (6H, m., aromatic) and 8.02-8.17 (4H, m., 
aromatic); Sq (50.31 MHz, C^HCIg) 72.33 (CH), 126.61 (ortho aromatic), 128.24 
(para aromatic), 129.79 (mefa aromatic), 134.05 (/pso aromatic) and 171.64 (CO).
Resolution (64).-^®^
Diphenyl phosphonate ester (62) (7.08 g, 20 mmol) was dissolved in dry dioxane
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(80 mi) and dibenzoyl-(2S)-tartaric anhydride (63) added (6.8  g, 20 mmol). The 
mixture was stirred until all solid dissolved and then left at room temperature for 3 
days. The solvent was then removed under reduced pressure, benzene added 
(20 ml) and the solution left at 0 °C overnight. The (S)-diastereomer at C-1 of the 
phosphophenylalanine residue crystallised out preferentially. Reduction of the 
volume of benzene caused crystallisation of a second crop. The required (R) 
diastereomer was obtained by removing the benzene under reduced pressure, 
adding diethyl ether (20 ml) to the oil and standing at 0 °C for one day. A second 
crop was obtained by reduction of the volume of the solution to 10 ml and. storing at 
0 °C overnight.
Diphenyl 1-amino-n-butyl phosphonate hydrobromide (65).-
This was produced in an identical manner to (61 ) using N-protected (48) (4.59 g, 
10 mmol). Recrystallisation from methanol/ diethyl ether gave the product as white 
crystals (3.85 g, 95%) of m.p. 172-173 °C. Sy (200 MHz, C^HgO^H) 1.16 (3H, t., J
7.1 Hz, CHg), 1.31-1.79 (4H, m., CHgCHg), 1.88-2.37 (2 H, m., CHgCHP), 4.14 (1H, 
d.d., Jqh 4.2 Hz, JpH 13.3 Hz, CHPO) and 7.17-7.52 (10H, m., aromatic); ôp (121.49 
MHz, C^HgO^H) 18.67; Ôq (50.31 MHz, C^HgO^H) 14.32 (CHg), 23.63 (CHgHHg),
29.14 (d., Jpc 8.54 Hz, C H gC H g^H g), 29.59 (d., JpQ 2.64 Hz, jQHgCH), 47.31 & 
50.46 (d., JpQ 158.5 Hz, CHPO), 121.93 & 122.03 (o/t/70 aromatic), 127.62 (para 
aromatic) and 131.51 (mefa aromatic).
Diphenyl 1-amino-2-methylpropylphosphonate hydrobromide (66).-
This was prepared in an identical manner to compound (61 ) using the N-protected 
compound (49) (4.59 g, 10 mmol). Recrystallisation from methanol/ diethyl ether
gave the product as white crystals (3.78 g, 92%) of m.p. 174-176 °C. 6^ (200 MHz,
C^HgO^H) 1.12 (6 H, d., J 5.9 Hz, (CHg)2), 1.83-2.19 (3H, m., (CHg)2CHCH2), 4.24
(1H, m., CHPO) and 7.08-7.52 (10H, m., aromatic); ôp (121.49 MHz, C^HgO^H)
18.13; ÔQ (50.31 MHz, C^HgO^H) 22.44f (1 of (C.Hg)2)CH), 23.23f (1 of (C.Hg)2)CH),
25.94 (d., Jpc 9.6 Hz, (CHg)2C.H), 38.57 and 35.59 (conformera of ^IHgCHP), 45.58
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& 48.74 (d., JpQ 158.9 Hz, QHPO) 122.02 & 123.41 (orf/?o aromatic), 127.65 (para 
aromatic), 131.56 (mefa aromatic) and 152.71 (/pso aromatic).
Diphenyl 1-amlno-/sopropyl phosphonate hydrobromide (67).-
This was prepared in an identical manner to (61) using the N-protected compound
(50) (4.33 g, 10 mmol). Recrystallisation from methanol/ diethyl ether gave the 
product as white crystals (3.54 g, 86%) of m.p. 173-5 °C. ô|_; (200 MHz, C^HgO^H)
1.16 t (6 H, d.d.’s, Jqh 6.9 Hz and JpH 1.2 Hz, (CHg)2CH), 1.56 (2 H, s., NHg), 2.37 
(1H, d.h., J  4.2 and 6.9 Hz, (CHg)2CH), 3.23 (1H, d.d., 4.2 and JpH 13.3 Hz,
CHPO) and 7.08-7.47 (10H, m., aromatic); Ôp (121.49 MHz, C^HgO ^H) 19.34; ÔQ 
(50.31 MHz, C^NgO^H) 17.88t ((CHg)g), 21.18f ((CHgjg), 29.75 (d. Jp^ 6.1 Hz, 
(CHg)g^lH), 53.71 and 56.57 (d., JpQ 143.5 Hz, CHPO), 121.04 {ortho aromatic),
125.53 (para aromatic), 130.22 (mefa aromatic) and 153.21 (/pso aromatic).
Diphenyl 1-amino-n-butyl phosphonate (68).-
This was prepared in an identical manner to (62) using the o-butyl hydrobromide 
(65) (3 g, 7.5 mmol) to give the product as a clear oil (1.96 g, 82%). m/z (Found: (M +
H)+ 320 .3514 . C iyH ggN O gP  requires 320.3515); Vf^ iax (Nujol) 3304 (N H ), 1266 
(P=0), 938 (P-O) and 765 cm‘ i (aromatic); ô^ (200 MHz, C^HCIg) 0.94 (3H, t., J  7.1 
Hz, C H gC H g),1.22-1.72 (5H, m., CHgChL2Cj[l2- and 1 of C jjg C H P ), 1.65 (2H, s.,
NHg), 2.04 (1H, m., 1 of CHgCHP), 3.32 (1H, app. d.t., Jqh 3-95 and Jp^ 9.4  Hz,
CHPO) and 7.08-7.47 (10H, m., aromatic); ôp (121.49 MHz, C^HCIg) 22.01; ôq (50.31 
MHz, C^HCIg) 14.31 (ÜHgCHg), 23.02 (CHgCHg), 29.75 (d., J 6 .8  Hz, CHgCHg^Hg),
31.7 (d., J  2.9 Hz, aHgCHP), 48.23 and 51.21 (d., Jpc 152.5 Hz, CHPO), 121.06 and 
121.0 (orfPo aromatic), 125.53 (para aromatic), 130.22 (mefa aromatic) and 153.83 J
(/pso aromatic); m/z (Cl) 320 ([M+ H]+, 24.8%) and 87 [M- PO(OPh)2]+, 100).
Diphenyl 1-amino-2-methylpropyiphosphonate (69).-
This was synthesised in an identical manner to (62) using hydrobromide (66) (3.8 
g, 9.5 mmol) giving the product as a clear oil (2.75 g, 91%). m/z (Found: (M + H)+ 
320.3514. C17H23NO3P requires 320.3515); v^ax (Nujol) 3295 (NH), 1286 (P = 0), 
927 (P-O) and 760 ca r' (aromatic); 8^ (200 MHz, C^HCIg) 0.92 (3H, d„ J  6.5 Hz, 1 
of (C H g);), 1.01 (3H, d., J  6.5 Hz, 1 of (C H g);), 1.55-1.87 (2H, m., (C H g );C ji and 1 
of C H ;), 1.62 (2 H, s.. NH;), 2.01 (1 H, m., 1 of C H ;), 3.41 (1H, m., CHPO) and 7.04-
7.47 (10H, m., aromatic); 8p (121.49 MHz, C^HCIg) 21.92; 8^  (50.31 MHz, C^HCIg) 
21.52t (((2 Hg)2 CH), 24.01t ((£H g);C H ), 24.59 & 24.87t ((C H g);< lH ), 40.29 (d„ JpQ
16.8 Hz, £ .H ;C H P ), 46.40 & 49.30 (d., Jpc 146.1 Hz, C H P O ), 120.96 (ortho  
aromatic), 125.58 {para aromatic), 130.23 (meta aromatic) and 151.20 ( ipso  
aromatic); m/z (Cl) 320 ([M+H]+, 20.4%) and 87 [/W- PO(OPh)2]+, 100).
Diphenyi 1-amino-/sopropyl phosphonate (70).-
This was prepared in an identical manner to compound (63) using the 
hydrobromide (6 8 ) (2.9 g, 7.5 mmol) giving the product as a clear oil (1.81 g, 79%). 
m/z (Found: (M+ H)+306.3245. C^gHgiNOgP requires 306.3244); v^ax (Nujol) 3297 
(NH), 1271 (P=0), 922 (P-O) and 757 cm'l (aromatic); Ôh (200 MHz, C^HCIg) 1.15 f 
(6 H, d., J 6.9 Hz, (Ch3 )2CH), 1.17f (1H, d.d., J 6.9 and 1.2 Hz, (CÜ3)2CH), 1.56 
(2H, s., NHg), 2.37 (1H, d.h., J 4.1 and J 6.9 Hz, CJH(CH3)2), 3.23 (1H, d.d., 41
and JpH 13.3 Hz, CHPO) and 7.08-7.47 (10H, m., aromatic); Ôp (121.49 MHz, 
C^HCIg) 21.71; ÔC (50.31 MHz, C^HCIg) 17.89f ((aH3)gCH), 21.19f ((^H3)2CH), 
29.76 (d., Jpc 11.6 Hz, (CH3)2llH ), 53.72 & 56.57 (d., Jpc 143.5 Hz, CHPO), 120.97 
& 121.06 (ortho aromatic), 125.53 (para aromatic), 130.22 (meta aromatic) and
152.64 (Ipso aromatic); m/z (Cl) 306 ([M+ H]+, 19.4%) and 73 [M- PO(OPh)2]+, 100).
(2S, 3R) N-Benzyloxycarbonyi-threonine (71).-
(2S, 3R)-Threonine (0.6 g, 5 mmol) was dissolved in water (50 ml) containing 
NaHCOg (1.05 g, 12.5 mmol) with vigorous stirring. Benzyloxychloroformate (0.8 ml,
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5.5 mmol) was added in five portions over 15 min. The mixture was stirred for 3 h. at 
room temperature, washed with diethyl ether (2 x 25 ml), acidified with concentrated 
HCI to pH 1 and extracted with diethyl ether (3 x 25 ml). The ethereal extracts were 
washed with brine (2 x 25 ml), dried (NagSO^) and evaporated under reduced 
pressure. The resulting oil was crystallised from ethyl acetate/ light petroleum to give 
white crystals (915 mg, 72%) of m.p. 101-103 °C (lit.454 i o i - 3  °C). m/z (Found: [M +
H)+ 254.1025. C12H15NO5 requires 254.1028); 4 in AcOH) (lit.454
-4.7° (c 4 in AcOH)); v^ax (Nujol) 3402 (NH), 1724-1710 (CO) and 1525 cm'l 
(aromatic); Ôh (90 MHz, c%-DMSO) 1.09 (3H, d., J 6.9 Hz, CHg), 4.3 (2H, m., C-2 & i
C-3 H), 4.95 (2H, s., PhCJHg), 6.07 (1H, d., J  9.1 Hz, NH), 7.07 (1H, br.s., OH), 7.18 
(5H, s., CgHg); ÔC (50.31 MHz, cfg-DMSO) 20.63 (CHgCH), 60.24 (CHgO), 65.81 
(CHNH), 66.73 (CHOH), 127.93, 128.09 & 128.63 (aromatic), 137.24 (quat. 
aromatic), 156.69 (urethane CO) and 172.64 (carboxyl CO); m/z (El) 253 (Af+, 2.1%),
209 ([M-COgf, 4.5), 108 (C7H7OH+, 92.1), 91 (CgHgCHg^ 38.4) and 79 (CgH7+
100).
Methyl (2S, 3R) N- benzyloxycarbonyl threonlnate (72).-
To an ice-cold solution of (71 ) (13.5 g, 53 mmol) in diethyl ether (70 ml) was added 
excess ethereal diazomethane (6.7 g, 0.16 mol) with stirring and the reaction 
allowed to warm to room temperature over 1 h. Un reacted diazomethane was 
removed in a stream of nitrogen and the solvent removed under reduced pressure to 
give a yellowish solid which was recrystallised from ethyl acetate/ light petroleum to 
give white crystals (10.6 g, 78%) of m.p. 91-92.5 °C (lit.^04 88-89 °C). m/z (Found: 
(M + H)+ 268.1185. CigH^gNO g requires 268.1184); [aj^^o . 14.50 (c 1 jp CHCIg) 
(lit.304 [ajo^o . 13.70 (Ç 1 in CHCIg)); v^nax (Nujol) 3446 (NH), 1716 (ester CO), 1688 
(amide CO), 1545 (aromatic) and 1300-1200 cm'^ (C -0); 6^ (200 MHz, C^H Clg) 1.21 
(3H, d., J  6.5 Hz, CHg), 3.74 (3H, s., OCHg), 4.36 (1H, d.q., J 6.5 Hz, J  3.6 Hz, 
CHOH), 4.58 (1H, d.d., Jch 3.6 Hz, J^h 8.5 Hz, CHNH), 5.14 (2 H, s., PhCHgO), 5.71 
(1H, d., J 8.5 Hz, NH) and 7.35 (5H, s., aromatic); ôq (50.31 MHz, C^HCIg) 19.76 
(CHg), 52.42 (COgjQHg), 59.59 (CH), 67.09 (CHgPh), 67.81 (CHNH), 127.96, 128.13 
& 128.53 (aromatic), 156.41 (urethane CO) and 171.67 (ester CO); m/z (El) 267 (M+,
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0.5%), 223 ([M-C021+, 4.6), 108 {C7 H7 OH+, 58.9) and 91 (C6H5CH2+, 100).
Methyl (2R, 3S)-(N- benzyloxycarbonyl)-2-amlno-3-bromobutyrate (73).-
Carbon tetrabromide (12.3 g, 37 mmol) and triphenylphosphine (9.71 g, 37 mmol) 
(both dried over phosphorous pentoxide for 12 h.) were dissolved in dry benzene 
(230 ml). The methyl ester (72) (6.9 g, 26 mmol) was added in several portions over 
30 min. at room temperature. The reaction was stirred for a further 90 min., after 
which time the triphenylphosphine oxide was filtered off and the pad washed with dry 
benzene (75 ml). The combined filtrates were concentrated under reduced pressure 
and the resulting oil was purified by flash column chromatography (3:1 ethyl acetate/ 
chloroform) and then recrystallised twice from ethyl acetate/ light petroleum to give 
the product as white crystals (2.88 g, 49%) of m.p 73-76 °C (lit.304 73-74  °C). m/z 
(Found: (M + H)+ 331.0341. C i3H,yN0 / % r  requires 331.0341); + 28.9 ° (o 1
In CHCIg) (llt.304 [a]D^°+31.5“ (c 0.47 in CHCIg)); (Nujol) 3301 (NH), 1740 
(ester CO), 1684 (amide CO), 1533 (aromatic) and 1300-1100 cm"' (C-O); 5|_, (200 
MHz, C^HCIg) 1.71 (3H, d., J7 A  Hz, CHg), 3.79 (3H, s., OCHg), 4.35 (1H, d.q., J  7.4 
& 3.6 Hz, C-2 H), 4.61 (1H, d.d., Jch 3-6, Jnh 8.5 Hz, C-3 H), 5.13 (2H, s., PhCH;0), 
5.72 (1H, d., J 8.5 Hz, NH), 7.38 (5 H, s., aromatic); Sg (50.31 MHz, C^HCIg) 23.23 
(ilH gC H ), 49.72 (CHBr), 53.2 (CHgO), 60.23 (CHNH), 67.85 (CHgPh), 128.65-129.07 
(aromatic), 136.44 (/pso aromatic), 155.9 (urethane CO) and 169.53 (ester CO); m/z 
(El) 331 & 329 (A ^ , Br isotopes, 0.6 & 0 .6%), 272 ([M-C0 2 Me]+, 4.6), 108 (C7 H 7 OH+,
42.8) and 91 (CgHgCHg"^, 100).
(2R, 3S)-2-amino-3-bromobutyric acid hydrochloride (74).-
The fully protected bromobutyrine (73) (1.4 g, 4.23 mmol) was refluxed in a mixture 
of 12 M HCI/ glacial acetic acid (35 ml, 6:4 v/v) for 2.5 h. The solvent was removed 
under reduced pressure to give a pale yellow solid. This solid was recrystallised from 
methanol/ diethyl ether to give white crystals (425 mg, 48%) of m.p 187-188 °C (dec.) 
(Iit.304 188 °C). [aJo^o +13.10 q.5 in H2O) (lit.304 [a]^20 +12 .7 ° (c 0.44 in H2O));
v^ax (Nujol) 3051 (NHg+), 1728 (CO) and 1280-1100 cm"1 (C-O); Ôh (270 MHz,
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2H ;0) 1.78 (3H, d , J  7 Hz, CHCJig), 4.20 (1H, d , J 2.9 Hz, C-2  H) and 4.68 (1H, q., |
J  2.9 Hz, CJdCHg): 5c (75.74 MHz. ^HgO) 19.25 (CH^Hg), 43.72 (CHNH), 57.88 j
(^HCHg) and 167.34 (CO); m/z (FAB) 184, 182 {[M+ H-CI]+, bromine isotopes, ;{
100%) and 102 {[M-Br]+, 10.6). |
(2S, 3S)-3-Methylaspartic acid (75).-
Mesaconic acid (13 g, 0.1 mol) was suspended in water (100 ml) and the pH 
adjusted to 9 with concentrated NHg. The solution was then concentrated in vacuo.
The resulting diammonium mesaconate was redissolved in water (125 ml) and 
magnesium chloride hexahydrate (250 mg, 62.5 mmol) and potassium chloride 
(45 mg, 28.5 mmol) were added, along with the enzyme 3-methylaspartase (150 
units). The reaction was incubated at 30 °C and aliquots (20 pi) were taken at 
intervals and the absorbance at 240 nm measured until no further decrease was 
observed (46 h.). The protein was denatured by boiling the solution for 2 min. and 
removed by filtration. The filtrate was evaporated to dryness, the residue dissolved in 
water (30 ml) and the pH was adjusted to approximately 3.5 with 12 M HCI. The 
product spontaneously precipitated as a yellow solid and was recrystallised twice 
from water/ ethanol to give white crystals (8.4 g, 55.7%) of m.p 270-273 °C (lit.^^^
276-278 °C). [ajo^o -9 .2 ° (c 0.6 in HgO) (lit.455 (c 0.42 in HgO)); v^ax
(Nujol) 2924 (NH), 1866 & 1681 (CO) and 1611 cm''^; Ôh (90 MHz, ^HgO) 1.13 (3H, 
d., J  8 Hz, CHg), 3.08 (1H, m., C-3 H) and 4.00 (1H, d., J  3 Hz, C-2 H); Ôq (50.31 
MHz, ^HgO, pD 1) 12.86 (CHg), 38.99 (CH), 54.16 (CHNH) and 167.21 & 174.9 (CO); 
m/z (FAB) 148 ([M+H]+, 5.9%).
a-Methyl N-trifluoroacetyl-(2S, 3S)-3-methylaspartate (76),-
Trifluoroacetic anhydride (48.5 g, 231 mmol) was added to a stirred suspension of 
(75) (4 g, 27.2 mmol) under nitrogen in dry THF (125 ml) at 0 °C over 30 min. The 
reaction was allowed to warm to room temperature and was left stirring for 2 h., when 
dissolution was complete. The solvent was removed in vacuo and the resulting 
anhydride (6.1 g, 99%) thoroughly dried (phosphorous pentoxide). The anhydride
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was treated with dry methanol (50 ml) at 0 °C and the solution was allowed to warm 
to room temperature over 2 h. The solvent was removed under reduced pressure to 
give an off-white solid (6.75 g, 96%) (a mixture of the a & p methyl esters); 0^ (90 
MHz, C^HCIg) 1.36 (3H, d., J  7.3 Hz, CHg), 3.07 ( 1 H, m., 0-3 H), 3.75 & 3.83 (p & a 
methyl esters respectively), 4.89 (1H, m., C-2 H) & 7.26 (1H, br.s., NH).
a-M ethyl N -trifiuoroacetyl-(2S , 3S)-3-m ethy!aspartyl-p-acid chloride
(77).-
The mixture of monoesters (76) from the above reaction (5 g, 19.4 mmol) were 
heated to reflux in thionyl chloride (60 ml) for 1 h. The solvent was removed under 
reduced pressure to give a pale yellow solid, which would not recrystallise from 
diethyl ether/ light petroleum. Consequently the crude product (4.34 g, 81%) was 
taken to the next step as an oil and the separation of the two diastereomeric ester/ 
acid chlorides was not achieved. 5|_| (90 MHz, C^HCIg) 1.31 (3H, d., J7Hz, CJHgCH),
3.53 (1H, m., C-3 H), 3.67 & 3.83 (P & a OMe respectively) 4.89 (1H, m., C-2 H) and
7.31 (1H, br. s., NH).
a-M ethyl N -trifluoroacetyl-(2S, 3S)-3-m ethylaspartyl-/n-chlprobenzoyl 
peroxide (78).-
The N-trifluoroacetyl-(2S, 3S)-3-methylaspartyl-a & p chlorides (77) (1 g of the 
crude oil) was dissolved in dry diethyl ether (30 ml) and 80-90% m-chloroperbenzoic 
acid (734 mg, 3.62 mmol) added and the mixture stirred under nitrogen in an ice/salt 
bath. Pyridine (246 mg, 3.6 mmol) in dry diethyl ether (2 ml) was added dropwise to 
the mixture and stirring continued overnight. The solution was filtered and washed 
with water ( 2 x 1 5  ml) and 1 M aqueous sodium carbonate ( 2 x 1 5  ml), dried 
(NagSO,!^) and the solvent removed under reduced pressure to give a white solid. A 
fractional crystallisation was then attempted, but this produced a white solid which 
was a mixture of the two diastereomers. Consequently this synthesis of L-a//o- 
threonine was abandoned.
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Methyl (2S, 3S)-N-benzyloxycarbonyl threonlnate (79).-
This was prepared in an identical manner to the (2S, 3R) diastereomer, but starting 
from (2S, 3S)-threonine (100 mg, 0.804 mmol). The crude (2S,3S)-N - 
benzyloxycarbonyl threonine was identified only by n.m.r. Ô|_| (90 MHz, C^HCIg) 
1 . 2 1  (3H, d., J 7  Hz, CHg), 4.22 (2H, m, C-2 & C-3 H), 5.05 (2 H, s., PhCHgO), 5.71 
(1H, s., OH), 6.31 (1 H, d., J  9 Hz, NH) and 7.27 (5H, s., aromatic). The N-protected 
(2 S, 3S)-threonine was dissolved in diethyl ether and treated with excess 
diazomethane as before, (73). Recrystallisation from diethyl ether/ light petroleum 
yielded white crystals of the methyl ester (103 mg, 46% over two steps) of m.p 57-
58.5 "C (lit.30‘‘ 58-59 °C). [a]D^o+12.1° (c 0.4 in CHCIg) (111.304 y o q.5 in
CHCig)); v^ax (CHCIg) 3430 (NH), 3030-2970 (CH, C H ;, CHg), 1755-1700 (ester & 
amide CO), 1510 (aromatic) and 1300-1100 cm ' (C-O); 5^ (90 MHz, C^HCIg) 1.21 
(3H, d., J  7Hz, 3-CHg), 2.50 (1H, s., OH), 3.76 (3H, s., OCHg), 4.12 (1H, m., C-3 H), 
4.39 (1H, m.. C-2 H). 5.11 (2H, s., PhCH;0), 5.68 (1H, d., J 9.1 Hz, NH) and 7.34 
(5H, s., aromatic); 5c (89.71 MHz, C^HCIg) 19.11 (CH£Hg), 52.58 (OCHg), 59.88 
(CHOH), 67.32 (OCH;), 69.23 (CHNH), 128.24, 128.43 & 128.75 (aromatic), 156.68 
(urethane CO) and 171.03 (ester CO); m/z{E\) 267 (M+, 0 .2%), 223 ([/W-CO;]+, 4.2), 
108 (C7H7OH+, 58.9) & 91 (CgHgCH;+, 100).
Methyl (2R, 3R)-(N-benzyloxycarbonyf)-2-amlno-3-bromobutyrate (80).-
This was prepared in an identical manner to the (2S, 3R) epimer, from methyl ester 
(79) (too mg, 0.36 mmol) except that further purification of the oil produced by the 
ethyl acetate: chloroform column was necessary. Thus a second flash column was 
performed, using chloroform as the eluant to give a clear oil which could not be 
crystallised (56 mg, 45%). [aJo^o + 2.6 ° (c 0.8 in CHCig) (lit.304 [ajgZO + 3.1 °) (c 1.76 
in C H C ig); v^ax (Nujol) 3305 (NH), 1737 (ester C O ), 1680 (amide CO ), 1533 
(aromatic) and 1300-1100 cm"' (C-O); 5^(90 MHz, C^HCIg) 1.65 (3 H, d., J  7 Hz, 3- 
CHg), 3.69 (3H, s., OCHg), 4.67 (2 H, m., C - 2  & C-3 H), 5.05 (2 H, s., P h C H ;0 ), 5.6 
(1H, d., J  9 Hz, NH) and 7.37 (5 H, s., aromatic); m/z (El) 331 & 329 {M*-, Br isotopes, 
0.6 & 0.6%), 272 ([AfCO;Me]+, 5.9 %), 108 (C7 H7 OH+, 84.3) & 91 (CgH 5 C H ;+ , 
100).
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(2R, 3R)-2-amino-3-bromobutyric acid hydrochloride (81).-
This was synthesised exactly as for its 3R epimer, from 55 mg (0.166 mmol) of (80) 
giving white crystals (20 mg, 55% ); ô^ (90 MHz, ^HgO) 1.64 (3H, d., J  7 Hz, CHg), 
4.18 (1H, d., J 2.9 Hz, C-2 H) and 4.64 (1H, m., C-3 H);
Methyl (2S, 3R)-N-ferf-butoxycarbonyl-threoninate (82)-
This was prepared as for the benzyloxycarbonyl analogue (72), using N-fe/t- 
butoxycarbonyl-(2S)-threonine (4 g, 18.3 mmol). After evaporation of the solvent the 
oily residue was purified by flash chromatography (ethyl acetate) to give the product 
as a clear oil (4.11 g, 96%). [ajp^o + 1 7 . 3 0  1 in CHCig); 0^ (200 MHz, C^HCIg) 1 . 2 2
(3H, d., J 6 .3  Hz, CHgCH), 1.44 (9H, s., (CHg)gC), 2.23 ( 1 H, s., OH), 3.74 (3H, s., 
O CHg), 4.28 (2H, m., C - 2  and C-3 CH) and 5.89 (1 H, br.s. NH); Ôq (74.76 MHz,
C^HCIg) 20.55 (ilH gC H ), 28.95 ((ÜHg)gC), 53.17 (OCHg), 61.10 (CH-NH), 68.76 
(CHOH), 80.79 ((CHg)g£), 157.40 (urethane CO) and 172.69 (ester CO).
Methyl (2R, 3R) N-ferf-butoxycarbonyl-2-amlno-3-bromobutyrate (83).-
This was prepared as for the benzyloxycarbonyl analogue, using ester (82) (4.01 g, 
17 mmol). After filtration and evaporation of the solvent the oily residue was purified 
by flash chromatography (ethyl acetate) to give the product as a clear oil ( 2 . 1  1 g , 
42%). ÔH (200 MHz, C^HCIg) 1.45 (9H, s., ((CHg)gC), 1.79 (3H, d., J 6.56 Hz, 
CÜ3CH), 3.79 (3H, s., OCHg), 4.32 (1H, q.d., J 3.5 & 6.56 Hz, CHBr), 4.54 (1H, d.d., 
Jnh 8.5 Hz Jqh 3.5 Hz, CHNH) and 5.41 (1H, br., NH).
Active-site model reactions (84).-
Succinic anhydride (114 mg, 1 mmol) was dissolved in dry THF (10 ml) and p- 
nitrophenylhydrazine (153 mg, 1 mmol) added in portions over 5 min. After 100 h. the 
solvent was evaporated, the residue taken up in chloroform (20 ml), filtered and the
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filtrate washed with saturated NaHCOg ( 4 x 1 0  ml), dried and the solvent removed 
under reduced pressure to give a dark red solid, v^gy (CHCig) 1736 (CO), 1599 
(aromatic), 1525 (NO2) and 736 cm’ "* (aromatic, p-substituted). 6^ (90 MHz, C^HCIg)
2.05 (4H, m., CH2 x2), 7.08 (2H, d., J 7.5 Hz, aromatic), 7.5 (1H, br.s, NH) and 8.15 
(2H, d., J 7.5 Hz, aromatic);
Phthalic anhydride (148 mg, 1 mmol) was dissolved in dry THF (40 ml) and p- 
nltrophenylhydrazine (153 mg, 1 mmol) was added in portions over 5 min. Almost 
instantly a cream-coloured solid began to precipitate, and precipitation appeared to 
be complete after 30 min. The mixture was filtered, and the solid washed with dry 
THF (10 ml) and dried, to give the product as a cream solid (1.84 g, 65%) of m.p. 
241-243 °C; v^ax (Nujol) 1672 (amide CO), 1648 (acid CO), 1592 (aromatic) and 
800-750 cm"'* (aromatic). Ôh (200 MHz, C^HCIg) 7.1 (4H, m., aromatic), 7.5 (1H, br.s, 
NH) and 8.05 (4H, m., aromatic); m/z (El) 283 (M^, 100%), 104 ([CeH4-CO]+, 71.1) 
and 76 (CgH^^, 60.8)
Resolution using dibenzoyl-(D)-tartaric acid (85).
Diphenyl 1-aminobenzyl phosphonate (82) (1.06 g, 3 mmol) was dissolved in 
ethanol/ methanol (4:1, 5 ml) and dibenzoyl □-(+) tartaric acid monohydrate (1.13 g, 
3 mmol) in ethanol (15 ml) added. After 3 h. stirring at room temperature the 
suspension was filtered and washed with ethanol to give a white solid that was 
recrystallised twice from ethanol to give a white solid (1.02 g, 73 %) of m.p. 175-177 
°C. The aminophosphonic acid was liberated from this salt by dissolving in 1 M 
sodium hydroxide (10 ml), saturating the aqueous layer with sodium chloride and 
extracting with chloroform (3 x1 5  ml). The organic extracts were dried (MgSO^) and 
the solvent removed under reduced pressure to give a white solid in all respects 
identical to compound (62) except that it has an optical rotation of - 45° (c 1 in 
MeOH).
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Lithium tri-ferf-butoxy aluminium hydride (86).-^ '^ ^
Lithium aluminium hydride (4.56 g, 120 mmol) was suspended in 120 ml dry 
diethyl ether and stirred for 30 min. at room temperature, after which time the mixture 
was filtered under an inert atmosphere through Celite. To the stirred filtrate was 
added dry fe/t-butyl alcohol (26.64 g, 360 mmol) in dry diethyl ether (150 ml) 
dropwise under nitrogen over 30 min. The resuting white solid was dried under 
reduced pressure and used directly.
Triphenyimethylamine (87).-^®^
Triphenylmethyl chloride (10 g, 36 mmol) was suspended in concentrated aqueous 
ammonia (50 ml) and stirred at room temperature for 2 days. The resulting 
suspension was filtered and the solid recrystallised from toluene/ light petroleum to 
give the product as a cream crystals (5.95 g, 64%) of m.p. 101-3 °C (lit.^®^ 103-104 
°C). ÔH (200 MHz, C^HCIg) 2.42 (2H, br., NHg) and 7.32 (15H, s., aromatic); ÔQ (50.31 
MHz, C^HCIg) 66.77 (Phg^-NH2), 127.12 (para aromatic), 128.48 (orf/?o aromatic), 
128.71 (mefa aromatic) and 149.20 (/psoaromatic); m/z{E\) 231 (PhgC+, 100).
Triphenylmethanimine (88).- Method 1
Amine (87) (2.59 g, 10 mmol) and paraformaldehyde (600 mg, 20 mmol) were 
dissolved in toluene (25 ml) and stirred at room temperature for 24 h. After this time 
magnesium sulfate was added and the mixture stirred for 20 min. then filtered. The 
filtrate was evaporated under reduced pressure to give a white solid that was 
recrystallised from toluene/ light petroleum (1.92 g, 71%), The compound was 
identical in all respects to that obtained from method 2 .
Method 2^G9
Amine (87) (2.59 g, 10 mmol) was dissolved in toluene (20 ml) and aqueous 
formaldehyde (1.7 g, 20 mmol) added. The mixture was vigorously stirred for 24 h. at 
room temperature and then sodium sulfate added and the suspension stirred for a 
further 20 min. The mixture was filtered and the filtrate evaporated under reduced
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pressure to give a cream crystalline solid. Recrystallisation from toluene/ light 
petroleum gave the product as white crystals (2.15 g, 79%) of m.p. 127-9 °C (lit.^^g 
134-6 °C). (Found: C, 88.81; H, 6.32; N. 5.16. Calc, for CgoH^^N: C, 88.52; H, 5.81;
N, 5.16); ÔH (200 MHz, C^HCIg) 7.05 (1H, d., J 15.9 Hz, 1 of CHg=N), 7.19-7.29 
(15H, s., aromatic) and 7.80 (1H, d., J 15.9 Hz, 1 of CH2=N); Ôq (50.31 MHz, C^HCIg)
80.60 (PhgCl), 127.81 (para aromatic), 128.50 (orf/?o aromatic), 130.37 {meta  
aromatic), 145.29 (/pso arc.,iatic) and 153.79 (C=N); m/z{C\) 231 (PhgC+, 100%). 1
Dimethyl 1-(triphenylmethylamino)methylphosphonate (89).-
N-Triphenylmethanimine (8 8 ) (2.71 g, 10 mmol) was dissolved in toluene (25 ml), 
dimethyl phosphite (5.5 g, 50 mmol) added and the mixture heated to 100 °C. After 5 
min, a white solid was deposited and after a further 25 min. the reaction was cooled, 
filtered and the solid recrystallised from chloroform/ methanol to give the product as 
white solid (2.59 g, 66%) of m.p. 208-9 °C (lit.369 210-11 °C). m/z (Found: {M+  H)+ 
381.1494, C22H24NO3P requires 381.14937); v^g^ (Nujol) 3326 (NH), 1238 (P=0),
1014 (P-OC) and 761 cm"'* (aromatic); 0^ (200 MHz, C^HCIgj 2.04 (1H, br., NH), 2.57 
& 2.54 (1H, d., JpH 13.83 Hz, 1 of CH2PO), 3.87 (6 H, d., Jp^ 10.65 Hz, PO(OCHg)2) 
and 7.15-7.61 (15H, s., PhgC); ôp (121.49 MHz, C^HCIg) 30.12; Ôq (50.31 MHz,
C^HCIg) 38.93 & 41.05 (d., JpQ 160.7 Hz, CH2PO), 53.83 (d., Jpg 6.82 Hz, 
PO(OCHg)2), 127.48 {para aromatic), 128.90 {ortho aromatic), 129.37 {meta  
aromatic) and 145.57 (quat. aromatic); m/z (Cl) 381 (A^, 4%), 304 ([M-Ph]+, 59 .8 ),
258 (PhgCNH+, 3), 243 (PhgC+, 100), 110 (H2NCH2PO(OCHg)2+, 2) and 91 
(PhCH2+,11.3). I
2-Hydroxy-N-benzyIoxycarbonyl glycine (90)-349
Freshly recrystallised glyoxylic acid mo no hydrate (19.6 g, 0.21 mol) was dissolved 
in dry diethyl ether (200 ml) and benzyl carbamate (28.9 g, 0.19 mol) added. The 
mixture was stirred overnight at room temperature and the resulting solid filtered and 
washed with diethyl ether to give a white solid. Recrystallisation from ethyl acetate/ 
light petroleum gave the product as a white solid (25.6 g, 63.5%) of m.p. 193-195 °C
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(lit.349 196-8 °C). v^ax (Nujol) 3324 (NH), 1731 (acid CO), 1696 (urethane CO) and
699 cm'l (aromatic); ô|_| (200 MHz, dg-DMSO) 5.06 (2H, s., PhCH2 0 ), 5.24 (1H, d., J
6.9 Hz, CH), 7.31 (5H, s., aromatic) and 8.12 (1H, d., J 6.9 Hz, NH); ôq (50.31 MHz,
C^HCIg) 71.19 (CHg), 78.93 (CH), 133.54 & 134.05 (aromatic). 142.57 (quat. 
aromatic), 161.22 (urethane CO) and 176.78 (carboxyl CO).
M e th y l  1 -m e th o x y -1 -a m ln o - (N -b e n z y lo x y o a rb o n y l)  e th a n o a te  ( 9 1 ) .-349
Compound (90) (11.27 g, 50 mmol) was dissolved in methanol (125 ml) and 
concentrated HgSO^ (2 ml) added. The solution was stirred at room temperature for 
48 h. then poured into ice-saturated 5% NaHCOg solution (75 ml). The solution was 
extracted with ethyl acetate (3 x 50 ml), the organic extracts dried (MgSO^) and the 
solvent removed under reduced pressure to give a colourless oil that solidified on 
treatment with light petroleum. This was purified by filtration through a short column 
of neutral alumina (deactivated by the addition of methanol), eluting with benzene to 
give the product as a colourless solid after removal of the solvent (9.87 g, 78%) of 
m.p. 74-76 °C (lit.349 76-78 °C). v^ax (Nujol) 3312 (NH), 1757 (ester CO), 1690
(urethane CO), 1430, 1358 & 738 cm-"* (aromatic); Ôh (200 MHz, C^HCIg) 3.43 (3H, 
s., CHOCHg), 3.81 (3H, s., COOCHg), 5.14 (2 H, s., PhCHgO), 5.33 (1H, d., J  8 . 2  Hz, 
CH), 5.90 (IK , br. d., J 8.2 Hz, NH) and 7.31 (5H, s., aromatic); Ôq (50.31 MHz,
C^HCIg) 53.48 (COOCHg), 56.77 (CHgO), 67.94 (CHg), 81.11 (CH), 128.72, 128.91 
& 129.11 (aromatic), 130.66 (quat. aromatic), 156.63 (urethane CO) and 168.17 
(ester CO).
M e t h y l  2 - b e n z y l o x y c a r b o n y l a m i n o - 2 - ( d l m e t h o x y p h o s p h l n y l ) - a c e t a t e
( 9 2 ) . - 3 5 0
Compound (91) (8.86 g, 35 mmol) was dissolved in toluene (35 ml) at 70 °C. 
Phosphorus trichloride (4.81 g, 35 mmol) was added and the solution stirred at 70 °C 
for 18 h. Trimethyl phosphite (4.34 g, 35 mmol) was then added and the mixture 
stirred at 70 °C for a further 2 h. The solvent was then removed under reduced
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pressure, the residue redissolved in ethyl acetate (40 ml) and the organic layer 
washed with 5% NaHCOg (3 x 20 ml) and dried (NagSO^). The solution was 
concentrated and stirred vigorously while hexane was added to precipitate the 
product as white crystals (7.81 g, 62%) of m.p. 78-79 °C (lit.350 80 °C). m/z (Found:
{M +  H)+ 332.0899. C igH ^gN O yP requires 332.0899); 5^ (200 MHz, C^HCIg) 3.75 
(3H, d., JpH 7.05 Hz, 1 of PO(OCHg)g), 3.81 (3H, s., COOCHg), 3.82 (3H, d., JpH 7.05 
Hz, 1 of PO(OCHg)g), 4.94 (1H, d.d., JpH 22.4 Hz, J^H 9.18 Hz, CH), 5.12 (2H, s.,
PhCHgO), 5.80 (1H, d., Jqh 9.18 Hz, NH) and 7.34 (5H, s., aromatic); ôp (121.49
MHz, C^HCIg) 18.74; 0^ (50.31 MHz, C^HCIg) 51.02 (COOCHg), 53.91 (CH), 54.68 w
(d., Jpc 27.3 Hz, PO(OCHg)g), 68.10 (CHg), 128.65-129.04 (aromatic), 136.30 (quat. 
aromatic), 156.06 (urethane CO) and 167.74 (ester CO); m/z (Cl) 332 {[M+ H]"^, 43.4),
224 ( [M -PO(OMe)g]+, 36.2), 196 {[M- Cbz]+, 8.5) and 91 (PhCHg+, 100).
3.1 Molecular biology and Enzymology 
Pepsin Assay (93).- Method 1
This assay is based on K n o w l e s '4 5 6  modifications of the method of A n s o n . 4 5 7  
Haemoglobin (125 mg) was dissolved in water (5 ml), filtered through glass wool and 
the pH of the filtrate adjusted to 1.8 with 0.3 M HCI. Pepsin (1 mg) was dissolved in 
water (10 ml) and 10 pi of this solution added to 200 pi of the haemoglobin solution 
at 37 °C. After 4 min. 5% w/v trichloroacetic acid solution (400 pi) was added and the 
solution left at 37 °C for a further 3 min. The resulting solution was centrifuged for 3 
min. and the supernatant removed carefully and its absorbance at 280 nm 
measured.
Method 2^92
The peptide Cbz-His-Phe(NOg)-Phe-OMe was dissolved in 40 mM citrate buffer 
(pH 4) to give concentrations in the range 0.15-0.25 mM. Typically 0.9 ml of peptide 
solution was added to 0.1 ml of a pepsin solution (0.007 - 0.05 mM) in the same
buffer at 37 °C. The change in absorbance at 310 nm was monitored (Aeg.,o=800).
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Inhibition of pepsin with acyl hydrazides (94).-
Inhibition experiments were carried out using the hydrazides (1), (2) and (4). In a 
typical experiment a thermally equilibrated sample (0.9 ml) of a 0.2 mmol solution of 
the hydrazides in water was added to a 7.5 pM solution of pepsin in water (0.1 ml, pH 
2). Parallel incubations were carried out, at 37 °C, and the activity of the pepsin after 
intervals of up to 72 h. compared to pepsin incubated under control conditions. No 
significant difference could be found in any of the incubations. The experiments were 
carried opt over a range of substrate (2 - 0.01 mmol) and enzyme (7.5 - 50 pmol) 
concentrations. The experiments were repeated in 40 mM citrate buffer (pH 4). 
Similar experiments were carried out using 100 mM stocks of the hydrazides in 
methanol or DMF to increase the hydrazide concentration in the incubation. 
However, at concentrations much over 2-5 mM the hydrazides precipitated.
After 96 h. incubation the mixtures were analysed by t.I.c. in various solvent 
systems to see if any of the cleavage products of the hydrazides could be identified. 
In no case could it be unambiguously shown that any of these compounds were 
produced by the incubation.
Freeze-quench experiments (95).-
A typical freeze-quench experiment was carried out by adapting the method of 
Wang and H o f m a n n . 4 5 8  A solution of the quench peptide, leucine tyrosine amide 
(11), at various concentrations (2-10 mM) in 50 mM citrate buffer (0.9 ml) (pH 4.5) 
was added to 0.1 ml of solutions of pepsin (3-9 mg ml""*) in the same buffer at 37 °C. 
At intervals these incubations were quenched by adding them to 20 ml of a stirred 
solution of sodium borohydride (5 mg mM) in THF or 4:1 THF/ absolute ethanol at 
-25 °C. The solutions were then evaporated to remove the organic solvents and 
examined by t.I.c. on silica plates, against an authentic sample of leucinol, eluting 
with chloroform/ methanol (3:1). To identify the products of transpeptidation the plates 
were eluted with MeOH/ EtOAc/ NHg (3 5 :6 5 :3 ).^^a The protein was isolated by 
desalting on a Sephadex G-25 column, collecting the eluate that absorbed at 
280 nm and freeze-drying. The protein was examined by polyacrylamide gel 
electrophoresis on 12% gels. The visualisation of pepsin on these gels proved to be 
problematic and various staining procedures were examined.
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Déphosphorylation of pepsin ( 96 ) , - M e t h o d  1 ^ 9 8
To pepsin (0.95 ml, 6 mg mM) in 50 mM Tris buffer (pH 10.5 or 8.5) was added 50 
or 100 pi of alkaline phosphatase solution (2.4 mg ml'^ in the same buffer) and the 
mixture incubated for 12-16 h. at 37 °C. The solutions were then examined by SDS 
PAGE. Further incubations were carried out at pH 6.5 (100 mM phosphate buffer). 
Following Perlmann’s p roce d u re ,in cu b a tio n s  were most often carried out at pH 
8.5.
Method 2
Pepsin (5 mg) was dissolved in water at pH 2 and pH 1, incubated overnight as 
above and examined by the same method.
HIV-1 protease assays (97).-
The assays are based upon the cleavage of the nonapeptide Lys-Ala-Arg-Val-Nle- 
(N0 2 )Phe-Glu-Ala-Nle between the norleucine and nitrophenylalanine residues to 
give a reduction in absorbance at 300 nm. The peptide is stored as a solution in
water (10 mg ml'"*) and the enzyme is stored as a 0.993 pM solution in 10 mM 
NaOAc, 0.05% 2-mercaptoethanol, 1 mM EDTA, 20% glycerol and 5% ethylene 
glycol. The assay buffer is;
100 mM NaOAc, 200 mM NaCI, 1 mM DTT pH 5.6.
The inhibitors were made up as 1-10 mM stock solutions in distilled MeOH and 
used at final concentrations in the range 1-100 pM. Methanol was added as needed 
to give a final concentration of 2%. Alternatively, the inhibitor was dissolved to 
100 pM in assay buffer and diluted with buffer to give the required final concentration 
in the range 1-100 pM. For the assays the enzyme (at a final concentration of 15 nM) 
was added to the assay buffer and the required concentration of inhibitor and 
preincubated for 15 min. at 37 °C. The reaction was then initiated by the addition of 
2-8 pi of substrate. The linear portion of the plot was used to give initial rates. Each 
inhibitor was assayed on at least two separate occasions and each concentration 
was tested at least twice on each occasion. The K|^ for the substrate was determined
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to be 33 pM under the assay conditions.
Time-dependency of inhibition (98).-
The enzyme (15 nM final concentration) and the inhibitor 3004 (see Discussion) as 
a 1 mM stock in methanol were incubated in assay buffer at 37 °C at a final methanol 
concentration of 2%, Aliquots were removed and activity assayed at intervals of 6-8 4
min. for 30 min. However, under these conditions the activity of the native enzyme 
was also found to decline rapidly. Therefore, incubation at 21 °C was substituted.
Production of competent JM 101 (99).-Method 14
An overnight culture of JM 101 (5 ml) was diluted into SOB medium (80 ml) and 
incubated at 37 °C until ODggg reached 0.5, when the cells were harvested by 
centrifugation (3,000p, 2 min.). The cells were resuspended in FSB buffer, (40 ml) 
and cooled in ice for 10 min. The suspension was then centrifuged (4000p, 10 min.) 
at 4 °C, the medium decanted off and the cells resuspended in FSB buffer (4 ml). 
DMSO (140 pi) was then added and the cells stored on ice for 15 min., after which 
time a further 140 pi DMSO was added and the mixture aliquoted in 200 pi portions 
into sterile, chilled eppendorf tubes and frozen at -70 °C.
Method 2
An overnight culture of JM-101 (0.1 ml) was diluted into LB broth (20 ml) and 
incubated at 37 °C until ODggo reached 0.15. Aliquots (1.5 ml) were then pelleted by 
centrifugation (5,000gr, 2 min.) and resuspended in ice-cold buffer A (0.5 ml). The 
cells were then pelleted again, resuspended in ice-cold buffer B (0.5 ml) and kept for 
1 h. on ice. The cells were then frozen at -70 °C as suspensions in 15% glycerol.
Buffer A: 10 mM MOPS, 10 mM RbCI, pH 7.0
Buffer B: 100 mM MOPS, 50 mM CaClg, 10 mM RbCI, pH 6.5
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PCR reaction (100).-
The oligonucleotide primers were purified by ethanol precipitation and air-dried 
prior to use, then made up into working solutions of 10 pM in distilled water.
The amplifications were made up as follows:
10 pi lOx Taq buffer 
1 0 p l2 mM dNTP’s 
10 pi 10 pM primer 5'-3'
10 pi 10 pM primer 3'-5'
1 pi template DNA solution 
0.5 pi Taq polymerase solution 
59 pi water
The mixture was covered in mineral oil (100 pi) and subjected to the following 
amplification cycle 25 times:
94 °C 1.5 min. (Dénaturation)
55 °C 1.5 min. (Annealing)
72 °C 2 min. (Extension)
The progress of the amplification was checked after the cycling process by 
removing a 5 pi aliquot, adding 5 pi of DNA dyes and running on an agarose gel. 
The gel showed one band, consistent with the presence of just one DNA sequence, 
the amplified one. The incubation solution was pipetted off and an equal volume of 
phenol added, the mixture was vortexed, centrifuged (5,000gf, 1 min.) and the phenol 
removed. An equal volume of chloroform was added and the solution vortexed, 
centrifuged (5,000g, 1 min.) and the chloroform removed. To the remaining aqueous 
layer was added 0,1 volumes of 3 M sodium acetate solution, followed by 0.6 
volumes of isopropanol and the mixture stored at -20 °C for 10 min. The precipitated 
DNA was pelleted by centrifugation (13,000p, 5 min.), the supernatant removed, the 
pellet washed with 70 % ethanol and air-dried.
204
-, .1- ■ 1- ’ i r -
Restriction digests (101)-
The DNA pellet from the PCR amplification was taken up in 38 pi of water and the 
following added:
5 pi 10x Eco R1/ Nco buffer.
5 pi 1 mg ml"”* BSA .
1 pi Bam H1 solution.
1 pi Eco R1 solution.
The solution was incubated at 37 °G for 4 h., after which time the DNA was purified 
by phenol/ chloroform extraction and ethanol precipitation as for (100) and taken up 
in water (10 pi).
In a similar fashion 5 pi of a solution of the plasmid pGEX-2T (1 mg ml"‘*)was made 
up to 38 pi with water and treated exactly as for the restriction of the PCR amplified 
protease gene. The reaction was checked by running a 5 pi aliquot on a 1% agarose 
gel. The DNA was purified exactly as for the PCR restriction, to give restricted 
plasmid pR I/H I.
Ligation (102).-
Ligatlon of the restricted PCR amplified DNA into the restricted plasmid (pRI/H I) 
was carried out as follows:
4 pi of amplified DNA 
2 pi pRI/HI 
2 pi 5x iigase buffer 
1 pi 4 mM ATP 
0.5 pi water 
0.5 pi T4 Iigase
After incubation at 37 °C for 1 to 3 hours the mixture was used directly in the 
tranformation step.
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Transformation (103).-
The ligated plasmid (102) was then transfected into competent JM 101 (99) by 
addition of the crude ligation mixture (3 pi) to aliquots of competent bacteria in 200 pi 
buffer B. The mixture of JM 101 and ligated DNA was stored on ice for 30 min., the 
cells were heat-shocked at 42 °C for 90 seconds, stored on ice for a further 2 min. 
then 200 pi SOC medium added. After 1-2 h. at 37 °C the cells (1 ml) were plated out 
on LM agar containg ampicillin (100 pg ml'^)at the incubation concentration and at a 
1:10 dilution and left overnight at 37 °C.
Screening (104).-
Individual colonies were picked from the agar plates and grown up in 10 ml LB 
broth (containing 100 pg mb'* ampicillin) until ODgoo reached 0 .6 , when they were 
induced with IPTG at a final concentration of 0.1 mM. After incubation at 37 °C for a 
further 3 h. with shaking, 1 ml of the broth from each incubation was decanted into an 
eppendorf tube and centrifuged (6,000gf, 2 min.). The supernatant was removed and 
the pellets resuspended in 100 pi of disruption buffer. The mixture was then boiled 
for 5 min. and 10 pi applied directly to a 12% SDS PAGE mini-gel. In some screens 
the cell pellet was sonicated before being boiled in disruption buffer for 3 min. and in 
others lysozyme treatment, followed by addition of Triton X-100 to 1% and vortexing, 
was used.
Once the gel had been run colonies that gave the largest amounts of recombinant 
protein were picked and grown up in 0.85 ml LB broth for 3 h., after which time 
glycerol (15Q.pl) was added and the suspensions frozen at -70 °G.
Plasmid preparation (105).-
A 500 ml culture of the transformed JM 101 was grown in LB broth containing 10% 
glucose to mid-log phase (ODgoo of 0 .6 ) and chloramphenicol added to give a 20 pg 
m l'f solution. The culture was grown to saturation overnight, then pelleted by 
centrifugation (7,000g, 1 min.). and the cells resuspended in 50 mM glucose, 25 mM
Tris.HCI pH 8.0, 10 mM EDTA (9 ml). Lysozyme (1 ml, 20 mg ml  ^ in 200 mM Tris.
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MCI, pH 7.5) was added, and the mixture left at room temperature for 5 min. A 
solution of 1% SDS in 200 mM sodium hydroxide (20 ml) was added, the mixture 
stored on ice for 5 min., followed by the addition of 5 M KOAc, (pH 5.4, 10 ml) and 
storage on ice for a further 15 min. The mixture was centrifuged (8,000gf, 5 min.), the 
supernatant filtered through cheesecloth and 0.6 volumes of isopropanol added.
After 15 min. at room temperature the solution was centrifuged (10,000g, 10 min.) 
and the supernatant removed. The pellet was washed with 70% ethanol, dried in air 
for 5 min. and taken up in 2 ml TE. This was split between 2 eppendorf tubes to 
which was added caesium chloride (1.2 g) and ethidium bromide (50 pi, 10 mg ml""*), 
left at room temperature for 5 min. and centrifuged for 3 min. The supernatant was 
then removed and centrifuged (100,000gf, 5 h.) and the plasmid band removed with a |
syringe. This solution was then extracted with equal volumes of butan-2-ol saturated 
with caesium chloride (five times) and the caesium chloride removed by dialysis 
against distilled water overnight. Sodium acetate (3 M, 0.1 vol) was added and the 
DNA precipitated by addition of 0.6 volumes of isopropanol and storage at -20 °C for 
20 min. After centrifugation (10,000g, 5 min.) and removal of the supernatant the 
DNA was taken up in 0.5 ml TEN and RNase A added to a final concentration of 50 
pg ml""* and the mixture left at 37 °C for 30 min. The solution was then extracted with 
phenol (0.5 ml) and chloroform (0.5 ml) and the DNA precipitated with sodium 
acetate and ethanol, washed with 70% ethanol, dried and stored in distilled water at 
-20 °C. The optimised yield was around 200 pg from a 500 ml culture.
The BND cellulose modification was performed as follows:
The isopropanol precipitate from a 250 ml culture was taken up in 50 mM Tris.HCi,
300 mM NaCI (pH 7.6, 2 ml). This was applied to a 2 ml column of BND cellulose in 
the same buffer. After washing with 3 column volumes of the same buffer, the plasmid 
was eluted with 50 mM Tris.HCi, 1 M NaCI and 1 ml fractions collected, the plasmid 
precipitated with 3 volumes ethanol and treated as for the standard procedure. 
Plasmid was also obtained by mini-preps using the Stratagene Plasmid Quik™ kit 
according to the manufacturers instructions. Prior to sequencing the purity of the 
plasmid was checked by agarose gel electrophoresis against Eco R1/ Hind III 
cleaved X phage DNA standards.
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Restriction analysis of pGEX-2T (106).-
Restnction was carried cut at 37 °C for 4 h. exactly as for (101 ) using the following 
solutions:
2 pi pGEX-2T solution 
20 pi water
2.5 pi Aat II buffer 
1 pi Sma1 solution 
1 pi Eco RV solution
Sequencing (107).-
Sequencing of the plasmid was carried out by the dideoxy m e th o d ,u s in g  the 
USB Sequenase 2.0 kit, according to the manufacturers instructions. The primers 
used for the sequencing were the primers used in the PCR reaction.
Primer solution (1 pi), reaction buffer (2 pi) and template DNA (7 pi, = 2 pg) were 
incubated at 65 for 2 mins., then allowed to cool slowly to room temperature in a 
small beaker of 65 °C water over 30 mins. The incubation was then placed on ice.
DTT (1 pi, 0.1M), was added followed by [a-^^S] dATP (0.5 pi, 10 pCi), labelling 
mix (1 :8 diluted) and Sequenase^*^ 2.0 enzyme solution (2 pi) and the mixture 
incubated at room temperature for 3 mins. Labelling was terminated by addition of
3.5 pi of the incubation to 2.5 pi each of the termination mixes (A, C, G and T) and the 
mixtures incubated for 10 mins. Stop solution was then added to the 4 incubations, 
the solutions mixed thoroughly and the tubes stored on ice. The samples were 
heated to 75 °C for 2 mins. and then run on polyacrylamide gels (7 M in urea, pre-run 
for 30 mins.) at 2000 V and visualised by autoradiography on Fuji X-25 film.
Cloning Into M13 (108).-
Restrictions were carried out as for (101) using 2 pi of Ml 3 DNA solution or 4 pi of 
the PCR amplified gene.
The Ml 3 DNA restriction was incubated at 37 °G for 2 h., then DNA dyes (10 pi)
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added. The mixture was electrophoresed on a 1% SeaPlaque™ low-melting 
agarose gel with TAE buffer containing ethidium bromide (1 pg ml"^) at 80 mA. The 
required band (corresponding to the cleaved RF M13) was cut from the gel and 
purified from the gel by the GeneClean™ kit or by melting the gel and extraction with 
phenol (2x), 1:1 phenohchloroform (1x), chloroform (1x) and precipitation with 3 
volumes of ethanol. The amplified gene restriction was purified as before, by phenol: 
chloroform extraction and ethanol precipitation or by gel electrophoresis as for the 
cleaved RF Ml 3 DNA.
TAE buffer 40 mM Tris-acetate, 1 mM EDTA, pH 8.0
Ligation into M13 (109)
Ligations were carried out exactly as for (102), using 3.5 pi of M l3 DNA solution 
and 2 pi of protease gene solution. The mixture was incubated at 37 °C for 1.5 h., 
then used directly in the transformation.
Transformation (110).-
5 pi of the ligation mixture (109) was added to 50 pi competent JM 101 on ice and 
stored for 30 min. on ice. The bacteria were then heated to 42 °C for 90 seconds, 
returned to ice for 2 min. and SOB without magnesium (175 pi) was added. Aliquots 
of the ligation mixture mixture (1, 10, 100 pi) were added to 300 pi of plating JM101 
(grown up overnight in LB broth from a colony picked from an M9 agar plate).
(2S)iquid SOB top agar (5 ml) containing BCIG (40 pi, 20 mg ml""* in DMF) and IPTG 
(4 pi, 200 mg ml'"* in water) was added immediately. The agar was then poured onto 
an LB plate (prewarmed to 37 °C), spread evenly by swirling and the plates 
incubated at 37 °C for 12 h.
Preparation of stocks of recombinant Ml 3 (111).-
A single clear plaque was picked from the plates above and used to inoculate 500
209
pi of an overnight culture of plating JM 101 in 20 ml L-broth. The culture was 
incubated for 4 h. and then centrifuged (12,000g, 5 min.) at room temperature. The 
supernatant was carefully dispensed into sterile 10 ml tubes and stored at 4 °C.
Plaque assay (112).-
To assess the level of virus production from the infected cells the viral stock 
produced above was serially diluted ten-fold ten times. These dilutions (0.1 ml) were 
added to 0.1 ml of plating JM 101 in 3 ml SOB top agar and plated out onto LB agar 
plates. After overnight incubation the number of colonies on the plates were counted, 
where practical, to give an estimate of the virus density in the stock, which was found 
to be around 5 x 10^^ pfu ml’ "*.
Preparation of single-strand Ml 3 DNA (113).-
Clear plaques were picked from the plates and grown up 2.5 ml of L-broth 
containing 25 pi of an overnight culture of JM 101 for 5 h. The cultures were then 
centrifuged (12,000p, 5 min.) at room temperature and the supernatant removed. A 
plaque assay of this supernatant gave a viral titre o f 5 x  10^^ p fy  m i- i  
An aliquot (2.5 ml) of this supernatant was added to 10 ml of an overnight culture of 
JM 101 and stored at room temperature for 5 min. The culture was used to inoculate 
p re warmed LB broth (250 ml) which was then incubated with shaking at 37 °C for 
5 h. The culture was then centrifuged (4000gf, 15 min.) at 4 °C, the supernatant 
removed and PEG 6000 (10 g) and sodium chloride (7.5 g) added with stirring. The 
mixture was stirred at room temperature for 45 min., then centrifuged (10,000g,
20 min.) at 4 °C and the supernatant removed. The solid was centrifuged again i  
(10,000fif, 5 min.) and the last of the supernatant removed with a drawn-out Pasteur 
pipette. j
The pellet was dissolved in 10 mM Tris.HCi pH 8.0 (10 ml), phenol (10 ml) was |
added, the mixture vortexed for 2 min. and then centrifuged (3000g, 5 min.) The |
organic layer was then removed and 1:1 phenol:chloroform (10 ml) added. After #
vortexing and centrifugation as before the organic layer was removed and sodium
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acetate (1 ml of 3 M solution) and ethanol (22 ml) were added. The solution was 
stored at 0 °C for 1 h. and then centrifuged (2,000g, 10 min.) at 4 °C. The precipitated 
single strand DNA was taken up in 1 ml of TE and stored at -20 °C.
STET plasmid preparations for restriction analysis (114).-
1.5 ml of an overnight culture of the transformed bacteria (103) was centrifuged 
(12,000g, 30 secs) and the supernatant removed. The pellet was resuspended in
STET solution (350 pi) and freshly prepared lysozyme solution (10 pi, 10 mg ml'"* in 
10 mM Tris.HCi, pH 8.0) added. The mixture was placed in a boiling water bath for 
40 seconds. The lysate was centrifuged (12,000g, 10 min.). The bacterial debris was 
removed, sodium acetate (35 pi of 3 M solution) and isopropanol (420 pi) were 
added and the mixture stored at room temperature for 5 min. The suspension was 
centrifuged (12,000g, 5 min.) at 4 °C and the supernatant removed. The tube was 
dried by inverting and then 1 ml of 70% ethanol was added. The centrifugation was 
repeated, the supernatant removed and the tube dried in air. The pellet was
dissolved in 50 pi TE containing RNAse A (5 pi of 20 pg ml'"*).
STET solution
0.1 M NaCI
10 mM Tris.HCi (pH 8.0) 
1 mM EDTA (pH 8.0)
5% Triton X-100
5x ligase buffer
250 mM Tris.HCi pH 7.8 
100 mM DTT 
50 mM MgCl2 
5 mM spermidine
lOx Taq buffer
100 mM Tris.HCi pH 8.3
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500 mM KOI 
15 mM MgCl2
0 .01% gelatin
In vivo assays for the protease inhibitors (115).- 
Antlgen reduction assay.-
C8166 T-lymphoblastoid cells were infected with 10 TCIDgg of HIV-1 of the RF stock 
( H I V - I r p ) and washed three times wih PBS. Aliquots of 2 x 10^ cells were 
resuspended in growth medium, RPMI 1640 supplemented by 10% fetal calf serum, 
with each compound to be tested at log dilutions from 0.001 to 100 pM. The cells 
were incubated at 37 °C for 72 h. under a 95% air/5% CO2 atmosphere. The HIV 
antigen was measured in duplicate in the supernatants using a commercial ELISA 
assay.
Toxicity assay,-
Aliquots of 2 X 10^ uninfected C8166 cells were suspended in 1.5 ml of the above 
growth medium and cultured with the test compounds at the same log dilutions for 72 
h. The cells were then washed with PBS and resuspended in 200 pi of grov\4h 
medium containing "*40 protein hydrolysate. The cells were harvested after 16 h. and 
the incorporation measured. Untreated cells were used as controls.
3.2 Molecular Modelling
3.2.1 Interactions In the S3 site
The inhibitor MVT-101 was used as the basis for constructing a model of the 
interactions of our inhibitors with the protease active site. The P4 acetyl group was 
removed and the side-chains at P3-P3’ replaced with those appropriate to our 
inhibitor 100. The proline residue was formed by cyclisation of the P,,' norleucine
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side-chain (without the terminal methyl group) onto its amide nitrogen and 
minimisation of the resulting ring, allowing only the ring atoms and the adjacent 
carbonyl groups to adjust. Minimisation was carried out using the PRCG conjugate 
gradient minimiser. Overlay of the ring onto the proline ring of JG-SeS^^o showed the 
two structures were very similar (r.m.s. deviation of around 0.06 Â), indicating that a 
reasonable ring geometry had been calculated. Minimisation was carried out in
Macromodel using the AMBER forcefield"^®^ and the Polak-R ibiere conjugate
gradient minimiser (PRCG)^®*  ^ to a convergence criterion of 0.001 kcai mol’ "*.
The new side-chains were relaxed into their binding pockets by a substructure 
minimisation procedure. The substructure consisted of all residues having one or 
more atoms within 5Â of any atom in our inhibitor. These atoms were allowed to 
move freely in the minimisation. A shell of atoms around this substructure was fixed 
with a force constant dependent on the number of bonds between the given atom 
and the nearest bonded atom in the substructure. Atoms within one bond were fixed
with a constant of 100 kJ mol'^ A '\  within two bonds at 500 kJ mol'"* Â’"* and within 3 
bonds at 1500 kJ mol’  ^ Â \  Any atom more than 3 bonds from the substructure was 
ignored in the calculation.
Once a reasonable structure had been calculated the conformational preferences of 
the Pg side-chain were examined by a Monte Carlo simulation. The residues of the 
Sg pocket chosen for inclusion in the calculation were those within 6Â of any atom in 
the Pg residue examined:
Arg SB, Leu 23B, Asp 29A, (lie 47A), Gly 48A, Gly 49A, (Phe 53A) and Val 82B.
lie 47A and Phe 53A are distant residues and probably do not contribute greatly to 
the binding.
The torsion angles of the side-chain were altered systematically (in 10° increments) 
or randomly and the energies of the resulting structures calculated. The low energy 
structures were then examined.
3.2.2 The configuration at phosphorus
A substructure consisting of residues 22-27 of each monomer and the central 
residues of the inhibitor was constructed. Molecular dynamics were carried out on
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minimised structures (gradient of less than 0.01 kJ mol''* A '”*) with the Verlet 
algorithm.^®'* A 1 fs time-step was used with S H A K E . T h e  substructure was 
equilibrated at 700K for 100 fs, then dynamics was carried out at 300K for 20 ps. A 
variant in which, after equilibration, the temperature was decreased from 700K to 
300K over 10 ps, followed by 10 ps of simulation was also performed. The results 
were found to be similar.
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APPENDIX B 
Restriction maps of pGEX-2T and pGEX-HPR
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lac Z
lac Iq
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Ori
Amp res - B-lactamase 
Ori - Origin of replication 
lad - lac repressor
lac Z - B-galactosidase gene
tac - tac promoter
Sj26 - glutathione transferase
M. C. S. - Multiple Cloning Site
The plasmid pGEX-2T
2 1 6
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Plasmid pGEX-2T plus the 
HIV-1 protease gene
Amp res - B-lactamase 
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laci - lac repressor
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STOP HIV-PRAat 11
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